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Early identification of risk factors, in particular first trimester teratogenic medications, for 
congenital anomalies (CAs) is essential. Despite similarities between different CAs and 
between different medications, current surveillance methods in Europe examine each CA 
and each medication separately. This thesis aims to investigate whether the use of 
hierarchical statistical methods combining information in groups can improve CA 
surveillance methods. 
Methods 
EUROCAT is a European network of population-based CA registries, with EUROmediCAT 
comprising those registries with additional information on medication use in pregnancy. 
Trends in CAs from 2003-2012 in 18 EUROCAT registries (n=81,147) were analysed using 
Poisson regression models considering each CA separately and using hierarchical models 
combining related subgroups. First trimester medication exposures from 1995-2011 in 13 
EUROmediCAT registries (n=15,058) were analysed. Firstly, groupings of medications and/or 
CAs were considered when determining the statistical significance of each medication-CA 
combination, using False Discovery Rate (FDR) procedures to adjust for multiple testing. 
Secondly, Bayesian hierarchical models were applied to directly model the group effects. 
The Australian classification system for prescribing medicines in pregnancy was used to 
independently identify “high risk” medications. The number of “high risk” medications 
identified by the FDR methods and Bayesian models were compared. 
Results 
For analysis of trends, grouping EUROCAT CA subgroups using hierarchical models did not 
provide additional information over that obtained from independent analyses of each 
subgroup. The double FDR method grouping medications by ATC3 level codes performed 
better than other FDR methods. Use of Bayesian hierarchical models did not produce 
enough of an improvement to justify the increased effort of implementing such models.  
Conclusions 
The current EUROCAT methods of analysing each CA separately remain an appropriate 
method for the detection of potential changes in prevalence of CAs. The double FDR 
procedure is recommended for use in routine signal detection analyses of CA data.  
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Chapter 1:  Thesis background and rationale 
1.1. Introduction 
This thesis investigates the use of hierarchical statistical methods as an approach to the 
routine analyses of congenital anomaly (CA) data in two main areas; firstly, the analysis of 
changes in prevalence of CAs and, secondly, the detection of medications that may 
potentially increase the risk of specific CAs when used in the first trimester of pregnancy. 
The current chapter introduces and contextualises the main topics explored in this thesis, 
including CA surveillance, Bayesian analysis and the use of hierarchical models.  
1.2. Surveillance of congenital anomalies 
CAs are structural or functional abnormalities that occur before conception or during a 
foetus’s development and are present at birth, whether clinically obvious at that stage or 
diagnosed later in life. As a leading cause of both foetal and infant death, around 303,000 
neonates globally die each year due to CAs, and it is estimated that around 3-6% of births 
worldwide are affected by a major CA [Parker et al., 2010, World Health Organization, 
2016]. For those who survive past the neonatal period, CAs can lead to lifelong chronic 
illness and disability, and this carries a significant social, public health, and economic 
burden. These conditions can be a result of harmful environmental factors known as 
teratogens; they may also be inherited (originating before conception), or can arise from a 
complex interaction between both genetic and environmental influences. This is a diverse 
group of disorders, for which known causal factors include maternal age, medication use, 
family history, and maternal illness [Harris et al., 2017]. However, only approximately half 
of all CAs can be linked to a specific known cause or risk factor [Christianson et al., 2005, 
World Health Organization, 2016], and it is therefore essential that continued efforts are 
made to identify new potential risk factors. 
1.2.1. Background to congenital anomaly surveillance 
Before the maternal rubella infection was discovered to be teratogenic in the early 1940s 
[Gregg, 1941], it was widely believed that the foetus was protected from harmful exposures 
by the placenta. Twenty years later, a widespread epidemic of deformities in children was 
linked to the drug thalidomide, which was taken as an anti-morning sickness medication 
during pregnancy by tens of thousands of women [McBride, 1961, Khoury et al., 1994]. The 
thalidomide tragedy was the first demonstration on such a large scale that medications 
could be harmful to the foetus. This led to the establishment and strengthening of 
regulatory bodies, including more structured regulations for the development and control 
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of medications. Population-based CA registries were also established across the world, in 
order to facilitate surveillance and research regarding environmental causes. Since CAs are 
typically rare diseases [EUROCAT Central Registry, 2012], it is necessary to collect 
information covering births across an extremely large study population of interest in order 
to have sufficient numbers to perform meaningful statistical analyses. In Europe, there are 
a number of regional and national registries collecting data on CAs at a population level. 
Consequently, a European network of population-based registries for the epidemiologic 
surveillance of CAs (EUROCAT, http://www.eurocat-network.eu/) was formed in 1979, 
allowing data to be pooled and compared across Europe, and sharing expertise across the 
different registries and countries involved. EUROCAT surveys over 1.7 million births from 43 
registries in 23 countries across Europe, covering around 30% of the European birth 
population. One of the main aims of EUROCAT is to perform annual monitoring of the birth 
prevalence of specific CAs and investigation of the occurrence of any increasing trends or 
clusters of cases [Dolk, 2005]. Other such networks including both population and hospital-
based CA registries include the Latin-American collaborative study of congenital 
malformations (ECLAMC) [Poletta et al., 2014] and the worldwide International 
Clearinghouse for Birth Defects Surveillance and Research (ICBDSR), which consists of 40 
registries worldwide and includes many of the EUROCAT registries [Botto et al., 2006b]. 
Collaborative networks also exist within countries; for example, the National Birth Defects 
Prevention Network (NBDPN) publishes studies from both state and regional level data in 
the US in an annual special issue of the journal Birth Defects Research Part A [Kirby and 
Browne, 2016]. There is some overlap between the different networks, e.g. some registries 
are members of both EUROCAT and ICBDSR. 
1.2.2. Analysis of medication use during pregnancy and the potential for use 
of congenital anomaly surveillance databases 
The first trimester of pregnancy is an essential stage of development for the foetus; during 
this time, organs undergo critical steps in their development, and most (although not all) 
non-inherited CAs occur [Sachdeva et al., 2009]. It is known that certain medications can 
cause CAs when taken during early pregnancy, yet exposure to prescription and over-the-
counter medication during pregnancy is common. It can be difficult for pregnant women to 
avoid medication use for a number of reasons. Estimates from studies in 1995, 2008 and 
2012 showed that 40% of pregnancies worldwide and around half of European pregnancies 
were unplanned [Sedgh et al., 2014]; early pregnancy exposures may therefore occur 
before a woman is even aware of her pregnancy. Medications are also needed before and 
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throughout pregnancy for the treatment of chronic diseases such as asthma, depression, 
diabetes or epilepsy. Furthermore, medication use can be a result of the pregnancy itself, 
for example in the treatment of severe morning sickness or gestational hypertension. Total 
avoidance of medication use during pregnancy is therefore often not possible. 
Furthermore, it may be detrimental to the health of the mother to avoid a medication that 
is incorrectly labelled as carrying a fetal risk. Therefore, the potential risks to the foetus 
must be carefully balanced with the health of the mother.  
Medication use during pregnancy has, in fact, become increasingly common in recent 
decades. A study of the use of prescription and over-the-counter medications during 
pregnancy in the US demonstrated a rise in the average number of 1st trimester 
medications from 1.5 in 1977 to 2.6 in 2007 [Mitchell et al., 2011]. This study showed that 
by 2008, approximately 50% of women had reported taking at least one medication during 
their first trimester. Similar numbers have been reported by studies in other developed 
countries; for example, in a web-based questionnaire designed to examine prescription 
medication use in women in Europe, North and South America and Australia, over 80% of 
women reported taking at least one medication during their pregnancy [Lupattelli et al., 
2014]. Despite their widespread use, however, information on the safety of medicines in 
human pregnancy is often unavailable, particularly for new products. A key reason for this 
lack of information is that pregnant women are usually excluded from pre-marketing 
medication safety studies. A review of research protocols submitted to a single institutional 
review board, for example, found that 90% of submissions involving drug studies 
specifically excluded pregnant women [Schonfeld et al., 2013]. Another study reviewed 
phase IV interventional studies posted on one US website and demonstrated that the 
exclusion of pregnant women from industry-sponsored clinical trials is common, with over 
95% of studies assessed excluding pregnant women, despite studying women of 
“childbearing potential” and not involving a medication classified as possibly teratogenic 
[Shields and Lyerly, 2013]. At the point of licensing a medication for marketing, therefore, 
little or nothing is generally known about the safety for its use during pregnancy. One study 
estimated that over 80% of medications, many of which had been on the market for up to 
20 years, had undetermined teratogenic risk for humans [Lo and Friedman, 2002]. Whilst 
information about reproductive toxicity is sometimes available from animal studies, these 
can be limited in their ability to predict possible risks of CA in humans [Wilson J. G., 1979]. 
For example, studies have demonstrated that rodents are not affected by Isotretonic (a 
treatment for severe acne), but that this substance is highly teratogenic to primates and 
humans [Nau, 2001]. As such, post-marketing surveillance strategies and studies are 
 
23 
necessary. Approaches to post-marketing surveillance have included teratogen information 
services [Schaefer et al., 2005, Chambers, 2011], voluntary adverse event reporting systems 
e.g. the US Food and Drug Administration [US Food and Drug Administration, 2016], 
registries for exposures to particular medications such as antiretroviral or antiepileptic 
drugs [Eldridge et al., 1998] and research studies for specific medications or CAs. These 
post-marketing surveillance strategies have produced important results, but they are 
generally not ongoing or systematic. To address this lack of systematic and continually 
updated knowledge, the potential of the EUROCAT network to carry out CA surveillance in 
Europe regarding medication safety was identified and described in Meijer et al. [2006]. 
Similarly, a study of routinely collected ICBDSR data suggested that international networks 
of CA registries could contribute to post-marketing surveillance of the teratogenicity of 
medications [Lisi et al., 2010]. The authors of these studies concluded that there was 
substantial opportunity for international CA networks to perform systematic and ongoing 
post-marketing surveillance of the fetal effects of medications, and that with existing 
systems and data only limited resources would be required to carry out this additional 
surveillance work. The EUROmediCAT research project was therefore established, building 
on the existing EUROCAT network to establish a European system for the evaluation of 
safety of medication use in pregnancy, in relation to the risk of CAs [de Jong-van den Berg 
et al., 2011]. EUROmediCAT aims to identify potential “signals” of adverse effects at the 
earliest possible stage post marketing, and one of its work packages has therefore 
developed a systematic signal detection method [Luteijn et al., 2016]. This method searches 
thousands of medication-CA combinations for potential associations, using a False 
Discovery Rate (FDR) procedure to adjust for multiple testing.  
Investigation of potential teratogens is part of the wider field of pharmacovigilance, in 
which there has been a vast amount of research and many applications of data mining 
methods to identify adverse drug reactions using spontaneous reporting data [Almenoff 
June et al., 2005]. Since existing knowledge on the teratogenic effect of medicines used 
during pregnancy is generally limited, it is difficult to determine a good reference set of 
known casual associations, on which signal detection methods can be evaluated. 
Classification systems for prescribing medicines in pregnancy have been used in Australia, 
Sweden and the US. These include pregnancy labelling regulations and the introduction of 
risk categories to assign to medications, from those thought to be of “low risk” when taken 
during pregnancy to those medications known to carry a high risk of permanent damage to 
the foetus [Sannerstedt et al., 1996]. The Australian system, for example, provides a 
publicly available database categorising the risks of medicines during pregnancy, which is 
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developed and sustained by medical and scientific experts [Australian Government 
Department of Health, 2016]. However, these types of categorisation systems do not 
identify specific CAs associated with each “high risk” medication, and so there is no “gold 
standard” for classifying risks according to specific CAs. Therefore, assessment of signal 
detection methods for CA data remains challenging. 
1.3. Motivation and rationale for thesis 
Regular and systematic analyses are essential in order to identify changes in the prevalence 
of any specific CA, or medications that might potentially be harmful to a foetus in its critical 
developmental period in early pregnancy. EUROCAT and EUROmediCAT provide a wealth of 
information regarding CAs across many European populations. Their resulting datasets are 
large, requiring careful handling and analysis. It is important that the statistical models used 
at this first stage of surveillance are able to make the most of the available data, and to 
ensure the efficient direction of consequent resources towards the most appropriate areas 
for further research. Any incorrect conclusions drawn may cause unnecessary stress or 
confusion in terms of the advice given to pregnant women; as such, statistically significant 
associations identified need to be confirmed using external data. 
Surveillance of CAs is generally performed using defined sets of subgroups, with many 
studies using the CA subgroups as defined by EUROCAT [EUROCAT, 2011]. These subgroups 
are coded according to a structured hierarchy, e.g. the nervous system CA group includes 
Neural Tube Defects (NTDs), which in turn includes the three subgroups spina bifida, 
anencephaly, and encephalocele. Similarly, the Congenital Heart Defects (CHD) subgroup 
includes specific CAs such as ventricular septal defect, atrial septal defect, and tetralogy of 
Fallot. Several subgroups from different body systems are also known to have a common 
aetiology and are likely to occur together. For example, around 75% of patients with spina 
bifida also have foot deformities, and a number of features of spina bifida (such as 
intrauterine positioning and muscle spasticity) are thought to contribute to the 
development of clubfoot [Broughton et al., 1994, Gunay et al., 2016]. However, despite 
known relationships and the existing coding hierarchy of CA subgroups, current surveillance 
methods examine trends in prevalence, clusters, and associations between risk factors and 
CAs within each subgroup separately [EUROCAT, 2011, Khoshnood et al., 2013, Loane et al., 
2013].  
In the analysis of medication use during pregnancy, there are known similarities between 
certain medications, for example in their chemical properties or particular therapeutic uses. 
Information regarding these factors has informed the classification and coding of 
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medications into the internationally used Anatomical Therapeutic Chemical (ATC) system, 
which was developed jointly by the World Health Organisation and the Nordic Council on 
Medicines [WHO Collaborating Centre for Drug Statistics Methodology, 2011]. The ATC 
system uses codes with up to seven digits to classify medications into a hierarchical system, 
such that codes can be aggregated into groups according to shared properties. Table 1.1 
shows how the ATC codes classify active substances into groups at five levels. The first level 
divides medications into 14 main anatomical groups; the next three levels represent further 
therapeutic/pharmacological/chemical classifications, and the final level gives the chemical 
substance. For example, Level 1 (ATC1) gives a one-digit code representing the main 
anatomical group on which the medication works. However, despite the known 
commonalities among medications, when examining medication risk during pregnancy, 
each medication and each CA is typically examined separately.  
 The classification of active substances into groups at five levels by the 
Anatomical Chemical Therapeutic (ATC) classification system. 







ATC1 Anatomical main group 1 N Nervous system 




4 N03A Antiepileptics 
ATC4 Chemical subgroup 5 N03AG Fatty acid derivatives 
ATC5 Chemical substance 7 N03AG01 Valproic Acid 
 
Since information on known relationships across CAs and medications is not currently being 
incorporated in CA surveillance analyses, important associations or trends might not be 
picked up by current methods. However, the grouping of medications or CAs by their 
potential teratogenic mechanism has been suggested [van Gelder et al., 2010], and the 
incorporation of information on known relationships may increase the number of true 
associations that are detected. For example, consider two CAs that are known to have 
similar aetiologies and which, when considered separately, both show a positive trend that 
is not statistically significant. It is feasible that when considered together in one analysis 
(i.e. sharing information between the two CAs) there may be stronger evidence of a trend 
across both of these CAs. This example highlights how there is potential for CA surveillance 
methods to combine information from several subgroups simultaneously, such that the 
analysis of any particular CA might be improved by considering what is happening in related 
CAs. Natural hierarchies in the ATC system of drug coding may likewise be used to group 
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similar drugs together in the analysis of medication use during pregnancy. Consider, for 
example, a medication for which there is a mild (i.e. not strong or convincing) association 
with a certain CA. It might be useful to also simultaneously consider the relationship of the 
same CA with medications that have a similar chemical make-up or therapeutic use, and/or 
what the effect of that particular medication is on other CAs that may be related (e.g. 
acting on the same part of the body).  
Another aspect of routine statistical monitoring for both CA prevalence and medication 
data is that large numbers of hypotheses are tested simultaneously in both analyses; this 
issue is known as multiple testing. In any situation where large numbers of hypothesis tests 
are being performed, there is a high probability that false positive associations will occur 
when decisions regarding individual hypotheses are based on unadjusted marginal P-values. 
Any potential medication safety concern or change in prevalence of a CA that is identified 
by analysis of routine surveillance data will already, of course, be subject to further detailed 
investigations when evaluating the strength of evidence regarding that particular 
association. However, what is of interest for this thesis is whether information regarding 
the relationships between different CAs and/or medications can be incorporated into the 
analysis at an earlier stage. This information will be used to try and improve the ability to 
identify true associations whilst limiting the workload involved in following up numerous 
false positive associations that may arise from testing multiple CAs and medications in each 
analysis. 
Public health importance 
It is important to continue to improve and refine methodology used to analyse CA data so 
that the most appropriate models are used. This will help to ensure that relevant and 
accurate information is communicated to healthcare providers and expectant mothers, as 
well as any woman who is considering or trying to become pregnant. Continued and 
updated identification of medications that may be harmful to the foetus will directly 
improve patient care. This is particularly relevant to the European population where 
chronic diseases such as asthma, depression and diabetes are leading causes of mortality 
and morbidity [Busse, 2010], and there are therefore large numbers of women requiring 
medication throughout pregnancy to control these conditions. 
Summary 
In summary, the main motivation for this thesis was to investigate whether knowledge 
about similarities between medications and/or CAs can provide logical groupings, which 
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might improve models for routine analysis of (i) trends in CA prevalence and (ii) potential 
signals of teratogenic medications. 
1.4. Use of hierarchical models and Bayesian methods 
This section introduces and summarises the key concepts behind two fundamental 
statistical approaches that are used throughout the thesis: hierarchical models and 
Bayesian statistics. 
1.4.1. What is a hierarchical model? 
Information regarding groupings of medications or CAs may be incorporated into analyses 
using hierarchical models. A hierarchical (or multilevel) model is called such for two 
reasons. Firstly, the data follows a structure that has some kind of nested hierarchy, for 
example, CAs clustered within groups according to which body system they belong. 
Secondly, the model itself has a hierarchy, in that the parameters of one level (e.g. effects 
of the CA itself) are controlled by those of the next level up in the model (e.g. the effects of 
the body system that the CA belongs to) [Gelman Andrew and Hill, 2007]. As such, multiple 
parameters in the model are related by the structure of the problem, and inference about 
one unobserved quantity can affect inference of another unobserved quantity. Figure 1.1 
presents the basic concept of a hierarchical model; on the left of is a non-hierarchical 
model, where 𝑦𝑖  are a set of independent observations treated as draws from a probability 
distribution. These are used to estimate θ, a set of parameters that define the data 




Figure 1.1. Example of a non-hierarchical (left) and a hierarchical (right) model. 
 
On the right hand side of Figure 1.1 is a simple hierarchical model, where the observations 
𝑦𝑖  now fall into 𝑚 groups, and the probability distribution over the outcomes is then 
determined by parameters both across (θ) and within (βj) these groups. An important 
difference is that there is now a second probability distribution across the group-specific 
β parameters, which are generated from a common distribution parameterised by 𝛴𝛽. In 
such a hierarchical model, it is generally expected that observations within any particular 
group will be more similar to each other compared with observations in other groups. 
Estimated parameter values are “fixed” if they are shared or constant across the groups 
(i.e. θ in Figure 1.1), or “random” if allowed to vary across the groups (i.e. 
the βj in Figure 1.1).  
1.4.2. Frequentist and Bayesian approaches 
“Frequentist” statistical inference assumes that observed data are a random repeatable 
sample, with unknown parameters that are fixed and constant across all potential samples. 
The Bayesian approach differs in that the observed data are assumed to be fixed, and the 
model parameters are assumed random. Frequentist inference is therefore based only on 
the sampling distribution of the observed data, whilst Bayesian inference is based on both 
the “likelihood” function of the parameters given the observed data, and some “prior” 
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foundations in Bayes’ theorem, a simple mathematical formula presented by Thomas Bayes 
in the 18th century that is used to calculate conditional probabilities. Bayes’ theorem 
combines the likelihood and the prior into a “posterior” distribution on which Bayesian 
inference is based. Bayesian analysis therefore aims to answer questions about unknown 
parameters using probabilistic statements regarding parameters of the posterior 
distribution.  
Bayesian approaches to reducing the number of errors that arise from multiple testing can 
lead to lower numbers of false positive findings than frequentist methods, in particular, for 
data with small cell counts. This is due to “shrinkage”, a Bayesian phenomenon wherein 
results tend to be biased towards the null [Gelman Andrew and Hill, 2007, Kruschke, 2014; 
section 9.3]. However, this also means that it may be harder to detect some of the true 
positive associations. In Bayesian Hierarchical Models (BHMs) with multiple levels, the 
estimates within each level will also demonstrate shrinkage towards the mean estimates 
for the level; for CA data, this means that the estimates in a group of similar CAs will shrink 
towards the average estimate across those CAs. In frequentist hierarchical models fixed 
effects are estimated directly, as they are for standard regression coefficients. Random 
effects are summarised in terms of their estimated variances, but are not directly 
estimated. Calculations of the variability around the estimates of random effects for 
frequentist models require further approaches such as parametric bootstrapping or 
likelihood profiling, and are therefore not generally reported. The use of simulation-based 
estimation methods in BHMs offers another advantage over frequentist approaches as 
estimates are produced for all model parameters, which can be then directly interpreted 
using their posterior distributions. A measure of uncertainty is thus provided for both 
individual and group level estimates in the form of a posterior credible interval, which can 
then be used as a decision rule to determine whether there are credible differences 
between the individuals and/or the groups [Kruschke and Vanpaemel, 2015]. In general, 
Bayesian approaches to hierarchical modelling are very flexible, and can avoid many of the 
challenging approximations and assumptions of frequentist methods for hierarchical 
modelling [Bolker et al., 2009]. The ability to make direct probability statements from the 
posterior distribution, combined with the ease of defining models specific to any situation, 




Chapter 2:  Thesis aims, objectives and further chapters 
2.1. Aim 
The overall aim of this thesis was to investigate the practicality and value of hierarchical 
modelling approaches that group together similar CAs and/or medications in the analysis of 
CA data.  
2.2. Objectives 
The specific objectives of this thesis were: 
i. To identify and apply suitable BHMs to analyse the change in annual prevalence of 
several EUROCAT CA subgroups simultaneously. 
ii. To compare the performance of models used to fulfil objective (i) to those used 
currently in annual EUROCAT surveillance programmes, which analyse individual CA 
subgroups and registries separately. 
iii. To identify and apply methods that group together CAs and/or medications when 
identifying signals of teratogenic medications in EUROmediCAT data, by: 
a) using a post-analysis FDR adjustment for multiple testing that takes groups 
of medications and/or CAs into account 
b) using BHMs to directly model potential group effects when analysing 
EUROmediCAT data 
iv. To compare the performance of methods used in objective (iii) to each other, and 
to the signal detection system currently used to analyse EUROmediCAT data.  
v. To enable implementation of these methods for use in routine surveillance 
programs, if they demonstrate improved performance over current methods. 
2.3. Outline of thesis chapters 
Further chapters in this thesis are summarised as follows 
❖ Chapter 3 investigates the use of BHMs for the routine analysis of CA prevalence data. 
An overview of methods currently used are first presented. The EUROCAT prevalence 
data are then described, and specific groups of CAs that illustrate interesting situations 
in which grouping CA together may be useful are discussed. BHMs used throughout the 
chapter are then specified, including details regarding the implementation of Bayesian 
models using R and JAGS software. Results from these models are then presented and 
compared to currently used methods of CA surveillance (meeting objectives i and ii). 
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❖ Chapter 4 presents an overview of the use of Bayesian methods in the field of 
pharmacoepidemiology, and identifies how these might be applied to CA surveillance 
data. Signal detection methods currently used for CA and medication data are then 
discussed. Potential improvements to these methods that incorporate information 
regarding groupings of CAs and/or medications are discussed, and the EUROmediCAT 
dataset used for these analyses is introduced and described. Finally, the Australian risk 
categorisation system for prescription of medications in pregnancy is presented, which 
is used to compare the methods of signal detection investigated in chapters 5 and 6. 
Potential drawbacks with the use of this categorisation system to compare these 
methods are highlighted. 
❖ Chapter 5 presents methods, results and discussion of approaches to EUROmediCAT 
signal detection that group similar medications and/or CAs together when determining 
the statistical significance of each test. Various FDR methods that consider groupings in 
their adjustment for multiple testing are specified and then applied to EUROmediCAT 
data. Results are compared to existing methods of signal detection for CA data using 
metrics defined by the Australian risk categorisation system (objectives iiia and iv). 
❖ Chapter 6 presents methods, results and discussion of approaches to EUROmediCAT 
signal detection in which information about groups of similar medications and CAs is 
incorporated using BHMs. Results are compared to those presented in Chapter 5, using 
metrics defined by the Australian risk categorisation system (objectives iiib and iv). 
❖ Chapter 7 provides a final discussion and overview of the research presented in this 
thesis. 
❖ The appendix includes: 
- Supplementary material for Chapters 3-6, including: additional information on 
EUROCAT subgroup coding; examples of R and JAGS scripts; additional details 
for some methods; full results from BHMs and sensitivity analyses; convergence 
plots and diagnostics; supplementary figures and tables. 
- A paper published in a peer-reviewed journal based on findings in Chapter 3 
[Cavadino et al., 2016] 





Publications and future work arising from this thesis 
A mentioned above, the findings presented in chapter 3 have been published in a peer-
reviewed journal [Cavadino et al., 2016]. At the time of submission of this thesis 
(September 2017), the results from chapters 5 and 6 are being written up as a scientific 
papers intended for publication in peer reviewed journals. The double FDR method 
described in chapter 5 is also being implemented in an updated signal detection analysis of 
EUROmediCAT data, which includes additional registries and recent years of data. These 
results will also be published separately.   
 
33 
Chapter 3:  Analysis of EUROCAT congenital anomaly 
prevalence data 
3.1. Introduction 
This chapter begins by describing and assessing the current methods for analysis of trends 
in CA prevalence data. The use of BHMs that group CAs together in these analyses are 
discussed and described. These methods are then applied to EUROCAT data to examine 
whether they offer any improvements over current methods for surveillance of trends in 
prevalence of CAs. 
3.2. Current methods for surveillance of trends in congenital anomaly 
prevalence 
Major CAs are defined by EUROCAT as those that “require surgical treatment (medical), 
have serious adverse effects on health or development (functional), or have significant 
cosmetic impact (cosmetic)” [EUROCAT Central Registry, 2012]. In Europe, over 80 specific 
major CAs are monitored systematically and annually by EUROCAT, a network of 
population-based registries for the epidemiologic surveillance of CAs. A review of the 
objectives and history of the first 25 years of EUROCAT’s CA surveillance is provided by Dolk 
[2005]. One of the aims of statistical monitoring systems is to enable the identification of 
unexpected changes or trends in CA prevalence, as these may indicate the presence of a 
new or unidentified risk factor. This is especially relevant when no specific prior hypotheses 
have been made regarding potential exposures, such that CAs of potential concern can be 
identified for which further resources should then be focussed on. CAs flagged in these 
studies are then subject to more detailed statistical analyses and further investigation by 
individual registries, to try and determine the potential causes of any observed changes in 
prevalence. A reported decrease or increase in the prevalence of a CA, for example, may be 
due to diagnostic or coding changes, and if so this should become apparent upon closer 
inspection of the data and registries involved. As such, statistical monitoring systems are 
also used to assess the impact of preventive measures or screening policies. Annual 
statistical monitoring is hence only one part of CA surveillance; another main aspect is 
hypothesis-driven studies of more specific risk factors and CAs (where such hypotheses may 
arise from findings of the hypothesis-generating statistical monitoring analyses). 
Analyses of the prevalence of CAs are generally done separately for each CA and each 
registry; the ICBDSR, for example, produces an annual report that monitors 39 selected CAs 
separately in each of their member registries, including all member registries submitting 
 
34 
data for that year [ICBDSR, 2014]. In the US, the NBDPN has published national prevalence 
estimates of selected birth defects using data from 1999–2001 [Canfield et al., 2006], and 
updated in 2004–2006 [Parker et al., 2010].The NBDPN does not (as yet) perform statistical 
monitoring across all states in terms of potential changes in CA prevalence. For the analysis 
of changes in prevalence, EUROCAT produces an annual statistical monitoring report in 
which both individual registry results and a crude pooling of the data across all registries 
are presented, with the latest report including data up to the end of 2012 [EUROCAT 
Central Registry, 2015]. Annual statistical monitoring performed by EUROCAT includes 
analysis of both five-year “short term” and ten-year “long term” trends, with pooled results 
providing pan-European estimates of trends in prevalence. 
Poisson regression is well suited to count data with rare events and is therefore frequently 
used to assess trends in CA prevalence [Kirkwood and Sterne, 2003]. Analyses are often 
done separately for each type of CA, whilst handling of data from the different registries 
varies, ranging from separate analyses in each registry to a complete pooling of data across 
all populations. In some studies of specific CAs, for example, registry or country effects have 
been adjusted for by inclusion as covariates in a regression model [Boyle et al., 2013, Loane 
et al., 2013] or specified as random effects in multilevel Poisson regression models [Loane 
et al., 2007]. Random effects Poisson models with linear splines have also been used to 
model long-term trends in NTDs in EUROCAT registries [Khoshnood et al., 2015]. Methods 
other than Poisson regression have also been applied in the analysis of CA prevalence data. 
For example, one study used sequential analysis techniques of cumulative sum and Shewart 
charts to detect changes in prevalence, and found these useful in identifying changes in 
reporting and detecting expected increases over time [Babcock et al., 2005]. However, 
these analyses were also done separately for each type of CA and by four geographical 
regions included in the study. The Cochran-Armitage test for trends in binomial proportions 
was also used to identify potential changes in prevalence of 96 CA subgroups over ten years 
in 21 participating EUROCAT registries [Loane et al., 2011b]. This approach was compared 
to the use of binomial and Poisson regression in a subset of registries and CAs, which 
showed agreement in results for 82% of the tests performed, and differences primarily 
occurring when the observed and/or expected number of cases was below the required 
minimum for the trend test (defined as at least 5 expected and 2 observed cases per 2-year 
interval). Although recognised as a “crude” analysis, the authors considered their methods 
suitable for their purpose of identifying areas requiring further and more careful 
consideration. This highlights that the priority in statistical monitoring analyses performed 
by CA consortia is to attain the highest possible detection rates, rather than focussing on 
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reducing the number of false positive results. The authors also suggest that sophisticated 
statistical techniques can be difficult to implement as routine screening analyses due to the 
insufficient numbers of cases that are often present within small registries or for specific 
types of less common CAs., .   
3.3. EUROCAT data 
Data for analyses in this chapter come from EUROCAT, a European network of population-
based registries established for the epidemiologic surveillance of CAs. In 2012, EUROCAT 
consisted of 43 multiple-source and high-quality registries in 23 countries (Figure 3.1), 
including over 1.7 million births per year and covering around 30% of births in the European 
Union [EUROCAT Central Registry, 2016]. Registries use multiple sources of information to 
ascertain all CA cases, including live birth, fetal death and termination of pregnancy for fetal 
anomaly. Data are obtained through a combination of active case finding and voluntary 
reporting (i.e. case notifications made directly to registries). Sources include hospital 
discharge lists, maternity, neonatal and paediatric centres, cytogenetic laboratories and 
fetal ultrasound screening [Greenlees et al., 2011].  
 





The World Health Organization’s International Classification of Diseases (ICD) is a 
standardised diagnostic classification system that is used worldwide for clinical and 
research purposes. ICD coding includes a chapter on “Congenital malformations, 
deformations and chromosomal abnormalities”; however, this often lacks specific or 
adequate detail for CAs, particularly for genetic syndromes [WHO/CDC/ICBDSR, 2014]. 
EUROCAT and the ICBDSR have consequently defined modified versions of this coding 
system such that their data may be analysed for surveillance and research purposes. The 
EUROCAT data management programme uses the ICD version 9 or 10 (including the British 
Paediatric Association extension where available, giving a supplementary one-digit 
extension to ICD-10 codes to allow greater specificity of coding) to assign all major CA cases 
to EUROCAT CA subgroups, with each case having up to 9 syndrome or malformation codes. 
EUROCAT produces and maintains standardised malformation coding guidelines and 
detailed clinical definitions for each EUROCAT subgroup. These enable pooling of data 
across the different member registries, such that the coding of CAs (which may originally be 
in the form of written text, for example) is standardised to account for differing levels of 
accuracy of information in recording. This translation of local to standardised coding 
requires expert interpretation and knowledge of local conditions for different registries. All 
coding in the data for this thesis was done according to EUROCAT guide 1.3 [EUROCAT 
Central Registry, 2005], which uses a hierarchy of codes to classify all cases of non-minor CA 
into 89 EUROCAT CA subgroups (as of 2012 version of coding; see Appendix Table A1 for 
details of CA subgroups included in this chapter). EUROCAT anomaly subgroups are 
grouped in a hierarchical structure, with CAs from the same body system/organ being 
grouped together. The highest level of EUROCAT coding gives the major organ subgroup, 
within which there are further classes; for example, spina bifida is in the NTD subgroup, 
which is within the nervous system group of CAs. A case may be counted only once in each 
EUROCAT subgroup; however, if a foetus has multiple CAs it can be counted in multiple 
subgroups. In this thesis, cases with a chromosomal CA as well as any other major (non-
chromosomal) CA are only included in the analysis of chromosomal subgroups. Foetuses 
with a chromosomal or other genetic syndrome are excluded from all other analyses since 
they are aetiologically different to “non-genetic” CAs. 
Data was extracted from the EUROCAT database, including all cases with an expected date 
of delivery between 1st January 1983 and 31st December 2012. Full and associate member 
registries with a total prevalence of all CAs of over 2%, available data for at least nine years 
of the time period from 2003 to 2012 and information available on maternal age according 
to five-year age groups for the population were included. These restrictions are based on 
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EUROCAT data quality indicators, which are used to ensure that the data are of sufficient 
quality [Loane et al., 2011a]. The resulting dataset available for this project included 18 
participating registries in 11 countries. The years of data available for each of these 
registries are presented in Figure 3.2. Many registries started contributing data 
considerably later than 1983 and only 6 registries had data covering the whole time period. 
The latest ten years of data were covered by the majority of registries (as per the inclusion 
criteria), with only 2012 not included for Basque country registry. Ten-year trends have 
previously been used to reflect recent “long term” trends in European CA prevalence in 
annual statistical monitoring performed by EUROCAT [Loane et al., 2011b]. Consequently, 
only data from 2003-2012 were considered for analyses in this chapter.  
 
Figure 3.2. Years of available congenital anomaly prevalence data for the 18 EUROCAT 
registries participating in this study.  
3.4. Congenital anomaly subgroups of interest 
Hierarchical methods for the analysis of EUROCAT prevalence data were applied to the 
following groups of CAs; neural tube defects (NTDs), congenital heart defects (CHDs), 
digestive system and chromosomal anomalies. The reasons these specific subgroups are of 
interest for these analyses are described below. Further details on EUROCAT coding and 

























































3.4.1. Neural tube defects 
NTDs are a group of malformations that are caused by the incomplete closure of the neural 
tube during its development, usually within 28 days of gestation [Elwood et al., 1992]. 
Three defects make up the NTD anomaly subgroups according to EUROCAT coding; spina 
bifida, encephalocele and anencephaly (subgroup “anencephalus and similar”). Spina bifida 
is an incomplete closing of the backbone and membranes around the spinal cord, causing 
an array of lifelong disabilities. Encephalocele is a very rare birth defect in which some part 
of the skull does not form properly, allowing part of the brain (and membranes that cover 
it) to protrude through the resulting gap in the skull. Anencephaly is a particularly severe 
NTD where the upper part of the neural tube does not close and large parts of the brain 
and skull do not develop at all, causing babies to be stillborn or die shortly after birth 
[Elwood et al., 1992]. These CAs do sometimes co-occur, in which case EUROCAT coding 
assigns the most severe NTD subgroup code, such that the spina bifida subgroup excludes 
any cases with encephalocele or anencephaly, and the encephalocele subgroup excludes 
any cases with anencephaly [EUROCAT Central Registry, 2005].  
The MRC vitamin study established 25 years ago that folic acid supplementation prior to 
and during early pregnancy can reduce the risk of having a pregnancy with an NTD [MRC 
Vitamin Study Research Group, 1991]. Over 70 countries worldwide have since introduced 
mandatory folic acid fortification programmes, including the US, Chile, Canada and 
Australia. Evidence of significant subsequent declines in NTD prevalence has been 
demonstrated [Honein et al., 2001, Lopez-Camelo et al., 2005, De Wals et al., 2007, Centers 
for Disease Control and Prevention, 2010]. However, no European countries have yet 
introduced mandatory fortification of food with folic acid [Flour Fortification Inititative, 
2017]. Despite existing supplementation recommendations and health campaigns across 
Europe [EUROCAT Central Registry, 2009b], the majority of European women still do not 
take folic acid supplementation prior to conception [Bestwick et al., 2014]. A report on 
differing policy and recommendations on folic acid supplementation and fortification across 
the world concluded that a public health policy of only recommendations alone (i.e. no 
fortification) does not effectively translate into population-wide declines in NTD rates 
[Botto et al., 2006a]. There has therefore been considerable interest in NTD prevalence 
rates across Europe, in particular in comparison to the rest of the world. A recent 
comprehensive systematic review assessing the current global burden of NTDs found that 
prevalence estimates vary widely, including within European registries [Zaganjor et al., 
2016]. Considerable variation in the size and precision of the estimates of prevalence across 
registries was therefore expected in an analysis of European trends. However, the NTDs 
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share similar aetiologies and should be equally sensitive to any changes in folic acid 
supplementation policies. Long-term trends from 1991 and 2011 of NTDs in Europe have 
already been assessed in EUROCAT registries, and the total prevalence of NTDs in 2011 was 
seen to be similar to that in 1991 [Khoshnood et al., 2015]. For this thesis, the effect of 
modelling the NTD subgroups together was assessed in order to determine whether this 
provided any additional useful information, regarding recent ten-year trends of a group of 
CAs where similar overall trends in prevalence are expected. 
3.4.2. Chromosomal anomalies 
Chromosomal anomalies occur when there is a change in the normal structure or number 
of chromosomes. Down syndrome, for example, is the presence of an extra full or partial 
copy of chromosome 21, resulting in a range of mild to moderate developmental 
disabilities. EUROCAT monitors five chromosomal CAs; Down syndrome (trisomy 21), 
Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), Turner syndrome and 
Klinefelter syndrome.  The prevalence of Down, Edwards and Patau syndromes are more or 
less constant up to a maternal age of around 30; after this age, the prevalence of these 
anomalies has been demonstrated to increase exponentially before levelling off again at 
around age 45 [Savva et al., 2010]. The average age of women giving birth in Europe has 
been steadily rising since around 1980 [Breart, 1997], and increasing maternal ages have 
thus led to greater numbers of affected pregnancies [Loane et al., 2013]. For these analysis, 
it was therefore expected that the chromosomal subgroups would show increasing trends if 
maternal age was not accounted for. This provided a scenario in which a similar trend in 
each of a group of related CAs was expected, and it was of interest to examine the effect of 
hierarchical models in this setting. Chromosomal anomalies were also considered as a 
group including only the three autosomal trisomies (trisomy 21, 18 and 13), for which the 
relationship with maternal age has been most clearly established [Loane et al., 2013].  
3.4.3. Digestive system anomalies 
The most recent EUROCAT statistical monitoring report included data up to the end of 
2012. In this report, similar increasing trends were found for three of the digestive system 
anomaly subgroups; oesophageal atresia with or without trachea-oesophageal fistula was a 
newly identified trend, and duodenal atresia and stenosis and ano-rectal atresia and 
stenosis were both identified as continuing increasing trends that had been present in the 
previous years’ statistical monitoring report [EUROCAT Central Registry, 2015]. There were 
a further five digestive system subgroups, for which no significant changes in prevalence 
were observed. The application of hierarchical models to all of the digestive system CAs 
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was therefore considered, as an example of a group of CAs where there are known trends 
in some (but not all) of the subgroups. 
3.4.4. Congenital heart defects 
CHDs make up the largest group of CAs, accounting for nearly a third of all major CAs [Dolk 
et al., 2011]. They are a large and heterogeneous group of CAs, which vary widely in terms 
of their prevalence, severity, morbidity and mortality. EUROCAT coding defines 16 standard 
CHD subgroups that have previously been grouped using a hierarchical severity ranking 
according to perinatal mortality rates in non-chromosomal cases. This is formed of three 
ordered groups from severity I (high perinatal mortality) to severity III (low perinatal 
mortality) [EUROCAT Central Registry, 2009a]. Severity I indicates CHDs with high perinatal 
mortality, comprising single ventricle, tricuspid atresia and stenosis, Ebstein’s anomaly, 
hypoplastic left heart and hypoplastic right heart. Severity II includes common arterial 
truncus, transposition of great vessels, atrioventricular septal defect, tetralogy of Fallot, 
pulmonary valve atresia, aortic valve atresia/stenosis, coarctation of aorta and total 
anomalous pulmonary venous return. Severity III indicates low perinatal mortality, including 
ventricular septal defect, atrial septal defect and pulmonary valve stenosis. Around 5% of 
all CHD cases are not included in any of the severity categories because they are subtypes 
of CHD that are not standard EUROCAT subgroups. There is also a EUROCAT anomaly 
subgroup defined as “severe CHD”, which includes all CHD subgroups in severity groups I 
and II (i.e. the two more severe groupings as described above). In the 2015 EUROCAT 
statistical monitoring report, increasing trends were found in the severe CHD group as well 
as in a number of the more specific CHD subgroups, including single ventricle, tetralogy of 
Fallot and atrioventricular septal defects [EUROCAT Central Registry, 2015]. For the current 
analyses, it was of interest to see how hierarchical models would perform with a large and 
heterogeneous group of CAs. A two level hierarchy that additionally included the grouping 
of CHDs by the severity subgroups was also considered. 
3.5. Methods 
Prevalence in EUROCAT analyses was calculated as follows, and is presented as prevalence 
per 10,000 births unless otherwise stated 
Total Prevalence =
Number of cases (LB+FD+TOPFA)
Number of births (live and still)
 x 10,000 
where cases = cases of CA in population, LB = live births, FD = fetal deaths, TOPFA = 
termination of pregnancy for fetal anomaly and the denominator includes all live and still 
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births in the population as declared on official birth registrations. Note that terminations of 
pregnancy for fetal anomaly are included in the numerator but not the denominator, 
leading to small discrepancies between the two. Such discrepancies, however, are not 
considered large enough to have an important effect on prevalence. Confidence intervals 
(CIs) for total prevalence estimates were calculated using the numbers of cases and births 
with the lower and upper 95% confidence limits defined by the Poisson distribution 
[Begaud et al., 2005] as follows 
95% CI = (
(
1.96
2 −  √𝑐𝑎𝑠𝑒𝑠 + 0.02)
2
𝑏𝑖𝑟𝑡ℎ𝑠
 x 10,000,  
(
1.96
2 +  √𝑐𝑎𝑠𝑒𝑠 + 0.96)
2
𝑏𝑖𝑟𝑡ℎ𝑠
 x 10,000) 
Poisson regression models were used to analyse trends in the prevalence of CA data. 
Methods of analysis currently used for statistical monitoring of trends in prevalence were 
compared to hierarchical models for groups of CAs detailed in the previous section. The 
latest ten years of data were assessed in order to reflect the latest “long term” trends in 
European CA prevalence, as done in annual statistical monitoring performed by EUROCAT. 
All data management and cleaning was performed using Stata, version 12 [StataCorp, 2011] 
The different models applied to each group of CAs are specified in detail below. 
3.5.1. A Poisson regression model for analysis of prevalence rates 
The Poisson distribution is commonly used to model variation in count data, describing the 
number of occurrences of an event during a specified time period or region [Kirkwood and 
Sterne, 2003]. For this chapter, prevalence rates were modelled for the number of cases of 
CAs each year, so the logarithm of the total births (including live and stillbirths) was 
included as an offset in models to account for the differing population size in each registry 
and each year, therefore modelling the relative prevalence of disease. If 𝑟𝑡 is the prevalence 






 . The classic Poisson 
regression model for these data was then specified as 
𝑦𝑡~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑡) = 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝑟𝑡𝑝𝑡) 
With the log link function such that the transformed mean followed a linear model 
log(𝜆𝑡) = 𝜇𝑡 = log(𝑝𝑡) + 𝛽0+𝛽1𝑥𝑡 
The units 𝑡 specify the year 𝑡 = 1, … , 𝑇 for a total period of T years, 𝑦𝑡 is the number of CA 
cases for year 𝑡 in a process with prevalence rate 𝜆𝑡 and total births (the relative 
“exposure”) 𝑝𝑡. Then log(𝑝𝑡) is the model offset, 𝜆𝑡 is the average yearly prevalence and 
the coefficient 𝛽1of 𝑥𝑡 is the expected log difference in 𝑦𝑡 for each additional unit of 𝑥𝑡, i.e. 
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the estimated average annual change in number of cases (on the log scale). In all models, 
the predictor variable 𝑥𝑡 was centred, such that the intercept 𝛽0 represents the expected 
log prevalence rate in the mean year across all observations. If this variable were 
uncentered, the intercept would represent the expected rate in year “0”, which is clearly 
not realistic or interpretable. 
Adjustment for multiple testing in Poisson models 
A multiple testing correction was applied to adjust the 95% CIs from individual Poisson 
models to account for multiple testing within each group of related CAs. Adjustments to CIs 
for individual models were done using a simple Bonferroni correction. In practice this 
means that instead of a 95% confidence level, a (1 −
𝛼
𝑘
) % interval was used, where 𝑘 is 
the number of tests in each group and α = 5% (see Appendix A1 and Table A2 for further 
details).  
Overdispersion in Poisson models 
A defining characteristic of the Poisson regression model is that it does not have a scale 
parameter, but the mean is restricted to be equal to the variance. This restriction often 
does not hold in practice, with the variance differing from the mean such that any extra 
between-subject variability beyond that explained by covariates in the model may be 
unaccounted for. Under- or overdispersed models can be used to account for this 
additional variability in cases where the conditional variance is substantially different to the 
conditional mean. A simple comparison of the sample mean and variance of the dependent 
count variable can give an indication of whether the data are over- or underdispersed. A 
crude test for dispersion in a generalised linear mixed model (GLMM) can also be 
performed by comparing the sum of squared Pearson residuals to the residual degrees of 
freedom, which are assumed to be equal if the data are equi-dispersed [Cameron and 
Trivedi, 2013]. A simple chi-square test can be performed on the ratio of these values, with 
the important caveat that due to issues with counting the number of parameters (and 
therefore degrees of freedom) in a GLMM, such a test should be considered approximate.  
Two common approaches to deal with overdispersed data are the use of quasi-Poisson or 
negative binomial models [Gelman Andrew and Hill, 2007]. In R, the quasi-Poisson model 
with estimated dispersion parameter can be fitted with the glm() function, by setting 
family=quasipoisson. This estimates a scale parameter from the data using a method of 
moments estimator, but is not maximum likelihood estimation and so model checks such as 
likelihood ratio tests or assessment of deviance cannot be used. A quasi-Poisson model can 
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be specified as follows, where estimates for the coefficients are unaffected but the 
overdispersion parameter 𝜙 is used to correct the standard errors 
𝑌 ~ 𝑄𝑃(𝜇, 𝜙),  𝐸[𝑌] = 𝜇, 𝑉𝑎𝑟(𝑌) = 𝜙𝜇 
The negative binomial model [Ross and Preece, 1985] allows the rate of events 𝜇 to vary 
across subjects by including a random subject effect in the model. The rate for each subject 
is then assumed to follow a gamma distribution, with dispersion parameter 𝛼 
𝑌 ~ 𝑁𝐵(𝜇, 𝛼),   𝐸[𝑌] = 𝜇,  𝑉𝑎𝑟(𝑌) = 𝜇 +  𝛼𝜇2 
When 𝛼=0, the negative binomial distribution coincides with the Poisson distribution. In the 
quasi-Poisson model, the mean is linearly related to the variance, whilst in the negative 
binomial model this relationship is quadratic. Gelman Andrew and Hill [2007; section 14.4 & 
15.1] describe how a data-level variance component can also be used to directly model 
overdispersion in a hierarchical model. This has elsewhere been referred to as a generalised 
Poisson [Martina et al., 2015] or Poisson-lognormal [Elston et al., 2001] model. In this 
formulation, the Poisson regression model, as described in 3.5.1, is extended by introducing 
an additional term 𝜀𝑡  to the log link function 
𝑦𝑡~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑡) 
log(𝜆𝑡)  =   𝜇𝑡 + 𝜀𝑡 =  log(𝑝𝑡) + 𝛽0+𝛽1𝑥𝑡 + 𝜀𝑡  
𝜀𝑡~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝜀
2) 
The size of the standard deviation 𝜎𝜀 associated with this new parameter 𝜀𝑡 can give an 
idea of how overdispersed the model is. When 𝜎𝜀 = 0, the Poisson-lognormal model 
reduces to a classic Poisson regression model. Functionally, the Poisson-lognormal model is 
similar to a negative binomial model [Ver Hoef and Boveng, 2007], and the improvement in 
model fit for the additional term in the model can be assessed using a deviance test.  
Models allowing for overdispersion were investigated to determine which type of model 
was most sensible for use throughout these analyses in this chapter. This was done using 
the CA subgroup encephalocele, as an example of a rare CA for which accounting for 
potential overdispersion may be useful. In all other analyses, models continued to be 
monitored for evidence of departures from dispersion, which could then be investigated in 
more detail as required. 
Zero-inflation in Poisson models 
CA prevalence data can potentially contain large numbers of zero counts due to under-
recording [Cameron and Trivedi, 2013]. For example, very rare CAs can be difficult to 
diagnose; if a particular anomaly is seen only occasionally then it may be less likely to be 
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recognised or correctly diagnosed when it does arise. In addition, there may be an excess of 
zeros due to the policy of specific registries not to record specific CAs. Issues of under-
recording and excess of zero count data have led to the development of zero-inflated 
[Lambert, 1992] and hurdle [Mullahy, 1986] models. These methods assume that the excess 
zeros are generated by a separate process from the count values and can therefore be 
modelled independently. Club foot, for example, might be considered in this context as this 
CA subgroup has known underreporting due to the policy of specific registries not to record 
cases of this particular anomaly (for example the Northern England registry), potentially 
resulting in zero inflated data. However, if a registry does not record a particular CA then 
this registry does not contribute to the analysis of this CA (since the observed and expected 
counts are both zero). This is not a clear logical reason for there to be an excess of zeros in 
the data that could be generated by a separate process from the count values. Zero-inflated 
models were therefore not considered appropriate for these analyses and were not 
investigated further.  
3.5.2. Bayesian hierarchical models for congenital anomaly data 
Hierarchical models  
Hierarchical or multilevel models are extensions of regression for data that has a 
hierarchical or clustered structure, in which model coefficients are allowed to vary 
according to these clusters or groupings. Clustered data arise when information can be 
classified into a number of groups (the clusters) based on certain characteristics of the 
group members, for which individuals within the same group are more similar to each other 
than to individuals in other groups. For example, children from the same family might be 
more similar to each other in terms of their physical and/or mental characteristics than 
children in other families. Hierarchical models allow for such structures in data by including 
residual components at each level, i.e. at both the child and the family level. The residual 
variance is split into two parts; the within-family variance (for the child-level residuals) and 
the between-family variance (for the family-level residuals). The family-level variance 
represents unobserved family characteristics that may affect the outcomes of the children, 
leading to correlations between the outcomes of children in the same family. The key 
difference between classic regression and hierarchical models is the modelling of the 
variation between the groups of similar individuals. Traditional alternatives for analysing 
data with a hierarchical structure are complete pooling, which ignores differences between 
groups, or no pooling, where each group is analysed in a separate model [Gelman Andrew 
and Hill, 2007]. For this chapter, hierarchical models allowed the grouping of similar CAs 
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together, essentially re-estimating the trend for each CA by combining information about 
its own prevalence with the overall information of all other CAs in a group. Each individual 
estimate incorporates a weighted average of the estimates for all CAs in the group, and 
estimates are therefore “pulled in” towards the overall group mean. This reduction in the 
variance of the estimates within a group is an effect known as shrinkage [Gelman Andrew 
and Hill, 2007, Kruschke, 2014; section 9.3]. Information from other members of the group 
can remove some of the uncertainty in estimates for group members with limited amount 
information, for example for rare CAs with small numbers of cases. Statistically significant 
effects in a non-hierarchical model might also be diminished when the group distribution is 
taken into account; shrinkage can therefore help in reducing false-positive results.  
Hierarchical modelling of count data can be done in a frequentist setting using GLMMs, 
which combine linear mixed models and generalised linear models in order to handle non-
normally distributed data that has a clustered or hierarchical structure. An assumption of 
GLMMs is that the parameters follow a multivariate normal distribution, such that the 
sampling distribution of the log likelihood is proportional to a chi-square distribution; tests 
for P-values of the fixed effects are therefore approximate, and for random effects no such 
estimates are generally reported. Methods of calculating the variability around the 
estimates of random effects in GLMMs include parametric bootstrapping and likelihood 
profiling [Bates D, 2015]. Another approach to inference for GLMMs is the use of Bayesian 
posterior sampling, which offers several advantages over frequentist methods; see Gelman 
Andrew and Hill [2007] for a comprehensive discussion about this. Amongst other features, 
BHMs are highly flexible, they allow direct probability statements to be made about the 
parameters of interest and can avoid some of the approximations and assumptions (e.g. 
reliance on the asymptotic approximation) of frequentist methods. For this thesis, 
therefore, BHMs were used to calculate the variability around the random effects 
estimates, and bootstrapping and likelihood profiling were not used. 
Bayesian models and the use of simulation-based estimation methods  
The Bayesian approach to statistical inference considers parameters as random variables 
that can be characterized by prior distributions based on previous beliefs or prior 
knowledge about the parameter of interest, combined with the likelihood function of the 







Here 𝑝(𝜃) is the prior probability density summarising prior knowledge about the 
parameter of interest, 𝑝(𝑦|𝜃) is the likelihood function of the parameters give the 
observed data, and 𝑝(𝜃|𝑦) the posterior density. The marginal likelihood 𝑝(𝑦) is the 
integral of 𝑝(𝑦|𝜃)𝑝(𝜃) over all values of 𝜃, and is regarded as a normalising constant which 
ensures that 𝑝(𝜃|𝑦) is a proper density [Congdon, 2007]. Bayes theorem can then be 
expressed as 
𝑝(𝜃|𝑦) ∝ 𝑝(𝑦|𝜃)𝑝(𝜃) 
In this equation, the relative influence of the data and the prior beliefs depend on both the 
“strength” of the data and how informative the prior is, i.e. how much weight is given to 
the prior belief in terms of its probability distribution. In Bayesian inference, therefore, 
priors are combined with the observed data to obtain “updated knowledge” in the form of 
the posterior probability distribution for the parameter of interest as follows 
𝑝(𝜃|𝑑𝑎𝑡𝑎) ∝ 𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑(𝜃) 𝑥 𝑝𝑟𝑖𝑜𝑟(𝜃) 
Calculation of the posterior distribution is done analytically if the combination 
(multiplication) of the prior distribution and the likelihood form a known distribution, i.e. 
one that can be summarised and graphed and which inferences can then be drawn from. 
There are certain well-known combinations of likelihood functions and probability 
distributions that, when multiplied together, give the same form of posterior distribution as 
the prior. These are known as conjugate priors [Raiffa and Schlaifer, 1961]. For example, a 
Normally distributed prior for a mean combined with a Normally distributed likelihood for a 
mean produces a Normally distributed posterior, where the posterior mean is then a 
weighted average of the two means, and the posterior precision (the inverse of the 
variance) is the sum of the two precisions. However, a posterior distribution can also have a 
more complicated expression if it is not possible to represent prior beliefs using a 
distribution that is a known conjugate. In such cases, statistics are often difficult to directly 
calculate and the density function may not be easily drawn. Alternative methods for 
summarising characteristics of the posterior distribution have therefore been developed, 
such as asymptotic approximations, numerical integration and sampling methods [Tierney, 
1994]. Simulation based sampling or Monte Carlo methods involve the generation of 
repeated samples that approximate or converge to a “target” posterior distribution. 
Parameters of interest are then estimated using characteristics of a random sample drawn 
from the posterior distribution [Congdon, 2007]. Sampling from a distribution can be done 
using a Markov Chain, which is a sequence of random draws 𝜃(1), 𝜃(2), … , 𝜃(𝑇) such that 
each value depends only on the value of the previous draw 
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𝑓(𝜃(𝑡+1)|𝜃(𝑡), … , 𝜃(1)) = 𝑓(𝜃(𝑡+1)|𝜃(𝑡)) 
The two most widely used Markov Chain Monte Carlo (MCMC) methods to generate 
samples from the target distribution are the Metropolis-Hastings algorithm [Hastings, 1970, 
Chib and Greenberg, 1995] and Gibbs sampling [Geman and Geman, 1984, Casella and 
George, 1992].  
The Metropolis-Hastings algorithm simulates a Markov chain for the parameter of interest 
𝜃 with target posterior distribution 𝑓(𝜃|𝑦), and is described by Ntzoufras [2009; page 43] in 
the following steps 
1. Set the initial values 𝜃(0) 
2. For t=1,…,T  
(a) Let 𝜃 = 𝜃(𝑡−1) 
(b) Generate new candidate values 𝜃′ from a proposal distribution  
𝑞(𝜃′|𝜃) 
(c) Calculate an acceptance probability 




(d) Update 𝜃(𝑡) = 𝜃′ with probability 𝛼; otherwise set 𝜃(𝑡)= 𝜃 
The Gibbs sampler is a special case of the Metropolis-Hastings algorithm that uses the full 
conditional distribution for the proposal distribution. This always results in an acceptance 
probability of 1, so the proposed candidate value is always accepted and the sampler 
moves to a new value at every step. However, since parameters are updated one at a time, 
this can lead to high autocorrelation, slow convergence and imprecise estimates. This can 
be particularly problematic when posterior parameters are highly correlated as it can be 
difficult to change the value of one of the correlated parameters without simultaneously 
changing the other. A disadvantage of Gibbs sampling, therefore, is that it can sometimes 
be ineffective when the posterior parameters are highly correlated. 
Implementation of Bayesian models using JAGS 
Just Another Gibbs Sampler (JAGS) is a programme for analysis of Bayesian models that 
uses MCMC methods [Plummer Martyn, 2003]. JAGS uses a Gibbs Sampling approach with 
several techniques that either enforce or substitute the standard Gibbs Sampler, for 
example slice sampling [Neal, 2003] or adaptive rejection metropolis sampling [Gilks et al., 
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1995]. For this thesis, JAGS was used to implement Bayesian models, along with the rjags 
package in order to work directly with JAGS from within the R language and environment. A 
JAGS model uses Bayesian inference Using Gibbs Sampling (BUGS) language, in which 
models are specified using the precision τ as a parameter for the Normal distribution rather 
than the variance 𝜎2. The precision is the inverse of the variance, i.e. 𝜏 =
1
𝜎2
. For example, a 
Normal distribution with mean 0 and variance 1002 is identified in BUGS language using 
dnorm(0,0.0001). Options to consider in the initialisation of a JAGS model include how 
many parallel chains to run and what initial parameter values should be used (i.e. the 
starting point for each chain). Using multiple chains with different starting points is 
recommended in order to determine how well the chains have mixed [Brooks, 1998]. In 
order to reliably detect convergence to the target (stationary) distribution, initial values 
should be chosen that are overdispersed with respect to the target distribution [Gelman 
Andrew and Rubin, 1992]. A random number generator can be used along with a set seed 
for each chain, in order to make output from a model reproducible. A sampler then acts on 
the set of parameters in the model, updating these at each iteration. An adaptive phase can 
be used at the start of the sampling process, whereby samplers used by the model are 
allowed to change in order to maximise their efficiency. Following this adaptive phase, 
MCMC output is generally divided into two parts: an initial burn-in period is discarded and 
the rest of the sample, where the output is considered to have converged sufficiently 
closely to the target distribution, is used to calculate posterior estimates. The R and JAGS 
code used to run all models in this chapter (as specified in section 3.5.3) is displayed in 
Appendix Table A3. An example of a JAGS script used to run a BHM in this chapter is 
presented in Appendix A4. 
“Statistical significance” in Bayesian models 
Uncertainty in Bayesian models is quantified via probability distributions, so the reporting 
of results is in terms of direct probability statements about the parameter values. This is 
done by calculating the area of the posterior distribution to the right (or left) of a 
parameter value, which is simply the proportion of values in the posterior sample for that 
parameter which are greater (or less) than that value. This information is used to report 
results of Bayesian models as means and 95% posterior credible intervals (PCIs) for the 
parameter estimates. The mean estimate, for example, is the average estimate over the 
whole of the posterior distribution, and the 95% PCI is the range from the 2.5th to the 97.5th 
percentile values. In this thesis, if the 95% CI (for frequentist models) or 95% PCI (for 
Bayesian models) did not include zero then this was considered a “statistically significant” 
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average annual change in prevalence. Note that, in contrast to individual Poisson models, 
adjustment for multiple testing was not done for hierarchical models. This is because each 
group of related CAs are tested together in one model rather than in a number of individual 
tests, hence when each individual CA is considered, the shrinkage to the mean (across the 
group of CAs being tested) already provides some level of correction.  
Choice of prior distribution 
Stipulating prior distributions in a Bayesian analysis is important because, together with the 
likelihood, these influence the posterior distributions on which we make inferences about 
parameters of interest. Prior distributions can be defined conveniently using parameters 
such as means and variances. If an estimate is believed to be accurate then the variance 
parameter for a prior distribution should be set as a low value and, conversely, where there 
is a large amount of uncertainty around the estimate a high value should be chosen. There 
is sometimes prior information available about a parameter of interest, for example 
through expert opinion or data from previous studies. If such information is available, it 
should be appropriately summarised by the prior distribution. “Informative” priors have a 
greater influence on the posterior distribution, which is less dominated by the likelihood 
when there is more information in the prior. It is often the case, however, that there is no 
such prior information available, in which case a prior distribution with minimal impact on 
the posterior should be chosen. These distributions are commonly called non-informative 
or vague priors, and these enable Bayesian methods to infer estimates for parameters in 
analyses where there is no further information beyond the data available [Gelman A., 
2006]. Non-informative priors are often thought of as reference models, in that they are a 
starting point in lieu of more informative prior distributions, as considered appropriate for 
“fully Bayesian” analyses [Bernardo, 1979]. For analyses in this thesis, prior distributions 
were chosen such that they did not disproportionately affect posterior distributions, 
generally known as vague or non-informative priors. However, these do contain some 
information, for example restriction of the prior variance to a certain range. As these priors 
did provide models with some level of information they are therefore referred to as 
“minimally” informative. The use of uniform prior distributions for the variance parameters 
in BHMs has been recommend [Gelman A., 2006], and were used throughout the analyses 
in this chapter.  
Convergence diagnostics for Bayesian models 
Parameter inference from the posterior distribution is only valid for MCMC chains that have 
converged to their stationary (target) distribution. The coda package [Plummer Martyn et 
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al., 2003] was used to assess model convergence and summarise the sample posterior 
distribution for each parameter in Bayesian models. Commonly used convergence 
diagnostics implemented in coda were considered. The Gelman-Rubin diagnostic, for 
example, aims to identify lack of convergence using multiple parallel chains by calculating 
the potential scale reduction factor (PSRF) separately for each parameter. The PSRF 
compares the within and between-chain variances, which should be similar if all chains 
have achieved convergence to the target distribution. A large PSRF indicates that the 
between-chain variance is substantially greater than the within-chain variance, meaning 
longer simulations are required to achieve adequate convergence. Chains are considered 
“stable” and likely to have reached their target distribution if the PSRF is close to 1. The 
Heidelberger-Welche and Raftery-Lewis diagnostic tests are used to indicated how long the 
“burn in” and total sample run (i.e. number of iterations) should be, based on accuracy of 
the estimation of the mean and quantiles of the posterior distribution, respectively 
[Plummer Martyn et al., 2003]. 
Autocorrelation is the correlation of a time series with its own past and future values. This 
can be problematic in MCMC sampling, where high values of autocorrelation within chains 
indicate slow mixing and convergence. High autocorrelation means parameter values at 
successive steps in a chain do not give independent information about the posterior, i.e. 
the chain is not changing much from one step to the next. It can be useful to “thin” a chain 
with high autocorrelation before calculating summary statistics, which involves keeping 
only one value out of every mth step in the chain and discarding all other sampled values. A 
thinned chain takes up less computing memory and can give a more precise estimate of the 
posterior sample, but is generally less efficient than using full chain [Link and Eaton, 2012]. 
It is important to have an idea of how much independent information is contained in each 
chain and one measure of this is the effective sample size, an estimate of what sample size 
would be required for a completely non-autocorrelated chain to give the same amount of 
information [Kruschke, 2014. Section 7.5.2]. The effective sample size is obtained by 
dividing the actual sample size (i.e. number of iterations in a chain) by the amount of 
autocorrelation 
𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒 𝑆𝑎𝑚𝑝𝑙𝑒 𝑆𝑖𝑧𝑒 =
𝑁
1 + 2 ∑ 𝐴𝐶𝐹(𝑘)∞𝑘=1
 
Here ACF(k) is the autocorrelation of the chain at lag  𝑘, i.e. two values 𝑘 steps apart from 
each other in the chain. An effective sample size of around 10,000 has been recommended 
as being generally sufficient for accurate and stable estimates of the 95% PCI for parameter 
values [Kruschke, 2014]. Convergence, mixing of chains and autocorrelation were also 
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assessed visually. Trace plots were examined for all models parameters to ensure 
appropriate mixing of chains, given dispersed starting values. Trace plots simply plot the 
sampled values for each iteration in each chain. Density plots of the posterior distribution 
for parameters were also used to assess the shape of the posterior distributions.  
Based on the above convergence and autocorrelation diagnostic checks, the posterior 
sample was trimmed and thinned as required, and the posterior distributions were 
summarised in order to obtain estimates for all parameters of interest.  
Evaluation and comparison of models 
Evaluation of overall goodness-of-fit and model complexity can be done using measures 
such as the deviance, a measure of error in which lower values indicate a better fit to the 
data. The deviance is defined as -2 times the logarithm of the likelihood function [Gelman 
Andrew and Hill, 2007] 
𝐷(𝜃) = −2 𝑙𝑜𝑔{𝑝(𝑦|𝜃)}  
Akaike Information Criterion (AIC) is a measure of model fit that includes a penalty based 
on the number of parameters 𝑘 in order to discourage overfitting [Akaike, 1973] 
𝐴𝐼𝐶 = −2 𝑙𝑜𝑔{𝑝(𝑦|𝜃)} + 2𝑘 =  𝐷(𝜃) + 2𝑘 
where 𝜃 is the maximum likelihood estimate of 𝜃. AIC is useful in comparison of non-nested 
models, and lower AIC values indicate models that give a better fit to the data. The concept 
of AIC and deviance also apply to hierarchical models, although in this setting the number 
of parameters is not so clearly defined, since this is dependent on the amount of pooling in 
the hierarchical model. The conditional Akaike information criterion (cAIC) has been 
proposed as an adjustment to the AIC, where the random effects structure of multilevel 
models are taken into account in the estimation of the number of parameters in the model 
[Vaida and Blanchard, 2005]. Various extensions to the cAIC for GLMMs are described by 
Saefken et al [2014] and are implemented using the R package cAIC4, which uses an 
analytical estimator to calculate the degrees of freedom [Saefken and Ruegamer, 2014]. 
The Deviance Information Criterion (DIC) can be thought of as a Bayesian hierarchical 
modelling equivalent of the cAIC, and is defined as the expected deviance ?̅? plus the 
effective number of parameters in the model 𝑝𝐷 [Spiegelhalter et al., 2002] 
𝐷𝐼𝐶 = 𝐷(?̅?) + 2𝑝𝐷 =  ?̅? + 𝑝𝐷 
The effective number of parameters 𝑝𝐷 gives an impression of the overall size or 
complexity of the model, and this quantity depends on the variance of group-level 
parameters in a model. This is not appropriately captured by AIC because of the presence 
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of random effects in hierarchical models. In a simple hierarchical model with one group of 
estimates, for example, the effective number of parameters may be anything from 1 (the 
average estimate across the group) up to the total number of estimates in the group. The 
definition of 𝑝𝐷 implemented by rjags is that proposed by Plummer M [2002]. As with AIC, 
models with lower DIC are preferable, with 𝑝𝐷 favouring models with less parameters in 
order to compensate for the decrease in DIC due to the value of the expected deviance (i.e. 
favouring a good fit of the model to the data). The cAIC and DIC were monitored for 
frequentist and Bayesian models, respectively. 
3.5.3. Model specifications 
Grouping of CAs according to hierarchies in the EUROCAT subgroup coding were 
considered, with results from the models outlined in Table 3.1 being compared. GLMMs for 
model 3 and 4 were implemented in R using the glmer command in the lme4 package 
[Bates D, 2015]. BHMs were run using JAGS via the R package rjags. Examples of R and 
JAGS code for each model are displayed in Appendix Table A3. A full description and 
specification of each model is presented in detail in this section and summarised in 
Appendix Table A4. An example of a script that was used to run a BHM (model 5) for this 




 Summary of models evaluated in Chapter 3 for routine analysis of trends in 
the prevalence of congenital anomalies (CAs). 
Model Model name Model description 
1 Individual models 
Separate Poisson regression models for each 
CA, pooling over registry 
2 Individual models + registry 
Separate Poisson regression models for each 








model + registry 
Poisson model for multiple CAs, including a 
random effect for registry 
5 Bayesian hierarchical model 
Bayesian Poisson model for multiple CAs, 
pooling over registry 
6A 
 
Bayesian hierarchical model 
+ registry (A) 
Bayesian Poisson model for multiple CAs, 
including random effect for registry.  
Random intercepts for registry (across all CAs) 
and for CA subgroup (across all registries) are 
included separately 
6B 
Bayesian hierarchical model 
+ registry (B) 
Bayesian Poisson model for multiple CAs, 
including random effect for registry.  
Each anomaly-registry combination is allowed a 
separate random intercept 
 
Model 1: Individual models  
Model 1 was a separate Poisson regression for each CA subgroup, pooling over registry to 
model prevalence rates in years 𝑡 = 1, … , 𝑇 for a total time period of 𝑇 years 
𝑦𝑡~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑡) 
With the log link function 
log (𝜆𝑡) = log(𝑝𝑡) + 𝛽0+𝛽1𝑥𝑡 + 𝜀𝑡  
𝜀𝑡~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝜀
2) 
Here 𝑦𝑡 was the number of CA cases for year 𝑡 in a process with prevalence rate 𝜆𝑡 and 
total number of births 𝑝𝑡. The coefficient 𝛽1of 𝑥𝑡 was the estimated average annual change 
in number of cases (on the log scale), and the intercept 𝛽0 represented the expected log 
prevalence rate in the mean year across all observations due to the predictor variable 𝑥𝑡 
being centred (i.e. 𝑥𝑡 was the difference between the year 𝑡 and the mean of all the years 
included in the model 𝑡 = 1, … , 𝑇). The term 𝜀𝑡 was included in the log link function to 
account for potential overdispersion (see section 3.5.1). This additional term was included 
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in practice by the addition of a unique identifier for each observation as a random term in 
the model.  
Model 2: Individual models + registry  
Model 2 consisted of separate Poisson regression models for each CA, but additionally 
included a random effect to account for heterogeneity in the prevalence rates. This was in 
order to account for heterogeneity in the prevalence rates but not in the trends, which 
were here assumed to be the same for all registries. This was done for 𝑗 = 1, … , 𝐽 registries, 
such that 
𝑦𝑡𝑗~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑡𝑗) 
log(𝜆𝑡𝑗) = log(𝑝𝑡𝑗) + (𝛽0 + 𝑢𝑗) + 𝛽1𝑥𝑡𝑗  + 𝜀𝑡𝑗  
 𝑢𝑗 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝑗
2),  𝜀𝑡𝑗 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝜀
2) 
In this model, the term 𝑢𝑗 denotes the random intercepts for each registry. These were 
assumed to follow a normal distribution with zero mean and standard deviation 𝜎𝑗
2. All 
other terms are as described in model 1.  
Model 3: Frequentist hierarchical model 
Model 3 was a hierarchical Poisson model that groups similar CAs together, with random 
effects for each CA and data being pooled over registry. The model for 𝑘 = 1, … , 𝐾 CAs was 
defined as 
𝑦𝑡𝑘~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑡𝑘) 
log(𝜆𝑡𝑘) = log(𝑝𝑡𝑘) + (𝛽0  + 𝑢0𝑘) + (𝛽1 + 𝑢1𝑘)𝑥𝑡𝑘  + 𝜀𝑡𝑘  
 𝑢0𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎0𝑘
2 ),   𝑢1𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎1𝑘
2 ),  𝜀𝑡𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝜀
2) 
In model 3 𝑢0𝑘 were the random intercepts and 𝑢1𝑘 the random slopes for each CA, and 
zero covariance was assumed between 𝑢0𝑘 and 𝑢1𝑘. This implied that the random 
intercepts and slopes for each anomaly were uncorrelated, i.e. that the prevalence of a CA 
was not correlated with the trend in prevalence for that CA. The overall intercept and slope 
in the model were 𝛽0 and 𝛽1 respectively, and the term 𝜀𝑡𝑘 allowed for potential 
overdispersion. 
As discussed previously (see section 3.5.2), estimates for the variability around the random 
effect estimates (for example the random slopes that are the estimates of the average 
yearly prevalence for each anomaly subgroup) are not reported using frequentist GLMMs, 
therefore CIs were not calculated for the intercepts and slopes for each anomaly subgroup 
in this model.  
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Model 4: Frequentist hierarchical model + registry 
Model 4 was a hierarchical Poisson model grouping CAs, with random effects for each CA 
and an additional random intercept for registry. This was defined for 𝑘 = 1, … , 𝐾 CAs and 
𝑗 = 1, … , 𝐽 registries, such that 
𝑦𝑡𝑗𝑘~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑡𝑗𝑘) 
log(𝜆𝑡𝑗𝑘) = log(𝑝𝑡𝑗𝑘) + (𝛽0 + 𝑢0𝑘  + 𝑢𝑗) + (𝛽1 + 𝑢1𝑘)𝑥𝑡𝑗𝑘  + 𝜀𝑡𝑗𝑘  
 𝑢0𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎0𝑘
2 ),        𝑢1𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎1𝑘
2 ),   𝑢𝑗 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝑗
2), 
𝜀𝑡𝑗𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝜀
2) 
Random intercepts for registry were again denoted by 𝑢𝑗, random intercepts and slopes for 
each CA were 𝑢0𝑘 and 𝑢1𝑘, respectively, and zero covariance between the random effect 
parameters was assumed. As in model 3, the mean intercept and slope were 𝛽0 and 𝛽1, 
respectively, and 𝜀𝑡𝑘 accounted for potential overdispersion in the data. Again, as in model 
3, CIs were not calculated for individual intercepts and slopes in this model since estimates 
of the variability around the random effects are not reported.  
Model 5: Bayesian hierarchical model 
Model 5 was a Bayesian specification of model 3: a Poisson BHM including multiple CAs and 
pooling data over registry. In this model, 95% PCIs were estimated for the random effects 
for 𝑘 = 1, … , 𝐾 CAs using the 2.5th and 97.5th percentile values of the posterior distribution 
for each parameter. The model is specified as follows 
Likelihood model: 
𝑦𝑡𝑘~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑡𝑘) 
log(𝜆𝑡𝑘) = log(𝑝𝑡𝑘) + 𝑢0𝑘 + 𝑢1𝑘𝑥𝑡𝑘  + 𝜀𝑡𝑘 
Priors for model parameters: 
 𝑢0𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢0, 𝜏𝑢0),  𝑢1𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢1, 𝜏𝑢1), 
 𝜀𝑡𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜏ԑ) 
Hyper-priors for model parameters: 
𝜇𝑢0,  𝜇𝑢1~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 0.001) 
𝜏𝑢0 =  
1
𝜎𝑢0
2 , 𝜏𝑢1 =  
1
𝜎𝑢1






𝜎𝑢0, 𝜎𝑢1, 𝜎ԑ𝑘~ 𝑢𝑛𝑖𝑓𝑜𝑟𝑚(0, 10) 
In this model, 𝜇𝑢0 denoted the mean intercept across the anomaly subgroups and 𝜇𝑢1 the 
mean trend. As in model 3, the random intercepts and slopes for each anomaly subgroup 
were denoted by 𝑢0𝑘 and 𝑢1𝑘, respectively, and zero covariance was assumed between 
random effect parameters. Minimally informative prior distributions were used for all 
parameters, with parameters for prior distributions as specified above.  
Model 6A: Bayesian hierarchical model + registry (A)  
Model 6A was a Poisson BHM including multiple CAs and a random registry effect. This was 
a Bayesian equivalent of model 4, which allowed estimation of the variability around the 
random effects.  
Likelihood model: 
𝑦𝑡𝑗𝑘~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑡𝑗𝑘) 
log(𝜆𝑡𝑗𝑘) = log(𝑝𝑡𝑗𝑘) +  𝑢𝑗 +  𝑢0𝑘 + 𝑢1𝑘𝑥𝑡𝑗𝑘  + 𝜀𝑡𝑗𝑘 
Priors for model parameters: 
 𝑢0𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢0, 𝜏𝑢0),  𝑢1𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢1, 𝜏𝑢1),  
 𝑢𝑗 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑗 , 𝜏𝑗) 
𝜀𝑡𝑗𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜏ԑ) 
Hyper-priors for model parameters: 
𝜇𝑢0,  𝜇𝑢1~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 0.001) 
𝜏𝑢0 =  
1
𝜎𝑢0
2 , 𝜏𝑢1 =  
1
𝜎𝑢1
2 , 𝜏𝑗 =  
1
𝜎𝑗




𝜎𝑢0, 𝜎𝑢1, 𝜎𝑗, 𝜎ԑ~ 𝑢𝑛𝑖𝑓𝑜𝑟𝑚(0, 10) 
In model 6A, 𝑢𝑗 denoted the random intercepts for registry and all other estimates were as 
described for model 5.  
Model 6B: Bayesian hierarchical model + registry (B)  
Model 6B was a Poisson BHM including multiple CAs and a random registry effect, differing 
from model 6A in that it each CA-registry combination was allowed to have a separate 





log(𝜆𝑡𝑗𝑘) = log(𝑝𝑡𝑗𝑘) +  𝑢0𝑗𝑘  + 𝑢1𝑘𝑥𝑡𝑗𝑘  + 𝜀𝑡𝑗𝑘 
Priors for model parameters: 
 𝑢0𝑗𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢0, 𝜏𝑢0),  𝑢1𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢1, 𝜏𝑢1), 
 𝜀𝑡𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜏ԑ) 
Hyper-priors for model parameters: 
𝜇𝑢0,  𝜇𝑢1~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 0.001) 
𝜏𝑢0 =  
1
𝜎𝑢0
2 , 𝜏𝑢1 =  
1
𝜎𝑢1




𝜎𝑢0, 𝜎𝑢1, 𝜎ԑ~ 𝑢𝑛𝑖𝑓𝑜𝑟𝑚(0, 10) 
Here  𝑢0𝑗𝑘 represented 𝐽𝑥𝐾 random intercepts (i.e. one for each anomaly-registry 
combination), and other parameters were as specified in model 6A. 
3.5.4. Sensitivity analyses 
Estimating trends separately in each registry 
The prevalence of many CAs is known to vary considerably between different regions in 
Europe and this is usually due to differences in reporting (e.g. due to availability of prenatal 
ultrasound in a particular population), although it may potentially be the case that an 
environmental risk factor is present only in a particular population. However, any general 
trend in prevalence may be expected to be broadly similar across the registries. Therefore, 
in the analysis of NTDs, the average annual trend in the prevalence of the subgroups was 
also estimated using a separate Poisson regression model for each registry-anomaly 
combination. This aimed to identify whether there were registries with trends markedly 
inconsistent with the overall European trend, and might have disproportionate influence on 
results in models that included all registries together.   
Use of alternative samplers in Bayesian models 
Where there was evidence of strong autocorrelation in Bayesian models, the use of 
alternative samplers were investigated using the programme Stan [Stan Development 
Team, 2015b]. This was done to assess whether the alternative samplers used by Stan (a 
Hamiltonian Monte Carlo variant called the No U-Turn sampler) might provide a solution in 
the case where the Gibbs samplers do not converge due to high autocorrelation. Models 
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were fitted in Stan via R, using the RStan package [Stan Development Team, 2015a] with 
the same model parameters as those described for JAGS models.  
Use of alternative prior distributions in Bayesian models 
Different choices of parameters for the prior distributions used in Bayesian models were 
considered, as discussed in section 3.5.2. When the number of groups in a BHM is small (i.e. 
less than 5), posterior distributions for the variance parameters tend to have long right-
tails. This can lead to unrealistically high values for estimated standard deviation 
parameters for the random effect and result in an “under shrinking” of the estimates of the 
random effects [Gelman A., 2006]. This means that the trends for each subgroup in a BHM 
may not demonstrate as much shrinkage as expected if there are only a small number of 
CAs in the model. In such situations, the half-Cauchy prior distribution with a weak 
constraint on the standard deviation has been shown to perform better than a uniform 
distribution [Gelman A., 2006]. A weakly informative half-Cauchy prior in this context is 
intended to constrain the posterior distribution, rather than being a representation of our 
actual state of prior knowledge. As a sensitivity analysis, therefore, a half-Cauchy prior was 
also evaluated for the variance parameters in models with less than five CAs. Appendix A3 




3.6.1. Description of EUROCAT prevalence data in 18 registries 
Data was available from 18 EUROCAT registries in 11 countries, with each registry having 
available data for at least nine years of the period 2003 to 2012 as required by the study 
inclusion criteria. The earliest year of data available ranged from 1983 (in six registries) to 
2002 (in Isle da la Reunion registry). The data were aggregated according to registry, year of 
birth, sex and maternal age (in five-year age groups), including and excluding chromosomal 
cases separately. For aggregate counts of non-chromosomal CA cases, the following 
exclusions were made: chromosomal anomalies, genetic syndromes or microdeletions, 
teratogenic syndromes with malformations, and sequences. Maternal age was defined as 
age at delivery of baby, and this was known for 96.2% of the population included in this 
study. Within each registry and year, the remaining 3.8% were assumed to follow the same 
maternal age distribution as those with known maternal age.  
The total prevalence of all CAs for the period 2003 to 2012 is displayed in Table 3.2, 
including and excluding chromosomal subgroups separately. Over all registries, the 
combined total of births in the population covered by these registries for these years of 
data was just over 4 million. This included 103,507 (2.5%) cases of CA, 81,147 of which did 
not have a chromosomal anomaly (78.4% of all cases). The highest total prevalence of all 
anomalies was in Vaud (3.8%) and the lowest was in Dublin (1.7%).  
Overall, there was a higher number of male CA cases (54.7%) than females (42.1%), with 
the remainder having indeterminate sex (0.1%) or listed as “Not known, or missing” (3.2%). 
The majority of mothers (71.4%) were under the age of 35 at the time of delivery, with only 




 Total number of births, cases and prevalence of congenital anomalies per 100 births in 18 EUROCAT registries from 2003-2012, including and 
excluding genetic conditions. 





Prevalence per 100 births 
(95% CI) 
Cases 
Prevalence per 100 births 
(95% CI) 
Austria Styria 103,492 3,193 3.09 (2.98, 3.19) 2,675 2.58 (2.49, 2.68) 
Belgium Antwerp 200,819 4,839 2.41 (2.34, 2.48) 3,991 1.99 (1.93, 2.05) 
 
Hainaut 126,689 3,021 2.38 (2.30, 2.47) 2,406 1.90 (1.82, 1.98) 
Denmark Odense 51,693 1,532 2.96 (2.82, 3.12) 1,194 2.31 (2.18, 2.44) 
France Paris 266,387 8,536 3.20 (3.14, 3.27) 6,302 2.37 (2.31, 2.42) 
 
Isle de la Reunion 146,462 3,974 2.71 (2.63, 2.80) 3,115 2.13 (2.05, 2.2) 
Germany Saxony-Anhalt 172,272 5,526 3.21 (3.12, 3.29) 4,876 2.83 (2.75, 2.91) 
Ireland Cork and Kerry 96,833 2,580 2.66 (2.56, 2.77) 2,024 2.09 (2.00, 2.18) 
 
Dublin 256,377 4,345 1.69 (1.64, 1.75) 3,172 1.24 (1.19, 1.28) 
Italy Tuscany 299,863 6,335 2.11 (2.06, 2.17) 5,234 1.75 (1.70, 1.79) 
Netherlands Northern Netherlands 180,927 4,832 2.67 (2.60, 2.75) 3,891 2.15 (2.08, 2.22) 
Spain Basque Country 184,570 4,503 2.44 (2.37, 2.51) 3,335 1.81 (1.75, 1.87) 
Switzerland Vaud 76,241 2,881 3.78 (3.64, 3.92) 2,186 2.87 (2.75, 2.99) 
UK East Midlands & South Yorkshire 717,264 15,335 2.14 (2.10, 2.17) 12,294 1.71 (1.68, 1.74) 
 Northern England 328,496 7,843 2.39 (2.34, 2.44) 5,982 1.82 (1.78, 1.87) 
 Thames Valley 254,090 5,224 2.06 (2.00, 2.11) 3,677 1.45 (1.40, 1.49) 
 Wales 343,245 12,668 3.69 (3.63, 3.76) 10,567 3.08 (3.02, 3.14) 
 Wessex 291,422 6,340 2.18 (2.12, 2.23) 4,226 1.45 (1.41, 1.49) 
All registries combined 4,097,142 103,507 2.53 (2.51, 2.54) 81,147 1.98 (1.97, 1.99) 
a Basque country did not include data for 2012 
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3.6.2. Accounting for potential overdispersion: encephalocele as an example 
Counts of encephalocele per year for the latest ten years of data are displayed in Figure 3.3. 
A number of the registries have a high number of years with no cases of encephalocele, i.e. 
zero counts. Over 40% of the yearly counts across all 18 registries were zero, however when 
counts were combined for all registries the smallest number of total cases in one year was 
29. 
 
Figure 3.3. Yearly counts of encephalocele cases in 18 EUROCAT registries from 2003-
2012. 
Figure 3.4 plots the mean against the variance of the encephalocele counts per year, 
showing that the mean and variance are similar for some registries, e.g. Odense and 
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noticeably above the diagonal line indicate overdispersion in the distribution of yearly 
counts for those registries, and those under the line indicate some amount of under-
dispersion. The majority of the points in Figure 3.4 lie fairly close to the diagonal line, 
indicating that there is not clear under or overdispersion for the encephalocele prevalence 
data. 
 
Figure 3.4. Mean against variance of yearly counts of encephalocele in 18 EUROCAT 
registries from 2003-2012. 
Results from different models taking departures from equidispersion into account when 
assessing trends in encephalocele are displayed in Table 3.3, including different 
distributions as well as different ways of including the registry effect in the model. All 
models estimated the same average yearly decrease in encephalocele, which was not a 
significant trend in any model. Furthermore, there was no significant evidence of dispersion 
for the data in any of the models considered here, with the dispersion parameter being 
estimated as not significantly different from 1 (where 1 indicates equidispersion) in all 
models. The estimated value of the shape parameter of the negative binomial distribution 
was very large in both the negative binomial models, with the iteration limit being reached 
whilst fitting this parameter (i.e. the convergence for the value of theta was not achieved). 
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overdispersion term was estimated to be zero. The different models considered for 
encephalocele were also assessed for a number of other rare CAs (including cystic 
adenomatous malformation of the lung and anotia). There was no indication for any of the 
CAs considered that there was strong overdispersion in the data or that the choice of model 
used to account for the overdispersion was having any effect on the estimated trends in 
prevalence. 
Based on these results, it was decided that a Poisson-lognormal model would be used for all 
further models considered. The standard deviation of this additional term was monitored 
throughout all models. 
 Summary of results from seven different models considering potential 


















Poisson GLM Pooled -0.021 (-0.05, 0.01) 0.863 8 0.547 
Poisson GLM Adjusted -0.022 (-0.06, 0.01) 1.075 160 0.246 
Quasi-Poisson GLM Adjusted -0.022 (-0.06, 0.01) n/a* 160 n/a 
Negative binomial 
GLM 
Adjusted -0.022 (-0.06, 0.01) 1.074 160 0.246 
Poisson GLMM Random effect  -0.021 (-0.05, 0.01) 0.977 176 0.572 
Negative binomial 
GLMM 
Random effect  -0.021 (-0.05, 0.01) 0.977 176 0.572 
Poisson-lognormal 
GLMM 
Random effect  -0.021 (-0.05, 0.01) 0.983 175 0.551 
a The dispersion parameter for the quasi-Poisson model is the same as estimated in the Poisson 
model 
A note on the presentation of results in chapter 3 
Full results from all models in all CAs considered in this chapter are displayed throughout 
Appendix A4 – A7. Note that models 3 and 4 estimated trends for each CA as random 
effects in a frequentist setting and, as discussed previously, estimates of the variability 
around these parameters were not calculated (see section 3.5). Results for models 3 and 4 
therefore are not included in figures that show estimated trends in prevalence for groups of 
CAs throughout this chapter. However, point estimates obtained using these models (3 or 
4) were in practice very close to those obtained when using the equivalent BHMs (i.e. 
models 5, 6A and 6B).   
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3.6.3. Neural tube defects  
Figure 3.5 shows estimates of the total prevalence and 95% CIs for each of the 18 EUROCAT 
registries from 2003-2012 in the three NTD subgroups and for the overall NTD subgroup. 
The European average prevalence with its 99% confidence intervals is shown as a vertical 
grey shaded band in order to visualise registries whose NTD prevalence was inconsistent 
with the European average. Several registries showed prevalence markedly different to the 
European-wide prevalence for each of the NTD subgroups, and in particular for the overall 
NTD prevalence. For anencephaly, for example, 11 of the 18 registries had 95% confidence 
limits that did not overlap with the 99% confidence limits for the European average. The 
rarest NTD was encephalocele, which had an average total prevalence of just above 1 case 
per 10,000 births across Europe over the last ten years of data. Prevalence of anencephaly 
and spina bifida was around four and five cases per 10,000 births, respectively. The total 
prevalence of all the NTDs combined across the 18 registries was around 10-11 cases per 




Figure 3.5. Total prevalence of neural tube defects and 95% confidence intervals in 18 EUROCAT registries from 2003 to 2012, with 99% confidence 
range for the average prevalence across all registries marked as grey shaded bands for each anomaly. 
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The yearly prevalence and 95% confidence intervals across all 18 registries is displayed in 
Figure 3.6, showing some fluctuations in NTD prevalence across this period, but no clear 
trends or patterns for any NTD subgroups.  
 
Figure 3.6. Average yearly prevalence and 95% confidence intervals for neural tube 
defects across 18 EUROCAT registries from 2003-2012. 
Estimated average annual trends in the prevalence of NTDs when considered separately 
(individual models) and combined (hierarchical models) as specified in section 3.5.3 are 
shown in Figure 3.7. For the aggregate group of the three NTDs combined, estimates from 
individual models are the total prevalence and 95% CI. For hierarchical models, the average 
of the estimated slopes for the three CAs are displayed, i.e. the 95% PCI for the 
parameter 𝜇𝑢0 (see section 3.5.3). Figure 3.7 shows that results across all models were 
consistent, with no evidence of trends in prevalence for any of the NTD subgroups whether 
considering CAs separately or combining them together in a hierarchical model. The 
average trend across the NTD subgroups was slightly decreasing, although this effect had a 
very large variance. In hierarchical models grouping the three NTDs together, there was a 
small amount of shrinkage towards this average trend. This can be seen in the estimates for 
encephalocele, which are slightly higher for BHMs than in individual models, and in those 
for spina bifida and anencephaly, which are very slightly lower. Appendix Table A5 includes 















































Figure 3.7. Average annual trends in prevalence of neural tube defects; estimates and 
95% confidence intervals from individual and hierarchical models as described in 
section 3.5.3.  
Assessment of hierarchical models for neural tube defects 
Convergence and model fit were assessed both graphically and using tests as described 
previously (section 3.5.2). Features of model fit for all the hierarchical models are displayed 
in Table 3.4. In frequentist hierarchical models 3 and 4, the CA intercepts and slopes were 
perfectly correlated (correlation coefficient r=1). These high levels of correlation are likely 
due to over-parameterisation, demonstrating that the models are attempting to estimate 
more parameters than the data can support. This means that both random effects (i.e. the 
intercepts and the slope) are not able to be reliably estimated. This is reflected in the small 
variance in the random effects; in models 3 and 4, there was very little difference in the 
estimated trends for the three NTDs and the estimated SD of the trends in the three NTDs 
was around 0.01. This is considerably smaller than the estimated SD of the intercepts 
(around 0.7). Over-parameterisation in the model was also was evident in the high 
autocorrelation and poor convergence of the estimated trend parameters as well as in the 
means and SDs for the trend parameters in the BHMs (models 5, 6A and 6B; see Appendix 
figures A5, A7-8, A10-14, A18).  
The estimated standard deviation of the mean trend across the subgroups was small in all 
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slope for each CA was similar (and in this case non-significant). The cAIC and Deviance were 
larger for models including registry as a random effect compared to those pooling over 
registry, reflecting the increased number of parameters added to the model when including 
a registry effect. The estimated standard deviation of the dispersion parameter was similar 
for all models, and some overdispersion was present for all models. Model notation for 
BHMs grouping NTD subgroups is summarised in Appendix Table A6.  
In the BHM that pooled information across registries (model 5), there was generally good 
mixing of chains and low levels of autocorrelation for the majority of parameters. Based on 
3 separate chains, the Raftery-Lewis diagnostic for this model indicated that a total sample 
size of around 14,100 iterations would be required to estimate the 95% PCI for all 
parameters in the model with an actual posterior probability between 92.5% and 97.5%.
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cAIC 232 2466 - - - 
Deviance 242 2513 - - - 
Residual DF 24 530 - - - 
Mean Deviance - - 223 2395 2362 
Penalty - - 9 72 68 
DIC - - 231 2467 2430 
Multivariate PSRF - - 1.02 3.47 1.02 
Mean SD for overdispersion parameter 0 0.124 0.029 0.120 0.064 
Mean SD of registry intercepts - 0.296 - 0.322 
2.268 a 
Mean SD of CA intercepts 0.692 0.695 2.282 2.311 
Mean SD of CA trends 0.010 0.009 0.070 0.054 0.059 
Estimated correlation between CA intercepts and slopes 1 1 - - - 
a SD of the intercepts across all registry-CA combinations 
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Model parameters that averaged across the subgroups required much larger posterior 
samples, with parameters for each NTD subgroup requiring around 1,100 iterations 
according to the Raftery-Lewis diagnostic (see Appendix A5 and Table A7 for details). For 
each BHM, therefore, 3 separate chains of 100,000 iterations with a thin of 5 were used, 
resulting in a posterior sample size of 20,000 iterations per chain. The parameter for the 
estimated variability of the mean of the trends for the NTD subgroups sigma.u1 in model 5 
showed high levels of autocorrelation for all three chains, and a low effective sample size 
compared to other parameters in the model (Appendix Table A8). The effective sample size 
for the overdispersion parameter sigma.e in model 5 was also relatively low and with high 
levels of autocorrelation, in particular for one of the three chains. These two parameters 
also had estimated dependence factors well above 5 following the Raftery-Lewis 
diagnostics (Appendix Table A7). Figure 3.8  shows the trace, density and autocorrelation 
plot for the estimated annual yearly European trend in spina bifida from model 5 
(parameter u1[3]), as an example of a parameter with good mixing of chains, convergence 







Figure 3.8. Example of a trace (A), density (B) and autocorrelation (C) plot for a 




The trace (Figure A1 and A2), density (Figure A3 and A4) and autocorrelation (Figure A5 and 
A6) plots for all parameters in model 5 are displayed in Appendix A4.  
Raftery-Lewis diagnostics, summary of the posterior distribution and trace, density and 
autocorrelation plots for models 6A (Table A9-A10 and Figures A7-A13) and 6B (Table A11-
A12 and Figures A14-A21) are displayed in Appendix A5. In both models 6A and 6B, the 
parameters 𝑢1[𝑘] for the trend in each NTD subgroup showed good mixing and 
convergence and high effective sample sizes. However, there was high dependency, poor 
mixing of chains, a lack of convergence and very high autocorrelation for the random 
intercepts parameters for registry and CA in model 6A. Effective sample sizes for these 
parameters were extremely low, for example, the random intercepts had an effective 
sample size of only ~12 for a total sample of 20,000 iterations per chain (Appendix Table 
A9). In model 6B, effective sample sizes were high for all parameters except for sigma.u1, 
the estimated variability around the mean of the trends for the NTD subgroups, and 
sigma.e, the overdispersion parameter, which both showed poor mixing of chains, high 
dependency and high levels of autocorrelation (Appendix Table A10 and A11). The 
estimated multivariate PSRF from the Gelman and Rubin diagnostic test was close to 1 for 
models 5 and 6B, but was substantially greater than 1 for model 6A, indicating an overall 




Figure 3.9 shows the trace, density and autocorrelation plot for the intercept of the trend in 
spina bifida from model 6A, as an example of a parameter with poor mixing of chains, lack 







Figure 3.9. Example of a trace (A), density (B) and autocorrelation (C) plot for a 
parameter with lack of convergence, poor mixing of chains and very high 
autocorrelation. 
Sensitivity analysis I: individual models for each registry 
The average annual trend in prevalence of NTD subgroups for 2003-2012 was also 
estimated using a separate Poisson regression model for each registry-CA combination. The 
trend in each of the NTD subgroups was consistent across all registries, with estimates and 
99% confidence limits for all registries overlapping or being very close to the 99% 
confidence band for the average European trend (Appendix Figure A21). 
Sensitivity analysis II: use of alternative sampling for MCMC chains 
Parameters in models that grouped CAs together were highly correlated. Since the Gibbs 
samplers used by JAGS can be ineffective in such a setting, the programme Stan was 
therefore also used to see whether its alternative samplers would provide a solution where 
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the Gibbs samplers did not converge. Models 5 and 6 were fitted using Stan with the same 
model parameters as those used in JAGS models, i.e. the same values for prior distributions, 
burn-in, thinning and total number of iterations.  
Table 3.5 shows that estimates of the average yearly trend in prevalence for NTDs from 
models using JAGS Gibbs sampling and Stan’s NUTS sampler were very similar. There was 
some difference in the estimated overall mean trend across the three NTDs in model 5, but 
estimates were nonsignificant in both cases. The estimated standard deviation of the NTD 
trends was slightly larger in Stan for model 6A.  
 Comparison of estimated trends in hierarchical models for neural tube 








5 Anencephaly 0.002 (-0.014, 0.020) 0.001 (-0.013, 0.019) 3.0 
 
Encephalocele -0.012 (-0.046, 0.013) -0.012 (-0.046, 0.012) 1.0 
 
Spina bifida -0.001 (-0.017, 0.015) -0.001 (-0.016, 0.014) 1.8 
 
Mean of trends for 
NTD subgroups 
-0.004 (-0.118, 0.102) -0.027 (-0.147, 0.074) 0.2 
 
SD of trends for 
NTD subgroups 
0.070 (0.001, 0.508) 0.083 (0.001, 0.470) 0.8 
6A Anencephaly 0.002 (-0.015, 0.019) 0.002 (-0.014, 0.020) 1.1 
 
Encephalocele -0.012 (-0.047, 0.013) -0.013 (-0.047, 0.012) 1.0 
 
Spina bifida -0.002 (-0.018, 0.013) -0.003 (-0.018, 0.013) 0.8 
 
Mean of trends for 
NTD subgroups 
-0.005 (-0.105, 0.089) -0.009 (-0.12, 0.100) 0.5 
 
SD of trends for 
NTD subgroups 
0.054 (0.001, 0.374) 0.078 (0.002, 0.469) 0.7 
6B Anencephaly 0.002 (-0.014, 0.018) 0.002 (-0.014, 0.019) 1.1 
 
Encephalocele -0.012 (-0.046, 0.013) -0.012 (-0.046, 0.014) 1.0 
 
Spina bifida -0.001 (-0.016, 0.013) -0.001 (-0.016, 0.014) 0.8 
 
Mean of trends for 
NTD subgroups 
-0.004 (-0.102, 0.093) -0.006 (-0.112, 0.096) 0.7 
 
SD of trends for 
NTD subgroups 
0.059 (0.001, 0.391) 0.066 (0.002, 0.425) 0.9 
 
Computational time in Stan was generally longer than in JAGS, with run times of almost 3 
times slower for model 5 and up to 37 times slower for model 6A (Appendix Table A13). 
Effective sample sizes were considerably smaller in Stan, with an average effective sample 
size of less than 400 compared to over 40,000 in the equivalent JAGS model (Appendix 
Table A13), indicating even higher levels of autocorrelation in estimates obtained using 
Stan. A full summary of the posterior distributions for Bayesian models using JAGS and Stan 
is displayed in Appendix Table A14. 
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Sensitivity analysis III: use of different prior distributions 
Different values for parameters of prior distributions were also considered for the BHM 
pooled over registry (model 5). Estimates and 95% PCIs for all parameters using 6 
combinations of different priors for the means and variances are displayed in Figure 3.10. 
Combination A shows the parameters as used in models previously presented; the other 5 
combinations used a Normal prior for estimation of means and a uniform or half-Cauchy 
prior for estimation of the variances, as described in the key to Figure 3.10. The estimated 
mean intercepts and trends in each NTD subgroup and for the overdispersion parameter 
remained similar for all types of prior considered (see Appendix Table A15 for exact values 
and related effective sample sizes). When introducing a wider (i.e. vaguer) variance on the 
uniform prior for the estimation of variances, the 95% PCIs for the mean and SD of the 
random intercepts became wider (B compared to A). The PCIs for the mean and SD of the 
random slopes, however (i.e. estimated average trend across the subgroups) became 
slightly narrower. When using a half-Cauchy distribution for the priors for variance 
parameters (D, E and F), a higher scale parameter lead to lower precision in the estimates 
of the mean and SD for the average intercepts and slopes across the NTD subgroups, 









Figure 3.10. Estimated intercepts and slopes in model 5 for neural tube defects with 
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3.6.4. Chromosomal anomalies 
The estimated total prevalence and 95% CIs for chromosomal CA subgroups within each 
registry for the latest ten years of data are displayed in Figure 3.11. As seen with the NTDs, 
the total ten-year prevalence for chromosomal subgroups varied considerably between 
registries. This was particularly the case for Down syndrome, for which the prevalence 
ranged from 13.3 cases per 10,000 births in Antwerp up to 31.9 in Paris.  
 
Figure 3.11.  Total prevalence of chromosomal anomalies and 95% confidence intervals 
in 18 EUROCAT registries from 2003 to 2012 from 2003 to 2012, with 99% 
confidence range for the average prevalence across all registries marked as grey 
shaded bands for each anomaly. 
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Figure 3.12 shows the average yearly prevalence and 95% CIs across 18 EUROCAT registries 
from 2003-2012 in the five chromosomal subgroups, on a log scale such that the difference 
between two lines on the y-axis represents a doubling in prevalence. Down syndrome was 
the most common chromosomal CA, with average yearly European-wide prevalence 
estimated at between 20 and 27 per 10,000 births throughout this time. The other 
chromosomal subgroups all had considerably lower average yearly prevalence, varying from 
around 1 per 10,000 births for Klinefelter syndrome to 7 per 10,000 for Edward syndrome. 
It can be seen in Figure 3.12 that the yearly prevalence of Down syndrome across Europe 
has increased slightly over this period and that of Klinefelter syndrome has decreased; 
however, it is not clear whether there has been a similar trend for the other subgroups. 
 
Figure 3.12.  Average yearly prevalence and 95% confidence intervals across 18 
EUROCAT registries from 2003-2012 in the five chromosomal anomalies. 
The estimated trends and 95% CIs or PCIs in the 5 chromosomal subgroups according to the 
individual models and BHMs are presented in Figure 3.13. There was an increasing trend for 
Down syndrome and decreasing trend for Klinefelter syndrome, with similar estimates in all 
models. The estimates for Klinefelter syndrome shrank slightly towards the null when using 
a BHM, going from an estimated 7.7% average yearly decrease in prevalence in model 1 to 












































Turner syndrome for any model. When considering each chromosomal subgroup 
individually, Poisson regression analyses estimated the increasing trend in Edward 
syndrome that was nonsignificant after Bonferroni correction to adjust for multiple testing. 
However, this trend was significant when using each of the BHMs, for which the estimated 
variability around the average yearly change in prevalence was narrower.  
 
Figure 3.13. Average annual trends in prevalence of chromosomal anomalies; estimates 
and 95% confidence intervals from individual and hierarchical models as described 
in section 3.5.3. 
Assessment of hierarchical models for chromosomal subgroups 
Some key features of model fit for hierarchical models are described in Appendix Table A16. 
The intercepts and slopes for chromosomal subgroups were highly correlated for models 3 
and 4, with the correlation coefficient estimated to be 0.82 and 0.83 respectively. As in the 
models for NTDs, this could be because of over-parameterisation in the model leading to a 
very small variance in either random effect, meaning that the model cannot reliably 
estimate both effects. Some amount of overdispersion was also present for all models, and 
the estimated standard deviation of the dispersion parameter was smaller for models that 
pooled information across registry.  
Parameters for model 5 and model 6B showed good convergence, with low levels of 
autocorrelation and good mixing of chains (data not shown). Effective sample sizes were 
All chromosomal
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high for most parameters in the model, with many having an effective sample size close to 
60,000 (i.e. the actual total sample size for all three chains after thinning) with the 
exception of the overdispersion parameter, which had an effective sample size of 3,527 and 
881 respectively for models 5 and 6B. As seen in the BHMs for NTDs, the parameters for the 
trend in each subgroup were well behaved; however, the random intercept parameters for 
model 6A showed poor convergence and mixing of chains, high autocorrelation and very 
low effective sample sizes (data not shown).  
Hierarchical models for chromosomal subgroups including only autosomal trisomy 
Figure 3.14 shows results from the hierarchical models that excluded Klinefelter and Turner 
syndromes, to evaluate the effectiveness of a model including only the autosomal trisomy 
subgroups. Estimated yearly trends for Down and Edward syndrome remained almost 
identical to those obtained in models that had included all five chromosomal anomalies. For 
Patau syndrome, the model including only the three trisomy subgroups gave a slightly 
higher estimated trend from just under 0.5% (in model 1) to around a 1% average annual 
change in prevalence in the three BHMs and with slightly narrower PCIs. This shows how 
the estimates for Patau syndrome in BHMs were influenced to some extent by significant 
increasing trends in the other trisomy subgroups; however, these estimates remained 
statistically nonsignificant for all models considered. Information regarding model fit for 
estimates displayed in Figure 3.14 is in Appendix Table A17. Model diagnostics were similar 
to those from models including all 5 subgroups, although the estimated correlation 
between the intercepts and slopes was perfect in this version of model 3 and 4 (r=1 




Figure 3.14.  Average annual trends in prevalence of autosomal trisomy subgroups.  
 
3.6.5. Digestive system anomalies 
Figure 3.15 shows the estimated total prevalence and 95% CIs for the 8 digestive system 
anomalies for 2003-2012. The total ten-year prevalence was generally more consistent 
across the 18 registries for the digestive system anomalies compared to NTDs or the 
chromosomal subgroups, although for come digestive CAs there were a number of 
registries with estimated prevalence outside the 99% confidence intervals for the European 
average.  
The average yearly European-wide prevalence for each of the digestive anomaly subgroups 
is displayed in Figure 3.16, ranging from around 0.1 cases per 10,000 live births for annular 
pancreas to between 2.5 and 3.5 cases per 10,000 for anorectal atresia and stenosis. There 
was no clear trend for any of the digestive system subgroups from 2003 to 2012, with the 
possible exception of duodenal atresia or stenosis, which had an estimated prevalence of 
just over 0.5 per 10,000 births in 2003 rising to 1 per 10,000 births in 2012. 
Figure 3.17 shows estimates of the average yearly change in prevalence in digestive system 
CAs from individual models and BHMs. There was a mix of increasing and decreasing trends 
across the 8 digestive system subgroups, none of which was significant for any model. 
When combining the eight anomalies together in a hierarchical model, estimated trends in 
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trend as this average is influenced by both positive and negative trends. For subgroups that 
were estimated with more uncertainty in the individual models (i.e. those with the widest 
confidence intervals for models 1 and 2), this shrinkage effect was visibly larger. 
Assessment of hierarchical models for digestive system subgroups 
Information regarding model fit for hierarchical models for digestive system subgroups are 
described in the Appendix Table A18. The CA intercepts and slopes were almost perfectly 
correlated for models 3 (estimated correlation coefficient r=0.99) and 4 (r=0.97), again 
implying that the model is not reliably able to estimate both effects due to over-
parameterisation.  Some amount of overdispersion was present for all models, with smaller 
estimated standard deviation of the dispersion parameter for models that did not pool 
information across registry. The majority of parameters for model 5 and model 6B showed 
good convergence, low levels of autocorrelation, good mixing of chains and reasonable 
effective sample size. However, in model 6B the overdispersion parameter had poor mixing 
of chains and convergence and a very low effective sample size of only 150. As seen in the 
BHMs for previous groups of anomalies analysed, the random intercept parameters for 
model 6A showed very poor convergence and mixing of chains, high autocorrelation and 




Figure 3.15.  Total prevalence and 95% confidence intervals of 8 digestive system CAs in 
18 EUROCAT registries from 2003 to 2012, with 99% confidence range for the 




















































































































































































































































































Figure 3.17. Average annual trends in prevalence of digestive system subgroups; 
estimates and 95% confidence intervals from individual and hierarchical models as 
described in section 3.5.3. 
3.6.6. Congenital heart defects 
The estimated prevalence and 95% CIs of the 16 CHDs for 2003-2012 are displayed in 
Appendix Figure A22 (severity group 1), Figure A23 (severity group 2) and Figure A24 
(severity group 3). The total ten-year prevalence was reasonably consistent across the 18 
registries for most CHDs in severity groups 1 (“very severe”) and 2 (“severe”) but varied 
widely between registries for the more common 3 subgroups in severity group 3. For 
example, ventricular septal defect had total lowest prevalence in the Wessex registry, with 
only 9 per 10,000 births recorded, while at the other end of the spectrum was Vaud with 
almost 55 cases per 10,000 births. Figure 3.18 displays the average prevalence each year 
across the 18 registries combined for each of the CHD subgroups. Visually it appears that 
the prevalence might have come down slightly for coarctation of aorta in severity group 2 
and atrial septal defect in severity group 3. There also appears to be a slight increase from 
2003 to 2012 in the prevalence of tetralogy of Fallot in severity group 2. For the rest of the 










































































































































































































































































































































































































































































































































































There was a mix of increasing and decreasing trends in the prevalence of CHD subgroups 
whether using individual Poisson models (Table 3.6) or BHMs (Table 3.7).  
Table 3.6 shows that, after Bonferroni correction to adjust for multiple tests across the 16 
CHDs, the only statistically significant estimates from individual models were an increasing 
trend for tetralogy of Fallot and a decreasing trend for pulmonary valve stenosis, both of 
which attenuated when including a registry effect in model 2. Three subgroups highlighted 
in bold showed increasing trends in prevalence in the latest EUROCAT statistical monitoring 
report; apart from tetralogy of Fallot in model 1, these trends were increasing but 
nonsignificant in individual models here.  
Table 3.7 shows that none of the estimated trends for these 3 CHDs was statistically 
significant in BHMs pooling the CHDs together. The estimated trends in prevalence shrink 
towards the average trend across the CHDs in BHMs, which was close to zero due to the 
influence of both positive and negative trends. Table 3.7Table 3.6 includes estimates from a 
BHM with an additional random effect for severity group (model 5sev). The decreasing 
trend for pulmonary valve stenosis seen in model 1 shrank towards the null in all BHMs 
except model 5sev. On the other hand, models 5, 5sev and 6B all showed a decreasing 
trend for atrial septal defect, which was not statistically significant in individual models 
after Bonferroni adjustment. There were no significant trends observed for any CHD 




 Estimated average annual trends in 16 congenital heart defects from individual models. 
Severity 
group 
Congenital heart defect 
Model 1:  
Individual models pooled over 
registry 
Model 2: 
Individual models with a  
random effect for registry  
1 Single ventricle a 0.041 (-0.025, 0.108) 0.046 (-0.020, 0.112) 
 Tricuspid atresia and stenosis 0.022 (-0.040, 0.084) 0.020 (-0.043, 0.083) 
 Ebstein’s anomaly -0.043 (-0.119, 0.033) -0.042 (-0.113, 0.029) 
 Hypoplastic left heart -0.010 (-0.044, 0.023) -0.010 (-0.043, 0.022) 
 Hypoplastic right heart 0.021 (-0.086, 0.128) 0.020 (-0.057, 0.097) 
2 Common arterial truncus -0.019 (-0.091, 0.052) -0.021 (-0.095, 0.053) 
 Transposition of great vessels 0.008 (-0.022, 0.038) 0.007 (-0.022, 0.037) 
 Atrioventricular septal defect a 0.023 (-0.013, 0.059) 0.022 (-0.019, 0.063) 
 Tetralogy of Fallot a 0.034 (0.003, 0.064)b 0.032 (-0.001, 0.064) 
 Pulmonary valve atresia -0.001 (-0.056, 0.054) 0.002 (-0.056, 0.059) 
 Aortic valve atresia/stenosis 0.006 (-0.044, 0.057) 0.012 (-0.039, 0.062) 
 Coarctation of aorta -0.014 (-0.041, 0.013) -0.015 (-0.048, 0.017) 
 Total anomalous pulmonary venous return 0.010 (-0.051, 0.070) 0.010 (-0.050, 0.071) 
3 Ventricular septal defect -0.001 (-0.012, 0.009) 0.003 (-0.014, 0.020) 
 Atrial septal defect -0.041 (-0.087, 0.006) -0.025 (-0.058, 0.008) 
 Pulmonary valve stenosis -0.028 (-0.054, -0.001)b -0.019 (-0.049, 0.010) 
- All subgroups -0.010 (-0.017, -0.002) -0.005 (-0.016, 0.006) 
a Rows in bold indicate subgroups that showed significant increasing trends in prevalence in the 2012 EUROCAT statistical monitoring report (published 2015) 




 Estimated average annual trends in 16 congenital heart defects from Bayesian hierarchical models. 
Severity 
group 
Congenital heart defect 
Hierarchical model: 
Pooled over registry 
(model 5) 
Hierarchical model: 




Random effect for 
registry (model 6A) 
Hierarchical model: 
Random effect for 
registry (model 6B) 
1 Single ventricle a 0.016 (-0.015,  0.053) 0.023 (-0.013,  0.069) 0.009 (-0.013,  0.043) 0.016 (-0.011,  0.050) 
 Tricuspid atresia and stenosis 0.009 (-0.021,  0.042) 0.013 (-0.020,  0.053) 0.005 (-0.017,  0.033) 0.008 (-0.019,  0.038) 
 Ebstein’s anomaly -0.017 (-0.054,  0.015) -0.019 (-0.070,  0.019) -0.006 (-0.037,  0.016) -0.012 (-0.045,  0.015) 
 Hypoplastic left heart -0.007 (-0.030,  0.015) -0.006 (-0.032,  0.018) -0.003 (-0.025,  0.016) -0.006 (-0.027,  0.013) 
 Hypoplastic right heart 0.007 (-0.025,  0.042) 0.012 (-0.025,  0.056) 0.004 (-0.019,  0.033) 0.006 (-0.022,  0.038) 
2 Common arterial truncus -0.009 (-0.042,  0.023) 1.2x10-8 (-0.034,  0.025) -0.003 (-0.032,  0.019) -0.006 (-0.036,  0.022) 
 Transposition of great vessels 0.005 (-0.017,  0.027) 0.007 (-0.012,  0.027) 0.002 (-0.016,  0.024) 0.004 (-0.015,  0.023) 
 Atrioventricular septal defect a 0.014 (-0.011,  0.040) 0.013 (-0.007,  0.038) 0.007 (-0.012,  0.033) 0.012 (-0.009,  0.036) 
 Tetralogy of Fallot a 0.022 (-0.003,  0.048) 0.019 (-0.002,  0.045) 0.009 (-0.009,  0.037) 0.018 (-0.003,  0.041) 
 Pulmonary valve atresia -0.001 (-0.029,  0.027) 0.004 (-0.022,  0.027) 0.0003 (-0.023,  0.024) 0.001 (-0.024,  0.027) 
 Aortic valve atresia/stenosis 0.003 (-0.023,  0.030) 0.006 (-0.017,  0.029) 0.004 (-0.017,  0.029) 0.005 (-0.018,  0.031) 
 Coarctation of aorta -0.010 (-0.032,  0.011) -0.003 (-0.027,  0.016) -0.005 (-0.028,  0.013) -0.010 (-0.029,  0.009) 
 Total anomalous pulmonary 
venous return 
0.003 (-0.027,  0.035) 0.007 (-0.019,  0.034) 0.003 (-0.020,  0.029) 0.004 (-0.022,  0.033) 
3 Ventricular septal defect -0.001 (-0.018,  0.016) -0.004 (-0.024,  0.016) 0.001 (-0.015,  0.019) 0.002 (-0.010,  0.015) 
 Atrial septal defect -0.032 (-0.052,  -0.011) b -0.038 (-0.058,  -0.017) b -0.009 (-0.031,  0.008) -0.022 (-0.038,  -0.005) b 
 Pulmonary valve stenosis -0.020 (-0.043,  0.001) -0.026 (-0.049,  -0.004) b -0.007 (-0.031,  0.011) -0.012 (-0.032,  0.006) 
 All subgroups -0.001 (-0.015,  0.013) -0.001 (-0.150,  0.147) 0.001 (-0.010,  0.013) 0.0005 (-0.011,  0.013) 
a Rows in bold indicate subgroups that showed significant increasing trends in prevalence in the 2012 EUROCAT statistical monitoring report (published 2015) 






Adding a random effect for severity group in hierarchical models for congenital heart 
defects 
When adding random effects for the severity subgroup indicator to the hierarchical model 
for CHDs, decreasing average yearly trends were observed for two of the CAs in severity 
group 3 (atrial septal defect and pulmonary valve stenosis; Figure 3.19, Table 3.6). There 
were no significant trends for any other CHDs or in the average prevalence across each 
severity group. Estimates for each severity group shrank slightly towards the average of 
that group rather than just towards the overall (null) average across all 16 subgroups. All 
estimates from model 5sev are shown in Appendix Table A19.  
 
Figure 3.19. Estimated average annual trends in 16 congenital heart defects in a 
hierarchical model with an additional term for severity subgroup. 
Assessment of hierarchical models for congenital heart defects 
Information regarding model fit in the hierarchical models for CHD subgroups is presented 
in the Appendix Table A20. The intercepts and slopes were negatively correlated for CAs in 
models 3 (estimated correlation coefficient r=-0.47) and 4 (r=-0.65), as in previous models 
indicating that the model cannot estimate both effects, likely due to very small variance in 
the estimated trends caused by over-parameterisation.  Some amount of overdispersion 
was present for all models, with smaller estimated standard deviation of the dispersion 
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model 5 and model 6B showed good convergence, low levels of autocorrelation, good 
mixing of chains and generally high effective sample size. For model 5 when including an 
additional term for severity group, all parameters showed good convergence and effective 
sample size, although the group level parameters (i.e. the estimated intercepts and slopes 
for each severity group, and for the group of CHDs overall) in this model showed less 
consistent mixing of chains (data not shown). There was high autocorrelation in the 
estimated SD parameter for each of the severity group trends. Once again, the random 
intercept parameters for model 6A showed very poor convergence and mixing of chains, 
very high autocorrelation and low effective sample sizes.   
3.7. Discussion 
In this chapter, BHMs were applied to EUROCAT data to assess the effect of modelling 
group effects for CAs and/or registries in analyses of European trends in the prevalence of 
CAs. Standard EUROCAT coding was used to group CAs together. BHMs that grouped 
together similar CAs were compared to models considering each CA separately, and results 
were found to be broadly similar for the four different groups of CAs considered.  
3.7.1. The Poisson regression model 
Poisson regression was used to model yearly counts of cases in each CA throughout all 
analyses in this chapter; therefore, the assumptions of Poisson regression needed to be 
considered, in particular that of equality of the mean and variance. Using the NTD 
encephalocele as an example, various models were considered to investigate potential 
overdispersion in the data, and to assess the effect of this on estimated changes in 
prevalence. However, throughout the different models in this chapter there was no 
evidence of overdispersion when considering trends over the past ten years of data. It is 
worth noting that since only ten years of data have been considered (to estimate recent 
trends) there may be insufficient data points to provide a reliable estimate of the amount 
of overdispersion in a model. However, estimates of the average yearly changes in 
prevalence of encephalocele and of the dispersion parameter were very similar for all 
models considered. The Poisson-lognormal model was therefore used for all other analyses 
in this chapter, since this model allowed for potential overdispersion in the data whilst 
being equivalent to the standard Poisson model when no overdispersion was present. In 
practice, the Poisson-lognormal model was also straightforward to implement for 
hierarchical models, in particular compared to approaches such as quasi-Poisson or 




3.7.2. Ten year trends in congenital anomalies analysed for this chapter in the 
context of previously published studies 
Estimated trends in prevalence were similar for all types of CA considered in this chapter, 
whether considering CAs separately in individual models or together in hierarchical models. 
Identified trends were largely as expected and consistent with those observed in other 
studies. Increasing trends in chromosomal anomalies were observed, which are known to 
be due to maternal age and changes in prenatal screening practices [Cocchi et al., 2010, 
Loane et al., 2013]. The decreasing trend in Klinefelter syndrome was also observed in the 
three most recent EUROCAT statistical monitoring reports. It was suggested by the authors 
that this decrease is more likely to reflect changes in prenatal screening than a true decline 
in prevalence, as there have been less invasive prenatal tests as a result of the first 
trimester screening test being implemented [EUROCAT Central Registry, 2014a]. NTD 
prevalence remained stable in EUROCAT registries, as has been observed elsewhere [Botto 
et al., 2006a, Khoshnood et al., 2015]. This might be explained by the lack of folic acid 
fortification in Europe and poor uptake of folic acid supplementation; in the UK, for 
example, less than 30% of women took folic acid prior to their pregnancy in 2011–2012 
[Bestwick et al., 2014]. Prevalence in three of the digestive system subgroups was found to 
be significantly increasing in the latest EUROCAT statistical monitoring report [EUROCAT 
Central Registry, 2015]. A similar estimated increase in prevalence in these three subgroups 
was observed here, although these trends did not reach statistical significance in 
independent models. A smaller number of EUROCAT registries were included in the dataset 
for this thesis, hence the lack of statistical significance in these analyses may be due to a 
relative lack of power. Increases in the prevalence of the CHD tetralogy of Fallot (severity 
group 2) was consistent with previous findings [EUROCAT Central Registry, 2015]. Although 
not reaching statistical significance, estimated increasing trends for single ventricle 
(severity group 1) and atrioventricular septal defect (severity group 2) were also consistent 
with the EUROCAT findings in terms of the direction of effect. Estimated decreases in 
prevalence of atrial septal defect and pulmonary valve stenosis (severity group 3), however, 
were not consistent with those observed in other studies, where either no significant 
changes or increasing trends have been previously observed [van der Linde et al., 2011, 
EUROCAT Central Registry, 2015]. For pulmonary valve stenosis, the decreasing trend was 
only observed in individual models pooling over registry (model 1) and a BHM additionally 
including a grouped effect for severity (model 5sev), but this trend was not significant in 




also known to vary substantially due to differing definitions of cases across studies. It is 
likely that the differences in estimated trends here reflect changes in reporting for these 
CAs rather than real changes in prevalence; since August 2007, for example, EUROCAT 
coding has required that only atrial septal defect cases that have been confirmed as still 
present after 6 months of age be reported [EUROCAT Central Registry, 2013]. Differing 
prenatal screening practices in the particular set of registries with data available for this 
thesis may also have influenced the observed trends [Hoffman and Kaplan, 2002, Garne et 
al., 2012b, Baardman et al., 2014]. 
3.7.3. Performance of Bayesian hierarchical models 
Many of the BHMs applied to groups of CAs in this chapter were over-parameterised, in 
particular when taking the registry effect into account, as this greatly increased the number 
of parameters being estimated by each model. Gibbs sampling is known to be inefficient for 
models in which the parameters are highly correlated, as this was seen here for the random 
effects parameters in hierarchical models. This was especially noticeable for smaller groups 
of CAs that only had a small number of random effects levels, e.g. hierarchical models 
grouping the 3 NTDs. The use of Stan was therefore investigated to see if its alternative 
samplers could provide a solution for parameters where the JAGS samplers did not 
converge. However, results from models using Stan were found to be very similar to those 
obtained using JAGS, and estimated trends in each CA remained similar across the different 
models whether using JAGS or Stan. For example, for all groups of CAs considered in this 
chapter, the random intercept parameters for model 6A showed poor convergence and 
mixing of chains, very high autocorrelation and low effective sample sizes. The over 
redundant information present in these models is illustrated in the trace plots for these 
model parameters; for example, in Figure A8 the trace plot for each chain (e.g. indicated by 
a different colour line) for the estimated random intercepts for each NTD balances with the 
corresponding chain for the registry intercepts in this model, shown in Figure A9 (i.e. the 
green line in Figure A8 is always low for each NTD, whilst the green line in figure A9 is 
always high). It is likely that this model does not converge because the second intercept 
parameter  𝑢𝑗 is balancing with the first 𝑢0𝑘 (see Table A4 for notation), whereas in model 
6B there is only one parameter 𝑢0𝑗𝑘, which achieves better convergence. Table A14 shows 
how both JAGS and Stan balance the estimates for the registry and the CA intercepts in 
model 6A (in JAGS the 𝑢𝑗 take larger negative values than the 𝑢0𝑘, and it is the opposite 




The use of different parameters for prior distributions were also considered for hierarchical 
models for NTDs. As expected, the estimated group means of random effects in these 
models had wider PCIs for larger values of the prior variance. The upper values for the 95% 
PCI of the estimated standard deviation for random effects parameters may start to be 
considered unrealistically high when the prior variance is allowed to take very large values. 
Estimated trends in prevalence of each NTD subgroup remained stable, however, across all 
choices of parameters considered. The amount of shrinkage of these estimates did not 
appear to be affected by the choice of prior parameter values. In addition, the estimated 
overdispersion parameter remained stable across the six different prior formulations 
considered here (see Figure 3.10). 
Varying levels of correlations were observed between the random effects, with perfect 
(negative or positive) correlation being estimated by frequentist hierarchical models for 
NTDs and the chromosomal trisomy subgroups, indicating that there was redundant 
information in these models. With only 3 subgroups for NTDs and the chromosomal 
trisomies (and therefore 3 levels for the random effect of CA), these very small groups of 
related CAs likely had too few levels to reliably estimate the random effects parameters in 
BHMs. Indeed, it is well known that a random effects model with less than five levels for 
the random effect parameter does not perform well, with such models often showing poor 
convergence and over-parameterisation [Greenland, 2000, Gelman Andrew and Hill, 2007]. 
Some of the hierarchical models in this chapter were effectively more complex than the 
data could support in practice, especially when including the effect of registry in the model. 
Hierarchical models that did not include the effect of registry performed better in terms of 
diagnostic model checks. It might therefore be inadvisable to include the effects of registry 
at the first stage of analysis, but rather identify CAs that show potential changes in 
prevalence and then further adjust and/or stratify for registry effects only for those CAs 
where a potential trend has been highlighted. However, this approach could possibly lead 
to important changes in prevalence that are country or region specific being missed, for 
example if due to some environmental hazard in one particular area that would not likely 
be present in the data overall when pooled across many registries. 
3.7.4. Use of hierarchical models in the analysis of congenital anomaly data 
Hierarchical models have proven useful in the field of pharmacovigilance, where they have 
been used in the detection of potential adverse drug reactions [Berry and Berry, 2004, Xia 




been used to group similar drugs or AEs together, such that models for each drug-adverse 
event combination incorporate information from analyses of other similar drugs and AEs 
[Prieto-Merino et al., 2011]. In this chapter, the same rationale was applied to CAs; 
however, the situation differs to that for adverse drug reactions, where the hierarchical 
classification systems may provide more natural hierarchies than the grouping of anomalies 
according to the defined subgroups. In practice, analyses in this chapter have shown that 
the EUROCAT subgroup coding hierarchy provides groups of CAs that, whilst similar in 
certain aspects, are still too heterogeneous to be grouped together sensibly when analysing 
changes in prevalence. This is because the shrinkage in BHMs will largely pull estimates 
towards the null if there is a mixture of increasing and decreasing trends, as for CHD and 
digestive CAs, for example. It is therefore possible that potential changes in prevalence in 
analyses of heterogeneous groups of CAs such as these could actually be masked by 
hierarchical models.  
On the other hand, this shrinkage can help control estimates based on small counts by 
including information from the rest of the group. Moreover, this can be thought of as a 
natural “penalisation” if we consider that a hierarchical model is simultaneously looking for 
changes in prevalence for a number of subgroups, compared to individual models where 
this multiple testing aspect is not taken into account (and a number of false positive results 
are therefore likely). Indeed, the use of hierarchical models has been recommended as a 
natural way of accounting for multiple comparisons. Gelman Andrew et al. [2012] advised 
that hierarchical models give better results in general than basic multiple comparisons 
corrections, and furthermore are not more difficult to implement than some of the more 
complex classical multiple comparisons correction procedures. For a group where the mean 
trend across subgroups is close to the null, this penalisation will mean that the estimated 
trend is no longer a “signal” in the hierarchical model, for example as seen for the CHD 
tetralogy of Fallot in severity group 2 (Table 3.6 and Table 3.7Table 3.6). For a group where 
the mean trend is not so close to the null, however, this penalisation might actually lead to 
an increase in the strength and/or precision of a signal, for example for atrial septal defect 
in severity group 3 (Table 3.6 and Table 3.7). Furthermore, the same signal might be 
reduced or enhanced depending on which grouping is used; for example, the trend in 
pulmonary valve stenosis attenuated if considering all CHD groups together, but was 
maintained when also including the severity grouping in the model (Table 3.6, Table 3.7, 




informative prior information, which here is influenced by the way the groups have been 
defined (rather than the use of informative parameters for prior distributions). 
In this chapter, EUROCAT subgroups that were considered related (being in the same organ 
system class) were found to vary considerably in terms of their differing proportional yearly 
changes in prevalence. There might be other CAs not considered in these analyses for which 
it might potentially be more relevant or useful to analysed together in a hierarchical model. 
Specific codes within EUROCAT subgroups could potentially be grouped together (such that 
the EUROCAT subgroup would itself become the group of similar codes), however these 
would likely contain too few cases to perform meaningful statistical analyses. There are also 
known relationships between CAs that lie within different groups of the EUROCAT 
hierarchy, producing a further level of complexity. In addition to NTDs, for example, there 
are a number of other anomalies across different body systems that are thought to be 
sensitive to folate levels during pregnancy, including CHDs, clefts and limb reduction 
defects [Wilson R. D. et al., 2015]. If there were evidence that folate levels had been 
increasing in Europe, then it might have been useful to analyse all these anomalies together 
in a hierarchical model. However, from examining the NTDs alone here (and in other 
studies), no such change has occurred in Europe and hence such models were not 
considered useful to investigate further. Similarly, EUROCAT now includes a 
VATER/VACTERL association subgroup that comprises anomalies of the vertebra, anal 
atresia, CHDs, trachea-oesophageal fistula, oesophageal atresia, radial anomaly and limb 
defect, which are known to occur together more frequently than expected by chance. 
However, the heterogeneity of trends observed in just the CHD component of this 
subgroup indicates that hierarchical models are not likely to add useful information to such 
an analysis.  
Another way of potentially improving the BHMs used in this chapter might be to include 
better (i.e. more informative) prior information in to the analysis. For example, the 
parameter for the intercept 𝑢0𝑘  in model 5 determines the baseline prevalence rate in that 
model, and it could be possible to include information about this parameter from known 
prevalence data in a relatively easy way, by centring the prior distribution for the 
parameter 𝑢0𝑘 on the known baseline (or average) prevalence of the group of CAs being 
considered in the model. Use of more informative priors in this way might potentially 
strengthen the BHMs in these analyses. 
When examining changes in CA prevalence there are multiple factors that can have an 




might therefore be more relevant when considering the risks of specific exposures in 
relation to the prevalence of CAs. One such important risk factor for CAs that is routinely 
monitored is medication use during early pregnancy, and the use of hierarchical models for 
analysis of these is explored in the following three chapters of this thesis. 
3.7.5. Strengths and limitations of EUROCAT data 
EUROCAT registries collect data that is ascertained from multiple sources and includes 
information on all major structural and chromosomal CAs [Boyd et al., 2011, Loane et al., 
2011a], providing high quality population-based data across multiple European countries 
and allowing the inclusion of a large number of CA cases covering over four million births 
over ten years for these analyses. EUROCAT registries include information on cases of 
prenatal diagnosis followed by termination of pregnancy, enabling the inclusion of cases 
that would otherwise have gone undiagnosed, or unreported amongst spontaneous 
abortions or stillbirths. EUROCAT have a detailed data quality strategy, which includes the 
development and annual update and monitoring of a set of data quality indicators relating 
to both diagnostic and registry processes [Loane et al., 2011a]. Despite this, the possibility 
that unknown data artefacts might be responsible (or partly responsible) for any observed 
changes in prevalence (or lack of observed trends) cannot be excluded. However, since the 
aim of this chapter was to compare statistical methods, the presence of any such effects 
would likely affect all models considered in a similar way.  
A potential limitation of these analyses is that it was not possible to include data from all of 
the EUROCAT member registries; hence, some trends that were seen in the latest statistical 
monitoring report did not reach statistical significance here, likely due to the smaller 
sample sizes included. However, it does not seem probable that increasing the sample size 
would have improved the performance of hierarchical models, since the issues were more 
related to CA group sizes and difficulty in forming larger groups that were sufficiently 
homogeneous such that grouping in a hierarchical model was useful. 
3.7.6. Summary and Conclusions 
Hierarchical models considered here did demonstrate how sharing information between 
subgroups of anomalies can provide a sensible “penalisation” to help avoid false positive 
signals by shrinking estimated trends towards the null when there is no evidence of other 
trends in the rest of the group, whilst maintaining signals of changes in prevalence when 
there are others in the group. Hierarchical models using the EUROCAT hierarchy of CA 




analyses of each subgroup. When using EUROCAT subgroups for analysis, therefore, 
considering each CA separately remains an appropriate method for the detection of 
potential changes in prevalence by relevant surveillance systems. Findings from this chapter 
have formed the basis of a journal article published in “Birth Defects Research Part A: 





Chapter 4:  Medication use during pregnancy and the 
associated risk of congenital anomalies: review, methods 
of model comparison and description of EUROmediCAT 
data. 
4.1. Introduction 
Pregnant women are excluded from the majority of safety studies for new medications, so 
little is known about the potential risks to a foetus for most medications. It is therefore 
important that statistical methods used in surveillance analyses of first trimester 
medication use and the related risks of CAs can provide pregnant women with access to the 
most up to date and relevant information regarding potential safety concerns that may 
arise. This chapter begins by reviewing current statistical methods for the systematic 
detection of harmful medications, both in general and more specifically for teratogenic 
medications during early pregnancy and the associated risk of CAs. Potential improvements 
to these methods are then discussed, which aim to incorporate information in the analysis 
about similarities amongst groups of medications or CAs. Difficulties in the evaluation of 
signal detection methods for CA data are discussed, and the Australian classification system 
for prescribing medicines in pregnancy is presented as a way of comparing the methods 
explored in chapters 5 and 6. The EUROmediCAT dataset used in chapters 5 and 6 is then 
described and summarised. 
4.2. Review of methods used to identify potentially harmful medications 
and rationale for new approaches to the analysis of EUROmediCAT 
data 
This section introduces signal detection (section 4.2.1) and the statistical methods that have 
been used in the analysis of potentially harmful medications. This is first discussed in the 
context of large Spontaneous Reporting (SR) databases of suspected adverse drug 
reactions, an area in which there has been a great amount of research and methodological 
developments (section 4.2.2). Whilst some of these databases do include cases of CA, this 
information is generally limited and has not been routinely analysed. Routine signal 
detection analyses of population-based CA data has only been initiated and developed in 
recent years, with the setting up of a European network of CA registries that collect data on 
medication exposures during pregnancy. The statistical methods currently used to perform 




4.2.1. What is signal detection? 
A “signal” for medication safety is defined by the World Health Organisation as ‘reported 
information on a possible causal relationship between an adverse event (AE) and a 
medication, the relationship being unknown or incompletely documented previously’ 
[Edwards and Biriell, 1994]. Note the use of the word “possible”, highlighting that a signal is 
not evidence of a causal relationship, but rather a warning sign that requires further 
investigation. With thousands of reports in any medication safety database, it is clearly not 
feasible to assess each individual report separately; quantitative methods of signal 
detection are needed in order to focus efforts to enable more detailed medical review on 
likely true signals. The main aims of quantitative signal detection are summarised by Bate 
and Evans [2009] as follows 
• to flag potential signals that might be missed 
• to prioritise resources for signal detection when combined with more 
traditional methods, focussing clinical review on the most likely 
candidates 
• to detect more complex dependencies in the data, which are hard to 
detect by manual review, in particular drug-interactions 
• to aid prioritisation of signals           [Bate and Evans, 2009, p.427] 
Signal detection is first step in a wider signal management process, which includes the 
follow up and assessment of signals in detailed literature searches and the collection of 
additional information, followed by the communication of resulting recommendations for 
action to all stakeholders involved, such as international drug monitoring organisations or 
relevant drug companies [European Medicines Agency, 2012].  
4.2.2. Statistical methods used in the analysis of spontaneous reporting data 
Pharmacoepidemiology is the study of the distribution and determinants of drug-related 
events, and the application of such studies to promote safe and effective drug treatment 
practices. Large SR databases have been set up with the aim of detecting signals of AEs by 
searching for drug-AE combinations that have unexpectedly high numbers of reports. These 
are determined using quantitative methods based on measures of “disproportionality”, 
which aim to identify drug-AE combinations that arise excessively often, i.e. with observed 




Spontaneous Reporting databases 
SR databases are large electronic databases comprising of systematically collected 
individual case safety reports for any suspected adverse drug reactions, which may come 
from a number of sources including medication manufacturers, consumers and healthcare 
providers. The WHO’s Vigibase, for example, includes reports from centres in 60 countries, 
who are members of the WHO programme for international drug monitoring [Lindquist and 
Edwards, 2001]. Data-mining methods have been developed and applied in order to 
identify statistical associations in SR databases. Note that since the counts in such data 
come from spontaneously reported cases, exposures are based only on the frequency with 
which particular medications and AEs are reported together, rather than the true frequency 
at which they might occur in practice. Because SR databases only include records of 
individuals that were exposed to at least one medication and had at least one AE, there is 
also no healthy control or comparison group. Reporting rates and calculated relative 
reporting ratios are therefore relative only to that of other drugs and other AEs in the 
database, and cannot be generalised to the population of those who have not taken any 
medications and/or have not had any AEs that were suspected to be related to a 
medication. Reported associations from such analyses must therefore be regarded as 
hypotheses about possible relationships between the drugs and AEs, and not an 
approximation to the relative risk of the specific medication in relation to the CA in the 
general population. Of course (as with any other reported association from a statistical 
analysis), signals may also be caused by factors other than a causal relationship between 
the drug and AE in question (i.e. residual confounding). In order to confirm or refute a 
potential association and/or causality, any signals resulting from disproportionality analyses 
should be carefully followed up in further, more detailed investigations, epidemiological 
studies or randomized clinical trials [Gould A. Lawrence et al., 2015].   
Multiple testing and frequentist methods of signal detection 
The most widely used frequentist estimates of disproportionality are the Proportional 
Reporting Ratio (PRR) [Evans et al., 2001] and the Reporting Odds Ratio (ROR) [van 
Puijenbroek et al., 2002]. These measures are analogous to the relative risk and the odds 
ratio, but with the “exposed” individuals being those who have recorded exposure to the 
drug of interest and the “unexposed” those with no record of exposure to the particular 
drug of interest, but with exposure to at least one other drug in the database. That is, the 
relative frequency of spontaneous reports for a given drug and a specific AE (versus all 




study. This gives the PRR if frequencies are expressed as proportions and the ROR when 
they are expressed as odds. Other less commonly used frequentist approaches to signal 
detection include a cumulative sum method using cumulative numbers of drug-AE reports 
[Lao, 1997], a Poisson probability approach [Tubert et al., 1992], the use of propensity 
scores [Tatonetti et al., 2012] and large-scale logistic regression [Caster et al., 2010]. All 
these methods essentially produce a statistical measure of association for each drug-AE 
pair of interest, usually in the form of a score for which different thresholds can then be 
applied; any scores exceeding the chosen threshold then indicate an association between 
those particular drug and AE combinations. These estimators can be imprecise for rare 
drug-AE combinations (i.e. low cell counts), and the issue of multiplicity also arises due to 
the large numbers of drug-AE combinations of interest. This means that the overall type I 
error rate is likely to be inflated, which can lead to an unacceptably high number of false 
positive associations being identified as signals. Some frequentist methods have attempted 
to account for multiplicity using P-value adjustment; the double FDR procedure, for 
example, corrects P-values according to hierarchical groupings of codes [Mehrotra and 
Heyse, 2004], meaning that P-values are adjusted based on the number of events within a 
group of similar events, as opposed to simply adjusting for the number of events across all 
events.  Another approach to reducing the number of false positive associations has been 
to increase the thresholds used to identify signals [Hauben and Reich, 2005, Slattery et al., 
2013]. However, any choice of threshold is subjective, and represents a trade-off between 
missing potential signals (if the threshold is set too high) and creating too many false 
positives (if the threshold is too low) [Deshpande et al., 2010]. This trade-off between true 
detection rates and false positive rates is an important issue in surveillance programmes, 
because while it is essential for patient safety that true associations between drugs and 
adverse reactions are not overlooked, it is also important that resources are not wasted on 
signals that are likely to be false positives. Whilst adjustment for multiple testing is 
commonplace, minimising the false positive rate (type I error) for true null associations can 
therefore come at the cost of an increase in false negative rates (type II error). It has been 
advocated by some that adjustments for multiple comparisons should not be made at all 
[Rothman, 1990, Savitz and Olshan, 1995]. These authors highlighted some of the 
problematic implication of multiple testing adjustment, in particular that the interpretation 
of a test depends on whether or not other tests are conducted. Savitz and Olshan [1995], 
for example, suggested that not adjusting for multiple comparisons could avoid “unjustified 




Bayesian approaches to signal detection 
Another approach to disproportionality analyses has been the widespread use of Bayesian 
shrinkage techniques. Shrinkage relates to the idea that an estimator may be improved if it 
is combined with other information, wherein the influence of all the estimates are 
considered simultaneously and hence “shrink” towards overall mean values. Estimates with 
large deviations from these overall means or those with greater uncertainty are penalised 
more strictly. Bayesian approaches to disproportionality analyses assume that reporting 
rates are similar (i.e. exchangeable) for all drug-AE combinations by assigning the 
combinations a common prior distribution. This can have a smoothing effect on the 
reporting rates estimated from the data. Such a prior may be estimated directly from the 
data at hand, estimated from previous data, or pre-specified by the researcher in a more 
subjective approach. If a minimally informative prior distribution is used then the 
smoothing effect is likely to be small, but estimates of disproportionality using Bayesian 
methods have generally been shown to shrink towards the null (in particular where there 
are low observed or expected counts) thus controlling for multiplicity by reducing the 
number of false positives (i.e. a conservative approach) [Roux et al., 2005]. However, this 
also means that positive associations may sometimes be less easy to discover and so the 
likelihood of false negative results can increase, once again highlighting the importance of 
the “trade-off” between detection and false positive rates. As in frequentist methods for 
signal detection, these Bayesian methods ultimately produce a statistical measure requiring 
some chosen threshold to identify drug-AE combinations as signals. The most commonly 
used Bayesian approaches to disproportionality analysis are the Gamma-Poisson Shrinker 
(GPS) [DuMouchel, 1999, DuMouchel and Pregibon, 2001] and the Bayesian confidence 
propagation neural network (BCPNN) [Bate et al., 1998]. These methods are used in 
practice to routinely detect signals for a number of large SR databases. Another Bayesian 
approach in this field has been the use of multi-level hierarchical Bayesian models, which 
have been applied to clinical trial data [Berry and Berry, 2004] and SR datasets [Crooks et 
al., 2012]. As well as incorporating Bayesian shrinkage, this use of hierarchical models is 
based on the idea that an estimation of the PRR (or ROR) of a drug-AE combination may be 
improved by combining this with information from other similar drugs (or AEs) according to 
specified groupings of these [Deshpande et al., 2010].  In this case shrinkage refers to the 
estimate for each member of a group being pulled in, (i.e. shrunk) towards the mean of all 




counts and/or limited data. These three Bayesian approaches to disproportionality analysis 
are summarised briefly below. 
The Gamma-Poisson Shrinker 
The GPS is an empirical Bayesian data mining approach, where prior distributions used in 
the analysis are estimated from the data itself. The GPS produces empirical Bayesian 
geometric mean scores [DuMouchel, 1999, Fram et al., 2003], which are a measure of 
association similar to the PRR, such that a score greater than 1 implies an increase in the 
risk of a particular AE associated with a particular drug. The GPS model assumes that the 
observed count for any cell (i.e. any combination of a specific drug and specific outcome) 
follows a Poisson distribution. Since there are no denominator counts for the medication 
exposures in this type of data (with no unexposed cases), the expected counts are derived 
from the available data under the assumption that the exposures and the outcomes are 
independent. That is, the expected counts are calculated as the product of the marginal 
totals (the total number of records across the whole dataset for a particular exposure or for 
a particular outcome) divided by the total count of all observed records. The prior 
distribution used for the estimated disproportionality measure is a mixture of two gamma 
distributions, and each estimate is assumed to have a common prior distribution. To 
generate signals, cells are ranked using various approaches according to the posterior 
distribution of each PRR, for example the 5th percentile is often used as a cut off 
[DuMouchel, 1999]. An example of the use of this method in practice is that of the US Food 
and Drug Administration, who use a GPS procedure for routine data mining system of their 
MedWatch database of voluntary reports of adverse drug events [Szarfman et al., 2002, 
Szarfman et al., 2004].  
The Bayesian Confidence Propagation Neural Network 
Bayesian neural network approaches to searching large numbers of drug-AE combinations 
are discussed in Bate et al. [1998]. The BCPNN aims to identify “unexpectedly” strong 
dependencies between drugs and AEs, as well as measuring how such dependencies change 
with the addition of new data. The measure of disproportionality used by the BCPNN is 
called the information component, which is a Bayesian implementation of the observed to 
expected ratio. A multinomial (rather than Poisson as in the GPS) model is used to produce 
shrinkage towards zero of the observed-to-expected number of AEs, with Bayesian prior 
parameters being fixed in advance (based on prior beliefs or existing knowledge/data) 




in practice is the World Health Organization programme for international drug monitoring, 
who have used this method since 1998 to identify drug safety signals in their international 
database of over two million case reports [Bate et al., 1998, Lindquist et al., 2000].  
Bayesian Multi-level hierarchical models 
A hierarchical structure based on AEs grouped within body systems has also been proposed 
in the form of a more flexible BHM, which was used to search for drug-AE signals in clinical 
trial data [Berry and Berry, 2004]. In the setting of a clinical trial, this model considers a 
three level hierarchy for the reporting of AEs and allows the generation of posterior 
distributions and risk differences. The comparison of the control and treatment groups is of 
less relevance to this thesis, but of note is the hierarchical structure that is implemented. 
This comprises three levels: the lowest level is the type of AE, the second level the body 
systems within which AEs could be grouped, and the highest level is then the collection of 
all body systems. In this framework of analysis, the priors for each drug-AE combination 
incorporate evidence from estimates for similar drugs and/or AEs in the same data. In 
addition, established expert epidemiological and medical knowledge can be incorporated. 
This model allows (rather than imposes) for the possibility that different AEs in the same 
body system might be related, and that rates of AEs are more likely to be similar within 
than across body systems. In these BHMs, the estimates for a particular drug-AE 
combination are adjusted towards the average of a defined group of similar drug-AE 
combinations, where members in the same group should be similar to each other in terms 
of relevant properties (e.g. drugs that act in a similar way or with a similar chemical 
makeup). The use of a mixture prior in the BHM [Berry and Berry, 2004] can allow for the 
possibility that many AEs could be completely unaffected by treatment by giving a point 
mass on the equality of the treatment and control rates. A mixture prior assigns some prior 
probability 𝜋 to the expected proportion of null effects (i.e. where 𝑃𝑅𝑅 = 1), and assigns a 
normal prior to the (1 −   𝜋)% thought to potentially have an effect (i.e. 𝑃𝑅𝑅 ≠ 1). A 
mixture prior for the 𝑙𝑜𝑔(𝑃𝑅𝑅) can then be expressed using a combination of two prior 
distributions for the proportion of expected null effects, where a stronger belief that there 
is no effect can be reflected by choosing a higher value of π. This model was further 
explored by Xia et al. [2011], who compared the use of normal and mixture priors for both 
binomial and Poisson BHMs and found that the use of a Poisson model gave statistical 
properties better suited for data with rare events. Crooks et al. [2012] further built on the 
model of Berry and Berry by considering confounding and interactions, application to SR 




one-dimensional in that there is a single exposure variable (data come from the trial of a 
vaccine with treatment and a control groups) and so a hierarchical structure is only 
considered for the outcome variable (the AEs). An extension of this model that considered 
information sharing for groupings of medications and AEs simultaneously has been 
previously proposed [Brook, 2011]. Brook presented a theoretical formulation of this model 
by extending and combining the Gamma-Poisson Shrinker of DuMouchel [1999] and the 
hierarchical models of Berry and Berry [2004]. When this method was assessed using a 
sample of the WHO pharmacovigilance database, it was recommended that a two-
dimensional model of information sharing could produce a more powerful BHM to detect 
true adverse drug reactions when compared to sharing information only in one dimension. 
Comparisons of Frequentist and Bayesian approaches to signal detection 
The different methods of disproportionality analysis described above have been evaluated 
and compared in a number of studies, with varying conclusions. One study, for example, 
compared six commonly used disproportionality measures (including those discussed 
above) when applied to the Netherlands Pharmacovigilance Foundation dataset, and found 
them to be largely comparable for combinations with at least four exposed cases [van 
Puijenbroek et al., 2002]. The authors recommended that a case-by-case approach be used 
when selecting a signal detection method according to the SR system or database in 
question. In another study, Xia et al. [2011] compared use of a BHM, a non-hierarchical 
Bayesian model, an unadjusted Fisher’s exact test and two FDR procedures, and found that 
a BHM was helpful compared to other methods in reducing the number of false positives 
whilst improving the power to detect true signals. Candore et al. [2015] also evaluated five 
commonly used signal detection algorithms (PRR, ROR, GPS, BCPNN and a model based on 
Fisher’s exact test) across three national or international SR databases as well as four safety 
databases from pharmaceutical companies, and found no method to be clearly superior but 
rather that the methods performed differently depending on which database was being 
considered. The authors therefore recommended that the absolute performance of a 
method should be assessed directly on the database of interest since its performance will 
be specific to that database [Candore et al., 2015]. In another study, Chen et al. [2015] 
compared eight methods for signal detection in terms of their detection and false positive 
rates, using data simulated to represent both SR databases and clinical trials. Here, BHMs 
were considered the most flexible approach, with consistently reasonable detection and 
false positive rates over a range of scenarios. On the other hand, the performance of BHMs 




and, compared to other methods, they were considered more complex and required longer 
computing times. Prieto-Merino et al. [2011] argued that the current standard methods of 
signal detection, e.g. those used in routine surveillance by the WHO and the FDA, do not 
exploit the full potential of Bayesian models. They recommend that the incorporation of 
medical knowledge and sensible hierarchies should be applied to order to share 
information across both medications and AEs in such databases.  
4.2.3. Review of statistical methods for the detection of teratogenic 
medications in early pregnancy 
SR databases such as the European Medicines Agency’s EnduraVigilence [European 
Medicines Agency, 2016], the Uppsala Monitoring Centre’s VigiBaseTM [Lindquist, 2008] 
and the US Foods and Drug Administration’s AE reporting system [Sakaeda et al., 2013] 
include coding for CAs as a potential type of adverse drug reaction, and can therefore be 
used to try and identify teratogens. However, SR databases can be limited in their utility 
due to a number of factors, including duplicate case reports, reporting biases and, in 
particular, the potential for underreporting [Suling and Pigeot, 2012, Sharrar and Dieck, 
2013]. Dissemination of a communication from the FDA regarding a drug’s safety, for 
example, can affect the likelihood that an AE for a particular medication is reported 
[Ishiguro et al., 2014]. In general, if a medication has had attention in the media, individuals 
might be more likely to report on their use of it (i.e. recall bias). SR databases also tend to 
have limited coding in relation to CAs, for example they often do not distinguish between 
chromosomal and non-chromosomal CAs. Another limitation of SR databases in this respect 
is that they do not identify the timing of medication exposures, so it cannot be determined 
at which stage of development of the foetus a medication exposure occurred. Furthermore, 
SR databases do not include cases of termination of pregnancy for fetal anomaly. 
Population based CA registries, in contrast, use multiple sources to actively capture all cases 
of major CA (including terminations) in the population covered by each registry, thus 
minimising underreporting biases in terms of CA prevalence. Due to these limitations of SR 
databases other approaches to the detection of teratogens in CA data have been used. For 
example, patient registries have been used to compare the risk of major CAs following 
maternal use of specific medications. One such patient registry is EURAP, which collects 
data internationally on the use of antiepileptic medications during pregnancy [Tomson et 
al., 2011]. In these patient registries, women are registered before the outcome of their 
pregnancy is known, therefore minimising some of the biases encountered by SR 




cannot therefore be used for signal detection across all types of medications. Instead, 
associations are typically evaluated in independent hypothesis-driven studies of specific 
types of medications or CAs. Carmichael et al. [2005], for example, performed a case-
control study to assess whether maternal intake of progestin in early pregnancy was 
associated with an increased risk of hypospadias. Anderka et al. [2012] investigated the risk 
of selected CAs for medications used to treat nausea and vomiting during pregnancy. In 
another example, Zaqout et al. [2015] investigated the impact of the common first 
trimester dydrogesterone use on CHDs. Potentially informative relationships with other 
medications or other types of CA might be overlooked in these types of studies. 
Furthermore, studies of specific medications and CAs are not systematic or hypothesis 
generating and are therefore limited in their ability to identify new teratogens at the 
earliest possible stage. 
Systematic signal detection for CAs in Europe: the EUROmediCAT network 
The EUROmediCAT project was established in 2011 to build a European system for the 
evaluation of the safety of medication use during early pregnancy in relation to the risk of 
CAs [Morgan et al., 2011]. EUROmediCAT was built upon the existing network of EUROCAT, 
including only those registries with  information on medication use during the first 
trimester of pregnancy [EUROCAT Central Registry, 2014b]. Only first trimester medication 
exposures are included in EUROmediCAT data because the critical period of development 
for most major CAs is in this period, during which time the organs of the foetus form 
[Czeizel, 2008].  
Current EUROmediCAT signal detection methodology  
A hypothesis-generating signal detection method has recently been developed, which uses 
the EUROmediCAT database to routinely identify potential teratogenic medications taken 
during the first trimester of pregnancy [Luteijn et al., 2016]. This method uses a one-sided 
Fisher’s exact test to compare the odds of exposure to a specific CA and medication to the 
odds of exposure to the same medication in the remainder of the dataset, i.e. all other 
medication-exposed CAs. Each medication and each CA is examined separately, using ATC 
codes for medication exposures (see Table 1.1) and EUROCAT subgroup codes for CAs (see 
chapter 3). Only medications coded to ATC level four (ATC4) or five (ATC5) are considered, 
giving five or seven digit codes, respectively, containing information regarding the chemical 
subgroup and the chemical substance of a medication. Exposures with information at only 




enough detail for the purposes of signal detection analyses. A separate analysis is 
performed for each medication-CA combination. An FDR procedure is then applied (see 
next section for further details) in order to adjust for multiple testing when determining the 
statistical significance of each test. A separate analysis is performed for ATC4 and ATC5 
codes, with duplicate statistically significant associations being excluded from the set of 
potential signals. Duplicate associations here refers to those involving an ATC4 code where 
a more detailed ATC5 code is associated with the same CA (e.g. if N03AG and N03AG01 
were both signals with the same CA), or those involving aggregate CA codes where a more 
specific code was associated with the same medication (e.g. if NTDs and spina bifida were 
both associated with the same ATC code). Statistically significant associations showing a 
protective association are not further investigated, since these are thought to be likely due 
to chance or due to bias arising from the study design [Luteijn et al., 2016]. A protective 
association is only in comparison to other CAs and medications in the database as there are 
no “healthy” controls, and does not imply that any particular medication is associated with 
a lower overall risk of a particular CA. This signal detection methodology was applied to 
EUROmediCAT data for the years 1995–2011, and it picked up some (but not all) known 
teratogens, as well as identifying new potential associations. The use of different FDR cut-
offs were assessed and an FDR of 50% was found to provide a reasonable balance between 
detection rate and minimising the workload created in terms of having to follow up 
potential signals; this means that up to 50% of medication-CA combinations found to be 
potential signals are expected to be false positive associations. A total of 39 combinations 
were considered signals after the FDR procedure, 28 of which were for antiepileptic, 
antidiabetic, antiasthmatic medications or selective serotonin reuptake inhibitors; these 
medication groups are already examined separately as part of other EUROmediCAT projects 
[de Jong-van den Berg et al., 2011] and were therefore not considered further in the signal 
detection process. The remaining 11 signals were discussed in a separate paper that 
examined the potential new associations in detail [Given et al., 2016]. In this paper an 
additional 16 signals were also considered for further examination, based on a previous 
signal detection analysis of the same EUROmediCAT dataset that had been reported prior 
to analytical refinements such as the combination of duplicate ATC codes and the specific 
(single FDR-adjusted) cut-off P-values for associations in ATC4 and ATC5 coding 
[EUROmediCAT, 2015]. Exposed cases for medication-CA associations identified using the 
signal detection method were then validated with local registries to confirm diagnoses and 




then adjusted for confounding by registry, and medication-CA associations persisting after 
this process were considered to be validated statistical signals. After data validation, Given 
et al. [2016] found that there remained evidence for a signal in 13 of the initial 27 
associations considered, for which a literature review was then performed to assess 
existing evidence of human teratogenicity. Prior evidence was found to support 6 of the 13 
signals, with the other signals requiring further confirmation in an independent dataset. 
Use of a false discovery rate procedure to adjust for multiple tests 
When determining the significance of each test separately, the conventional cut-off level of 
5% for statistical significance means that 5% of all medication-CA combinations with a 
statistically significant result will be labelled as signals due to chance alone. For example, if 
1000 tests are performed then 50 of these are expected to be statistically significant, but 
not true associations. It can then be difficult to determine a true association (if indeed 
there are any) amongst all of the positive results, due to the proportion that that are not 
true associations; if there was only one true association in this example it would need to be 
picked out from the 51 statistically significant results. One approach to this problem is to 
control the proportion of false positive results among the set of all positive results; this is 
the FDR. In other words, the FDR is the proportion of incorrect rejections amongst all 
rejections of the null hypothesis. FDR control can be achieved using a multiple testing 
method such as the Simes procedure [Benjamini and Hochberg, 1995]. In the above 
example the FDR would be 50/51, implying that around 98% of identified signals might be 
false positive associations. 
Limitations of current EUROmediCAT methodology and rationale for methodology 
applied in this thesis 
A main strength of the EUROmediCAT signal detection method is that it is systematic and 
ongoing, in that it aims to be repeated when new data becomes available. The issue of 
multiple testing is also addressed through use of an FDR adjustment. However, this 
adjustment for multiple testing is done across the whole database and, as discussed in 
Chapter 1, potential relationships between medications or CAs are not considered. 
Medications in the same ATC classes are often known to work in similar ways, and this 
information may be useful for signal detection methodology. Similarly, certain CAs are 
thought to be more sensitive (compared to other types of CAs) to medications in general. 
Methods used in pharmacovigilance for SR and clinical trial data are able to specify that 
medications in the same class (e.g. within a particular chemical or therapeutic subgroup) 




associations for groups of related medications can be considered simultaneously. These 
methods have not yet been explored for use in routine single detection for population-
based CA data. An objective of this thesis was therefore to refine the signal detection 
component of EUROmediCAT surveillance methodology. To achieve this, two different 
approaches were considered  
1. using post-analysis FDR adjustments that take groups of medications and/or CAs 
into account (Chapter 5) 
2. using BHMs to directly model potential group effects for groups of similar 
medications and/or CAs (Chapter 6) 
The statistical models used in the following two chapters incorporate aspects of the current 
EUROmediCAT methodology combined with signal detection methodology used in more 
general pharmacovigilance settings (i.e. SR databases or clinical trials data), such that 
models applied in this thesis are novel approaches to the routine signal detection analyses 
of population-based CA data. 
Calculating measures of disproportionality congenital anomaly data: the “exposed 
malformed” design 
The “exposed malformed” design refers to the fact that all individuals in the dataset are CA 
cases that have been exposed to at least one medication; as such, the “controls” in each 
comparison  are malformed foetuses with at least one major CA and who were exposed to 
at least one medication other than the specific CA and medication under consideration. 
Table 4.1 displays an example 2x2 table for the test of association between a specific 
medication and a specific CA, for a measure of the risk associated with medication 𝑖 for CA 
𝑗, compared to all other CAs and medications in the data.  
 The “exposed malformed” design in analysis of the relationship between a 






Foetuses with CAs 
other than 𝑗 
Total 
Exposed to medication 𝑖 𝑐𝑖𝑗 𝑐𝑖𝑗′  𝑐𝑖. 
Unexposed to 𝑖, but exposed 
to at least one other 
medication in the data 
𝑐𝑖′𝑗 𝑐𝑖′𝑗′  𝑐𝑖′. 





The most commonly used measures of disproportionality are the ROR and the PRR. These 
can be explained in the context of EUROmediCAT data using notation from Table 4.1, which 
presents the observed count 𝑐𝑖𝑗  for the number of exposures to drug 𝑖 for foetuses with 





𝑃𝑅𝑅𝑖𝑗 =  
𝑐𝑖𝑗  / 𝑐𝑖.
 𝑐𝑖′𝑗 /  𝑐𝑖′.
 
A PRR or ROR of 1 indicates that there is no suspected association between the medication 
and CA of interest.  
Use of the proportional reporting ratio 
The PRR was the measure used for signal detection analyses in this thesis, as this is 
naturally used by models for count data. RORs and PRRs have been shown to be similarly 
effective in practice as measures of disproportionality [van Puijenbroek et al., 2002, Waller 
et al., 2004]. The link between these two measures is similar to the approximation of the 
rate ratio through the use of an odds ratio in a case-control study, and the use of the PRR 
rather than the ROR should not have a material effect on our conclusions. Indeed, the two 
measures are known to give very similar results when the count 𝑐𝑖𝑗  is a low proportion of 
the total exposures to medication 𝑖 (𝑐𝑖.), and the count 𝑐𝑖′𝑗 is a low proportion of the total 
exposures to all other medications in the database (𝑐𝑖′). This may not be the case for all 
types of CA; the CHDs, for example, are the most common type of CA and these affect up to 
35% of cases in the EUROmediCAT data [Luteijn et al., 2016]. The counts 𝑐𝑖𝑗  and 𝑐𝑖′𝑗 are 
therefore likely to represent a relatively high proportion of the total exposures in the 
dataset, especially for some of the more common CHD subgroups.   
Protective associations in signal detection analyses 
Statistically significant associations resulting from models that showed a protective 
association (i.e. a PRR < 1) were not flagged as signals, as is the case in the existing 
EUROmediCAT methodology. The aim of signal detection is to identify potentially harmful 
medications, and this is why a one-sided significance test is used in EUROmediCAT analyses. 
This does not mean, however, that no protective associations are expected; some are likely 
to occur e.g. due to chance or bias arising from the study design. The number of 
combinations showing a protective association were therefore monitored throughout all 




protective associations here does not imply that a particular medication is associated with a 
lower overall risk of a particular CA, since there are no healthy controls and hence the 
comparison is only to other CAs and medications in the database. 
4.3. Validation and comparison of signal detection methods for CA data 
A way of judging how good these different methods are was required in order to be able to 
decide which method is most appropriate for use in the analysis of medication safety during 
pregnancy. For example, it would be useful to be able to quantify how many medications 
that are known to be harmful are being picked up by each method. Aside from a few well-
known exceptions, however, there is in fact very little available or substantial evidence 
regarding which medications are likely to be teratogenic. This was highlighted by a recent 
comprehensive review, which confirmed a lack of existing knowledge on the teratogenic 
effect of medicines used during pregnancy [van Gelder et al., 2014]. This review 
emphasised that prescription rates are not associated with current knowledge on 
teratogenicity of many medications; those known to be most commonly used during 
pregnancy were not generally the medications for which teratogenic risks have been well 
studied or evaluated. Nevertheless, associations reported from case-control studies in this 
review were used to evaluate the signals obtained by the recently developed 
EUROmediCAT signal detection system, resulting in only a small set of eight associations 
available for validation [Luteijn et al., 2016]. In order to consider the relative value of the 
methods quantitatively, however, a more comprehensive set of known medication-CA 
associations would ideally be identified. The proportion of associations detected by each 
method could then be calculated and directly compared. 
4.3.1. Risk classification systems for the prescription of medications during 
pregnancy 
The Australian classification system for prescribing medicines in pregnancy [Australian 
Government Department of Health, 2016; https://www.tga.gov.au/prescribing-medicines-
pregnancy-database] was identified as a potential source of information for use as a 
comprehensive means of method validation, where the number of “high risk” medications 
(as independently identified using this database) could be used to quantitatively judge the 
signal detection methods for CA data. This system was established in 1963 by the Australian 
Medication Evaluation Committee, to advise on the safety of new medications being 
introduced into Australia and to monitor and evaluate potential AEs of medications already 




developed and maintained by medical and scientific experts according to available evidence 
of recorded risks associated with taking particular medicines while pregnant. All 
medications in this database are divided into five main lettered categories, which are 
summarised in Table 4.2. Category A medications are considered to be safe for use during 
pregnancy. Medications in categories B1, B2 and B3 have not shown any evidence of 
harmful effects or increased frequency of malformations for human foetuses. Those in 
category C may carry harmful effects to human foetuses, but without any evidence of 
causing malformations. Finally, medications in categories D and X are considered to carry 
moderate to high risk as they are believed to increase the frequency of human fetal 
malformations and can lead to permanent and irreversible damage.  
 Definition of categories in the Australian system for prescribing medicines in 
pregnancy. 
Category Summary of medications in category  Risk a 
A • Taken by large number of pregnant women /women of 
childbearing age 
• No increase in frequency of malformations observed  
Low 
 
B1-B3 • Taken by limited number of pregnant women /women of 
childbearing age 
• No increase in frequency of malformations observed  
B1: no evidence of increased fetal damage from animal studies 
B2: no evidence of increased fetal damage from animal studies, 
available studies inadequate or lacking 
B3: evidence of increased fetal damage in animal studies, 
significance for humans uncertain 
Low 
C • Caused /suspected of causing harmful effects on human foetus, 
without causing malformations 
• Effects may be reversible 
Low 
D • Caused/ suspected /expected to cause increased incidence of 
human fetal malformations, or irreversible damage 
High 
X • Medications with a high risk of causing permanent damage to the 
foetus  
• Should not be used in pregnancy or if there is a possibility of 
pregnancy 
High 
a Risk associated with causing malformation to the foetus, categorisation as defined for use in this 
thesis 
A teratogenic signal detection method should be expected to pick up more medications in 




medications in categories D and X that are identified as signals increases this should 
indicate improvements in the sensitivity of a signal detection method. 
The Australian categorisation system gives an online table of all medications in its database 
with five fields of information for each medication listed. These fields are medication name 
(given by the active ingredient or the generic medication name rather than any trade or 
commercial names), specified risk category and three levels of classification according to 
the pharmacological group or action of the medication. Further additional information can 
be obtained from the database for certain medications, including a full description of the 
given risk category and any safety statements relating to the particular medication, where 
applicable. An example of the information given for one such medication is displayed in 
Table 4.3.  
 Example of information given for a specific medication in the Australian 






Drugs which have caused, are suspected to have caused or may be 
expected to cause, an increased incidence of human fetal 
malformations or irreversible damage. These drugs may also have 
adverse pharmacological effects. Accompanying texts should be 
consulted for further details. 
Classification 1: Cardiovascular System 
Classification 2: Antihypertensive 
Classification 3: Angiotensin II receptor antagonists and renin inhibitors 
Additional 
Information: 
When used in pregnancy during the second and third trimesters, 
drugs that act directly on the renin-angiotensin system can cause 
injury and even death in the developing foetus. Although no adverse 
fetal effects have been linked to first trimester drug use of ARAs, the 
number of exposures reported is too small to determine conclusively 
that ARAs are safe in the first trimester. Pregnant women who are 
taking ARAs should be changed as quickly as possible to other 
antihypertensive medication to maintain normal blood pressure. It is 
generally advisable not to use ARAs for the management of 
hypertension in women who are likely to become pregnant. 
 
It can be seen in this example that the additional information (for which many substances 
do not have anywhere near this amount of detail, if any at all) contains little information 
specific to particular CAs. For this particular medication, the risks to the foetus at different 




there is inconclusive evidence about the risks in early pregnancy, so may not in reality be a 
high risk medication for first trimester exposure data. 
Issues with the use of risk categorisation systems to address the safety of medications 
during pregnancy 
Similar categorisation systems have been in place in Sweden since 1978 and the US since 
1979, including pregnancy labelling regulations and the introduction of similar letter risk 
categories. However, the distribution of drugs into the various categories is sometimes 
known to vary between the Swedish, US and Australian systems [Sannerstedt et al., 1996]. 
There are also further issues with these types of categorisation systems. There has not 
been sufficient research into the effects of many medications, for example, to be able to 
adequately assess their risks for human foetuses, and consequently medications within the 
same risk category do not necessarily have similar risks. This issue is particularly relevant to 
the US categorisation system, where the majority of medications have generally been 
allocated to the “risk cannot be ruled out” category due to the stringent quality of data 
required to classify a medication as being “high risk” [Sannerstedt et al., 1996]. This issue 
contributed to the decision to introduced new labelling rules to replace the food and drug 
administration’s letter risk categorization system in the US in June 2015 [US Food and Drug 
Administration, 2014]. The updated system requires labelling for new medications to 
include three detailed subsections describing the risks of that medication during pregnancy, 
not only in the context of fetal risk but also other factors including maternal disease 
severity, co-existing conditions and potential alternative therapies [Mosley et al., 2015]. 
New medications in the US are therefore no longer assigned to one of the letter risk 
categories. These new rules aimed to provide more detailed information for each individual 
medication and to better guide clinical decisions for pregnant and breastfeeding women. 
Other concerns about this type of classification for medications include a lack of 
differentiation between uses of the same medications for different conditions, and the fact 
that the stage of pregnancy at which the medications might be taken is not considered 
[Ramoz and Patel-Shori, 2014]. In particular for analyses of CA data, it is important to note 
that there is no information as to which specific CAs are affected by any particular 
medication (e.g. as can be seen in Table 4.3). As such, whilst classifications are made 
separately for medications they are not specific to different types of CA. If a medication is 
assigned to the “high risk” category this is the case for all combinations of that medication 
with a CA, despite the fact that the medication may only be teratogenic for certain types of 




teratogen that has been associated with an increased risk of certain CAs, including spina 
bifida, atrial septal defect, cleft palate, hypospadias, polydactyly and craniosynostosis 
[Jentink  et al., 2010]. There is no evidence, however, that valproic acid is also a “high risk” 
medication for all other CAs, so we may not expect it to have any effect on the relative PRR 
of all other types of CA. The set of all medication-CA combinations that are identified as 
being “high risk” in EUROmediCAT data is therefore likely to be overestimated in this thesis. 
A further complication specific to these data is that medications in category X are likely to 
be underrepresented in the EUROmediCAT data since pregnant women are advised against 
these known teratogens. In fact, as soon as a medication becomes known as a teratogen, 
there can be a rapid switch in prescription practises worldwide. Some exposures to such 
medications would still be expected in CA databases e.g. due to medication use during early 
stages of unplanned pregnancies, or for women who might be taking a medication for a 
chronic or life threatening condition. However, there is likely to be insufficient numbers to 
provide the power to detect an association in such cases, even when the medication is 
known to be truly teratogenic. 
Lack of a gold standard reference set of known teratogens 
Due to the above issues, none of these classification systems can be considered as a gold 
standard against which the results from the current signal detection methods may be 
compared and evaluated. However, what was required for this thesis was a way of directly 
comparing the different possible methods of signal detection that may be used in practice 
with CA data. Whilst the categorisation system cannot provide an absolute measure of how 
good any chosen model is, each model will have the same lack of data and power for 
known teratogens, so use of measures based on the Australian categorisation system were 
considered a potentially useful way of directly comparing the relative strengths of the 
models applied to EUROmediCAT data in the following chapters. 
Mapping the Australian risk categories to EUROmediCAT data 
In order to compare different methods using the proportion of signals detected in “low” 
and “high” risk categories (see Table 4.2), the online database of the Australia 
categorisation system was downloaded in table format [Australian Government 
Department of Health, 2016]. Medication names given in this database were matched to 
the EUROmediCAT data using substance names for ATC coded medications. Where 




manually. Where available, the given risk category according to the Australian classification 
system was then included for each specific ATC code in the EUROmediCAT data. 
4.3.2. Defining measures for the comparison of signal detection methods 
In signal detection analyses, the detection rate is the proportion of all the true positive 
associations that are identified as signals. Of course, it is not possible to get a realistic 
estimate of this detection rate for CA data since there is no comprehensive or reliable 
reference list of all true associations. For this thesis, therefore, the proportion of all the 
“high risk” medications that were identified as signals was calculated using the risk 
categories of the Australian classification system. This was called the identification rate, and 
was defined as 
𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐫𝐚𝐭𝐞 =
Number of "high risk" medications identified as signals
Total number of "high risk" medications in the data
 
The proportion of medication signals that were “high risk” out of all the identified 
medication signals (i.e. including those with “low” or unidentified risk) was also be used to 
compare the different methodologies considered. This can be thought of as an estimate 
similar to the positive predictive value, which is the number of true positive associations 
out of the total number of associations identified as signals. For this thesis, the “high risk” 
proportion was defined as 
“𝐇𝐢𝐠𝐡 𝐫𝐢𝐬𝐤” 𝐩𝐫𝐨𝐩𝐨𝐫𝐭𝐢𝐨𝐧 =
Number of medication signals in "high risk" category
Total number of medications identified as signals
 
Another important consideration in signal detection analyses is to balance the potential 
workload with the false discovery and detection rates. Every association flagged as a 
potential signal needs to be followed up separately in further studies, which requires time 
and effort for each individual signal being assessed. It is important, therefore, that whilst 
achieving the highest possible detection rate, a realistic restriction is placed on the total 
number of signals identified that can be followed up in practice. This must also be balanced 
with the number of signals that are likely to be true associations such that time and 
resources are not wasted in following up large numbers of false positive associations. 
Alongside the identification rate and “high risk” proportion, methods were therefore also 
compared in terms of how many signals they identified, in order to quantify the workload 
created by each method. This is referred to as the “effective workload” and was defined as 
follows 




Note that rather than the total number of medication-CA combinations identified as signals, 
the number of medications within this set of signals is considered the resulting workload. 
This reflects the fact that the actual medications are considered the risk factors, whether 
they are associated with one or more CAs. In terms of the required follow up of potential 
signals, each additional medication flagged up as a signal presents a more significant 
increase in workload than any number of additional signals of a medication that has already 
been flagged (with a different CA). 
4.4. EUROmediCAT data 
4.4.1. Data sources and included congenital anomalies and medications 
Data for these analyses were from 13 EUROmediCAT registries in 11 countries that agreed 
to participate in this study, covering a total population of around 7 million births in the 
period 1995-2011. Note that this did not include two of the registries (Mainz; Cork and 
Kerry) that contributed data to the previous EUROmediCAT signal detection analyses, and 
for two registries (Zagreb; Poland Weilkopolska) an additional year of data from 2011 was 
available that had not been included previously. As the exact same dataset could not be 
obtained for this project, results using the current EUROmediCAT methodology would not 
be identical to those published by Luteijn et al. [2016]. However, since the majority of the 
data used was the same, any signals detected or overall conclusions drawn when using the 
same single FDR methodology were considered comparable. 
Congenital anomalies monitored for the purposes of signal detection 
EUROmediCAT data were coded in the same way as the data on CAs in EUROCAT (see 
Chapter 3), here consisting of cases of non-genetic CAs. Cases with any of the following CAs 
were excluded, since they are inherited and therefore ca not potentially be caused by 
teratogenic medications: chromosomal anomalies, skeletal dysplasia, genetic syndromes 
and microdeletions. Foetuses with isolated congenital dislocation of the hip as their only 
major CA were also excluded, since the aetiology of this CA is known to be mechanical (i.e. 
caused by physical pressures from outside the uterine environment). The cases in the 
analysis were foetuses with that specific CA for 55 pre-defined EUROCAT subgroups 
[EUROCAT Central Registry, 2013]. The highest level of EUROCAT coding gives the major 
organ subgroup, within which there are further classes; these higher level groups are also 
referred to as aggregate subgroups. The aggregate subgroups include all cases listed in the 
subgroups at lower levels as well as cases that do not have this more detailed information. 




recorded, this case will still be counted in the aggregate CHD subgroup. In the previous 
EUROmediCAT signal detection analyses, the only aggregate subgroups that were 
monitored were NTDs, CHDs and severe CHD. In EUROmediCAT data, the vast majority of 
cases in aggregate CA groups are also attributed a more specific subgroup code, so 
including these groups when considering CAs simultaneously means that a large number of 
cases would be counted twice in the analysis. In the analyses of Luteijn et al. [2016], this 
issue was dealt with at a later stage by removing duplicate statistically significant 
associations involving aggregate CA codes where a more specific code was associated with 
the same CA. For this thesis, however, no aggregate subgroups were monitored because 
this would have led to a large overlap of information when considering methods that 
grouped medication--CA combinations. For the aggregate group of NTDs, all the cases in 
this dataset also had a more specific code giving the type of NTD. For those with a recorded 
CHD, however, 542 had no further information regarding the specific type of defect; these 
cases were therefore combined into a separate subgroup (“Unspecified CHD”) for analysis 
purposes. In addition, two subgroups that were monitored in the recent EUROmediCAT 
signal detection analysis (neural crest and complete absence of a limb) were not included 
here because a more recent version of EUROCAT coding was used for the extraction of data 
for this thesis. The newer version of coding also included five further CAs that were not part 
of the previous signal detection analyses and hence (for comparison purposes) these were 
not monitored for this thesis. The following EUROCAT subgroups were included in the data 
as malformed controls, but are not monitored for signal detection: cystic adenomatous 
malformation of lung, hypoplastic left heart, indeterminate sex, congenital skin disorders, 
teratogenic syndromes with malformations, fetal alcohol syndrome, valproate syndrome, 
and maternal infections resulting in malformations. 
Medication exposures in EUROmediCAT data 
Maternal medication exposure data in EUROmediCAT are typically obtained from 
prospectively recorded maternity records [Boyd et al., 2011, Bakker and Jonge, 2014]. 
Information on medication exposures are collected by registries, with some registries also 
having additional data sources such as general practitioner records, maternity passports, 
maternal interview before or after birth and medical records of the infant [Bakker and 
Jonge, 2014]. Inclusion in EUROmediCAT database requires exposures to have occurred in 
the first trimester, which is defined as the time from the first day of a woman’s last 
menstrual period up to her twelfth week of gestation. The two Polish registries, however, 




exposures was performed to ensure that only exposures that were known to have occurred 
during the first trimester were included. EUROmediCAT codes all medications using the ATC 
system (see Table 1.1), with an unlimited possible number of first trimester exposures 
being coded, each including up to seven digit codes and free text information. Malformed 
foetuses that were exposed to at least one recorded medication in the first trimester of 
pregnancy were included as cases in the data for analyses. Foetuses that were exposed only 
to vitamins, minerals and/or folic acid were excluded. Cases exposed exclusively to 
medication codes with less than 5 digits (i.e. not coded up to at least ATC4 level), topical 
medications (ATC codes S01-S03, D01A, D02-D04, D05A, D06-D09, D10A, D11AA, D11AC, 
D11AE, D11AF, D11AH01-D11AH03, M02 and all D11AX codes except for oral preparations) 
and those taken in the 2nd/3rd trimester or with unknown timing were also excluded. ATC 
codes subject to alterations over time were obtained from the WHO website [WHO 
Collaborating Centre for Drug Statistics Methodology, 2015], and older codes were updated 
where available. ATC5 codes were analysed; where there was only information available to 
ATC4 level, this was included in the analysis as a separate code. As the majority of codes in 
the dataset included information up to ATC5 level, this allowed these few ATC4 codes to be 
incorporated in the groupings. This meant as much information was included as possible 
whilst avoiding duplication of analyses and results that occur when ATC4 and ATC5 codes 
are analysed separately. 
4.4.2. EUROmediCAT data description 
A summary of the EUROmediCAT dataset as extracted for this thesis is displayed in Table 
4.4. A total of 31,197 foetuses with at least one first trimester medication exposure 
(excluding exposures to only folic acid, minerals and/or vitamins) and a major CA (excluding 
genetic conditions) born from 1995 to 2011 were extracted from the EUROmediCAT central 
database for 13 registries. Of these, 905 foetuses with isolated congenital dislocation of the 
hip, 1,219 with no ATC4 or ATC5 level medication exposures recorded and 452 with only 
topical medication exposures were excluded, leaving 28,621 foetuses with valid medication 
exposures. Foetuses with exposures outside the first trimester of pregnancy (n=1,490) or 
with unknown timing (n=12,073) were further excluded, for a remaining 15,058 foetuses 
available for analysis. Poland and Wielkopolska registries had the largest data loss due to 
unknown exposure timings, with over 82% of foetuses being excluded where it was not 
possible to verify whether the medications reported had in fact been taken in the first 




timings was for the Northern Netherlands registry, where notes in records about timings 
led to the exclusion of 25% of records. However, the distribution of types of CA were similar 
for those pregnancies included and excluded due to unknown timing, suggesting that the 
cases remaining in the dataset for these registries should not be prone to selection biases in 
this respect. All other registries had less than 5% data loss due to cleaning by timing of 
medication exposures. On average, there were 1.55 recorded ATC-coded non-topical 
medications per pregnancy, ranging from one (in 65% of cases) up to 16 (in one case) 
recorded medication exposures per pregnancy. The total number of medication exposures 
for the 15,058 foetuses was 23,410. Of these, 22,624 were exposures to medications that 
appeared at least 3 times in the dataset. Around 4% of exposures were coded using only a 
five digit ATC4 code (n=1,037) rather than a full seven digit ATC5 code. Overall, there were 
893 unique ATC5 medication codes in the data, and a further 123 codes with information 
only up to ATC4. After the exclusion of medication codes with less than 3 exposures overall, 
523 ATC medications remained for analyses, of which 39 (7.5%) were coded only to ATC4 
level. With 55 CAs, this gave a total of 28,765 potential medication-CA combinations 









CAs and at least 
one valid 
exposure 
Foetuses with CAs 
following data cleaning 
by timing of exposure a 















Denmark, Odense 1995-2011 240 240 0 367 346 1.53 
France, Paris 2001-2011 658 658 0 970 897 1.47 
Italy, Tuscany 1995-2011 1,083 1,033 4 1,417 1,352 1.37 
Netherlands, North Netherlands 1995-2011 2,451 1,848 25 3,133 2,933 1.70 
Italy, Emilia Romagna b, c 1995-2011 2,350 2,349 0 3,860 3,736 1.64 
Switzerland, Vaud 1997-2011 309 297 1 458 433 1.54 
Croatia, Zagreb 1995-2011 198 190 2 243 218 1.28 
Malta 1996-2011 306 305 0 461 453 1.51 
Belgium, Antwerp 1997-2011 349 347 1 508 478 1.46 
UK, Wales 1998-2011 2,057 2,057 0 3,030 2,924 1.47 
Norway 2005-2010 3,051 3,051 0 5,535 5,481 1.81 
Poland, Wielkopolska 1999-2011 3,180 469 85 640 632 1.36 
Poland (excluding Wielkopolska) 1999-2010 12,389 2,214 82 2,788 2,741 1.26 
Total 1995-2011 28,621 15,058 47 23,410 22,624 1.55 
a After exclusion of CA registrations with only medication exposures of unknown timing 
b During the period 1995 to 2004 Emilia Romagna database had space for only 5 medications to be recorded 





Table 4.5 displays the number of foetuses and the proportion (of 15,058 malformed 
foetuses) affected by each type of CA. Over a third of malformed foetuses exposed to at 
least one first trimester medication were born with a CHD, the most common type of which 
was ventricular septal defect (17% of all exposed cases).  
 Number of cases with a congenital anomaly (n=55) analysed for signal 
detection in 15,058 malformed foetuses. 






Nervous  Neural tube defects  - 562 3.73 
System         Anencephalus 1 162 1.08 
         Encephalocele  2 88 0.58 
         Spina Bifida 3 312 2.07 
 Arhinencephaly/holoprosencephaly 4 44 0.29 
 Hydrocephaly 5 308 2.05 
 Microcephaly 6 121 0.80 
Eye Anophthalmos/microphthalmos 7 79 0.52 
 Congenital cataract 8 87 0.58 
 Congenital glaucoma 9 28 0.19 
Ear, face & 
neck 
Anotia 10 23 0.15 
Heart Congenital heart defects (CHDs) - 5,250 34.86 
    Severe CHDs - 1,300 8.63 
      Aortic valve atresia/stenosis 11 122 0.81 
      Atrioventricular septal defect 12 144 0.96 
      Coarctation of aorta 13 226 1.50 
      Common arterial truncus 14 38 0.25 
      Ebstein’s anomaly 15 32 0.21 
      Hypoplastic right heart 16 22 0.15 
      Pulmonary valve atresia 17 73 0.48 
      Single ventricle 18 56 0.37 
      Tetralogy of Fallot 19 207 1.37 
      Total anomalous pulmonary venous return 20 31 0.21 
      Transposition of great vessels 21 234 1.55 
      Tricuspid atresia and stenosis 22 56 0.37 
 Atrial septal defect 23 1,342 8.91 
 Pulmonary valve stenosis 24 308 2.05 
 Ventricular septal defect 25 2596 17.24 
 Patent ductus arteriosus (only CHD in term 
infants) 
26 264 1.75 
 Unspecified CHD 27 542 3.60 
a aggregate subgroup codes are not included in signal detection analyses for this thesis (in bold) 





The next most commonly occurring CAs were atrial septal defects and hypospadias, with 
over 8% of malformed foetuses affected with each of these. The aggregate subgroups of 
NTDs, CHD and severe CHDs are not included in signal detection analyses as separate 
subgroups due to their overlap with the more specific subgroups. 
 
Table 4.5 (continued). Number of cases with a congenital anomaly (n=55) analysed for the 
purpose of signal detection in 15,058 malformed foetuses. 






Respiratory Choanal atresia 28 38 0.25 
Oro- facial clefts Cleft lip ± palate 29 713 4.73 
 Cleft palate 30 503 3.34 
Digestive  Ano-rectal atresia and stenosis 31 222 1.47 
system Annular pancreas 32 16 0.11 
 Atresia of the bile ducts 33 17 0.11 
 Atresia/stenosis, other parts of small 
intestine 
34 61 0.41 
 Diaphragmatic hernia 35 188 1.25 
 Duodenal atresia or stenosis 36 58 0.39 
 Hirschprung’s disease 37 61 0.41 
 Oesophageal atresia 38 182 1.21 
Abdominal wall Gastroschisis 39 167 1.11 
 Omphalocele 40 139 0.92 
Urinary Bilateral renal agenesis 41 71 0.47 
 Bladder exstrophy and/or epispadia 42 44 0.29 
 Congenital hydronephrosis 43 788 5.23 
 Multicystic Renal dysplasia 44 209 1.39 
 Posterior urethral valve and/or prune belly 45 73 0.48 
Genital Hypospadias 46 1,291 8.57 c 
Limb Club foot 48 848 5.63 
 Limb reduction defects 47 443 2.94 
 Polydactyly 49 613 4.07 
 Syndactyly 50 386 2.56 
Other  Congenital construction bands 52 33 0.22 
anomalies Conjoined twins 53 4 0.03 
/syndromes Craniosynostosis 51 132 0.88 
 Laterality Defects d 54 82 0.54 
 Situs inversus 55 53 0.35 
a aggregate subgroup codes are not included in signal detection analyses for this thesis (in bold) 
b This index identifies the congenital anomalies in Figure 4.1 and Figure 6.5–Figure 6.9 
c Hypospadias are a birth defect of the urethra in males only, therefore affecting 14.75% of male 
foetuses 
d The laterality defects subgroup comprises CAs where an organ has formed on the wrong side of the 
body, including: atrial isomerism, dextrocardia, situs inversus, broncho-pulmonary isomerism, 




Table 4.6 shows the number of EUROCAT coded CAs per malformed foetus in 15,058 
women. The average number of CAs per malformed foetus was 1.3, and 79% of foetuses 
were affected with only one recorded major CA. When considering the 55 CAs monitored 
for the purposes of signal detection in this thesis, 85% of foetuses were affected with only 
one CA and there was an average of 1.2 CAs recorded per pregnancy. Fifteen percent 
(n=1,887) of malformed foetuses in the dataset had more than one of the 55 monitored 
CAs recorded, with a maximum of seven CAs recorded in one particular foetus.  
 Number of congenital anomalies (CAs) per malformed foetus for 15,058 
pregnancies in signal detection dataset. 
Number of CAs per 
malformed foetus 
Number of pregnancies:  
counts for all CAs in data a 
Number of pregnancies:  
counts for 55 CAs included in 
signal detection analyses 
1 11,857 10,524 
2 2,292 1,431 
3 571 339 
4 210 81 
5 82 29 
6 33 6 
7 11 1 
8 2 0 
Total 15,058 12,411 b 
Average CAs per 
malformed foetus 
1.3 1.2 
a The counts are for all CAs excluding congenital dislocation of the hip and genetic conditions 
b 2,647 individuals only had CAs that are not monitored for signal detection purposes. These are 
included in the data as malformed controls. 
 
Table 4.7 shows the number of first trimester medication exposures for 15,058 malformed 
foetuses according to each anatomical main group (ATC1), with counts for the most 
common ATC2 groups. The most common type of medications used in the first trimester 
were genitourinary system and sex hormones, with 4,085 medication-CA combinations 
recorded for 27% of foetuses. Medications acting on the nervous system (23% of foetuses 
exposed), antiinfectives for systemic use (22%) and respiratory system medications (17%) 





 Number of exposures to 523 first trimester medications monitored for signal 
detection analyses in foetuses with non-chromosomal congenital anomalies 













Alimentary tract and metabolism A 2175 14.4 
Antacids and medications for peptic ulcer A02 626 4.2 
Medications for functional gastrointestinal 
disorders 
A03 735 4.9 
Blood and blood forming organs B 615 4.1 
Antithrombotic agents B01 571 3.8 
Cardiovascular system C 914 6.1 
Antihypertensive C02 215 1.4 
Vasoprotective C05 159 1.1 
Beta blocking agents C07 248 1.6 
Calcium channel blockers C08 185 1.2 
Dermatological D 21 0.1 
Genitourinary system and sex hormones G 4085 27.1 
Other gynaecological G02 943 6.3 
Sex hormones G03 2870 19.1 
Systemic hormonal prep., excl. sex hormones and 
insulins 
H 1449 9.6 
Thyroid therapy H03 1157 7.7 
Antiinfectives for systemic use J 3328 22.1 
Antibacterial for systemic use J01 3049 20.2 
Antineoplastic and immunomodulating agents L 115 0.8 
Musculoskeletal system M 558 3.7 
Antiinflammatory and antirheumatic 
products 
M01 531 3.5 
Nervous system N 3414 22.7 
Analgesics N02 1730 11.5 
Antiepileptics N03 538 3.6 
Psycholeptics N05 632 4.2 
Psychoanaleptics N06 660 4.4 
Antiparasitic products, insecticides and repellents P 166 1.1 
Respiratory system R 2570 17.1 
Nasal preparations R01 377 2.5 
Anti-asthmatics R03 1253 8.3 
Cough and cold preparations R05 202 1.3 
Antihistamines R06 944 6.3 
Various V 184 1.2 
All other therapeutic products V03 169 1.1 






Exposure counts in the crossing of 55 congenital anomalies and 523 medications  
When considering the crossing of all 55 CAs and 523 medications considered for signal 
detection analyses, there were 26,765 exposure counts across 28,765 possible medication-
CA combinations. The distribution of these counts is summarised in Table 4.8, where it can 
be seen that that the majority of combination counts are zero. This means that 77% of the 
possible combinations between a medication and a CA did not occur in the data. Only 29% 
of the non-zero medication-CA combinations had three or more exposures recorded. The 
largest count in the data was 213 exposures for the combination of the most common CHD 
ventricular septal defect with the thyroid hormone medication H03AA01.  
 Distribution of recorded exposure counts in the crossing of 523 medications 
with 55 congenital anomaly (CA) subgroups. 
Exposure count 
Number of medication-CA 
combinations 
% of all 
combinations 
% of non-zero 
combinations 
 0  22,204 77.2 - 
 1  3,560 12.4 54.3 
 2  1,121 3.9 17.1 
 3  553 1.9 8.4 
 4  329 1.1 5.0 
 5-9  591 2.1 9.0 
 10-49  375 1.3 5.7 
 50-99  23 0.1 0.4 
 100-149  5 0.02 0.1 
 150+  4 0.01 0.1 
Total  28,765 100 100 
 
Exposures for 3,355 combinations of 55 CAs with the 61 ATC2 codes are displayed as a heat 
map in Figure 4.1, where ATC2 groups are used as there is insufficient space to graph the 
data separately for either the 116 ATC3 groups or the 523 medications. An exposure is a 
record of one of the 523 ATC5 coded medications taken in combination with one of the 55 
CAs. A woman may be counted more than once in either dimension in this data; she may 
have taken more than one medication (i.e. contributing to more than one row) and/or have 
had a malformed foetus with more than one CA recorded (i.e. contributing to more than 
one column). Darker shading in Figure 4.1 shows a more commonly occurring medication-
CA combination. Represented by white squares in Figure 4.1, 47% (n=1,582) of all possible 
combinations of a CA and an ATC2 group of medications had no recorded exposures. Just 
over half (52%, n=1,735) of the CA and ATC2 combinations had between one and 100 
exposures. Only five ATC2-CA combinations had more than 300 exposures, including the 
ATC2 groups G03 (Sex hormones) and J01 (Antibacterials for systemic use) in combination 





Figure 4.1. Heat Map of exposure counts for 55 congenital anomalies (CAs) monitored for signal detection, according to ATC2 medication groupings.
CAs with >100 exposures for 1 or 
more ATC2 group* 
*See Table 4.4 for a full list of index 




Medication exposures per congenital anomaly and congenital anomalies per 
medication 
The number of exposures for each of the 523 medications included in the analysis are 
displayed in Figure 4.2. These make up the marginal row totals in the two-dimensional 
crossing of all medications and CAs. The majority of medications (n=471; 90%) had less than 
100 counts in combination with any CA. Only seven medications had more than 500 cases 
of a CA recorded across the data, these were: G03DA04 progesterone (n=1,104), H03AA01 
levothyroxine sodium (n=1,017), N02BE01 paracetamol (n=950), G03DB01 dydrogesterone 
(n=871), J01CA04 amoxicillin (n=787), R03AC02 salbutamol (n=772) and G02CA 
sympathomimetics (n=556).  
 
Figure 4.2. Distribution of the number of congenital anomaly subgroups recorded per 
ATC medication code for 523 medications monitored for signal detection analyses. 
In the other dimension, the number of exposures for each of the 55 CAs included in the 
analysis are displayed in Figure 4.3. These make up the marginal column totals in the two-
dimensional crossing of all medications and CAs. The highest number of medication 
exposures recorded were for ventricular septal defect (n=3,917), atrial septal defect 
(n=2,033), hypospadias (n=2,022), clubfoot (n=1,297), congenital hydronephrosis (n=1,195) 
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least medication exposures (n=6). Over half of the 55 CAs monitored (n=29) had less than 
200 recorded exposures to medications monitored for these analyses. 
 
Figure 4.3. Distribution of medication exposures per CA for 55 congenital anomaly 
subgroups monitored for signal detection analyses. 
 
Foetuses exposed only to medications or CAs not monitored for signal detection 
analyses 
Of the 15,058 women in the dataset, there were 278 and 3,998 who only had medication 
exposures or CAs, respectively, other than the 523 medications or 55 CAs monitored in this 
thesis. For example, this may include a woman with only one exposure that was a 
medication for which there were no other exposures recorded in the dataset, because such 
a medication would not be monitored for signal detection analyses with an overall count in 
the data of less than three. Another example would be a malformed foetus with only one 
recorded CA, where that CA was included in the dataset but not monitored separately for 
signal detection analyses, e.g. cystic adenomatous malformation of lung. These individuals 
were included in the counts as “controls” and hence they contributed to the marginal total 
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4.4.3. Merging information from the Australian risk categorisation database 
with EUROmediCAT data  
Table 4.9 displays the breakdown of the risk categories for the 523 medications and the 
28,765 medication-CA combinations for ATC4 and ATC5 codes in the EUROmediCAT 
dataset. The majority of ATC5 codes were identified as belonging to one of the risk 
categories. Very few medications coded only to ATC4 level were specified in the Australian 
categorisation database; however, ATC4 codes were only considered in the analysis for 
cases where a more specific ATC5 code was not available (less than 5% of exposures). Three 
medications (chloroquine, cyproterone and medroxyprogesterone) could be mapped to a 
code in both “low risk” and “high risk” groups depending on the dosage at which they were 
used. As there is no information on dosage in EUROmediCAT data, these medications were 
not assigned to either risk category, and were instead coded as “no risk category 
identified”. Overall, 65% of the 28,765 combinations available for signal detection analyses 
were mapped to one of the risk categories. Only 44 (8.4%) of the medications (or the 
medication-CA combinations) were assigned to the “high risk” category. It is important to 
note that the number of medication-CA combinations identified as “high risk” may be 
overestimated since these categorisations are specific only to the medications and not the 
type of CA. This is likely to be the case as most medications will carry a higher risk of only a 
few specific CAs, rather than an increased risk for all CAs in general. The number of 
combinations in this data that will be true signals of teratogens is therefore likely to be 
considerably less than 8.4%. 
 Number of medication-congenital anomaly (CA) combinations in the “Low” 
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This chapter has discussed signal detection methods used in the context of SR databases 
and in the context of first trimester medications and CAs. In the following two chapters the 
identified approaches to try and improve current EUROmediCAT signal detection methods 
are investigated and assessed. This was done by considering groupings of medications 
and/or CAs, using two approaches to signal detection analyses that are new for CA data. 
Chapter 5 presents different FDR procedures that group similar medications and/or CAs 
when determining the statistical significance of each test, and chapter 6 investigates the 




Chapter 5:  Analysis of EUROmediCAT safety of medication 
use during pregnancy I: false discovery rate 
5.1. Introduction 
This chapter begins by describing a number of approaches to FDR multiple testing 
procedures that consider groupings of medication-CA combinations when determining the 
statistical significance of each test. Results from these analyses are directly compared to 
those from an FDR procedure that does not consider any such groupings, as this is the 
current approach used by EUROmediCAT. In order to directly compare the methods 
proposed here with those used currently, methodology from the recent EUROmediCAT 
signal detection analyses [Luteijn et al., 2016] was used. The main aim of these approaches 
was to determine whether the signal detection process recently developed by 
EUROmediCAT could be improved at a basic level by considering an alternative multiple 
testing procedure when adjusting P-values post-analysis.  
5.2. Methods 
A one-sided Fisher’s exact test of association was performed separately for each 
medication-CA combination in this “exposed-malformed” study design (see Table 4.1). This 
was followed by one of four FDR procedures (described in the following section) to adjust 
for multiple testing when determining statistical significance of each combination. Since the 
dataset consisted only of CA cases, the power to detect protective associations was very 
low. Furthermore, since the purpose of signal detection analyses is to screen for potentially 
harmful teratogenic medicines, any preventive associations that are identified by these 
methods would not be flagged as signals or be recommended for further examination. 
Therefore, a one-sided hypothesis test was used for each medication-CA combination 
rather than a two-sided test. Only medications with at least 3 exposures were investigated, 
although foetuses exposed only to medications not reaching this threshold were included in 
the data as controls. Furthermore, whilst combinations of medications and CAs with less 
than three exposed cases were included in the multiple testing, these were not considered 
in the resulting set of potential signals. A lack of low powered associations would violate 
the underlying assumptions of the multiple testing procedure, as this markedly shifts the 
distribution of P-values towards zero, hence these associations were retained in the 




5.2.1. False discovery rate procedures 
Four variants on the FDR procedure were considered in this chapter; firstly, a Simes 
procedure [Benjamini and Hochberg, 1995] that did not consider any groupings was 
applied, as this is the existing methodology used in EUROmediCAT signal detection. Three 
FDR methods that incorporate groupings of medications or CAs were then considered. The 
way in which these four FDR procedures were implemented is described below. 
Benjamini-Hochberg false discovery rate procedure (single FDR) 
For a total of 𝑚 tests and tolerating that a given proportion α of discoveries will be false, 
the basic Benjamini-Hochberg, Simes or single FDR procedure [Benjamini and Hochberg, 
1995], is specified as follows 
• Order the P-values 𝑃𝑖  according to their magnitude 𝑃1 < ⋯ < 𝑃𝑚 
• Let ?̃?𝑖 denote the corresponding FDR adjusted value for 𝑃𝑖, where  
?̃?𝑚 = 𝑃𝑚 
?̃?𝑖 = 𝑚𝑖𝑛 (
𝑚
𝑖
𝑃𝑖  , ?̃?𝑖+1)    𝑓𝑜𝑟 𝑖 ≤ 𝑚 − 1 
• Null hypotheses with ?̃?𝑖 ≤  α are rejected; these combinations are the potential 
signals  
The FDR “cut-off” is defined for a pre-specified proportion α between 0 and 1; for example, 
α = 0.1 corresponds to an FDR of 10%, which means that up to 10% of combinations that 
are identified as signals are expected to be false positives. FDR-adjusted P-values are 
calculated in ascending order of magnitude; if an FDR-adjusted P-value is 0.1 this means 
that 10% of all the combinations with an adjusted P-value less than this might be false 
positives. Benjamini and Hochberg [1995] showed that for 𝑚 independent tests, this 
controls the FDR at the level  
𝑚0
𝑚
α ≤ α, where 𝑚0 is the number of true null hypotheses.  
False discovery rate procedure by groups (FDR by group) 
The FDR by group method uses a two-step procedure in which a number of groups are first 
eliminated from the set of P-values, and then each remaining group of medications is 
considered separately, with P-values adjusted within each group. This method will increase 
the number of signals identified compared to single FDR, but also increases the overall 
proportion of these signals that are likely to be false positive associations. In order to 
reduce the dimension of the data, a first step in this process is to disregard groups of 




procedure is based on the original “double FDR” procedure of Mehrotra and Heyse [2004], 
which groups similar AEs together in the safety analysis of clinical trials data. The original 
double FDR procedure is implemented only after an initial step, in which all of the rare AEs 
are eliminated from the data. This is done for the purposes of dimension-reduction as well 
as to exclude those rare AEs that could not possibly reach statistical significance even at the 
conventional 5% significance level without any adjustment for multiple testing. In the 
original double FDR procedure, the smallest P-value within each group is first identified and 
then a single FDR is performed across this set of representative minimum P-values from 
each group; only groups with an FDR-adjusted minimum P-value below a certain 
significance level 𝛼1 are considered further. In a second stage, FDR adjustments are then 
done within each group separately, with a significance level 𝛼2. However, this method 
requires nonparametric bootstrapping to determine the optimal values for the cut-offs 
𝛼1 and 𝛼2 in order to minimise the overall FDR level 𝛼 for the particular scenario under 
consideration. Mehrotra and Heyse determined that a reasonable choice for controlling the 
overall FDR was to choose values of 𝛼1 =
𝛼2
2
, which they demonstrated maintained an 
overall FDR at level 𝛼 = 𝛼2. This was suggested as an ad-hoc alternative to bypass the 




, for various levels of 𝛼2. In practice, the groups that are thrown out in the first stage 
of this process would be unlikely to include any potential signals after FDR adjustment to P-
values in the second stage, even at the increased cut-off level of 𝛼2 = 2𝛼1. This procedure 
therefore provides similar results as would be obtained from a separate FDR procedure for 
each group (i.e. not excluding any groups first, as is done here).  
The FDR by group procedure was specified for 𝑖 = 1, … , 𝑛 groups each with a total of 
𝑔𝑖 (𝑗 = 1, … , 𝑔𝑖) medications as follows 
Step 1: Let 𝑃𝑖 be the minimum P-value from each group of medications 𝑖 
𝑃𝑖 = min (𝑃𝑖𝑗; 1 ≤ 𝑗 ≤ 𝑔𝑖) 
and order the 𝑃𝑖  by magnitude for 𝑖 = 1, … , 𝑛 where  𝑃1 < ⋯ <  𝑃𝑛.  
Then ?̃?𝑖 denote the corresponding FDR adjusted P-values, where 
?̃?𝑛 = 𝑃𝑛 
?̃?𝑖 = 𝑚𝑖𝑛 ( 
𝑛
𝑖
𝑃𝑖  , ?̃?𝑖+1)    𝑓𝑜𝑟 𝑖 ≤ 𝑛 − 1 
Step 2: Apply further FDR adjustments to the 𝑔𝑖 P-values within each group 𝑖 for 
which ?̃?𝑖 ≤ 𝛼1, such that ?̃?𝑖𝑗
(𝑖)




in 𝑖. Then null hypotheses are rejected for all tests where ?̃?𝑖𝑗
(𝑖)
≤ 𝛼2; these 
combinations are the potential signals. 
Group Benjamini-Hochberg method (Group BH) 
Another FDR method that enables groupings to be considered is the group Benjamini-
Hochberg (group BH) method of Hu et al. [2010]. Intended for use in large-scale 
applications such as genome-wide association studies, this is a two-step method that 
weights P-values in a first step and then applies an FDR adjustment to these weighted P-
values in a second step. The idea behind this approach is that those groups in which there 
are proportionally more true signals are given a greater statistical weight in the adjustment 
to P-values. The actual proportion of true signals is, of course, unknown, and must 
therefore be estimated.  
The two-step group BH procedure can be summarised for 𝑖 = 1, … , 𝑛 groups each with a 
total of 𝑔𝑖  (𝑗 = 1, … , 𝑔𝑖) medications as follows 




 and estimate the true number of null hypotheses 𝜋0𝑖 (i.e. for which there 
is no true association) in group 𝑖 using  the number of null hypotheses 𝜑0𝑖 in group 













Then the weighted P-value for combination 𝑖𝑗 is defined as 
𝑃𝑖𝑗
𝑤 =  
?̂?0𝑖
1 − ?̂?0𝑖
 𝑃𝑖𝑗 , where 𝑃𝑖𝑗
𝑤 = ∞  𝑖𝑓  ?̂?0𝑖 = 1 
Step 2: The weighted P-values for all groups with  ?̂?0𝑖 < 1 are pooled together and 
a second FDR adjustment is performed across the remaining set of weighted P-
values to get ?̃?𝑖𝑗
𝑤, the FDR-adjusted value corresponding to 𝑃𝑖𝑗
𝑤. A signal is then 
flagged for all ?̃?𝑖𝑗
𝑤 ≤ 𝛼𝑤, where  
𝛼𝑤 =
𝛼
(1 + 𝛼)(1 − ?̂?0)
 
Note that in the extreme case that the proportion ?̂?0𝑖 = 1, all P-values in that group are re-
scaled to infinity to ensure that no combinations are flagged as signals in a group where it is 
estimated that all null hypotheses are true, and the attention is therefore focused on 




Double false discovery rate procedure (Double FDR) 
In a more recent paper, Mehrotra and Adewale [2012] set out an updated double FDR 
procedure, in which implementation of their original double FDR method was simplified by 
eliminating the need to perform bootstrap sampling to find the best choice of 𝛼1 and 𝛼2. 
Demonstrating better control of the overall FDR, the key difference compared to the 
original double FDR procedure [Mehrotra and Heyse, 2004] is in the choice for the 
representative P-values 𝑃𝑖 for each group in the first step. Various choices for the 
representative P-value 𝑃𝑖
∗ for each group 𝑖 are discussed, with the recommend choice for 
𝑃𝑖
∗ (see below) being shown to provide the highest power to detect signals whilst 
maintaining a similar FDR to other options considered [Mehrotra and Adewale, 2012]. 
This method is referred to as the double FDR, and is specified for 𝑖 = 1, … , 𝑛 groups each 
with 𝑔𝑖  (𝑗 = 1, … , 𝑔𝑖) medications as follows 
Step 1: First perform a single FDR adjustment within each group 𝑖 to get ?̃?𝑖𝑗, then 
let 𝑃𝑖
∗ denote the smallest FDR-adjusted P-value in each group  
𝑃𝑖
∗ =  min (?̃?𝑖𝑗; 1 ≤ 𝑗 ≤ 𝑔𝑖) 
Then apply an FDR adjustment to the 𝑃𝑖
∗ to get the set of representative FDR-
adjusted P-values ?̃?𝑖
∗, where 𝑃1











∗ )    𝑓𝑜𝑟 𝑖 ≤ 𝑛 − 1 
Then all groups 𝑖 for which ?̃?𝑖
∗  ≤ 𝛼 are taken to the second step of the procedure. 
P-values from groups with ?̃?𝑖
∗ > 𝛼 are not considered further. 
Step 2: Let 𝐹 ≡  {𝑃𝑖𝑗 | ?̃?𝑖
∗  ≤ 𝛼 } be the family of all P-values from groups flagged by 
their representative FDR-adjusted P-values ?̃?𝑖
∗ in step 1. Then apply a single FDR 
procedure across all P-values in 𝐹 such that ?̃?𝑖𝑗
(𝐹)
 is the FDR-adjusted P-value for 
all 𝑃𝑖𝑗 ∈ 𝐹. Then null hypotheses are rejected for all tests where ?̃?𝑖𝑗
(𝐹)
≤ 𝛼; these 
combinations are the potential signals. 
Note that the key difference between the original double FDR of Mehrotra and Heyse (here 
the FDR by group procedure) and the “new” double FDR is that the adjustment in the 
second step of the newer procedure is made across all P-values in the groups remaining at 
the same time, rather than separately within each remaining group. The actual overall FDR 




at least one true signal, hence it may be possible that in practice the overall FDR exceeds 
𝛼 in some scenarios [Mehrotra and Adewale, 2012].   
5.2.2. Groupings used for false discovery rate methods 
Medications 
Groupings of medications were defined using the ATC coding hierarchy. Firstly, this was 
done according to the ATC2 level, which classifies drugs according to the main therapeutic 
use of their main active ingredient. One such group, for example, would be A10 “Drugs 
used in diabetes”, within which are nested 85 specific ATC5 codes. The next level of 
grouping medications was to use the ATC3 level classification of pharmacological subgroup. 
In the previous example, instead of having the 85 medications that fall under the ATC2 
classification A10 together as one group, for example, there were 3 separate groupings as 
follows: A10A “insulins and analogues”, A10B “blood glucose lowering drugs, excluding 
insulins” and A10X “other drugs used in diabetes”. Grouping using ATC4 level classification 
of chemical subgroup was also considered as a sensitivity analysis. This choice of grouping 
was not included in the main results as it was expected to provide too many groups to be 
useful for these analyses (since there would be many groups and each with only a small 
number of medications within them). The only other ATC level that could potentially have 
been used for grouping was ATC1, however this describes the 14 anatomical main groups 
and these were too broad to be useful here as each resulting group would include such a 
large number and variety of different medications.  
Congenital anomalies 
Another way of considering groupings in the adjustment for multiple testing was to use the 
55 CAs to group medication-CA combinations, such that one group would then include the 
combination of each of the 523 medications with a single CA. This could make use of the 
fact that there are likely to be more signals within certain CAs, as well as taking account for 
the fact that a number of subgroups may have had no signals at all (i.e. contain only null 





5.2.3. Summary of methods used in this chapter 
In summary, groupings by ATC2 and ATC3 medication codes and by CA were considered in 
the application of four approaches to adjustment for multiple testing to determine the 
statistical significance of each test:  
1. FDR across all tests (single FDR) 
2. FDR procedure separately within each group, after excluding groups in a first step 
(FDR by group) 
3. Two-step weighted FDR procedure considering groupings (group BH) 
4. Double FDR procedure considering groupings (double FDR) 
The PRR for each medication-CA combination was plotted against the Fisher’s exact test P-
value using a smileplot [Newson, 2003]. As described in chapter 4, results from all models 
were compared in terms of their identification rate and “high risk” proportion according to 
the Australian risk categorisation system for ATC coded medications. Briefly, these 
measures were defined as  
 
𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐫𝐚𝐭𝐞 =
Number of "high risk" medications identified as signals
Total number of "high risk" medications in the data
 
 
“𝐇𝐢𝐠𝐡 𝐫𝐢𝐬𝐤” 𝐩𝐫𝐨𝐩𝐨𝐫𝐭𝐢𝐨𝐧 =
Number of medication signals in "high risk" category 
Total number of medications identified as signals
 
 







For a description and summary of the EUROmediCAT dataset used for these analyses see 
Chapter 4 (section 4.4.2). Briefly, data on 15,058 foetuses was available for analysis, with 
523 ATC medications and 55 CAs being monitored for signal detection purposes giving rise 
to 26,765 total exposure counts across 28,765 possible medication-CA combinations. 
5.3.1. Fisher’s exact test and a single FDR procedure 
There was no data to perform an analysis for 369 medication-CA combinations for which 
there were no registries with at least one record of both that specific medication exposure 
and the specific CA. Fisher’s exact test was therefore performed for 28,396 medication-CA 
combinations, the results of which are displayed in a smileplot in Figure 5.1. Each marker on 
this plot represents a different medication-CA combination, with different symbols used to 
show the risk category of the medication in each combination. The dashed horizontal lines 
show some of the possible cut-off values of α for the FDR, and the solid vertical line 
indicates a PRR of one (i.e. no effect). The points above each dashed line and to the right of 
the vertical line correspond to those medication-CA combinations that would be flagged as 
potential signals using that particular FDR cut-off. Using single FDR, only one “high risk” 
combination out of 2 total combinations were identified as signals for an FDR cut-off of 5% 
(points above the uppermost dashed line in Figure 5.1). For FDR cut-offs of 20% and 50% 
there was one “high risk” out of 4 total signals and 5 “high risk” out of 10 total signals, 
respectively. This means that only 5 (11%) of the 44 “high risk” medications in the data 
were identified as a signal when using single FDR with the highest cut-off of 50%. Note that 
the count for the FDR 50% does not include the two points above the dashed FDR 50% line 
that are to the left of the vertical solid line, since these estimates have a PRR of less than 
one, indicating a “protective” association for that particular medication-CA combination. If 
the data were analysed without any consideration for multiple testing and at a significance 
level of 5% (i.e. using the P-value cut off of 0.05) then n=252 combinations would be 
identified as signals, after excluding those combinations with a frequency of less than 3 or a 





Figure 5.1. Smile plot of the observed PRR against the unadjusted P-value from Fisher’s exact test for 28,396 medication-CA combinations, with different 
shading/symbols according to Australian risk categories. Single FDR cut-off levels are indicated by dashed horizontal lines and two P-values of 1.4e-








































5.3.2. False discovery rate procedures considering groupings of medications 
or congenital anomaly subgroups 
Before comparing the FDR procedures directly, the way in which combinations could 
potentially be grouped was first considered for all 3 methods that took grouping into 
account. Grouping by ATC2 provided 61 groups with an average of 9 (range 1-54) 
medication codes and 1,074 (range 53-2,936) medication-CA combinations per group. Using 
ATC3 grouping resulted in 116 distinct groups with an average of 4.5 (range 1-20) unique 
medications and 487 (range 53-1,086) medication-CA combinations per group. Grouping by 
CA gave 55 distinct groups with an average of 518 (range 325-523) unique medication-CA 
combinations per group. Note that the number of combinations was not a multiple of 55 
(for medication groupings) or 523 (for grouping by CA) in all of the groups due to the 369 
combinations for which there was no data to perform Fisher’s exact test after excluding 
registries without that specific exposure or CA. 
Number of signals identified using ATC2, ATC3 and CA groupings 
Table 5.1 displays the number of signals of unique ATC coded medications detected using 
each type of FDR procedure and grouping, with separate rows for each method over a 
range of cut-off levels from 5% to 50%. All counts in Table 5.1 exclude those associations 
found to be significant (after the relevant FDR procedure) that had less than 3 exposures for 
that particular medication-CA combination and those with a PRR<1 (i.e. protective 
associations). The number of groups without any signals (i.e. in which no null hypotheses 
were rejected) after each FDR procedure is shown in the first set of columns; on average, 
around 80-90% of groups contained no signals after the FDR procedures. The lowest 
proportion of groups with no signals was seen for the highest FDR cut-off of 50%, in 
particular for CA groupings using FDR by group, where only 42 (76%) of the CA groups did 
not have any potential signals. The highest proportion was seen for the lowest FDR cut-offs 
of 5% (single and double FDR) and 10% (double FDR) where 114 (98%) of ATC3 groups had 
no signals. The second set of columns in Table 5.1 show the number of medication signals 
that are in the “high risk” category and the final set of columns gives the total number of 
medications identified as potential signals. Note that the number of signals is the same for 
all three columns for single FDR, as this method does not consider any groupings. For all 
methods and groupings, the number of “high risk” and the total number of signals both 





 Summary of the number of medications identified as signals (effective 





Groups with no 
signals after FDR 
“High risk” 
medication signals 
Total number of 
medication signals 
Type of grouping 







ATC2 ATC3 CA ATC2 ATC3 CA 
5% Single FDR 59 114 53 ——— 1 a ——— ——— 2 a ——— 
 
FDR by group 55 110 48 3 3 4 7 7 9 
 
Group BH 55 110 48 3 3 4 7 7 9 
 
Double FDR 59 114 53 2 2 3 3 3 5 
10% Single FDR 57 112 51 ——— 1 ——— ——— 3 ——— 
 
FDR by group 54 108 46 5 5 5 10 14 12 
 
Group BH 54 108 46 5 5 5 10 14 12 
 
Double FDR 59 114 51 2 4 3 3 5 11 
20% Single FDR 55 110 48 ——— 3 ——— ——— 7 ——— 
 
FDR by group 53 104 45 5 6 5 14 20 18 
 
Group BH 53 106 46 5 6 5 14 18 16 
 
Double FDR 56 112 50 4 5 5 11 11 13 
30% Single FDR 55 110 47 ——— 3 ——— ——— 7 ——— 
 
FDR by group 52 101 44 5 7 7 16 26 30 
 
Group BH 53 104 45 5 6 5 14 20 19 
 
Double FDR 55 109 48 5 6 5 12 15 18 
40% Single FDR 54 109 46 ——— 3 ——— ——— 8 ——— 
 
FDR by group 51 98 43 5 8 7 18 31 40 
 
Group BH 52 101 44 5 7 7 15 25 29 
 
Double FDR 55 109 47 6 6 5 16 15 20 
50% Single FDR 54 109 46 ——— 3 ——— ——— 8 ——— 
 
FDR by group 48 96 42 7 8 8 28 34 55 
 
Group BH 53 100 43 5 7 7 16 27 38 
 
Double FDR 53 109 46 7 6 5 21 16 24 








Effective workload according to risk categories for ATC2, ATC3 and CA groupings 
Figure 5.2, Figure 5.3 and Figure 5.4 show the effective workload broken down by risk 
categories for the FDR by group, group BH and double FDR, respectively, comparing each 
type of grouping (ATC2, ATC3 or CA) for a range of FDR cut-offs in 5% increments from 5% 
to 50%. For FDR by group (Figure 5.2), the number of “high risk” medication signals was 
similar for all three groupings, although ATC3 groupings identified more “high risk” signals 
for some levels of FDR cut-off. The overall number of signals identified was lowest for ATC2 
groupings, and was notably higher for grouping by CA. For group BH (Figure 5.3), ATC3 
grouping consistently identified slightly more signals up to an FDR of 40%, past which the 
CA groupings provided more signals but without any increase in the number of “high risk” 
signals. The number of “high risk” signals identified by each type of grouping was similar 
throughout; grouping by ATC2 resulted in slightly fewer “high risk” signals for FDR cut-offs 
of 20% and higher. For double FDR (Figure 5.4), ATC3 groupings identified a similar number 
of “high risk” signals but often with less signals overall compared to other groupings. For an 
FDR cut-off of 50% the ATC2 groupings identified one additional “high risk” medication, 
however this was for an additional five medication signals in total.  
“High risk” proportion and identification rate for ATC2, ATC3 and CA groupings 
Figure 5.5 shows the “high risk” proportion plotted against the effective workload for the 
three groupings and methods. There are ten points for each type of grouping, with each 
point representing a different level of FDR cut-off in a sequential order by increments of 5% 
from 5% to 50%. For each method, therefore, the points in Figure 5.5 with the lowest and 
highest total number of identified signals correspond to the FDR of 5 and 50%, respectively. 
A higher point on Figure 5.5 indicates an improvement in “high risk” proportion, i.e. that a 
greater percentage of the set of signals requiring follow up are in the “high risk” category. 
For FDR by group and group BH the performance of the three groupings was very similar. 
Grouping by CA performed worse when identifying around 30 or more medication signals 
for FDR by group and for most levels of double FDR. The double FDR with ATC3 groupings 
generally had the highest percentage of signals identified being in the “high risk” group for 
the lowest total number of signals across different levels of FDR, although ATC2 groupings 






Figure 5.2. Effective workload and the number of medication signals in each risk category using the FDR by group procedure. Results are for grouping of 
medication-CA combinations by ATC2, ATC3 codes and CAs according to cut-offs for FDR level from 5% to 50%. 




















































Figure 5.3. Effective workload and the number of medication signals in each risk category using the group BH procedure. Results are for grouping of 
medication-CA combinations by ATC2, ATC3 codes and CAs according to cut-offs for FDR level from 5% to 50%.  




















































Figure 5.4. Effective workload and the number of medication signals in each risk category using the double FDR procedure. Results are for grouping of 
medication-CA combinations by ATC2, ATC3 codes and CAs according to cut-offs for FDR level from 5% to 50%.  




















































Figure 5.5. “High risk” proportion (percent of all medication signals that are in the “high risk” category) against effective workload (the total number of 
medication signals) for FDR by group, group BH and double FDR methods. Grouping is by ATC2, ATC3 codes and by CA, and each point corresponds 




The identification rate is plotted against the effective workload in Figure 5.6 for the three 
groupings and methods, again with ten points for each type of grouping, each representing 
a level of FDR cut-off from 5% to 50%. In Figure 5.6, points lying closer to the top left hand 
corner of the graph indicate a higher identification rate for a smaller total number of signals 
requiring follow up i.e. representing a better signal detection scenario. For FDR by group 
and group BH all the groupings performed similarly overall. For double FDR, ATC3 grouping 
had slightly improved performance compared to ATC2 grouping, which in turn had higher 
identification rates for the same effective workload as grouping by CAs. When using CA 
groupings, the double FDR showed no improvement in identification rate for FDR cut-offs of 
above 20%; the effective workload increased without any additional “high risk” medication 
signals being identified. 
Sensitivity analysis: false discovery rate methods using ATC4 groupings 
As a sensitivity analysis, FDR procedures were repeated using the ATC4 chemical subgroups 
as the groupings. Groupings by ATC4 gave 245 groups with an average of 2.1 (range 1-8) 
unique medication codes and 184 (range 42-440) medication-CA combinations per group. 
The ATC4 groupings for FDR by group and group BH methods gave a larger number of 
overall signals and effective workload than grouping by ATC2 or ATC3, generally without 
any increase in the number of “high risk” medications being detected (Appendix Figure B1 
and Figure B2). Only CA groupings at a cut-off level of 45-50% identified more overall 
signals then ATC4 groupings. Conversely, when using double FDR the ATC4 groupings gave 
the smallest overall total numbers of signals, with considerably less “high risk” medications 
being identified as signals compared to the other ATC groupings (Appendix Figure B3). 
When considering the “high risk” proportion, identification rates and effective workloads, 
grouping combinations by ATC4 level codes did not show any improvement over other 
groupings considered (Appendix Figures B4 and Figure B5).  
Summary of false discovery rate methods by ATC2, ATC3 and CA groupings 
Overall, for the FDR by group and group BH method the three groupings gave similar 
results. For the double FDR method, however, the ATC3 groupings performed slightly better 
in terms of “high risk” proportion and identification rate across the range of cut-off choices 
for the FDR. In the following section, therefore, the focus will be on ATC3 groupings when 
directly comparing the FDR methods that group medication-CA combinations to the single 





Figure 5.6. Identification rate (proportion of all “high risk” medications that are 
identified as signals) against effective workload (the total number of medication 
signals) for FDR by group, group BH and double FDR methods. Grouping is by ATC2, 
ATC3 codes and by CA, and each point corresponds to a different level of FDR for 




5.3.3. Comparison of single and grouped FDR procedures using ATC3 codes to 
group medications 
Figure 5.7 presents the number of signals identified in each risk category using ATC3 
groupings for each of the four FDR methods across a range of FDR cut-offs from 5% to 50% 
(these numbers were also displayed in Table 5.1). Higher FDR cut-offs resulted in a greater 
total number and proportion of signals being identified for all methods. An FDR of 50% 
resulted in 4 to 5 times as many signals being identified as for an FDR of 5%. When 
considering the FDR cut-off of 50%, single FDR produced only 8 potential medication signals 
compared to 34 for the FDR by group, 27 for group BH and 16 for double FDR methods. 
Three (38%) potential signals identified by single FDR were in the “high risk” category 
compared with 8 (24%), 7 (26%) and 6 (38%) in the FDR by group, group BH and double FDR 
methods, respectively (Figure 5.7, Table 5.1). For single FDR 3 “high risk” signals were 
identified at an FDR cut-off of 15%; no further “high risk” medications were identified at 
higher choices of FDR cut-off for this method. Instead only one additional “low risk” 
medication was identified as a signal at an FDR cut-off of 35% and above. The number of 
“high risk” medications identified by grouped FDR methods was often close to the total 
number of signals identified by single FDR (Figure 5.7, Table 5.1). FDR by group and group 
BH methods generally identified an additional “high risk” medication signal compared to 
double FDR, but at the expense of a marked increase in the total effective workload.  
Statistically significant associations that were not considered to be signals  
Statistically significant associations with a medication-CA count of less than 3 or a PRR<1 
(protective associations) were excluded from the list of potential signals. Table 5.2 shows 
the number of these associations that arose when using ATC3 groupings, for each of the 
four FDR methods. No combinations with less than 3 counts were identified as significant 
associations by any FDR method with a cut-off of 10% or less. With an FDR cut-off of 10% or 
higher, FDR by group provided the most associations based on small numbers, with 18 
medication-CA combination associations having less than 3 counts for an FDR cut-off of 
50%. Group BH identified around half as many associations with under 3 counts as FDR by 
group, and double FDR less again. Single FDR did not identify any combinations with less 
than 3 counts as being associations. Across all levels of FDR cut-off, single and double FDR 
each identified at most 2 combinations with a PRR<1. FDR by group and group BH identified 
slightly more protective associations, with a maximum of 8 and 5, respectively, when using 
a cut-off of 50%. The final columns in Table 5.2 show the total number of combinations and 





Figure 5.7. The number of signals detected in each risk category using ATC3 codes to group medication-CA combinations according to four FDR 
procedures, with FDR cut-offs ranging from 5% to 50%.  





























































 Medication-CA combinations passing FDR adjustment but subsequently 
excluded from the set of potential signals due to low cell counts or protective 




















5% Single 2 - - 2 2 
  By group 12 - 2 10 7 
  Group BH 12 - 2 10 7 
  Double 5 - - 5 3 
10% Single 4 - - 4 3 
 
By group 19 - 2 17 14 
 
Group BH 19 - 2 17 14 
 
Double 7 - - 7 5 
20% Single 9 - 1 8 7 
  By group 32 4 2 26 20 
  Group BH 28 4 2 22 18 
  Double 13 - - 13 11 
30% Single 10 - 1 9 7 
 
By group 50 7 4 39 26 
 
Group BH 33 4 2 27 20 
 
Double 21 1 1 19 15 
40% Single 12 - 2 10 8 
  By group 67 12 6 49 31 
  Group BH 46 7 3 36 25 
  Double 21 1 1 19 15 
50% Single 12 - 2 10 8 
 
By group 80 18 8 54 34 
 
Group BH 53 8 5 40 27 
  Double 29 2 2 25 16 
a This is the effective workload 
 
“High risk” proportion, identification rate and effective workload 
Figure 5.8 shows the “high risk” proportion and identification rate for the four FDR methods 
using ATC3 groupings. The “high risk” proportion was lowest using the FDR by group and 
group BH methods, and decreased as the FDR cut-off level increased and more signals were 
identified overall. For all methods, the effective workload also increased as the 
identification rate increased. Double FDR gave the highest “high risk” proportion and 
identification rates per effective workload across most levels of FDR cut-off. The estimated 
identification rate was higher for group BH and FDR by group methods for levels of FDR cut-





Figure 5.8.  “High risk” proportion (percent of all medication signals that are in the 
“high risk” category; left panel) and identification rate (proportion of all “high risk” 
medications that are identified as signals; right panel) plotted against the effective 
workload (the total number of medication signals) for four FDR procedures using 
ATC3 groupings. 
Another smileplot of P-values from all medication-CA combinations is displayed in Figure 
5.9, now in which the black symbols highlight the 25 combinations (16 unique medications) 
identified as signals by double FDR with a cut-off of 50% and ATC3 groupings. Each data 
point in grey is a medication-CA combination that was not identified as a signal using 
double FDR with a cut-off of 50%, with different shaped markers used to show the assigned 
risk category of the medication in each combination. The data points above each dashed 
horizontal line correspond to medication-CA combinations that remain associations using 
that particular cut-off with the single FDR. There is only one combination in grey above the 
dashed line with a PRR>1 for the 50% cut-off. This combination was in the “low risk” 
category and is identified as a signal using single FDR with a cut-off of 50%, but was not a 
signal using the double FDR of 50%. Conversely, an additional 13 medications (16 
combinations) shown in black below the FDR 50% dashed line were signals using double 
FDR 50% that were not signals using a single FDR of 50%. Of these, 4 belonged to the “high 







Figure 5.9. Smile plot of the observed PRR against the unadjusted P-value from Fisher’s exact test for 28,396 medication-CA combinations, with different 
symbols according to Australian risk categories. Symbols in black indicate medication-CA combinations identified as potential signals using a double 
FDR with a cut-off of 50%. Single FDR cut-offs are indicated by dashed horizontal lines. Two P-values of 1.4e-17 and 2.0e-17 are shown at P=1.0e-10 








































Table 5.3 shows the distribution of “high risk” combinations within each type of ATC 
grouping considered, including the additional grouping by ATC4 coding. The proportion of 
groups without any “high risk” medications was 9% higher in the ATC3 than ATC2 grouping, 
and 7% higher again when using ATC4 groupings. Note that when grouping medication-CA 
combinations by CA, the proportion of groups with no “high risk” medications was always 
non-zero and almost identical for every group, since each CA was tested once in 
combination with each medication. The only variation here comes from the fact that there 
was no data to perform Fisher’s exact test for 369 combinations. 
 Number of “high risk” medications per group according to different ATC 
groupings for medication-CA combinations. 
Number of “high risk” 
medications in group  
ATC2 (3 digits) 
 
ATC3 (4 digits) 
 





N %  
0 44 72%   94 81% 
 
215 88%  




18 7%  
2 2 3%   5 4% 
 
7 3%  




4 2%  
4+ 4 7%   1 1% 
 
0 -  
Total number of 
groups 
61     116     244   
 
 
Table 5.4 provides details for the 16 medications (25 combinations) identified as signals by 
double FDR with a 50% cut-off and ATC3 groupings, as well as one additional medication 
signal identified by the single FDR 50%. Signals from double FDR included 5 antiepileptic 
medications (9 combinations), 4 insulin medications (7 combinations), 3 sex hormones (4 
combinations), 2 antiasthmatic medications (3 combinations) one gynaecological 
medication (coded only to ATC4) and one medication for acid related disorders. Single FDR 
50% identified only 7 of these medication signals over 10 combinations, including 2 of the 
antiepileptics (5 combinations), 2 antiasthmatics (2 combinations), one insulin-related 
medications and one sex hormone. Single FDR 50% also identified one further signal for the 




















Acid related A02B A02BB01 X Misoprostol Anencephaly 47.8 (18.5, 123.6) 3.0E-05 3 Both 
Insulin A10A A10AB01 - Insulin (human) Atrial septal defect 3.1 (1.9, 5.0) 3.9E-04 12 Double 
  A10AB04 A Insulin lispro Patent ductus arteriosus 6.0 (2.8, 12.9) 5.1E-04 6 Double 
  A10AB05 A Insulin aspart Lateral anomalies 7.0 (2.6, 18.7) 0.003 4 Double 
     Ventricular septal defect 1.8 (1.3, 2.4) 3.8E-04 35 Double 
  A10AC01 - Insulin (human) Atrial septal defect 2.0 (1.4, 3.0) 0.002 21 Double 
     Unspecified CHD 2.6 (1.5, 4.6) 0.004 11 Double 
     Patent ductus arteriosus 5.5 (3.1, 9.8) 7.1E-06 11 Both 
Gynaecologic G02C G02CA - Sympathomimetic Tricuspid atresia/stenosis 4.5 (1.9, 10.3) 0.002 8 Double 
Sex G03D G03DA03 D Hydroxyprogesterone Atrial septal defect 1.9 (1.4, 2.7) 8.0E-04 27 Double 
Hormones  G03DA04 - Progesterone Atrial septal defect 1.3 (1.1, 1.6) 0.002 127 Double 
  G03DB01 - Dydrogesterone Atrial septal defect 2.2 (1.9, 2.6) 1.4E-17 150 Both 
     Hypospadias 1.3 (1.1, 1.6) 0.004 94 Double 
Antiepileptic N03A N03AA02 D Phenobarbital Cleft lip ± palate 4.9 (2.5, 9.7) 5.0E-04 7 Double 
  N03AF01 D Carbamazepine Atrioventricular septal defect 4.4 (2.0, 9.8) 0.003 6 Double 
     Spina Bifida 3.6 (2.0, 6.5) 3.1E-04 11 Double 
  N03AG01 D Valproic acid Atrial septal defect 1.6 (1.2, 2.3) 0.003 34 Both 
     Cleft palate 2.8 (1.8, 4.2) 4.2E-05 21 Both 
     Hypospadias 1.9 (1.4, 2.6) 1.0E-04 38 Both 
     Spina Bifida 7.2 (5.1, 10.2) 2.0E-17 32 Both 
  N03AX09 D Lamotrigine Spina Bifida 5.0 (2.7, 9.0) 4.1E-05 10 Both 
  N03AX14 B Levetiracetam Cleft palate 6.2 (2.6, 15.0) 0.003 4 Double 
Anxiolytic N05B N05BA09 C Clobazam Atrioventricular septal defect 29.2 (11.0, 77.6) 1.4E-04 3 Single 
Antiasthmatic R03A R03AC02 A Salbutamol Congenital hydronephrosis 1.8 (1.4, 2.3) 5.5E-06 66 Both 
 R03C R03CA02 A Ephedrine Congenital hydronephrosis 9.8 (4.8, 20.0) 4.2E-04 4 Double 




Table 5.5 displays the estimates, risk category and the FDR thresholds for single and double 
FDR for each of eight known medication-CA associations taken from the review by van 
Gelder et al. [2014], as used to validate signals in Luteijn et al. [2016] for the initial 
EUROmediCAT signal detection analysis. There were no exposures for combination of cleft 
lip ± palate with oxprenolol, hence this was not included in the analysis. The combinations 
of naproxen and phenytoin with cleft lip ± palate had only zero and one exposures, 
respectively, hence these PRRs were very imprecisely estimated. The combination of 
progesterone with hypospadias was present in the data and had a PRR>1, but was not a 
statistically significant association. Valproic acid in combination with both atrial septal 
defect and cleft palate were picked up by double FDR at lower cut-offs than for single FDR 
(for atrial septal defect this was not a signal for any single FDR cut-offs lower than 50%). 
Single and double FDR both picked up the signals for valproic acid with spina bifida at the 
same thresholds, however neither method retained the combination of valproic acid and 
craniosyntosis as a signal after FDR adjustments at a cut-off of 50% or less.  
Sensitivity analysis: medications not assigned a risk category 
Of the 523 medications in the EUROmediCAT data for these analyses, 35% were not present 
in the Australian classification system database and so these were not assigned a risk 
category (see section 4.4.3 and Table 4.9). Sensitivity analyses were therefore performed to 
check the effect on FDR results according to a number of hypothetical situations. Firstly, 
medications without a risk category were assumed to either be all “high risk” or all “low 
risk”, representing the two most extreme situations. The effect of assuming that a 
medication without a known risk category was “high risk” if there was at least one other 
“high risk” medication in that group, and “low risk” if all medications in the same group 
were either “low risk” or did not have a risk category assigned was also investigated. For 
these three situations, comparisons between the different FDR methods were the same as 






 Evaluation of methodology as done for previous EUROmediCAT signal detection, using selected known medication–CA associations identified 
by van Gelder et al [2014].  















G02CC02 Naproxen Cleft lip ± palate 3 0 0 (0 – 25.13) 0.86 - - C 
C07AA02 Oxprenolol Cleft lip ± palate 0 0 NA NA - - C 
N03AB02 Phenytoin Cleft lip ± palate 17 1 1.15 (0.03 - 7.45) 0.59 - - D 
G03DA04 Progesterone Hypospadias 1108 106 1.14 (0.92 - 1.41) 0.12 - - NA 
N03AG01 Valproic acid Atrial septal defect 235 34 1.75 (1.17 - 2.54) 0.003 >50% <45% D 
N03AG01 Valproic acid Cleft palate 235 21 2.92 (1.75 - 4.63) 0.00004 <20% <5% D 
N03AG01 Valproic acid Craniosynostosis 235 6 3.06 (1.09 - 6.94) 0.017 >50% >50% D 
N03AG01 Valproic acid Spina bifida 235 32 8.19 (5.35 - 12.18) 2.0E-17 <1% <1% D 





In this chapter, methodology from the recent EUROmediCAT signal detection analyses was 
compared to methods of multiple testing adjustment that incorporated prior information 
about the grouping of medications or CAs into the analyses when determining the 
statistical significance of each medication-CA combination.  
5.4.1. Comparing different groupings of medication-CA combinations  
Three different types of grouping for the medication-CA combinations were first assessed, 
and grouping by ATC3 codes was found to have slightly better performance in terms of 
proportion of “high risk” signals being identified as well as the balance between 
identification rate, “high risk” proportion and effective workload. The proportion of groups 
containing no “high risk” medications was highest when using ATC4 groupings and lowest 
using ATC2 groupings (Table 5.3).  
Groups with a greater number of “high risk” medications should be expected to contain 
more signals; in the ATC3 and ATC4 groupings it was therefore expected that more groups 
would be “thrown out” at the first stage of the grouped FDR methods compared to use of 
ATC2 groups, since there were less groups including a “high risk” signal. If a greater number 
of groups are excluded after this first stage, then the second stages of the grouped FDR 
procedures are done across smaller numbers of medication-CA combinations, leading to 
less strict adjustment to individual P-values (as a smaller number of tests requires less 
stringent adjustment to achieve the required level of FDR control). This may result in more 
signals being picked up for groups where there is at least one signal, although this does 
depend on which particular groups are excluded because each group does not have the 
same number of medications. For example, there was an average 242 combinations per 
ATC3 group with a minimum of 55 (i.e. one medication in combination with 55 CAs) and a 
maximum of 1,071 (i.e. 20 medications in combination with 55 CAs, excluding some 
combinations for which there was no data to perform Fisher’s exact test - see section 
5.3.2). On the other hand, a greater number of groups also means a stricter threshold in 
practice for the first stage of the grouped FDR procedures. This is because the adjustments 
in the first step are done across the set of P-values made up of one representative P-value 
from each group, and a greater number of tests requires more stringent control to achieve 
the same level of FDR. However, the double FDR (for example) calculates the 
representative P-values using a single FDR adjustment within each group to obtain a 




overall number of groups is larger (since each group size will be smaller). These two factors 
may have balanced the effect of varying the number of groups on how stringent the FDR 
adjustment to the P-values is in the first stage of the grouped FDR procedures. This means, 
for example, that a group which has one signal that is statistically significant at a level of 
adjustment using the 116 ATC3 groups may have been excluded in the first stage of double 
FDR when using the 244 ATC4 groups since there will be more than twice as many P-values 
in this multiple correcting adjustment. As a sensitivity analysis, therefore, FDR procedures 
were repeated using the ATC4 codes as the grouping; however, this did not offer improved 
performance for any of the FDR methods considered.  
Grouping by CA resulted in 55 distinct groups with an average of 518 (range 325-523) 
unique CA-ATC5 medication combinations per group previously (see section 5.3.2). In the 
previous chapter, Table 4.9 also showed that 44 of the 523 unique medications in these 
analyses were in the “high risk” group category. When grouping combinations by CA, 
therefore, the maximum possible number of “high risk” medications per group was 44, and 
this was the case for 32 (58%) of the groups in the analysis. A further 20 (36%) CAs 
contained 43 of the “high risk” medications and only three subgroups contained fewer: 
30/325 combinations for the conjoined twins subgroup, 41/501 for lateral anomalies and 
42/504 for congenital glaucoma. Grouping using the CAs for FDR adjustment did not 
perform better than the groupings by ATC codes, which might be influenced by the use of 
the Australian classifications to judge the methods, since these are not specific to the type 
of CA. 
To summarise, the type of groupings used in this chapter did not give markedly different 
results and so it is unlikely that further types of grouping based on available ATC or 
EUROCAT coding structures would provide a more useful comparison of the methods 
assessed. For double FDR, however, ATC3 grouping provided the highest proportion of 
signals being in the “high risk” category, with a similar effective workload as the other types 
of grouping (see Figure 5.4, Figure 5.5 and Figure 5.6). The ATC3 groupings were therefore 
used to directly compare the different FDR methods.  
5.4.2. Comparison of FDR procedures grouping combinations using ATC3 level 
codes 
When using ATC3 groupings the double FDR performed better than the other two methods 
that grouped medication-CA combinations, and use of this method is therefore 
recommended in practice when considering groups in signal detection analyses for CA data. 




compared to double FDR for most levels of FDR cut-off; however, this was at the expense of 
a disproportionate increase in the total effective workload. Double FDR showed the best 
“high risk” proportion and identification rate across all levels of FDR cut-off. FDR by group 
and group BH only performed better than double FDR in terms of identification rate for 
larger numbers of medications (i.e. at least 20) being identified as signals. A considerably 
larger number of total medication signals for follow up were required to achieve these 
higher identification rates, representing a potentially unrealistic workload, of which less 
than 30% may be expected to be “high risk” signals (Figure 5.8). 
Choice of FDR cut-off threshold 
Another variable to consider in FDR methods is the choice of FDR cut-off level 𝛼, which here 
was allowed to range in 5% increments from 5-50%. The choice of FDR cut-of aims to 
balance the proportion of false negative and false positive associations. If this value is too 
high, the resulting workload for follow up investigation of associations may be larger than is 
acceptable, depending on available resources. There may also be potential for unwarranted 
anxiety to be caused for pregnant women if false positive associations are reported for 
medications that they may have to take, even if the resulting investigations are 
inconclusive. A very low FDR cut-off, conversely, may miss important signals and result in a 
delay of detecting a teratogen until more data (i.e. more women being exposed to a 
potentially harmful medication) are available. The cut-off value for the FDR should 
therefore be re-evaluated frequently, and in practice this will depend on the resources 
available to investigators for follow-up of signals. It is important also to remember that 
signal detection is only the first step in the process of safety surveillance for medication use 
in pregnancy. Results from signal detection are subject to detailed evaluation to determine 
which medications require independent confirmation or further investigation [Given et al., 
2016]. EUROmediCAT also separately considers four medication classes (new antiepileptics, 
insulin analogues, antiasthmatics, and antidepressants/SSRIs) in more detailed analyses, 
with an emphasis on hypothesis testing rather than hypothesis generating [de Jong-van den 
Berg et al., 2011]. When combined, these different approaches to signal detection limit 
should the consequences of setting an FDR cut-off that is too strict, because many resulting 
signals are likely to already been investigated or be under investigation elsewhere. In these 
more detailed later stages of the signal detection process further factors are also 
considered, including data quality, registry-specific queries, consistency with other 




The actual value of the cut-off chosen for the FDR represents the estimated maximum 
proportion of observed associations that are likely to have arisen due to chance; an FDR 
cut-off of 50% means that up to 50% of the signals identified are expected to be false 
positive associations, i.e. as many as half of the observed associations are likely to have 
arisen by chance. Note that this is a percentage of the associations identified by the 
method and does not take into consideration those associations that were not included in 
the resulting set of signals after exclusions, e.g. 30 total combinations were identified as 
associations after double FDR 50% with ATC3 groupings, of which only 25 were identified as 
signals after exclusions based on low frequency and PRR<1 (Table 5.2). Associations with 
low cell counts (<3) are excluded specifically because evidence from such a small number of 
cases is judged to be insufficient, and these associations may therefore be more likely to 
have arisen due to chance i.e. to be the expected false positives. In general, then, when 
using FDR methods for signal detection a smaller proportion than 𝛼% of the resulting 
signals may therefore arise due to chance alone. As such, the cut-off choice of 𝛼 for the FDR 
methods is not a clear indication of how many of the signals are likely to be true 
associations. In these analyses, the “high risk” proportion was also evaluated, which aimed 
to estimate the proportion of signals that are likely to be “true associations” (i.e. because 
these are already known to be “high risk” medications for CAs). Figure 5.8 showed that the 
proportion of medication signals known be “high risk” decreased as the FDR cut-off 𝛼 
increased; with a higher 𝛼, a greater proportion of signals are expected to be false positives 
and a lower proportion of “high risk” medications is therefore observed. 
The group BH method, as described by Hu et al. [2010], was of interest for these analyses 
because it is aimed specifically for situations where there are thousands of P-values, as is 
the case in analysis of EUROmediCAT data. However, the FDR control for this method at the 
target level of 𝛼 is maintained only in an asymptotic sense i.e. for very large numbers of 
tests. All groupings considered here provided very high estimates ?̂?0 of the average 
proportion of null hypothesis across the groups, reflecting the fact that the majority of 
groups do not contain any signals (i.e. the majority of groups have only true null 
hypotheses), such that most types of medication taken are not teratogenic. For all 
medication-CA combinations in this data, ?̂?0 was estimated to be 0.9992, 0.9989 and 
0.9992 for ATC2, ATC3 and CA groupings, respectively. Hu et al. [2010] noted that the group 
BH method performs best in situations where the estimate ?̂?0𝑖 of the proportion of null 
hypotheses in each group significantly differs across the groups. This was not the case for 




rejected null hypotheses for all types of grouping and level of FDR cut-off. For those groups 
where ?̂?0𝑖 < 1, the remaining estimates of ?̂?0𝑖  were around 0.98 on average, ranging from 
0.84 to 0.99 across all groupings and FDR cut-off levels. This may explain why the group BH 
method did not perform particularly well for these data.  
For the FDR by group method, the choice of cut-off level 𝛼1for the first stage of the FDR 
process can fail to control the overall FDR rate at 𝛼 (= 2𝛼1). A simulation study by 
Mehrotra and Adewale [2012] indicated that the actual FDR associated with this approach 
can in fact be up to 2-3 times larger than the target overall FDR level in some situations. In 
practice, the groups that dropped out after the first stage of this process were unlikely to 
include any potential signals after FDR adjustment in the second stage, even at the 
increased cut-off level of 𝛼2 = 2𝛼1. This procedure therefore provided very similar results 
as would be obtained from a separate FDR procedure for each group, i.e. not excluding any 
groups first, as is done here. Note that FDR adjustments at a level 𝛼 applied separately to a 
number of groups does not necessarily imply FDR control at level 𝛼 overall (i.e. across the 
whole study) [Benjamini and Yekutieli, 2005].  
Despite these considerations surrounding the choice of FDR cut-off, the focus for these 
analyses was to compare workload and identification rate for the methods explored, and 
hence the actual level of FDR control was not a key concern. More important is to achieve 
the highest possible detection rate (here estimated using the identification rate) for a 
workload that would be deemed acceptable for follow up of signals in practice. The choice 
of FDR cut-off for any FDR method should therefore be considered flexible and be adjusted 
accordingly to reflect the available resources for follow up of signals of any particular 
project.   
5.4.3. Signals identified by single and double FDR 50% with ATC3 groupings 
Signals identified by FDR methods in the context of evidence from other studies 
Further evaluation of associations identified in a signal detection process was not an aim of 
this thesis; however, this section will briefly refer to the existing evidence and knowledge 
regarding the 17 medications in 26 combinations identified as signals by the single and 
double FDR methods with a cut-off of 50% (as displayed in Table 5.4) in order to provide 
some context for these associations. The most common type of signals were in the group of 
antiepileptics; these are well-established as being a teratogenic group of medications [Bruni 
and Willmore, 1979, Petersen et al., 2017, Veroniki et al., 2017]. The next most common 




also well-recognised that it is poor control of maternal hyperglycaemia that causes an 
increased risk of malformations, rather than the insulin itself [Allen et al., 2007, Zabihi and 
Loeken, 2010, Charlton R. A. et al., 2016, de Jong et al., 2016b]. An increased risk of specific 
CAs has also been demonstrated following first trimester exposure to some antiasthmatics 
[Blais et al., 2010, Lim et al., 2011]. Progesterone and its derivatives have been linked to an 
increased risk of hypospadias [Carmichael et al., 2005] and CHDs [Zaqout et al., 2015]. 
Misoprostol is the only medication in Table 5.4 that is in the highest risk category X, 
indicating there is a high risk that it causes permanent damage to the foetus. This 
medication has various uses including ulcer prevention, labour or abortion induction and 
the treatment of postpartum bleeding, and has been shown to cause birth defects such as 
brainstem injuries [Vauzelle et al., 2013]. The combination of the ATC4 coded 
sympathomimetic medication G02CA with tricuspid atresia and stenosis was unexpected in 
that a labour suppressing medication is not usually taken as early in pregnancy as the first 
trimester. Exposures to this particular combination were present only in the two Italian 
registries, Emilia-Romagna (n=2) and Tuscany (n=6). Across the whole dataset, however, 
there were 583 exposures with the ATC4 level code G02CA, and 97% of these were in 
Emilia-Romagna (n=210) or Tuscany (n=357). Further exposures to more specific ATC5 
codes G02CA01 (n=232) and G02CA03 (n=68) were reported, meaning exposures to a 
G02CA medication were present in seven registries: Emilia-Romagna, Tuscany, Zagreb, 
Poland excluding Wielkopolska, Poland Wielkopolska, Antwerp and Vaud. Exposures to 
G02CA medications in the Polish registries and Vaud were specified as labour suppressants 
taken in the first trimester, according to additional notes fields. For cases in the Tuscany 
registry this medication was generally named as Vasosuprina; no specific medication name 
was specified for Emilia-Romagna. The efficacy of Vasosuprina’s active ingredient 
(isoxsuprine hydrochloride) as a treatment for women at risk of abortion or preterm labour 
has been evaluated in a number of (mostly Italian) studies [reviewed by Giorgino and Egan, 
2010]. This medication was taken at all gestational ages, including the first trimester in 
almost half the studies assessed in this review, and it therefore seems reasonable to 
assume that it was indeed taken in the first trimester in practice here, particularly given 
that there are a considerable total number of exposures to this medication in the data. 
However, although first trimester medication use is a pre-requisite for inclusion of a case in 
this data, records often lack detailed information regarding the specific timing of 
medication use. It is therefore also possible that these medications were taken at a later 




would be followed up with the specific registries as part of the next stage of the signal 
management process, which can help determine whether there is a possibility of 
misreporting or data errors. Another thing to note about this combination is that the 
reason it was a signal after double FDR only (and not after a single FDR adjustment) is 
because G02CA belongs to the ATC3 group G02C “other gynaecological” group of 
medications, in the group of genitourinary system and sex hormone medications. This ATC3 
group passed the first stage of the double FDR adjustment due to the small P-value 
(P=0.00004) of the medication G02CA in combination with atrial septal defect, another 
CHD. The combination of G02CA with atrial septal defect is in fact a protective association 
(see page 170 for further discussion of protective associations), but it is of note that this 
medication is the only association in Table 5.4 for which there is not already a combination 
in the same ATC3 group that was also a signal when using a single FDR. This highlights how 
P-values of combinations in groups including at least one signal (i.e. in groups that pass the 
first stage of the double FDR) are penalised less strictly by double FDR than single FDR, 
because the adjustment is done on a smaller set of combinations overall after discarding 
information from all groups not passing the first stage of the double FDR.  
There was only one combination that was a signal using single FDR but not double FDR, for 
the CHD atrioventricular septal defect in combination with the anxiolytic medication 
clobazam (N05BA09). This medication was also a signal in the EUROmediCAT signal 
detection analysis of Luteijn et al. [2016], but was not included for follow-up in Given et al. 
[2016] because the anxiolytics are a therapeutic subgroup of the psycholeptic medications 
and these were included in the separate EUROmediCAT work package for analysis of 
selective serotonin reuptake inhibitors, since these two classes of medications are 
frequently co-prescribed [EUROmediCAT, 2011]. An excess risk of the CHD Ebstein’s 
anomaly was reported for the group of psycholeptic medications in this study, but it was 
noted that there was limited staticstical power to assess these medications; the reported 
association was based on small numbers and hence requires further follow-up 
[EUROmediCAT, 2011].  
Comparison of signals from single and double FDR in this chapter with results from 
previous EUROmediCAT signal detection analyses 
The previous EUROmediCAT analysis identified 39 signals for future follow-up [Luteijn et al., 
2016]. As part of the EUROmediCAT project, any signals belonging to four groups of 
medications were already being separately investigated: insulin/insulin analogues [de Jong 




[Charlton R. et al., 2015, de Jong et al., 2016a] and psycholeptic medications / selective 
serotonin reuptake inhibitors [Wemakor et al., 2015]. Of the 39 signals identified by Luteijn 
et al, 14 were signals for insulin/insulin analogues, 4 for anti-asthmatic medications, 8 for 
antiepileptic medications, 2 for selective serotonin reuptake inhibitors / psycholeptic 
medications. There were 11 signals of other types of medications, which were then 
followed up in more detail in a separate study as the next stage of the signal management 
process [Given et al., 2016]. When considering these 39 signal combinations in the analyses 
done for this thesis:  
➢ 21 of these combinations were signals, of which 
• 10 combinations were also signals in these analyses: 3 after double FDR only, 
1 after single FDR only, and 6 after both a single and a double FDR procedure 
• 8 combinations were with ATC4 coded medications, but for which there was a 
signal of a more specific ATC5 medication with the same CA in the current 
analyses 
• 3 combinations were with the aggregate subgroup of CHDs, but for which 
there was a signal in the analysis of a more specific CHD subgroup with the 
same ATC code in the current analyses 
➢ 13 of these combinations were not present in the current analysis dataset, of which 
• 5 were medications in combination with an aggregate subgroup of CHD or 
severe CHD, which were not included separately in these analyses 
• 8 were ATC4 coded medications that were not included separately in these 
analyses (since a more detailed ATC5 code was available) 
➢ 5 of these combinations did not reach statistical significance to be judged signals in 
these analyses 
For the latter point, some of these are likely to be due to the smaller sample, as there were 
smaller numbers for many of the same medication-CA combinations in the dataset for this 
thesis. On the other hand, some combinations may have dropped out of the set of signals 
because the level of P-value cut-off differs by ATC3 group when using double FDR (and this 
will be lower than the overall P-value cut-off of the single FDR for some groups).  
Of the 26 medication-CA combinations displayed in Table 5.4, 6 were not signals in Luteijn 
et al, where their P-values were slightly above the FDR-adjusted cut-off for statistical 
significance. Ten of the remaining combinations in Table 5.4 were signals in Luteijn et al, of 




single FDR (in both Luteijn et al. and in this thesis), but not when using double FDR. For 
ATC3 groupings, the P-value for this combination was the minimum representative P-value 
in its group N05B, which included 9 different medications in this data. However, the N05B 
group was not included in the second stage of the double FDR procedure as it was dropped 
in the first stage (after FDR adjustment across the representative P-values from each of the 
116 ATC3 groups). This highlights the way in which the double FDR procedure can result in a 
stricter adjusted P-value threshold for certain groups compared to the single FDR 
procedure. A further 6 combinations in Table 5.4 included the same medication but were 
only signals in Luteijn et al. only in combination with the aggregate subgroup of CHDs (i.e. 
being a signal with a more specific CHD in this chapter). Three combinations were a signal 
for the ATC4 code with the same CA (i.e. being a signal with a more specific ATC5 code in 
this chapter). 
Comparison with other existing studies of teratogens 
Table 5.5 highlighted the results from single and double FDR for eight known medication-CA 
associations taken from a review by van Gelder et al. [2014]. This review was a 
comprehensive synthesis of evidence regarding teratogens in scientific literature up to 
2013, addressing the lack of evidence regarding teratogenicity of medications. The eight 
signals presented in Table 5.5  are reported associations between an ATC4 or an ATC5 
coded medication and a specific CA, including those observed in case-control studies that 
were confirmed in at least two studies (and not refuted in any other studies). Whilst this list 
of eight medications is not comprehensive and does not consider associations of any newer 
medications that have appeared on the market since 2013, it is an objective set of known 
associations and was therefore used to evaluate the EUROmediCAT signal detection 
method [Luteijn et al., 2016]. Note that Table 5.5  shows similar estimates to those in Table 
4 of Luteijn et al. Results for this small set of combinations indicate that double FDR 
performed slightly better than single FDR, in that two of the combinations were identified 
as signals by lower FDR cut-off levels. However, even in this small selection of combinations 
for which there was considered to be good evidence of an association, there were 
insufficient cases in the data for 3/8 of the combinations to even potentially be included in 
the resulting set of signals (less than 3 exposures to the specific medication-CA). This raises 
the point that known teratogenic medications may be underrepresented in the data, since 
they are rarely or no longer used in practice. Published studies documenting the use of 
oxprenolol, for example, have all been based on data prior to 1997 [Yakoob et al., 2013]. 




of known associations such as this is therefore limited in its ability to judge a signal 
detection method. An approach that evaluates combinations across the whole dataset 
should be less prone to this issue, and this is why the Australian categorisation system was 
used here to try and identify “high risk” medications across the whole dataset. 
Protective associations identified by single and double FDR procedures 
A number of combinations with PRR<1 remained associations after the FDR procedures, 
indicating a “protective” association of a medication for a particular CA. Such associations 
are likely to be due to chance (i.e. up to 50% of observed associations are expected to be 
due to chance with an FDR cut-off of 50%) or due to biases as a result of the case-
malformed control study design, where the controls all have at least one CA and one 
medication exposure. The antiepileptic medication lamotrigine (N03AX09), for example, 
was a signal for spina bfida in this dataset (Table 5.4); when the association between 
lamotrigine and different CA is examined, a large proportion of the controls are likely to be 
associated with lamotrigine via their association with spina bifida. A protective effect may 
therefore be observed for other CAs due to the large numbers of controls that are 
associated with lamotrigine. There was a significant protective association for the CHD 
ventricular septal defect in combination with lamotrigine (n=7) when using double FDR, but 
this association was not significant in analyses using single FDR. There were also protective 
associations for two medications G02CA (labour repressants, n=34) and N02BE01 
(paracetamol, n=55) with the CHD atrial septal defect. It should again be noted that 
protective here is in comparison to other CAs and medications in the database, and does 
not imply that the overall risk of a CA is lowered by such a medication.  
5.4.4. Use of risk categories to compare signal detection methods 
Various drawbacks regarding the use of the risk categorisation system have been discussed 
previously (see chapter 4). The teratogenic risk of a medication is often specific to certain 
CAs, rather than there being an increased risk of malformations in general [Mitchell, 2016]. 
A key issue for these analyses is that there is no such differentiation between the 
categorised risks of each medication in terms of different CAs, since specific CAs are not 
taken into account in the Australian risk categorisation system. This may have an effect on 
the “high risk” proportion and identification rates assessed in this chapter, since these 
measures therefore do not differentiate between a medication associated with only one CA 
and one associated with a number of different CAs. For example, the medication valproic 




congenital hydronephrosis (Table 5.4); however both medications contribute only once 
each to the overall “high risk” proportion and to the identification rate.  
Of the 16 medication signals identified by double FDR 50% 6 were “high risk”, 5 “low risk” 
and 5 were not assigned a risk category (Table 5.4). Due to 5 medications here having 
unknown risk categorisation, the proportion of medication signals that are likely to be “high 
risk” may be either under- or overestimated. On one hand, it may be assumed that if a 
medication is not given a risk category in the Australia categorisation system it is more 
likely to be of low risk, assuming that the harmful medications have already been identified. 
However, this would not be the case for newer and/or rarer medications, which are 
primarily what signal detection methods aim to identify. In fact, 35% of all medications 
included in the analysis were not assigned a risk category, and it is possible that the “high 
risk” proportion and identification rate have been underestimated. Two of the medications 
in Table 5.4 listed as “low risk” category A medications were insulin medications. It is not 
surprising to find the insulin medications in the low risk category according to the 
Australian classification system because, although the association between insulin 
medications and increased risk of CHDs is well known, this is often a result of the fact that 
the mother has diabetes, rather than the insulin medications being a risk factor in 
themselves. So whilst it is recognised that the insulin medications are often unlikely to be 
teratogenic themselves, it is important that they are appearing as signals in any signal 
detection method, and the risk categorisation system will not reflect this. In Table 5.5, two 
of the medications that were deemed to show evidence of being teratogenic in van Gelder 
et al. (naproxen and oxprenolol) are assigned as “low risk” category C medications 
according to the Australian risk categorisation system. This highlights the fact that the 
assigning of medications to the categories in these types of systems can be based on 
differing expert opinions and assessments of the available evidence regarding the potential 
risks of each medication for use in pregnancy. A third medication in Table 5.5, 
Progesterone, was not assigned a risk category at all, although this medication can be found 
in the same group of codes as G03DA02 (medroxyprogesterone) and G03DA03 





5.4.5. Summary and conclusions 
In summary, this chapter showed that the double FDR using ATC3 groupings performed 
better than other methods considering grouping, including the currently used single FDR 
procedure. Difficulties in the comparison of these methods was discussed, specifically the 
ability to judge the absolute strengths of any signal detection method due to issues with 
their validation. However, the double FDR was judged to be superior based on the findings 
and metrics used in these analyses, and this method can also be easily implemented in 
practice (the Stata code used to run a double FDR procedure with ATC3 groupings is 
presented in Appendix B2). However, FDR procedures presented in this chapter considered 
grouping of medications and/or CAs at the point of determining the statistical significance 
following a separate statistical test of each medication-CA combination. The next chapter 
considers the use of BHMs to directly model potential group effects in EUROmediCAT data, 
in order to determine whether such models provide better results than FDR procedures for 




Chapter 6:  Analysis of EUROmediCAT safety of medication 
use during pregnancy II: Bayesian hierarchical models 
6.1. Introduction 
In this chapter, methodology from DuMouchel [1999], Berry and Berry [2004] and Brook 
[2011] is applied to EUROmediCAT data to investigate whether use of BHMs that group 
together medications and/or CAs can improve signal detection methods for CA data. These 
models were developed in the context of signal detection in SR databases or for clinical 
trials of experimental pharmaceutical medications, but have not previously been applied to 
CA data. Results are compared to those obtained using a single FDR, as this is the method 
currently used by EUROmediCAT for signal detection purposes, as well as the double FDR 
method with ATC3 medication groupings, which showed improvement over the single FDR 
in Chapter 5. 
6.2. Methods 
Signal detection analyses in this chapter were investigated using BHMs that take groupings 
of medications (using ATC3 codes) and/or CAs (using type of CA grouped by their organ 
system classes) into account. Individual Bayesian models not incorporating any groupings 
were also analysed for comparison purposes. The methodology in this chapter combines 
the Gamma Poisson Shrinker and a BHM (see section 4.2.2 for further details) to apply to a 
large database containing many cells determined by combinations of a specific medication 
and a specific CA.  
Calculation of expected values 
As described in Table 4.1, the PRR was defined as 
𝑃𝑅𝑅𝑖𝑗 =  
𝑐𝑖𝑗  / 𝑐𝑖.
 𝑐𝑖′𝑗 /  𝑐𝑖′.
 
Assuming no association between 𝑖 and 𝑗, the expected count for 𝑐𝑖𝑗  was calculated using 





Under assumption of independence between the medications and the CAs, the PRR was 
expressed as the ratio of the observed to expected counts 







To illustrate this, a hypothetical 2-by-2 table of counts for the combination of a medication 
𝑖 with a CA 𝑗 is displayed in Table 6.1. In this example, there are a total of 1,250 exposures 
(𝑁) in which the observed marginal count for medication 𝑖 is 140 (𝑐𝑖.) and the observed 
marginal count for CA 𝑗 is 150 (𝑐.𝑗). Under the assumption that medication 𝑖 and CA 𝑗 are 
independent, 12% (=150/1250) of exposures to medication 𝑖 would be expected to also 
have CA 𝑗, and the expected count for this particular combination would then be 17 
exposures, i.e. 12% of 140 or 
140𝑥150
1,250
. When comparing the observed and the expected 
count in this example, 30 is therefore being compared to 17 such that 30/17 = 1.76 implies 
that the observed combination was 76% more likely than expected if medication 𝑖 and CA 𝑗 
were independent. 
 Example of a hypothetical 2x2 table for analysis of the relationship between 






Foetuses with CAs 
other than 𝑗 
Total 
Exposed to medication 𝑖 𝑐𝑖𝑗 = 30 𝑐𝑖𝑗′ = 110 𝑐𝑖. = 140 
Unexposed to 𝑖, but exposed 
to at least one other 
medication in the data 
𝑐𝑖′𝑗 = 120 𝑐𝑖′𝑗′ = 990 𝑐𝑖′. = 1,110 
Total 𝑐.𝑗 = 150 𝑐.𝑗′ = 1,100 𝑁 = 1,250 
 
Note that the above definition for 𝐸𝑖𝑗  means that the count 𝑐𝑖𝑗 for each individual 
combination is essentially contributing twice to the model, since it is counted in the 
marginal totals for both the medication and the CA. As a sensitivity analysis, therefore, the 
expected counts were also calculated using an alternative definition to assess whether the 
expected number of exposures for each medication-CA combination under the assumption 
of independence between medication 𝑖 and CA 𝑗 may be better estimated. In this 
alternative definition, the total number of exposures, the probability of exposure to 
medication 𝑖 independent of CA 𝑗, and the probability of CA 𝑗 independent of medication 𝑖 
were multiplied together as follows 










6.2.1. Data structure for Bayesian models according to different types of 
grouping for medications and congenital anomalies 
Separate Bayesian models for each medication-congenital anomaly combination 
Firstly, a separate Bayesian model was applied to each medication-CA combination, without 
considering any groupings of medications or CAs. This data structure is displayed in Table 
6.2; in this setting, each count 𝑐𝑖𝑗  of a particular medication 𝑖 in combination with a 
particular CA 𝑗 was modelled separately (i.e. no information sharing) in an individual 
Bayesian analysis with minimally informative priors. This formulation can be thought of as 
the Bayesian equivalent of a “frequentist” analysis that does not take multiple testing into 
consideration. This should be comparable to performing a Fisher’s exact test separately for 
each medication-CA combination and then using a P-value of 0.05 as the cut-off for 
statistical significance. However, as a Bayesian analysis places prior distributions on the 
model parameters, some shrinkage was expected due to the fact that the prior for the 
estimated PRR was centred on a PRR of 1 (no effect). This prior distribution will have some 
non-infinite variance, and the amount of shrinkage will also depend on the size of this 
variance. Estimates with low cell counts, for example, are more likely to be influenced by 
such a prior distribution as there is less information in the data itself for such combinations. 
These individual Bayesian models were therefore expected to identify less signals than the 
equivalent Frequentist models. 
 Layout of cell counts 𝑐𝑖𝑗  for each medication-CA combination in a two-
dimensional model for EUROmediCAT data with no information sharing. 










   
   
   
 CA (𝑗) 
ATC5 (𝑖) 
1 2 … 𝒏𝒋 Total 
1 𝑐11 𝑐12 … 𝑐1𝑛𝑗 𝒄𝟏. 










𝒏𝒊 𝑐𝑛𝑖1 𝑐𝑛𝑖2 … 𝑐𝑛𝑖𝑛𝑗 𝒄𝒏𝒊. 







Discrete groupings of either medications or congenital anomalies 
The structure of the data when considering information sharing for medications using 
discrete groupings of four digit ATC3 codes is displayed in Table 6.3. In this setting, the 
effects for each group of medications were averaged across all the CAs, such that the CAs 
were treated as coming from one overall group (i.e. allowing a distribution of effects across 
the group of all CAs separately for each group of ATC3 medications). In Table 6.3, each 
𝑑 represents a group of medications according to their ATC3 codes. There were 𝑑 = 1, … , 𝐷 
groups, and within each group 𝑑, there were 𝑖 = 1, … , 𝑛𝑑 unique ATC5 medication codes. 
In the other dimension were the 𝑗 = 1, … , 𝑛𝑗 CAs as one group. A combination of a 
particular medication 𝑑𝑖 with a particular CA 𝑗 was denoted 𝑐𝑑𝑖𝑗. Each group of medications 
𝑑 can be considered a set; for example, the grey shading in Table 6.3 represents the 𝑑 =
2 group of medications across the 𝑛𝑗 CAs.  
 Example of data structure for a model of information sharing by discrete 
groupings of medications. 










   
_
_
_  CA (𝑗)_    1 2 … … … 𝑛𝑗 
ATC3 (𝑑) ATC5 (𝑖) 
1 
1       
2       
…
 
      
𝑛1       
2 
1       
2       
…
 
      





      
𝐷 
1       
2       
…
 
      
𝑛𝐷       
 
The structure of the data when considering information sharing in the other dimension, i.e. 
for CAs only, is displayed in Table 6.4. In this model, the CAs were discretely grouped by 
their EUROCAT organ system class groupings, and the effects for each group of CAs were 
averaged across the medications (allowing a distribution of effects across the group of all 
medications separately for each group of CAs). Then there were 𝐴 groups of CAs and 
𝑗 = 1, … , 𝑛𝑎 CAs within each group. In the other dimension were the 𝑖 =




medication 𝑖 was denoted 𝑐𝑖𝑎𝑗. Here, each group of CAs 𝑎 is considered a set; for example, 
the grey shading in Table 6.4 represents the 𝑎 = 2 group of CAs across the 𝑛𝑖 medications. 
 Example of data structure for a model of information sharing by discrete 
grouping of CAs. 
   Congenital anomalies 










   
ATC5 (𝑖) CA (𝑗)_ 1 2 … 𝑛1 1 2 … 𝑛2  1 2 … 𝑛𝐴 
1               
2               
…
               
𝑛𝑖 
              
 
Two-dimensional discrete groupings of both medications and congenital anomalies 
The structure of the data when considering discrete groupings by both medications and CAs 
is displayed in Table 6.5. In this model, sets of cells were created according to crossings of 
the two variables. Again 𝑑 represented groupings of medications by ATC3 codes; there 
were 𝑑 = 1, … , 𝐷 groups and 𝑖 = 1, … , 𝑛𝑑 unique ATC5 medication codes within each 
group 𝑑. In the other dimension 𝑎 denoted groupings of CAs by their EUROCAT organ 
system classes. There were 𝐴 groups of CAs and 𝑗 = 1, … , 𝑛𝑎 CAs within each group. Any 
two-dimensional crossing of a group of CAs 𝑎 with a group of medications 𝑑 was then 
considered a set; for example, the lighter grey shading in Table 6.5 represents a set that is 
the crossing of the 𝑑 = 2 group of medications with the 𝑎 = 2 group of CAs 𝑎. Any 
combination of a particular medication 𝑑𝑖 with a particular CA 𝑎𝑗 was denoted 𝑐𝑑𝑖𝑎𝑗. The 
group 𝑎 = 2 may denote, for example, the “nervous system” group of CAs, in which there 
are 𝑛2 = 6 CAs. Similarly, the group 𝑑 = 2 may denote the N03A “Antiepileptics” group of 
ATC3 coded medications, within which there are 𝑛2 = 13 distinct ATC5 codes in the data. 
Suppose that the second CA in 𝑎 = 2 is spina bifida, and the first medication code in 𝑑 =
2 is N03AA01; the cell 𝑐2122 then denotes the cell of interest in the analysis of the 
combination of medication N03AA01 with the CA spina bifida; this is the darkest shaded cell 
in Table 6.5. Each set in the hierarchy in Table 6.5 (i.e. one set is the cells shaded in lighter 
grey) had a group distribution from which the elements of that set were drawn, such that 
each medication-CA combination within that two-way group shared a common prior 
distribution. There was also a prior distribution for the set of all top-level sets i.e. an 





 Example of data structure for a model of information sharing by discrete 
grouping of both medications and CAs. 
 
Table 6.6 demonstrates one possible two-dimensional set in the EUROmediCAT data, using 
the previously mentioned example of the nervous system CAs in combination with the 
antiepileptic medications. It can be seen that most of the information in the set for this 
example comes from the most common nervous system CA spina bifida, and from the three 
most common N03A medications (N03AF01, N03AG01 and N03AX01). The majority of the 
cell counts in this set contain little or no information (a zero cell count is indicated by a “-”).   
6.2.2. Specification of Bayesian models for signal detection analyses 
Bayesian models were applied assuming a Poisson distribution according to the four types 
of groupings described in the previous section. Models for this chapter were also initially 
defined assuming a negative binomial distribution in order to ascertain which model 
provided a better fit for these data (since a negative binomial model can allow for more 
flexible modelling of the variance and can therefore be useful if there are large departures 
from the equidispersion assumption; see Chapter 3 for previous discussion on this).  
Table 6.6 presents all model formulae and notation, showing how the observed counts 𝑐𝑖𝑗  
for each combination of a medication 𝑖 and a CA 𝑗 were modelled using a Poisson or 
negative binomial distribution. The code used to specify these models in JAGS is presented 
in Appendix C1.  
   Congenital anomalies 










   
_
_
_  CA (𝑗)_    1 2 … 𝑛1 1 2 … 𝑛2  1 2 … 𝑛𝐴 
ATC3 (𝑑) ATC5 (𝑖)              
1 
1              
2              
…
 
             
𝑛1              
2 
1              
2              
…
 
             





             
𝐷 
1              
2              
…
 
             




 Exposure counts for an example set of an ATC3 medication group and a group of congenital anomalies in the two-dimensional discrete 
grouping of EUROmediCAT data. 




















N03AA01 - - - - 1 - 
N03AA02 - - - 1 1 1 
N03AA03 - - - - - 1 
N03AB02 - - - 1 2 - 
N03AD01 - - - - - - 
N03AE01 - - - - 1 1 
N03AF01 1 - - 3 2 11 
N03AF02 - - - - - 2 
N03AG01 2 - - 7 3 32 
N03AG04 - - - 1 - - 
N03AX09 - - - 4 1 10 
N03AX11 - - - - 1 1 
N03AX12 - - - 1 - 1 
N03AX14 - - - - - 2 
N03AX15 - - - - -  






 Notation for Bayesian models applied to observed counts of 523 medications and 55 CAs in chapter 6. 
Grouping Distribution Model definition 
Prior distributions for model 
parameters 
Hyper-prior distributions 
for prior parameters 
No grouping: 
𝑖 = 1, … , 𝑛𝑖  medications 
𝑗 = 1, … , 𝑛𝑗 CAs 
Poisson 𝑐𝑖𝑗|𝜆𝑖𝑗 ~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝑒
𝜆𝑖𝑗𝐸𝑖𝑗) 𝜆𝑖𝑗  ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜇𝑖𝑗 , 𝜏𝑖𝑗) — 
Negative 
Binomial 
𝑐𝑖𝑗|𝜆𝑖𝑗 ~ 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑝𝑖𝑗 ,    𝑟𝑖𝑗) 
𝑝𝑖𝑗 = 𝑒
𝜆𝑖𝑗𝐸𝑖𝑗 = 𝑃𝑅𝑅𝑖𝑗𝐸𝑖𝑗 
𝜆𝑖𝑗  ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜇𝑖𝑗 , 𝜏𝑖𝑗) 
 𝑟𝑖𝑗  ~ 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(𝑏1𝑟 , 𝑏2𝑟) 
— 
Discrete grouping by medications 
only: 
𝑑 = 1, … , 𝐷 ATC3 groups 
𝑖 = 1, … , 𝑛𝑑  medications in each group 
𝑗 = 1, … , 𝑛𝑗 CAs 
Poisson 𝑐𝑑𝑖𝑗|𝜆𝑑𝑖𝑗 ~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝑒
𝜆𝑑𝑖𝑗𝐸𝑑𝑖𝑗) 
𝜆𝑑𝑖𝑗 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜃𝜆𝑑, 𝑡𝜆𝑑) 
𝑡𝜆𝑑 = 1/𝜎𝜆𝑑
2  
𝜃𝜆𝑑 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜇𝜃 , 𝜏𝜃) 
 𝜎𝜆𝑑 ~ 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(𝑏1𝜎, 𝑏2𝜎) 
Negative 
Binomial 
𝑐𝑑𝑖𝑗|𝜆𝑑𝑖𝑗 ~ 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑝𝑑𝑖𝑗, 𝑟) 
𝑝𝑑𝑖𝑗 = 𝑒
𝜆𝑑𝑖𝑗𝐸𝑑𝑖𝑗 = 𝑃𝑅𝑅𝑑𝑖𝑗𝐸𝑑𝑖𝑗 
𝜆𝑑𝑖𝑗 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜃𝜆𝑑, 𝑡𝜆𝑑) 
𝑡𝜆𝑑 = 1/𝜎𝜆𝑑
2  
𝑟 ~ 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(𝑏1𝑟 , 𝑏2𝑟) 
𝜃𝜆𝑑 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜇𝜃 , 𝜏𝜃) 
𝜎𝜆𝑑 ~ 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(𝑏1𝜎, 𝑏2𝜎) 
Discrete grouping by CAs only: 
𝑖 = 1, … , 𝑛𝑖  medications 
𝑎 = 1, … , 𝐴 groups of CAs 
𝑗 = 1, … , 𝑛𝑎 CAs in each group 
 
Poisson 𝑐𝑖𝑎𝑗|𝜆𝑖𝑎𝑗 ~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝑒
𝜆𝑖𝑎𝑗𝐸𝑖𝑎𝑗) 
𝜆𝑖𝑎𝑗  ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜃𝜆𝑎, 𝑡𝜆𝑎) 
𝑡𝜆𝑎 = 1/𝜎𝜆𝑎
2  
𝜃𝜆𝑎 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜇𝜃, 𝜏𝜃) 
𝜎𝜆𝑎 ~ 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(𝑏1𝜎 , 𝑏2𝜎) 
Negative 
Binomial 
𝑐𝑖𝑎𝑗|𝜆𝑖𝑎𝑗 ~ 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑝𝑖𝑎𝑗 , 𝑟) 
𝑝𝑖𝑎𝑗 = 𝑒
𝜆𝑖𝑎𝑗𝐸𝑖𝑎𝑗 = 𝑃𝑅𝑅𝑖𝑎𝑗𝐸𝑖𝑎𝑗 
𝜆𝑖𝑎𝑗  ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜃𝜆𝑎, 𝑡𝜆𝑎) 
𝑡𝜆𝑎 = 1/𝜎𝜆𝑎
2  
𝑟 ~ 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(𝑏1𝑟 , 𝑏2𝑟) 
𝜃𝜆𝑎 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜇𝜃, 𝜏𝜃) 
𝜎𝜆𝑎 ~ 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(𝑏1𝜎 , 𝑏2𝜎) 
Discrete grouping by medications 
and CAs: 
𝑑 = 1, … , 𝐷 ATC3 groups 
𝑖 = 1, … , 𝑛𝑑  medications in each group 
𝑎 = 1, … , 𝐴 groups of CAs 
𝑗 = 1, … , 𝑛𝑎 CAs in each group 
Poisson 𝑐𝑑𝑖𝑎𝑗|𝜆𝑑𝑖𝑎𝑗 ~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝑒
𝜆𝑑𝑖𝑎𝑗𝐸𝑑𝑖𝑎𝑗) 
𝜆𝑑𝑖𝑎𝑗  ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜃𝜆𝑑𝑎, 𝑡𝜆𝑑𝑎) 
𝑡𝜆𝑑𝑎 = 1/𝜎𝜆𝑑𝑎
2  
𝜃𝜆𝑑𝑎 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜇𝜃, 𝜏𝜃) 
𝜎𝜆𝑑𝑎 ~ 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(𝑏1𝜎 , 𝑏2𝜎) 
Negative 
Binomial 
𝑐𝑑𝑖𝑎𝑗|𝜆𝑑𝑖𝑎𝑗 ~ 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑝𝑑𝑖𝑎𝑗 , 𝑟) 
𝑝𝑑𝑖𝑎𝑗 = 𝑒
𝜆𝑑𝑖𝑎𝑗𝐸𝑑𝑖𝑎𝑗 = 𝑙𝑜𝑔 (𝑃𝑅𝑅𝑑𝑖𝑎𝑗) 𝐸𝑑𝑖𝑎𝑗 
𝜆𝑑𝑖𝑎𝑗  ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜃𝜆𝑑𝑎, 𝑡𝜆𝑑𝑎) 
𝑡𝜆𝑑𝑎 = 1/𝜎𝜆𝑑𝑎
2  
𝑟 ~ 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(𝑏1𝑟 , 𝑏2𝑟) 
𝜃𝜆𝑑𝑎 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜇𝜃, 𝜏𝜃) 




Description of models in Table 6.7 
Each form of 𝜆 according to the different groupings presented in Table 6.6 denotes 
the 𝑙𝑜𝑔(𝑃𝑅𝑅) for the combination of a medication 𝑖 and a CA 𝑗. The negative binomial 
model essentially introduces an additional “dispersion parameter”, which can be used to 
adjust the variance independently of the mean. There are a number of different 
characterisations and formulations of the negative binomial distribution, which have been 
discussed in detail by Cameron and Trivedi [2013]. For these analyses, a Poisson-gamma 
mixture was used to specify the negative binomial model. This model is based on the 
assumption that the data follow a Poisson distribution with additional Gamma-distributed 
unobserved individual heterogeneity, which is described by an additional dispersion 
parameter 𝑟 (this is also known as the shape parameter, see Table 6.6). As 𝑟 → ∞, the 
negative binomial distribution tends to a Poisson distribution, where if 𝑘 =
1
𝑟
 then 𝑘 = 0 
represents no overdispersion. The parameters of the negative binomial distribution 
𝑝 and 𝑟 were given prior distributions through 𝜆. 
Prior distributions for model parameters  
For individual Poisson and negative binomial models, each 𝜆 followed a Normal prior 
distribution with mean 𝜇 and precision 𝜏. A choice of 𝜇 = 0 represents a distribution 
centred on an average 𝑙𝑜𝑔(𝑃𝑅𝑅) of zero, i.e. an average PRR of 1, or of no effect. Suppose 
that most of the effects are believed likely to have a PRR of between 
1
30
 and 30, 
corresponding to a 𝑙𝑜𝑔(𝑃𝑅𝑅) of between -3.4 and 3.4. This choice of limits for the prior 
variation in the PRRs was somewhat arbitrary; however it was considered unlikely that 
effects would be larger than a PRR of 30 or smaller than 
1
30
 (particularly given that only a 
small number of protective associations are expected; see the following section for further 
discussion on this). The standard error for each 𝜆 was then 𝜎 =
3.4
1.96
= 1.74, with the 






= 0.33 therefore being used as the parameter value 
for the precision of the prior distribution for 𝜆. Other values of 𝜏 were also considered in 
order to assess the sensitivity of models to these choices of prior parameters. For negative 
binomial models, the limits of the uniform prior for each overdispersion parameter  𝑟 were 
chosen to ensure that this was always positive, i.e. 𝑏1𝑟 = 0 and with a large value for the 
upper limit such as 𝑏2𝑟 = 1000. A relatively large value for 𝑏2𝑟 was chosen to ensure that 




distribution if that was a better fit. Different choices of 𝑏2𝑟 were assessed for their effect 
on model fit and results.  
Hyper-prior distributions for prior parameters 
For BHMs grouping medications and CAs, the 𝑙𝑜𝑔(𝑃𝑅𝑅) for each medication-CA 
combination followed a Normal prior distribution mean 𝜃, representing the average 
𝑙𝑜𝑔(𝑃𝑅𝑅) across the group to which each medication-CA belonged. Similarly, 𝜎2 denoted 
the variance of the average 𝑙𝑜𝑔(𝑃𝑅𝑅) the group to which each medication-CA belongs (and 
with 𝑡 the related precision), i.e. representing the variation in estimates of combinations 
within the same group. These two parameters were then given their own prior 
distributions, using a Normal distribution for 𝜃 and a uniform distribution for 𝜎2. Normal 
distributions for 𝜃 were given minimally informative hyper-parameters centred on zero and 
with relatively large variance, i.e. 𝜇𝜃, = 0 and 𝜏𝜃 = 0.33 (as described previously). A 
uniform prior distribution is commonly used for the standard deviation of variance 
parameters in BHMs [Gelman A., 2006]; the limits of the uniform distribution used for 𝜎 
ensured that the variance was positive whilst also allowing 𝜎 to take a relatively large value, 
i.e. 𝑏1𝜎 = 0 and 𝑏2𝜎 = 100. Different choices of 𝑏2𝜎 were also assessed for their effect on 
model fit and results. 
6.2.3. Further characteristics of Bayesian models for signal detection 
Choice of parameters for prior distributions 
The amount of shrinkage in a hierarchical model can depend on the choice of parameters 
for the prior distributions. Minimally informative priors were therefore used for all 
parameters and hyper-parameters, as described above, in order to assess the effect of the 
groupings themselves on the model results, as opposed to measuring the effect of the 
choice of prior distribution. The limits used for the prior distribution of the 𝑙𝑜𝑔(𝑃𝑅𝑅) were 
based on the assumption that the PRRs are not likely to be smaller than 
1
30
 or greater than 
30. One of the strongest known teratogenic associations is that of valproic acid and spina 
bifida; the increase in risk associated with taking valproic acid in first trimester of pregnancy 
has been estimated to be around 13 times higher compared to the risk for women that took 
no antiepileptic medications, with a 95% CI ranging from around 8 up to 21 times an 
increase in risk [Jentink  et al., 2010]. It was therefore considered unlikely that any signal 
would involve a risk much larger than this upper 95% CI value of 21, hence the selected 
value of 30 was thought to be a sensible upper limit for the PRR in this chapter. As a quick 




approximate 95% confidence limits for the observed PRR for each combination with at least 
3 exposures were calculated as follows (see Table 4.1 for notation) 
𝑃𝑅𝑅𝑖𝑗 =  
𝑐𝑖𝑗  / 𝑐𝑖.
 𝑐𝑖′𝑗 /  𝑐𝑖′.
 













95% 𝐶𝐼 = 𝑒log(𝑃𝑅𝑅𝑖𝑗)± 1.96 𝑥 𝑆𝐸(𝑙𝑜𝑔(𝑃𝑅𝑅𝑖𝑗)) 
Using this approximation, none of the observed PRRs had a lower 95% confidence limit 
lower than 1/30, whilst only seven (all with a count of only 3 exposures) had an upper 95% 




 or greater than 30 was therefore considered reasonable for use in prior parameters 
in BHMs for this chapter.  
Overdispersion in count models 
An important assumption of the Poisson distribution for these data is that the conditional 
mean and variance should be equal, i.e. that the data are equi-dispersed. One way in which 
this assumption might be violated is if there is an underlying structure to the data that leads 
to a lack of independence in the exposure counts, these being medications and the number 
of specific types of CAs; a woman may have more than one count in the database for either 
or both of these. It is often the case that a malformed foetus has more than one major CA, 
and such co-occurrences are not necessarily independent. Respiratory and ear, face and 
neck defects, for example, were found to be the types of CA most likely to occur in 
combination with other CAs [Calzolari et al., 2014]. Of the 5.2 million births in the EU each 
year, around 2% are babies with at least one CA; if multiple CAs in the same baby occurred 
independently of each other, then the risk of a second CA in an affected pregnancy should 
be approximately 2% of those with at least one CA. In the data for this thesis, around 300 
(2%) of the 15,058 malformed foetuses would then be expected to have a second CA; the 
expected number of foetuses with 3 CAs would be around 6 (0.04%), and less than one 
foetus (0.0008%) would be expected to have 4 or more CAs. However, Table 4.6 showed 
that these numbers were actually much higher in the data, with 1,431 (9.5%), 339 (2.4%) 
and 117 (0.8%) of the 15,058 malformed foetuses having 2, 3 and 4 or more CAs, 
respectively. Under the assumption of independence, the observed number of multiple CAs 




multiple medications during pregnancy has also become increasingly common. A study in 
the US, for example, found that that  the average number of medications used in the first 
trimester of pregnancy increased from 1.6 in 1976-1978 to 2.6 in 2006-2008, with 82.3% of 
women in 2008 taking at least one medication during this stage of their pregnancy [Mitchell 
et al., 2011]. Combinations of medications taken together may not be independent; in the 
management of asthma, for example, inhaled short-acting beta-2-agonists are taken for 
symptom relief and these are often used alongside inhaled corticosteroids and other 
medications [Garne et al., 2016]. As the structure of the observed data may therefore 
violate the independence assumptions for both the CA and medication exposure counts in 
the BHMs used for this chapter, an alternative way of modelling the exposure counts was 
also considered by using the number of exposed individuals as the marginal totals, instead 
of the sum of the exposure counts. 
Definition of signals in Bayesian models 
Signals were identified using the 2.5th percentile values of the posterior distribution 
thresholds as a potential cut-off, representing the lower limit of the 95% PCIs. In this way, 
any medication-CA combination for which the posterior 2.5th percentile value for the 
𝑙𝑜𝑔(𝑃𝑅𝑅) was greater than zero was considered a signal. This represents the situation 
where 97.5% of the posterior distribution for the 𝑙𝑜𝑔(𝑃𝑅𝑅) of interest lies above zero, or 
equivalently that 97.5% of the posterior distribution for the PRR of interest lies above one. 
Equally, if a 95% PCI for a 𝑙𝑜𝑔(𝑃𝑅𝑅) includes the value of zero, this would not be 
inconsistent with there being no effect of that particular medication on that particular CA 
(i.e. a PRR of 1). As with the frequently used 5% level of significance in frequentist 
hypothesis tests, this choice of cut-off value is arbitrary. The effect of choosing a stricter 
0.5th percentile as a cut-off (corresponding to the lower limit of a 99% PCI) on the resulting 
set of signals for each model was also assessed. Note that by using the lower limit of the 
posterior distribution, any “protective” associations that may arise were thus disregarded, 
as seen in the previous chapter with the use of a one-sided Fisher’s exact test. Whilst such 
associations were not identified as potential signals (since the point of these analyses is to 
identify teratogens), the number of such associations were again monitored to check that 
they were not occurring more frequently than expected. This was done by identifying those 
combinations with a 97.5th (or 99.5th) percentile value for the posterior distribution of 





6.2.4. Summary of models applied to EUROmediCAT data in this chapter 
In summary, the following models were applied to the EUROmediCAT data, each using a 
Bayesian analysis with minimally informative priors 
1. No information sharing (individual Bayesian analyses) 
2. Discrete information sharing for medications 
3. Discrete information sharing for CAs 
4. Discrete information sharing for both medications and CAs 
Poisson and negative binomial models were first compared, in order to ascertain which 
model offered an improved fit to the structure of the data. All models as specified in Table 
6.6 were run using JAGS via the programme R and its package rjags. As described 
previously, the coda package [Plummer Martyn et al., 2003] was used to assess model 
convergence and to summarise the sample posterior distribution for each parameter. This 
included calculation of convergence statistics as well as visual inspection of trace, density 
and auto-correlation plots for the parameters in each model. These measures were also 
used to determine the required number of total iterations and thinning. See Chapter 3 
(section 3.5.2) for further details on the assessment of convergence for Bayesian models.  
As described in chapter 4, results from all models were compared in terms of their 
identification rate and “high risk” proportion according to the Australian risk categorisation 
system for ATC coded medications. Briefly, these measures were defined as  
 
𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐫𝐚𝐭𝐞 =  
Number of "high risk" medications identified as signals
Total number of "high risk" medications in the data
 
 
“𝐇𝐢𝐠𝐡 𝐫𝐢𝐬𝐤” 𝐩𝐫𝐨𝐩𝐨𝐫𝐭𝐢𝐨𝐧 =
Number of medication signals in "high risk" category 
Total number of medications identified as signals
 
 
𝐄𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐰𝐨𝐫𝐤𝐥𝐨𝐚𝐝 = Total number of medication signals 
 
Results from Bayesian models were also compared with those obtained using the single and 







Chapter 4 (section 4.4.2) described and summarised the EUROmediCAT dataset used for 
analyses in this thesis. Briefly, data on 15,058 foetuses was available, with 55 CAs and 523 
ATC medications being monitored for signal detection purposes. This included 26,765 total 
exposure counts across 28,765 possible medication-CA combinations. 
6.3.1. Assessment of Bayesian hierarchical models 
Convergence of parameters in BHMs was assessed by visual inspection of autocorrelation, 
trace and density plots for all models (data not shown). For each type of grouping and 
model, an adaptive phase of 1000 iterations was used, followed by a burn-in of 1000 
iterations being discarded. Models were then run using three chains each with 20,000 
iterations. A large thin was used due to high levels of autocorrelation, meaning that only 
one in every 20 successive iterations was used to summarise the posterior distribution. The 
thinned posterior samples generally demonstrated good mixing of chains and low 
autocorrelation. Posterior density distributions were generally reasonably symmetric, 
although some distributions were skewed.  
6.3.2. Modelling count data using Bayesian hierarchical models 
Estimating the presence of dispersion using a negative binomial model 
Table 6.8 summarises the posterior distributions for the estimated dispersion parameter 𝑟 
for the negative binomial models according to different choices of parameters for the prior 
distribution for 𝑟.  
 Posterior distribution of dispersion parameter 𝑟 in negative binomial models 
grouped by ATC3 medications and/or congenital anomaly (CA) subgroups. 
Prior parameters for 𝒓 Type of grouping in model 
Median of posterior 
distribution for 𝒓 (95% PCI) 
Uniform(0, 100) CAs 71 (39 – 98) 
 Medications 89 (63 – 100) 
 Medications and CAs 94 (76 – 100) 
Uniform(0, 1000) CAs 500 (81 – 976) 
 Medications 633 (167 – 982) 
 Medications and CAs 773 (336 – 990) 
Uniform(0, 10000) CAs 5124 (326 – 9817) 
 Medications 5385 (690 – 9802) 
 Medications and CAs 5891 (916 – 9766) 
 
Across these different scenarios, the parameter 𝑟 had a distribution that generally 







close to zero), in which the negative binomial distribution should be approximately similar 
to a Poisson distribution. It is therefore unlikely that the dispersion parameter substantially 
improves the model fit for these data, implying that the use of a Poisson model was 
reasonable for these data. This was checked by confirming that the use of a Poisson rather 
than a negative binomial model did not have any important effect on the actual model 
estimates (i.e. the estimated PRRs). To do this, Poisson and negative binomial models were 
both implemented for each type of grouping in order to assess which was a better fit for 
the data, and whether there was any evidence of overdispersion. Results are presented in 
the following section. 
Comparison of estimates from negative binomial and Poisson models 
The “high risk” proportion is plotted against the effective workload for Poisson (filled grey 
symbols) and negative binomial (hollow black symbols) models in Figure 6.1, using a 95% 
PCI (panel A) and a 99% PCI (panel B) as cut-offs for defining signals. Both axes are plotted 
on a logarithmic scale, such that the distance between two consecutive horizontal gridlines 
represents a doubling in “high risk” proportion. Note that because the “high risk” 
proportion is calculated as a percentage of the effective workload, this is sensitive to small 
changes at the lower scale of the x-axis (i.e. the left hand side of Figure 6.1). Differences 
between points towards the lower end of the scale on both axes therefore look greater 
than differences of the same size at the top of the scales. For example, grouping by type of 
CA using a negative binomial model identified four fewer medication signals than a Poisson 
model with the same grouping (4 compared to 8) when using a 95% PCI cut-off to classify 
associations as signals (Figure 6.1 panel A). For models without any grouping the two 
markers appear much closer together, but the absolute difference in effective workload 
between the negative binomial and Poisson model for this grouping is in fact only six (total 
of 153 compared to 159 medication signals). Although this looks far greater on the scale 
used here, this is similar to the difference between the negative binomial and Poisson 
models using CA groupings. The choice of a 99% PCI cut-off for definition of signals shown 
in Figure 6.1 shows that smaller numbers of medication signals are identified by this stricter 
threshold, but with better “high risk” proportions. This can be seen in that all points in 
panel A of Figure 6.1 are higher and further left than for the same models and groupings 
shown in panel B. When grouping by CAs and using a 99% PCI, the negative binomial and 
Poisson models both gave three medication signals (hence the markers for these models 
are in the exact same point on Figure 6.1). Of these three medications, one was “high risk”, 








Figure 6.1. “High risk” proportion (percent of all medication signals that are in the “high 
risk” category) vs. effective workload comparing the use of Poisson (filled grey 
markers) and negative binomial (hollow black markers) distributions to model the 
cell counts, using (A) 95% PCI and (B) 99% PCI to define signals in Bayesian models 
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For some groupings, the negative binomial resulted in improved “high risk” proportion 
compared to the Poisson model, but these differences were not consistent across the 
groupings or cut-offs (Figure 6.1). All differences in “high risk” proportion were due to only 
one or two additional “high risk” signals being identified by the negative binomial model, or 
to the same number of “high risk” signals but a greater number of medication signals 
overall affecting the “high risk” proportion. The differences in “high risk” proportion and 
effective workload between the negative binomial and Poisson models were small relative 
to the effect of the type of grouping used by either model.  
The Identification rate is plotted against the effective workload in Figure 6.2 for all Poisson 
(filled grey symbols) and negative binomial (hollow black symbols) models, using a 95% PCI 
(panel A) and a 99% PCI (panel B) as cut-offs to define signals. As with the “high risk” 
proportion, the identification rate was similar for comparable effective workloads when 
using a Poisson or a negative binomial model. Again, the 99% PCI cut-off for definition of 
signals shown in panel B of Figure 6.2 shows that smaller numbers of medication signals are 
given by this stricter threshold, and with lower proportions of the total potential “high risk” 
medications in the dataset being identified as signals (when compared to the use of a 95% 
PCI to define the signals, as shown in panel A). 
In summary, Figure 6.1 and Figure 6.2 demonstrate that there were no substantial 
differences in results whether using a negative binomial or Poisson distribution to model 
the count data. Instead, the main differences in the metrics presented arise from the type 
of grouping and the choice of cut-off level of PCI for assigning combinations as signals, and 
these are explored in detail in the following sections. Furthermore, the Poisson model is 
more parsimonious (has less parameters) and straightforward to implement compared with 
the negative binomial models. For the rest of this chapter, therefore, results are presented 









Figure 6.2. Identification rate (proportion of all “high risk” medications that are 
identified as signals) vs. effective workload comparing the use of Poisson (filled 
grey markers) and negative binomial (hollow black markers) distributions to model 
the cell counts, using (A) 95% PCI and (B) 99% PCI to define signals in Bayesian 
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Calculation of expected counts 
As a sensitivity analysis, two variants on the calculation of the expected count used to 
determine the expected-to-observed ratio (i.e. the PRR) were assessed. Firstly, when 
considering the potential violation of the assumption of independence of exposure counts 
in the data, the number of individuals were used as the marginal totals for calculation of 
the 𝐸𝑖𝑗, instead of the total number of exposures. In practice this meant that a malformed 
foetus with two CAs and an exposure to one medication, for example, would only be 
counted once in the marginal (row) total for that medication, despite being present in two 
separate CAs (once in each of two columns). Similarly, a malformed foetus with two 
medication exposures and one CA would only be counted once in the marginal total for that 
CA, despite being counted in each row for the two medications. One problem with this 
approach was that the sum of the marginal totals for the medications and the sum of the 
marginal totals for the CAs do not add up, therefore the choice of the overall total 𝑁 (see 
Table 4.1) was not clear. A number of different values were therefore used for 𝑁 to see if 
this approach was feasible, including a simple average of the two sums of marginal totals, 
an average weighted by the total number of medications and CAs and using just one or the 
other sum of the marginal counts. For all choices of 𝑁 considered, however, it was found 
that the expected counts were always much lower than the observed counts. Although the 
number of “protective” associations did completely diminish when using this alternative 
calculation for the expected count, the total number of signals increased hugely to the 
point where BHMs produced thousands of signals (data not shown). This did not represent 
a realistic resulting workload, and with such a high number of potential signals a very high 
number of false positives would be likely. A second alternative definition of the expected 
count was also considered to address the fact that the exposure count for each particular 
medication-CA combination was included twice in the calculation of each 𝐸𝑖𝑗  (see section 
6.2 for details). Use of this alternative calculation for 𝐸𝑖𝑗  did not, however, have a material 
effect on the results for any of the BHMs; although one or two additional “high risk” 
medications were identified for a number of the BHMs when using this alternative 
definition, this was at the expense of an increased total number of signals for very similar 
“high risk” proportion and identification rates (data not shown). Since neither of these 
variants of the expected count appeared to improve the BHMs used, all results in this 







6.3.3. Signal detection using Poisson Bayesian hierarchical models, with 
comparison to single and double FDR procedures  
A summary of the main results from Fisher’s exact test (see Chapter 5) and Poisson BHMs 
are displayed in Table 6.9. Different cut-offs used to define signals are displayed, starting 
with more “lenient” choices (identifying a greater total number of signals) for each method; 
the first method, for example, shows results from Fisher’s exact test where combinations 
were defined as signals if they had an unadjusted P-value <0.05 (first row of Table 6.9) or 
<0.01 (second row). For FDR methods, the different cut-off levels correspond to the 5 
points for each of these methods in Figure 6.3 and Figure 6.4. FDR methods used cut-offs 
ranging from 5% to 50% in 5% increments; for some cut-off levels, however, it took more 
than one 5% increment to see a change in the resulting number of signals. For example, the 
set of signals using single FDR was the same for any FDR cut-off value between 15-25%. This 
is why there are only 5 (rather than 10) points for each method in Table 6.9, Figure 6.3 and 
Figure 6.4. Table 6.9 shows the number of ATC3 groups without any signals (column “ATC3 
groups with no signals”) increased as the cut-off level for each method became stricter and 
fewer signals were identified (column “Combinations identified as signals: total”). Fisher’s 
test and individual BHMs (i.e. no grouping or adjustment for multiple testing) identified the 
most signals across more groups. The number of medication signals is also shown for each 
method (effective workload, column in bold), including a breakdown by the type of risk 
category according to the Australian classification system. More “high risk” DX medications 
were identified by use of individual Poisson BHMs; this method also, however, identified 
the greatest overall number of combinations signals and gave an effective workload of 159 
unique medications to follow up, representing 30% of all medications in the analysis. The 
“strictest” method was single FDR with a cut-off of 5%, identifying only two medication 
signals, of which one was “high risk”. The “high risk” proportion, identification rate and 
effective workload were similar using (i) a BHM grouped by both medications and CAs with 
a 95% PCI cut-off, and (ii) Fisher’s exact test with an unadjusted P-value cut-off P<0.01. The 
only models with higher identification rates were individual BHMs with a 95% PCI cut-off 
and Fisher’s exact test with an unadjusted P-value cut-off P<0.05; both these methods 
identified an extra 10% of the “high risk” signals, but at the expense of a two-fold increase 
in effective workload (compared to methods with the next highest workload). Compared to 
double FDR with a cut-off of 50%, individual BHMs with 95% PCI cut-offs and unadjusted P-
value<0.05 models both gave an effective workload almost 10 times higher for a gain in 




 Summary of results from Fisher’s exact test with various adjustments for multiple testing, and from BHMs with a Poisson distribution. 
Type of model and 
grouping 
Cut-off level 









identified as signals 
 

















A, B or C 
“High risk” 
category: 








P <0.05 56 354 f 252  100 16 39 155 10 36 49 
P <0.01 79 54 f 91  38 11 18 67 16 25 34 
Fisher’s test: single 
FDR (no grouping) 
FDR 50% g 109 0 10  3 3 2 8 38 7 9 
FDR 30% 110 0 9  2 3 2 7 43 7 8 
FDR 20% g 111 0 7  1 3 2 6 50 7 6 
FDR 10% 112 0 4  1 1 2 4 25 2 4 
FDR 5% 114 0 2  0 1 1 2 50 2 2 
Fisher’s test: double 
FDR with ATC3 
grouping 
FDR 50% g 109 1 25  5 6 5 16 38 14 14 
FDR 30% g 109 0 19  4 6 5 15 40 14 11 
FDR 20% g 112 0 13  3 5 3 11 45 11 8 
FDR 10% 114 0 7  0 4 1 5 80 9 5 
FDR 5% 114 0 5  0 2 1 3 67 5 4 
a out of a total of 116 ATC3 groups of medications 
b out of a total of 523 unique ATC coded medications 
c “High risk” proportion: the proportion of all medication signals that are “high risk” category D or X medications 
d Identification rate: the proportion of “high risk” category D or X medications that are identified as signals, out of n=44  category D or X medications in the dataset 
e out of a total of 55 CAs 
f Combinations with less than 3 exposures are not considered signals when using Fisher’s exact test 
g FDR cut-off levels were assessed in 5% increments from 5% to 50%, but some cut-off levels resulted in the same values for this table; for single FDR cut-offs in the ranges 15-




Table 6.9 (continued). Summary of results from Fisher’s exact test with various adjustment for multiple testing, and from BHMs with a Poisson distribution. 
Type of model and 
grouping 
Cut-off level 









identified as signals 
 

















A, B or C 
“High risk” 
category: 






BHMs: no grouping 
95% PCI 47 59 223  98 17 44 159 11 39 48 
99% PCI 88 2 53  18 7 18 43 16 16 24 
Poisson BHM: discrete 
grouping by ATC3 
95% PCI 107 0 21  3 4 8 15 27 9 9 
99% PCI 112 0 7  1 2 2 5 40 5 6 
Poisson BHM: discrete 
grouping by CA 
95% PCI 110 0 10  2 2 4 8 25 5 6 
99% PCI 113 0 3  1 1 1 3 33 2 3 
Poisson BHM: discrete 
grouping by ATC3 & CA 
95% PCI 70 44 112  33 10 28 71 14 23 36 
99% PCI 105 1 24  6 3 7 16 19 7 14 
a out of a total of 116 ATC3 groups of medications 
b out of a total of 523 unique ATC coded medications 
c “High risk” proportion: the proportion of all medication signals that are “high risk” category D or X medications 
d Identification rate: the proportion of “high risk” category D or X medications that are identified as signals, out of n=44  category D or X medications in the dataset 




The “high risk” proportion for all models displayed in Table 6.9 is plotted against the 
effective workload in Figure 6.3 using a 95% PCI (panel A) and a 99% PCI (panel B) as a cut-
off to define signals, with results for FDR cut-offs of 5-50% for both FDR methods of P-value 
adjustment as previously described. Similarly, the identification rate is plotted against the 
effective workload in Figure 6.4, again using a 95% PCI (panel A) and a 99% PCI (panel B) to 
define signals. These figures show that the double FDR resulted in the highest “high risk” 
proportion and identification rate for comparable effective workloads when using other 
methods. Whilst the ungrouped BHMs and those grouped discretely by both medications 
and CAs sometimes identified greater numbers of “high risk” medications, this was at the 
expense of a substantial increase in effective workload. 
Figure 6.5 and Figure 6.6 are heatmaps showing which combinations of CAs and ATC2 
medication groups involved signals from single and double FDR, respectively, each using an 
FDR cut-off of 50%. Figure 6.7, Figure 6.8 and Figure 6.9 show the same information for 
BHMs using a 95% PCI cut-off, with groupings by CAs, by medications and by both 
medications and CAs, respectively. In Figure 6.5 to Figure 6.9, the shading represents the 
number of medication-CA combinations that are a signal in each grouping of and ATC2 
medication with a CA, according to each method. The N03 and G03 medication groups 
contained the most signals for all methods, followed by the A10 group of medications, 










Figure 6.3. “High risk” proportion (percent of all medication signals that are in the “high 
risk” category) vs. effective workload: comparing the use of single and double FDR 
procedures with Poisson BHMs using (A) 95% PCI and (B) 99% PCI as a cut off for 
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Single FDR (5%, 10%, 20%, 30%, 50%) Fisher's test: unadjusted P-value<0.05
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Single FDR (5%, 10%, 20%, 30%, 50%) Fisher's test: unadjusted P-value<0.01








Figure 6.4. Identification rate (proportion of all “high risk” medications that are 
identified as signals) vs. effective workload: comparing the use of single and double 
FDR procedures with Poisson BHMs using (A) 95% PCI and (B) 99% PCI as a cut off 
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Single FDR (5%, 10%, 20%, 30%, 50%) Fisher's test: unadjusted P-value<0.05
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Figure 6.5. Number of signals in each ATC-2 group of medications for each of 55 
congenital anomalies, identified using a single FDR procedure with an FDR cut-off 
of 50%. 
 
Figure 6.6. Number of signals in each ATC-2 group of medications for each of 55 







Figure 6.7. Number of signals in each ATC-2 group of medications for each of 55 
congenital anomalies, identified using a BHM with grouping by congenital anomaly; 
95% PCIs used to define signals. 
 
Figure 6.8. Number of signals in each ATC-2 group of medications for each of 55 
congenital anomalies, identified using a BHM with grouping by medications; 95% 






Figure 6.9. Number of signals in each ATC-2 group of medications for each of 55 
congenital anomalies, identified using a BHM with two-way grouping by congenital 
anomaly and medications; 95% PCIs used to define signals. 
6.3.4. Different signals according to different approaches: the effect of 
shrinkage in Bayesian models 
Differences between BHMs were apparent in the overall numbers of signals as well as 
which medication-CA combinations were identified as signals, as highlighted by the 
heatmaps in Figure 6.5 to Figure 6.9. This section presents examples of medication-CA 
combinations that were signals using some methods but not others, highlighting the effect 
of shrinkage in the BHMs. Estimates from combinations across the different Bayesian 
models and from a Fisher’s exact test followed by a single or double FDR procedure are 
compared and discussed.  
Example of shrinkage to the null:  antiepileptic medications and atrial septal defect 
Firstly consider an example of shrinkage to the null when using BHMs, where a signal 
attenuates towards the null due to the influence of other combinations in that group, 
meaning the group average is close to 𝑙𝑜𝑔(𝑃𝑅𝑅) = 0 (i.e. no evidence that the medications 
in this group alter the risk of that particular CA). One example of this is the combination of 
the antiepileptic N03A medications with the CHD subgroup atrial septal defect. Figure 6.10 
displays the estimated 𝑙𝑜𝑔(𝑃𝑅𝑅) and 95% PCIs for association of the 16 antiepileptic 




analysis. Combinations considered a signal by any method are highlighted in black, whilst 
estimates in grey were not considered a signal according to that particular analysis. Note 
that a 𝑙𝑜𝑔(𝑃𝑅𝑅) was not estimated for combinations with a zero cell count when using 
Fisher’s exact test (i.e. models with no P-value adjustment, single FDR or double FDR 
adjustment). However, the BHMs produced an estimate and PCI for all combinations, 
including those with a cell count of zero. Estimated 𝑙𝑜𝑔(𝑃𝑅𝑅𝑠) for such combinations were 
sometimes non-zero due to the influence of other estimates in the group; however the 95% 
PCI for combinations with zero cell counts always crossed the null value of 𝑙𝑜𝑔(𝑃𝑅𝑅) = 0. 
Therefore no combinations with zero cell count were identified as a signal in any Poisson 
BHM. The first two methods in Figure 6.10 are those without any adjustment for multiple 
testing: firstly signals identified using Fisher’s exact test with no adjustment to the P-values, 
and secondly using individual Bayesian models with minimally informative priors. With no 
consideration of multiple testing, a frequentist analysis highlighted 3 N03A medications 
signals at the 5% significance level (i.e. using a P-value cut-off of 0.05). For individual BHMs, 
only 2 of these medications remained signals in combination with atrial septal defect; the 
estimate for N03AX11 was attenuated by the inclusion of a prior distribution for the 
𝑙𝑜𝑔(𝑃𝑅𝑅) that was centred on a mean of zero. Note that the 95% PCI estimates for this 
model were generally a little wider than for other models. The third method in Figure 6.10 
is the single FDR procedure, adjusting P-values across the whole dataset to account for 
multiple testing using a cut-off of 50%. This procedure did not consider any groupings but 
instead averaged estimates across all medication-CA combinations, and did not identify any 
N03A medications as signals in association with atrial septal defect. The double FDR 
method (again with a cut-off of 50%) considered the antiepileptics as a group, and in this 
case N03AG01 (valproic acid) was identified as a signal for atrial septal defect. This 
demonstrates how the double FDR method works in practice; the smallest P-value in the 
group here “passed” the first stage of the double FDR procedure, and all the N03A 
medications were therefore taken to the second stage. In this second stage of adjustment, 
a single FDR procedure was then applied across the set of medication-CA combinations 
from all the ATC3 groups whose minimum P-value passed the first stage of the double FDR. 
A BHM with grouping by medications gave the same result for N03A medications with atrial 
septal defect, with only N03GA01 being a signal. The last two methods in Figure 6.10 are 
BHMs considering groupings of CAs only and of CAs in combination with medication groups. 
For both these methods, Figure 6.10 demonstrates that the average estimates for 





Figure 6.10. Estimated 𝑙𝑜𝑔(𝑃𝑅𝑅) and 95% PCIs for association of the N03A antiepileptic medications with atrial septal defect, according to seven methods 
of analysis. The number of exposures 𝑐 for each medication in combination with atrial septal defect is shown in brackets after each ATC5 medication 
code. Estimates for all methods are truncated at -2 and 2 for visual purposes; those in black indicate combinations that are considered signals 








































































Example of shrinkage to the group mean (I):  insulin medications and congenital heart 
defects 
Shrinkage to the mean can also occur if one strong signal in a group has an effect on the 
estimates for other combinations in that group. Table 6.10 summarises the number of 
signals in the set of A10A insulin medications (19 ATC5 and 2 ATC4 coded medications) in 
combination with CHDs (17 subgroups) according to single and double FDR with a cut-off of 
50%, and to the BHM grouping by both medications and CAs.  
 Signals for group of A10A insulin medications (n=11) and congenital heart 
defect CAs (n=17) according to single and double FDR (50% cut-off) grouped by 





Congenital heart defect 
(CHD) subgroups 















Patent ductus arteriosus 







and BHM  
3 
Atrial septal defect  














Coarctation of aorta 
Pulmonary valve atresia 
Tetralogy of Fallot 
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Pulmonary valve stenosis 
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pulmonary venous return 
Tricuspid atresia and 
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- - - 
Total number of A10A-CHD combinations as signals 1 6 27 
Total number of A10A medication signals in CHD 
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The medication A10AC01 (human insulin) was a signal for the CHD patent ductus arteriosus 
across all three of the methods in Table 6.10. Every combination including an A10A 
medication was taken to the second stage of the double FDR adjustment due to the 
minimum P-value for that group (the combination of A10AC01 with patent ductus 
arteriosus; P=7.1x10-6) passing the first stage of FDR adjustment. All A10A medication-CA 
combinations were then considered in the second stage of P-value adjustment. Note that 
this procedure does not take groups of CAs into account, but averages across all CAs (i.e. 
not just the CHDs) when considering the statistical significance of each test. The double FDR 
method identified six signals of an A10A medication with a CHD, for four A10A medications 
across four CHD subgroups. When considering grouping by both medications and CAs using 
a BHM, there were 27 signals in the two dimensional A10A-CHDs set. This included at least 
one signal for every medication in the A10A group, in combination with 10 of the 17 CHD 
subgroups. 
Another example where there was one combination that had an effect on the estimates for 
other combinations in that group was the A10A medications in combination with 
ventricular septal defect, where Figure 6.11 shows that the estimated 𝑙𝑜𝑔(𝑃𝑅𝑅𝑠) shrank 
towards to the average estimate across this two-dimensional set. Note that Figure 6.11 
shows there were four medications (A10AB, A10AB05, A10AC01 and A10AD05), where the 
estimated 𝑙𝑜𝑔(𝑃𝑅𝑅) had a 95% CI or 95% PCI that did not cross the null value of zero in any 
of these three models. Using single FDR adjustment, however, none of these combinations 
were considered signals. After double FDR, only one medication (A10AB05; insulin aspart) 
was a signal in combination with ventricular septal defect. In the BHM grouping by ATC3 
medications and by CAs, all four combinations were flagged as signals. This highlights the 
way in which a BHM “borrows” information within each two-dimensional group; the model 
considers the evidence of an association to be stronger for these four combinations 
because they are similar CAs (i.e. CHDs) and belong to the same pharmacological subgroup 
of ATC coding (i.e. ATC3 group A10A). Figure 6.11 also illustrates how the large cell count 
for one or two CA-medication combinations can influence the group as a whole. The most 
common medications in combination with ventricular septal defect were A10AB05 (35 
exposures) and A10AC01 (29 exposures) and for these combinations the effect of shrinkage 
appeared small, with the estimate and 95% PCI very similar to those obtained in the 
Frequentist analysis. Less common medications in this group, on the other hand, such as 




smaller estimates for the 𝑙𝑜𝑔(𝑃𝑅𝑅). This demonstrates how combinations with fewer 
exposures (i.e. more limited information) have less influence on the average posterior 
distribution than combinations that are much more common. 
 
Figure 6.11.   Estimated 𝑙𝑜𝑔(𝑃𝑅𝑅) and 95% PCIs for association of A10A medications 
with ventricular septal defect according to single FDR, double FDR grouped by 
ATC3 codes and a BHM grouped by ATC3 codes and CA groups. The dashed line in 
the BHM shows the mean 𝑙𝑜𝑔(𝑃𝑅𝑅) across the group of A10A medications and 
CHDs. 
The shrinkage of estimates for A10A medications with patent ductus towards the average 
of all 𝑙𝑜𝑔(𝑃𝑅𝑅𝑠) in this two-dimensional set is displayed in Figure 6.12. This is another 
example of one strong association in the group that was a signal across the three methods 
displayed. In this example, an additional signal was identified in the same group when using 
double FDR, and three extra signals when using a BHM grouping by both medications and 
CAs. Note that the BHM estimates for A10A medications in combination with this CA were 
again markedly affected by shrinkage, having narrower 95% PCIs than their corresponding 
frequentist 95% CIs. There were generally less exposures for A10A medications with patent 
ductus arteriosus than in the previous example of ventricular septal defect (which is the 
most common CHD), and in particular there were four medications with a cell count of only 
one exposure. For these medications the effect of shrinkage was clear, with the 95% PCIs 
being narrower and one of these medications (A10AE05) becoming a signal due to this 























































previously, combinations with a cell count of zero do have an estimated 𝑙𝑜𝑔(𝑃𝑅𝑅) in the 
BHM, but these always have a 95% PCI including zero (A10AD05, A10AC and A10AB in 
Figure 6.12). Another medication with a slightly higher count (A10AB05, n=5) was also a 
signal for patent ductus arteriosus in the BHM. 
 
Figure 6.12. Estimated 𝑙𝑜𝑔(𝑃𝑅𝑅) and 95% PCIs for association of A10A medications with 
patent ductus arteriosus as only CHD in term infants, according to single FDR, 
double FDR grouped by ATC3 codes and a BHM grouped by ATC3 codes and CA 
groups. The dashed line in the BHM shows the mean 𝑙𝑜𝑔(𝑃𝑅𝑅) across the group 
of A10A medications and CHDs.  
Example of shrinkage to the group mean (II):  antiasthmatic medications and 
multicystic renal dysplasia 
Notable shrinkage towards the group mean also occurred for groups where the data were 
very sparse; one such example is the combination of the urinary CA multicystic renal 
dysplasia with groups of medications for obstructive airway diseases. In Figure 6.13, 
estimates are shown for the four ATC3 groups within the ATC2 group R03 in association 
with multicystic renal dysplasia. There were no medication exposures for the medications in 
the two ATC3 groups R03B and R03C with this CA, so within these groups there were no 
reported signals according to any method assessed (although the BHM did produce 
estimates for these combinations). Another of the ATC3 groups R03D had limited 
information, with four of its seven combinations having no medication exposures. There 























































frequentist analyses, but this association did not remain a signal after either single or 
double FDR adjustment, and shrank toward the group average (which is the null in this 
case) in a BHM. In the group R03A there were more exposures but again no signals when 
using single or double FDR, despite there being three medications (R03AL01, R03AK06 and 
R03AC02) with an estimate and 95% CI above zero (Figure 6.13). When using a BHM with 
two-dimensional groupings, the two commonest combinations in the group R03A became 
signals as they shrank towards the group mean. The association for R03AL01, however, was 
not a signal in this method either, and the related 𝑙𝑜𝑔(𝑃𝑅𝑅) shrank towards the null with a 
95% PCI that included zero.  
 
Figure 6.13.  Estimated 𝑙𝑜𝑔(𝑃𝑅𝑅) and 95% PCIs for association of multicystic renal 
dysplasia with R03 medications according to single FDR, double FDR grouped by 
ATC3 codes and a BHM grouped by both ATC3 and CAs. Some lower 95% PCI limits 
are truncated at -4 for illustrative  purposes. The dashed lines in the BHM show the 
mean 𝑙𝑜𝑔(𝑃𝑅𝑅) across each group of ATC3 codes for obstructive airway diseases 
medications in combination with the urinary CAs. 
6.3.5.  “Protective” associations in Bayesian Hierarchical Models 
The number of significant “protective” associations according to each method is presented 
in Table 6.11, as well as the total number of combinations identified as signals (as shown 
previously in Table 6.9) for comparison purposes. Significant “protective” associations are 
those with a PRR<1 and a P-value passing the FDR procedure (for FDR methods), or a PRR 

























































































 Number of signals and “protective” associations according to different 






































95% 59 223 29 19 69 





95% 0 21 0 3 14 




95% 0 10 0 1 7 






95% 44 112 19 16 53 
99% 1 24 1 5 9 
a No combinations with a zero cell count were identified as signals by any method 
 
Single and double FDR with a cut-off of 50% resulted in the smallest number of “protective” 
associations. When considering the total number of signals identified by each method, all 
BHMs resulted in a substantial number of combinations that were “protective” 
associations. As a proportion of the total number of signals, this was lowest for an 
ungrouped BHM using a 95% PCI cut-off; for this model there were 223 signals, but a 
further 69 (almost a third again, i.e. 31% of 223) of the remaining combinations were also 
statistically significant, i.e. had a PRR and upper 95% PCI limit below 1. As a proportion of 
the total number of signals, the highest number of “protective” associations was for BHMs 
grouping only by CAs (giving 10 signals and 7 “protective” associations) and BHMs grouping 
only by medications (21 signals and 14 “protective” associations). Note that both 
“protective” associations for single FDR in Table 6.11 were for the CHD atrial septal defect 
in combination with G02CA and with N02BE05, and that atrial septal defect also had a 




6.4. Discussion  
In this chapter, BHMs were applied to EUROmediCAT data in order to assess the effect of 
directly modelling group effects for medications and/or CAs in signal detection analyses. 
The way in which the groups were specified was the main source of prior information in 
these Bayesian models. Use of BHMs were compared to the multiple testing adjustment 
procedures investigated in the previous chapter (using the same dataset). The comparison 
was made to results from a single FDR, as this is the method currently used by 
EUROmediCAT for signal detection purposes, as well as the newer double FDR method, 
which showed some improvement over the single FDR in the previous chapter.  
6.4.1. Use of Bayesian hierarchical models to detect signals of teratogenic 
medications in EUROmediCAT data 
Overdispersion and the independence assumption in count models 
An important assumption of the Poisson and a negative binomial distributions is that events 
in the data occur independently, i.e. that the exposures are independent from each other. 
Independence of reports is an underlying assumption in the calculation of confidence 
intervals for any signal detection method reporting a PRR (or ROR), and in practice for SR 
data it is often the case that a single individual case safety report may involve multiple 
medications and multiple AEs. Violation of this independence assumption can bias the 
estimation of the variance for the PRR, in turn affecting the number of combinations that 
are identified as signals. If analyses are done using counts of individual case safety reports, 
rather than numbers of medication or AE reports, violations of this assumption may be 
minimised [European Medicines Agency, 2012]. In EUROmediCAT data, a malformed foetus 
often has more than one CA and/or has been exposed to more than one medication, and 
can therefore contribute exposure counts to multiple medication-CA combinations in the 
dataset. In the data for this thesis, there was an average of 1.2 CAs and 1.5 medications per 
pregnancy (when looking at those subgroups and medications being monitored for signal 
detection analyses, see section 4.4.2). This means exposures are unlikely to be fully 
independent, since a count in one cell may refer to the same malformed foetus as an 
exposure to a different medication or CA counted in another cell. This may have led to 
overdispersion in EUROmediCAT data; in addition to a Poisson model, the negative binomial 
distribution was therefore also used to assess if overdispersion was present, and whether 




In addition to cases having multiple CAs and multiple medications, there were other 
correlations in this data structure. Certain CAs and medications, for example, may be more 
likely to co-occur within pregnancies, even across the groupings used. Similarly, exposure to 
a certain medication may increase the likelihood of exposure to another medication, for 
example it is common to take several different asthma medications together. On the other 
hand, it may be the case that if a woman is taking one particular medication, then it is very 
unlikely that she will have been exposed to any other medications in that group, i.e. 
medications within a group may be mutually exclusive. These kind of situations could 
introduce specific dependence structures within the data that are not necessarily easy to 
quantify across the whole dataset. These would need to be considered on a case-by-case 
basis, which isn’t realistic in practice for large databases like EUROmediCAT.  
However, despite this potential for overdispersion and other dependencies in the data, 
there was little difference in the results when modelling the data using a Poisson or a 
negative binomial model (i.e. when assessing the effective workload, “high risk” proportion 
and identification rate). Furthermore, the estimated dispersion parameter in negative 
binomial models tended towards a large value for various choices of parameters for the 
prior distribution, indicating that inclusion of such a parameter did not materially affect or 
improve the model fit. The Poisson model, which is more parsimonious and easier to 
implement, was therefore used throughout analyses in the rest of the chapter.  
Information sharing by groupings of either medications or CAs 
Two of the BHMs considered in this chapter used discrete groupings for only one variable, 
i.e. for the medications or the CAs but not both. In these models, the variable that was not 
grouped was given an overall group prior distribution, such that there was also some level 
of information sharing within this variable. For example, when grouping only the 
medications (using their ATC3 codes) the CAs were given a common prior distribution 
within each ATC3 group, implying a common distribution of effects for each ATC3 group of 
medications across all of the CAs. However, if a similar distribution of effects for a group of 
medications would not be expected across all the CAs, then it might have made sense to 
allow for a different distributions within each CA. For example, certain antiepileptic 
medications are known to be teratogenic for certain CAs, but would not be expected to 
have similar effects across all of the different types of CAs; in general, a single teratogen 
may increase the risk for a number of different CAs, but would not be associated with an 
increased risk of all CAs. However, this opposite approach would have introduced a large 




model (e.g. additional parameters for the mean and variance for a further 54 prior 
distributions would be required to give each of the 55 CAs their own distribution of effects 
for each groups of medications if grouping by ATC3 codes).  
Protective associations in Bayesian hierarchical models 
The purpose of signal detection analyses is to screen for potentially harmful teratogenic 
medicines; any “protective” associations identified are not, therefore, flagged as signals or 
recommended for further examination. In addition, the power to detect protective 
associations is low in these analyses due to there being no healthy controls in the data. 
However, some “protective” associations did arise in the analyses, and there are a number 
of potential reasons for this. Firstly, these may indicate a true potentially “protective” 
effect of a medication; for example, if an insulin medication is demonstrating a “protective” 
effect this may indicate that it is providing better glycaemic control (i.e. treatment of the 
underlying disease) in comparison to other medications, which may in turn affect the risk of 
that foetus having a particular CA. Note that this is only in comparison to other medications 
and CAs, rather than a potentially preventive effect in general. On the other hand, it is 
unlikely that the “protective” associations encountered in these analyses present true 
treatment effects, as there are other potential factors that must be considered. In any 
signal detection analysis using disproportionality measures, frequently reported outcomes 
can make it difficult to detect signals relating to the medication in question. In the context 
of SR databases, particularly extreme signals can lead to the PRR being less than one for 
combinations of that medication with other AEs, as well as potentially affecting the 
detection of signals of that AE with other medications [Waller et al., 2004]. For example, an 
extreme signal may be for a particular combination of a harmful medication A with a 
common outcome (outcome 1), then in examining the association between that medication 
and a different outcome (outcome 2). Therefore, when considering everyone who has 
taken medication A, a large proportion of the these will have outcome 1.  When a second 
outcome is then considered, those on medication A and with outcome 1 are now the 
“controls” in the association of medication A and outcome 2, meaning that outcome 2 will 
appear less frequent amongst those taking medication A compared to those who are not 
taking medication A. This could make it appear as though there is a protective effect of the 
medication on outcome 2.  
For EUROmediCAT data, if there is a particular medication-CA combination where the 
medication has a high prevalence, then the expected cell counts for combinations of other 




will be driven up by the larger marginal total, which is being dominated by the common 
medication. If there is a signal (with a PRR>1) for this particular medication-CA 
combination, this may in turn cause one or more “protective associations” of that 
medication with other CAs. This is because the expected cell counts are more likely to be 
higher than the observed cell counts for the other combinations also including that 
particular medication. This issue is highlighted by the fact that all but one of such 
“protective” associations that arise in models for EUROmediCAT data were for CAs or 
medications that were signals in other combinations. For example, the insulin medications 
(ATC3 group A10A) are known to be associated with an increased risk of CHDs, and many of 
these combinations did show up here as signals (across all methods considered). This might 
be an example of confounding by indication, whereby the medication has been prescribed 
to treat a disease (i.e. diabetes) that is associated with the outcome (CHDs). Maternal 
insulin-dependent diabetes has long been known to be an important risk factor for 
congenital malformations. Mills [2010] presented a review highlighting consistent evidence 
of increased risks for a range of CAs amongst infants of diabetic mothers, including 
cardiovascular, musculoskeletal, genitourinary and other types of malformations. Signals of 
insulin medications are therefore expected to occur in any unadjusted analysis that does 
not adjust for information on maternal illnesses, such as the signal detection analyses 
considered here. It has been suggested that the use of insulin analogues in pregnancy may 
be associated with a higher risk of CAs in comparison to human insulin; however, a recent 
literature review found that there was no evidence of such an increased risk for insulin 
analogues [de Jong et al., 2016b]. A EUROCAT study found that CHDs occurred around twice 
as frequently in diabetic pregnancies compared to other CAs, and these accounted for the 
majority of the excess risk of CAs amongst exposed pregnancies [Garne et al., 2012a]. 
Garne et al. also found that oro-facial clefts and limb defects were less likely to be 
associated with diabetic pregnancies, relative to other CAs. Likewise, in this thesis, a 
number of the insulin medications were also “protective” associations with oro-facial clefts 
and limb CAs. For these groups of CAs the expected counts used in BHMs were driven up by 
the higher prevalence of these medications overall (due to high numbers amongst the heart 
defect subgroups), therefore making the observed values for other CAs much lower than 
the expected (Appendix Table C1). An example of this situation is for the medication 
A10AC01 (human insulin), which was seemingly “protective” for oro-facial clefts and limb 
defects, relative to other CAs. This is likely to be driven by the high numbers of exposures to 




important to note that the presence of such “protective” associations does not mean that 
either insulin or maternal diabetes are likely to be protective for oro-facial clefts or limb 
defects, but rather reflects that the comparison here is of the effect of a particular 
medication compared to other medications in the database. It is not possible to quantify 
the effect of a medication compared to any other possible medication or, indeed, 
compared to the effect of taking no medications at all on the risk of any particular CA. 
Likewise, the risk for any specific CA in the data is made in comparison to all other CAs in 
the database, and is not a comparison to a pregnancy without a CA. It should therefore be 
again be noted that a “protective” association is not protective per se, but may be 
indicative that a particular medication is less of a risk than another medication in the 
database (that may be teratogenic). As such, the insulin medications may be thought of as 
carrying less of a risk for limb and cleft CAs when compared to their risk for CHDs. 
Nearly all the protective associations in these analyses included a medication or CA present 
in another combination that was identified as a signal (Table 6.11) ; the only exception to 
this was the digestive system CA ano-rectal atresia and stenosis in combination with the 
medication A03FA01 (metoclopramide; a propulsive medication for functional 
gastrointestinal disorders). This combination had a cell count of only 2, and was present as 
a signal only in a BHM with grouping by both medications and CAs. Appendix Figure C2 
displays the estimates for combinations of the 8 digestive CAs and 3 medications within this 
medication-CA set according to the single and double FDR models as well as a two-
dimensional BHM. The “protective” association for A03FA01 in the BHM with grouping by 
CA and medications was influenced in this example by the group mean, which was a 
𝑙𝑜𝑔(𝑃𝑅𝑅) < 0 due to cell counts of zero for the majority of combinations (i.e. for which 
there were no exposures to that particular medication and CA combination) within this 
group. Since, by definition, the marginal total for each medication and for each CA must 
both be at least 3 to be included in the signal detection analysis dataset, the expected cell 
counts will always be greater than zero. Therefore comparing observed and expected 
values for combinations with a cell count of zero will always result in a PRR<1 (and 
a 𝑙𝑜𝑔(𝑃𝑅𝑅) < 0, as in Appendix Figure C2). Whilst the medication and the CA in this 
protective association were not involved in any other signal combinations, there was a 
signal in common with another medication in this group for a different type of CA (A03FA 
with the respiratory system CA choanal atresia), and there were four signals for digestive 
system CAs with medications in other groups (G02CA01 and H02AB01 with diaphragmatic 




6.4.2. Comparison of Bayesian hierarchical models and false discovery rate 
procedures for signal detection in medication safety data for congenital 
anomalies 
The double FDR identified more “high risk” signals (increased “high risk” proportion and 
identification rate) for comparable effective workloads as BHMs. Ungrouped BHMs and 
those grouped by both medications and CAs sometimes identified greater absolute 
numbers of “high risk” medications, but this was at the expense of a substantial increase in 
effective workload. When also taking into account the increased computational time and 
effort involved in the implementation of BHMs compared to the double FDR method, it is 
therefore recommended that the double FDR method be used in practice for the detection 
of signals of teratogenic medications using EUROmediCAT data.  
Different signals according to FDR and BHM approaches 
 A selection of results were presented in greater detail in section 6.3.4 to highlight the way 
in which the different approaches to signal detection analyses and the choice of grouping 
within BHMs resulted in different sets of combinations being signals. In BHMs, shrinkage 
was expected to have a similar effect to adjustment for multiple testing in a frequentist 
setting in terms of a reduction in the overall false positive rate. Information considered 
within and around each cell of interest led to adjustment of PCIs and therefore the resulting 
set of signals. When other combinations in a group contain additional information to that of 
the combination of interest, this can reduce the significance level for results that are likely 
to be false positives, whilst enhancing the significance of those likely to be true 
associations. For combinations with smaller cell counts and/or lower marginal totals, more 
of a shrinkage effect was expected, since the posterior for such combinations is influenced 
more by the prior and less by the likelihood function (i.e. the actual data) due to there 
being less information in the data itself. How useful this is depends, of course, on the 
strength of information in the other cells in any set (i.e. whether there is actually useful 
information within that particular group). 
One example that was presented of differing signals from the different approaches was the 
double FDR and BHM with grouping by ATC3, which both identified the combination of 
valproic acid with the CHD atrial septal defect as a signal. However, this combination was 
not a signal using single FDR or BHMs with CA grouping (Figure 6.10), implying that there 
was a null effect on average across the antiepileptic medications in combination with the 
CHDs as a group. A significantly increased risk of atrial septal defect has previously been 




no antiepileptic medications or a control group taking any other antiepileptic medication 
monotherapy [Jentink  et al., 2010]. This highlights how different groupings can have 
different conclusions, even for a known teratogenic medication such as valproic acid. 
In methods that did not consider grouping CAs or medications in the analysis stage, 
combinations with a cell count of only one or two were not considered signals even if they 
showed a significant association, since estimates based on such small counts are not judged 
sufficient information on which to base a conclusion and can be more likely to be false 
positive associations. One of the potential advantages of using BHMs here was that it might 
strengthen the analysis of combinations with low cell counts by using information in the 
surrounding cells, allowing them to potentially be included in the set of resulting signals. 
However, no combinations with a cell count lower than three were identified as signals in 
BHM with discrete grouping only by medications or CAs. In the BHM with discrete 
groupings by both CAs and medications, 34 medications over 44 combinations with a count 
of one (n=26) or two (n=18) were identified as signals (Table 6.9), including 3 “high risk” 
medications, 18 “low risk” medications and 13 medications with no known risk category. If 
these combinations had been excluded from the list of potential signals (as in FDR 
methods) there would be an improvement in the proportion of signals that were “high risk” 
(“high risk” proportion increases from 14% to 17%) but a decrease in the percentage of all 
potential “high risk” medications being identified (identification rate decreases from 23% to 
16%). This is because three out of the 10 (see Table 6.9) “high risk” medications in the set of 
signals were combinations with a frequency of only one or two in the data.  
The double FDR 50% and a BHM using the same grouping by ATC3 medications (in both 
cases averaging over all CAs) resulted in 16 and 15 medications being identified as signals, 
with a total of 25 and 21 combinations, respectively (Table 6.9). However, two more “high 
risk” medications (6 vs. 4) were identified by double FDR. Ten medications, including 15 
combinations, were signals according to both methods. Of the remaining signals for these 
two methods: 
➢ 5 medications identified by a BHM with discrete grouping by medications were not 
signals when using double FDR. One was a thyroid hormone H03AA01 in combination 
with the CHD ventricular septal defect. There has been some evidence of an increased 
risk of birth defects (including CHDs) following the use of thyroid medications in 
pregnancy in a Danish population based cohort study [Andersen et al., 2013]; however, 
this particular thyroid medication H03AA01 is a “low risk” category A medication in the 




combination with Oro-facial clefts (cleft palate and cleft lip ± palate subgroups). 
Evidence regarding this medication is limited, although antacid use has been associated 
with a decreased risk of clefts in a case-control study of the treatment of nausea and 
vomiting during pregnancy and the risk of various common non-cardiac CAs in the US 
[Anderka et al., 2012]. The remaining three medications were A03AD02 with cleft lip ± 
palate, G02CA with ventricular septal defect (although this medication was a signal in 
combination with tricuspid atresia & stenosis, another CHD subgroup, when using 
double FDR) and G04BX with atrial septal defect. These medications all had unknown 
risk category and a lower 95 % PCI for the PRR close to 1, i.e. they were close to the 
threshold of being defined as a signal.  
➢ On the other hand, 6 medications (9 combinations) were signals using double FDR but 
not in a BHM grouped by medications. These were the 9 least frequent combinations 
in the set of signals resulting from the double FDR with ATC3 groupings (each with an 
exposure count of 8 or less). Perhaps most notable of these is the combination of 
Anencephaly with misoprostol (A02BB01), a “high risk” category X medication for which 
there has been evidence of an increased risk associated with birth defects such as 
brainstem injuries [Vauzelle et al., 2013]. This medication was not a signal in any of the 
BHMs that considered grouping. The ATC3 group A02B included ten distinct ATC5 
coded medications of which eight were “low risk” (category B) medications, one did not 
have a risk category assigned, and the final “high risk” (category X) medication was 
A02BB01. The majority of combinations of any A02B medication with one of the 55 CAs 
in the analysis had a zero count. For the BHM with groupings by ATC3, the average PRR 
across the A02B group of medications was 0.9, i.e. a reduced risk across the CAs when 
compared to other medications in the data. The majority of medications in this group 
were “low risk” and, in addition, this combination had an exposure count of only three, 
hence it is not surprising that using a BHM shrinks the estimate for the one “high risk” 
medication to the null. Of the other six medications that were signals in double FDR but 
not a BHM with ATC3 grouping, there were two antiepileptic medications in the “high 
risk” category (N03AA02 and N03AF01). The other three such signals were “low risk” 
medications (A10AB04, N03AX14 and R03CA02) and one had unknown risk category 
(G02CA). 
Masking in signal detection analyses 
The PRR is a ratio and therefore depends on both the numerator, which includes only 




reports involving other medications. The numerator may suffer from biases due to issues 
with reporting for the medication of interest. For example, if there is excessive reporting for 
a common medication (e.g. due to media influences) then the overall rate for this 
medication will be inflated, and other associations may be concealed. If the CA of interest is 
significantly associated with medications other than that under consideration, the 
denominator will be inflated as the background reporting rate (i.e. the marginal total) for 
that medication and event in combination is increased. In practice this means that the 
expected count will be higher for other medications in combination with the CA, so the 
observed to expected ratio may then be close to one, even if there is a true signal for 
another medication. This statistical issue is known as masking and has previously been 
discussed in a number of articles on data mining techniques for pharmacovigilance [Gould 
A. L., 2003, Almenoff June et al., 2005, Hauben et al., 2005]. Confounding by co-reported 
medications may also occur if two medications are frequently prescribed together but only 
one causes the CA of interest [Hauben et al., 2005]. For EUROmediCAT data, masking may 
also occur due to the use of malformed controls if a proportion of the control group is 
related to the medication of interest. The most common type of CA in the EUROmediCAT 
database, for example, are CHDs, which accounted for 35% of all malformed foetuses 
(Table 4.5). Of all recorded CAs in the data, 17% had ventricular septal defect, the most 
common CHD. If a particular medication is reported frequently in combination with 
ventricular septal defect, this could mask the association of another (less common) CA with 
the same medication, as the expected count for such a combination will be inflated by the 
high prevalence of this medication with ventricular septal defect.   
Studies have demonstrated that the removal of a masking effect may help lead to new 
signals of public health relevance being discovered [Gould A. L., 2003, Pariente et al., 2012]. 
It is also thought, however, that significant masking is not common in large SR databases, 
and where present it mostly affects rarely reported AEs [Zeinoun et al., 2009, Wang et al., 
2010, Maignen et al., 2014]. Various approaches to deal with masking in SR databases have 
been described and assessed by Wang et al. [2010], who concluded that considerable 
resources could be required to unmask only a small number of masked signals, that may 
have only weak evidence for additional causal associations. Another potential issue with 
identifying and dealing with masking is that the type I error (false positive) rate can be 
artificially inflated [Maignen et al., 2014]. Attempts to unmask associations should 
therefore be based on prior information on known specific associations that may be 




computationally intensive methods to try and account for masking in the analysis. After 
signal detection it may be beneficial to perform a secondary analysis to assess the effect of 
unmasking in such cases where there is a strong previously known association. This raises 
the question of how to deal with previously known associations in updated signal detection 
analyses (see section 7.4.2 for further discussion on this point). 
6.4.3. Strengths and limitations of EUROmediCAT data 
A major strength of EUROmediCAT data is the detailed and standardised coding of the CA 
outcomes across the registries due to the existing EUROCAT network upon which 
EUROmediCAT is based [Boyd et al., 2011], as well as detailed information regarding 
medications taken during the first trimester of pregnancy. Good agreement between the 
medication that was actually used and that recorded in one EUROmediCAT registry has also 
been demonstrated in a study that used additional data sources compared to those used to 
contribute data to EUROmediCAT [de Jonge et al., 2015a]. One weakness of EUROmediCAT 
data is that there is no information available regarding the dosage of medications. In 
addition, the timing of exposures could not be confirmed in a number of cases in the data 
for this thesis. In particular, a high proportion of recorded cases for the Polish registries 
could not be confirmed as first trimester medications, and were therefore excluded from 
these analyses. This will have resulted in a loss of power and may be a source of potential 
bias. However, similar distributions of types of CA were present in the Polish registries for 
those with confirmed first trimester medications and those with unknown timing, such that 
those cases that were included were considered not dissimilar to those excluded due to 
unconfirmed medication timing (and any related potential biases minimised). Data cleaning 
for timing of exposure meant that all included cases were supposedly confirmed first 
trimester exposures, however it is not possible to know that the mothers definitely took the 
medication during the critical period for development of each specific CA [Czeizel, 2008]. 
Another potential limitation is that there is known under ascertainment of some 
medications in EUROmediCAT data [Bakker and Jonge, 2014, de Jonge et al., 2015b] and 
this may reduce the sensitivity of any signal detection analyses. In addition, ATC coding 
changes over time were taken into account and updated as far as possible; however, it is 
feasible that some changes were missed and this this may potentially have led to signals 




6.4.4. Summary and conclusions 
In this chapter, the use of Bayesian models showed some interesting properties in terms of 
shrinkage to group means and identification of different medication-CA combinations as 
being signals. However, in general the BHMs did not produce enough of an improvement in 
terms of the signals identified to justify the increased complexity and workload of 
implementing these models. Only the BHM that grouped combinations discretely by both 
medications and CAs identified more “high risk” medication signals compared to the double 
FDR, but this came at the cost of a much larger resulting workload of signals to follow up in 
the next stage of the signal management process. Overall, no BHM performed better than 
the double FDR1, which is relatively straightforward to implement and is therefore 
recommended for use in future signal detection analyses for EUROmediCAT data. 
                                                          





Chapter 7:  Synthesis of thesis findings 
7.1. Introduction 
This thesis investigated whether taking existing hierarchical structures in the coding of CAs 
and medications into account would lead to more accurate statistical models in the analysis 
of CA prevalence data. Data sources, statistical methods, results and conclusions for these 
different approaches to the improvement of CA surveillance methods were presented. 
These were applied to two datasets; one including counts for CA prevalence from 
population-based registries across Europe, and the other coming from those registries that 
had additional information regarding first trimester medication use. In this chapter, the 
findings from this thesis are summarised and discussed, including methodological questions 
and potential areas for future research. 
7.2. Summary of work presented 
Chapter 1 introduced the thesis, comprising a background to the main themes of CA 
surveillance, Bayesian analysis and the use of hierarchical models. Chapter 2 presented the 
overall aim and specific objectives of this thesis. Chapter 3 investigated the use of BHMs for 
the routine analysis of CA prevalence data. Specific types of CA were explored that 
illustrated situations in which grouping CAs together was considered potentially useful. 
BHMs demonstrated some interesting properties with regards to shrinkage to group means 
when sharing information within EUROCAT defined groups of CAs. However, overall there 
was little difference in results when compared to models that analysed each CA 
individually. In addition, BHMs were more complex and time consuming to implement, and 
some models showed a lack of convergence. The next three chapters moved on to the 
analysis of medication use during first trimester of pregnancy and the associated risk of 
CAs; chapter 4 reviewed methods for signal detection in SR databases and in CA data, using 
these to identify two approaches that might improve the detection of teratogenic 
medications in EUROmediCAT data. The EUROmediCAT dataset for use in these analyses 
was then described, and the Australian risk categorisation system for prescribing 
medications during pregnancy was presented as a way of independently identifying the 
number of “high risk” medications that each method was picking up. Chapter 5 considered 
different FDR procedures that incorporated information about groups of similar 
medications and/or CAs when determining the statistical significance of the test for each 




the potential group effects. Throughout this thesis, various applications of BHMs did not 
produce enough of an improvement to justify implementing such models. The double FDR 
method grouping medications by ATC3 level codes performed better than BHMs and other 
FDR methods (including the currently used single FDR) in terms of metrics based on the 
number of “high risk” signals identified by the Australian risk categorisation system. In 
conclusion, it was recommended that (i) when using EUROCAT subgroups for analysis, 
considering each CA separately remains an appropriate method for the detection of 
potential changes in prevalence by relevant surveillance systems, and (ii) the double FDR 
procedure grouping medications by ATC3 level codes should be used in future signal 
detection analysis for CA data using ATC coding for medications and EUROCAT coded CAs.  
7.3. Methodological considerations 
7.3.1. Use of Bayesian hierarchical models 
BHMs were applied to both CA prevalence and first trimester medication data, however in 
both scenarios the models investigated in this thesis did not produce enough of an 
improvement over other methods to justify their use. When assessing recent ten-year 
trends, it is likely that there were not sufficient data points to support the additional 
random effect parameters required to group CAs together, especially for models that also 
included random effects for registry. In addition, for small groups of related CAs (e.g. the 
three NTD subgroups) there were not enough levels for random effects parameters to be 
reliably estimated. Indeed, estimation of random effects parameters with less than 5 levels 
have been shown to perform poorly in BHMs, resulting in a lack of convergence and over-
parameterisation [Greenland, 2000, Gelman Andrew and Hill, 2007]. On the other hand, 
there was too much heterogeneity in the prevalence of EUROCAT subgroups for more than 
5 CAs (such as the CHDs) to be grouped together as random effects in a BHM, even for 
those CAs within the same organ/body system.  
Application of BHMs to both CA prevalence and medication data also demonstrated the 
effect of shrinkage. In signal detection analyses using EUROmediCAT data, estimates were 
affected by the groupings used such that medication-CA combinations were signals only in 
certain models. In some cases this shrinkage appeared potentially useful, for example there 
were signals for 4 insulin medications in combination with the CHD ventricular septal defect 
when using a BHM with groupings by both medications and CAs, however single FDR 
resulted in no signals and double FDR only one signal in this group (A10A medications in 




medications are thought to be a marker of the increased risk of CHDs associated with 
maternal diabetes (rather than an indication that these medications themselves are 
teratogenic), a signal detection method should identify the type of associations where 
further investigation is worthwhile. On the other hand, shrinkage in BHMs also attenuated 
the estimated risk for some known teratogens; for example the known association between 
valproic acid (N03AG01) and the CHD atrial septal defect was a signal after double FDR, but 
in a BHM with groupings by both medications and CA this combination was not a signal due 
to an overall average null effect across the group of antiepileptic medications and CHDs 
(Figure 6.10). It is not ideal for a method to miss a known teratogenic signal when another 
method picks this signal up using the same data.  This example highlights the potential for 
shrinkage in Bayesian models to have a “self-fulfilling prophecy”, where if there are truly 
different trends across “similar groups of CA” then shrinkage will make them “disappear”. 
This may be problematic since CAs that are grouped together are not necessarily similar in 
terms of their aetiology, risk factors or temporal trends. 
All BHMs in this thesis used minimally informative prior distributions for parameters, 
whereby the means followed a Normal distribution centred on a 𝑙𝑜𝑔(𝑃𝑅𝑅) of zero, and 
standard deviations followed a uniform distribution. The sensitivity of these priors was 
tested for all models to ensure that they were robust to changes in parameter values, such 
as the choice of limits for the uniform distribution or the variance of the Normal 
distribution. In the analysis of EUROCAT prevalence data, BHMs often demonstrated 
overfitting and a lack of convergence. BHMs for EUROmediCAT data generally showed good 
mixing and convergence, although high levels of autocorrelation were present and long 
chains with a large thin were therefore required. The thinning of chains in MCMC samples is 
frequently used in practice, although greater precision in estimates is obtained by working 
with chains that have not been thinned [Link and Eaton, 2012]. However, from a practical 
perspective, computing memory and storage limitations must also be taken into 
consideration; for very large chains that are not thinned, post sampling calculations (i.e. 
model assessment and summarising posterior distributions) can impose a substantial 
computational burden.  
7.3.2. Treatment of registry in analyses 
In the analysis of CA prevalence, models are frequently adjusted for the effect of registry 
(see section 3.2) since prevalence often varies in the different registries. This can reflect 




also be due to differences in coding practices and/or information sources in each region. 
Adjustment for registry also accounts for the fact that registries have differing maternal age 
structures and can contribute to different time periods in EUROCAT data. Since CA 
prevalence data are expected to be prone to regional differences, it was important that the 
effect of adjusting for registry was assessed in models in chapter 3. For medication data, 
however, a teratogen is expected to act in a similar way regardless of where it is taken. One 
aspect that may vary between registries within EUROmediCAT data is that of varying usages 
and/or availability in different countries for certain medications. As there are very small 
numbers for many medication-CA combinations, the best approach to an ongoing signal 
detection process is considered to be investigation of any potential registry effects at a 
later stage in the analysis. Indeed, this is part of the next step of the signal detection 
process, where the first step in the follow-up of any potential new associations resulting 
from the signal detection analyses is to perform data validation, which includes the 
adjustment of estimates for confounding by registry [Given et al., 2016]. 
7.3.3. Importance of grouping choices for medications and congenital 
anomalies 
The main objective of this thesis was to investigate the use of groupings of ATC codes 
and/or CAs in the analysis of EUROCAT and EUROmediCAT data. For FDR methods, the 
different types of ATC groupings had less of an effect on the results than the type of FDR 
procedure that was used. For grouping in BHMs, minimally informative parameters were 
used in prior distributions and the main source of “informative” prior information therefore 
came from the groupings that were used. These groupings essentially tell the model what 
our beliefs are regarding how the medications and/or CAs relate to each other, and the way 
in which the groupings were defined is therefore important. In an ideal situation, groups 
would be defined on a case-by-case basis, using expert opinion and judgements to specify 
relationships between different medications and CAs to achieve the most sensible 
groupings, in that group members should share similar properties and have the same 
differences in comparison to medications and CAs in other groups. The large EUROmediCAT 
dataset for signal detection analyses, however, means it was not practical to specify the 
groups on a case-by-case basis. In analyses for this thesis, there were 523 medications; it 
would take considerable time and effort to go through each of these individually deciding 
how they should be grouped. This would also require a wide range of expert opinions as the 
data includes a variety of different types of medication, and consensus in opinions 




would likely be difficult to achieve. Since CAs are a very heterogeneous group of conditions, 
with vastly differing and often unknown sets of risk factors [Oliveira and Fett-Conte, 2013], 
they also should not be considered as a single outcome (and this would not be possible in a 
signal detection dataset where there are no non-malformed controls). A pragmatic 
approach to grouping medications and CAs was therefore taken, by using existing 
hierarchies in routinely used coding systems.  
For CA prevalence data, the EUROCAT coding system groups defined CAs according to the 
main organ system or part of the body affected by each major CA. However, chapter 3 
demonstrated that EUROCAT subgroups considered to be related (in the same organ 
system class) were found to vary considerably in terms of their differing proportional yearly 
changes in prevalence. Furthermore, there are known relationships between CAs that lie 
within different groups of the EUROCAT hierarchy, which cannot be accounted for using 
this structure of coding.  
For EUROmediCAT data, medications were grouped according to their ATC codes. However, 
relationships between characteristics captured by the ATC classification system and the 
actual biological or pharmacological interactions that lead to a resulting adverse drug 
reactions are also likely to be variable or unknown [Wang et al., 2010]. Grouping 
medications that have similar chemical properties therefore does not necessarily imply that 
they will actually have similar potential adverse effects. In practice, the ATC4 groupings 
might be too narrow, providing small groups and too large a total number of groups for use 
in statistical models taking groupings into account. On the other hand, ATC2 (or even ATC3) 
groupings may be considered overly broad for some types of medication. As expected for 
analyses in chapters 5 and 6, models considering grouping only by type of CA were limited, 
since they averaged over all medications in the data. Grouping by both CAs and 
medications appeared more useful in terms of the number of “high risk” signals that were 
identified, although the resulting effective workloads were considerably higher, and the 
models were computationally intensive in comparison to results obtained by a double FDR 
procedure.  
Overall, the reliance of the performance of BHMs in this thesis on the choice of groupings 
of both CAs and/or medications is an important point. In particular for groupings of CA, 
current knowledge in this field did not allow appropriate groupings to be adopted in order 
to inform suitable hierarchical models for this work. Moreover, shortcomings in the 
available information regarding which medications are likely to be teratogenic and the 




makes the evaluation of different approaches to signal detection more difficult and 
uncertain. 
7.3.4. Choice of thresholds used to define signals in EUROmediCAT data 
An important consideration in signal detection analyses is what threshold to use to define 
the signals [Deshpande et al., 2010]. In this context, a “threshold” is defined as the choice 
of cut-off value for statistical significance of a P-value (i.e. in a Frequentist analysis such as a 
FDR procedure) or the percentile of the posterior distribution from an estimate in a 
Bayesian analysis (e.g. some lower percentile of the estimated posterior distribution for the 
PRR). The choice of different thresholds can change the sensitivity and number of false 
positive associations, hence has a potentially significant effect on any signal detection 
process. Other factors that may have an impact include the choice of whether to include 
combinations with low cell counts in the set of signals; for example, EUROmediCAT single 
FDR methodology only defines associations as being signals if they have at least 3 
exposures.  
The choice of thresholds for statistical significance when using the PRR have previously 
been investigated using a set of known safety signals to quantify how many would be 
predicted by various choices of thresholds for the PRR in SR data [Slattery et al., 2013]. This 
study indicated that the choice of threshold of 1 for the PRR025 was acceptable, but that an 
increase in the required exposure count from 3 up to a maximum of 6 may be warranted, 
and that this may substantially reduce the proportion of signals that are false positive 
associations. This would also reduce the sensitivity, however Slattery et al. [2013] 
suggested that any missed signals due to a loss of sensitivity in this setting would likely be 
detected by other means, i.e. by other aspects of their signal management processes 
separate from the initial signal detection analyses. For analysis of CA data, other such steps 
might include separate studies of specific CAs and/or medications, e.g. two of 
EUROmediCAT’s main packages aimed to quantify the risk of CA related to four specific 
drug classes, and these particular medication types were therefore considered in more 
detail alongside signal detection analyses [de Jong-van den Berg et al., 2011]. However, 
unknown new potential associations can still be missed if they are in drug classes that are 
not considered separately or already include suspected teratogens. Other authors have also 
discussed statistical thresholds for use in signal detection. Ahmed et al. [2012] compared 
five signal detection methods, including three established methods and two methods they 




methods is a frequentist approach that assumes a mixture model for the marginal 
distribution of the P-values resulting from a Fisher’s exact test [Ahmed et al., 2010], and the 
second uses a Bayesian decision making approach using posterior probabilities of null 
hypotheses to rank medication–event pairs. These five methods were compared using a list 
of reference signals from the French national pharmacovigilance system database 
[Thiessard et al., 2005]. Advantages for their Bayesian method were demonstrated using 
the related metrics, although there was no measure of the total workload generated by 
each method. Another study discussed briefly the adjustment of the lower threshold for the 
Empirical Bayesian Geometric Mean (EBGM) and PRR estimates in order to balance the 
number of signals and enable a comparison of the two methods [Almenoff J. S. et al., 2006]. 
Berlin et al. [2012] also considered various signalling thresholds for an EBGM estimate and 
an OR. Their focus was on finding a threshold that maximised the number of true signals, 
which was to use a threshold of 2 (rather than 1) for the lower limit of the EBGM or the OR 
and only including those combinations with an exposure count of at least 3.  
Cut-off levels used in FDR procedures 
The choice of FDR cut-off threshold was discussed in Chapter 5 (see section 5.4.2). By 
definition, the value chosen for the FDR cut-off is the estimated proportion of the observed 
associations that are likely to be false positive associations. By definition for an FDR of 50%, 
for example, around 50% of associations are expected to be false positives, so it is essential 
that investigators are available to follow-up all identified associations to try and exclude the 
false positives. However, it is unlikely that an FDR of 50%, for example, will translate into a 
set of signals for which exactly half are false positives and half are true associations, in 
particular due to the way signals are selected in FDR procedures (i.e. after exclusions based 
on low frequency and PRR<1). Therefore, the FDR cut-off should be considered in terms of 
the resulting workload in light of available resources for investigators to follow-up potential 
signals at the time of each updated signal detection analysis (as a higher choice of FDR cut-
off will always result in a larger workload). In practice, the use of FDR methods should 
therefore include frequent re-evaluation of the choice of FDR cut-off value.  
Thresholds used to define signals in Bayesian hierarchical models 
The thresholds used for BHMs in this thesis were a lower 2.5% confidence bound of 1 for 
the PRR (PRR025) and an exposure count of at least 1. These are  well established 
thresholds that are commonly used in practice, for example by the European Medicines 




higher cut-off for the PRR (as suggested by Berlin et al. [2012]) would be overly strict if 
applied to the BHMs in this chapter, with a very low resulting number of signals being 
identified for each method; for example only 8 signals would be identified using a BHM 
grouped by both medications and CAs if using a cut-off of 2 for the lower limit of the 95% 
PCI for the PRR (see Appendix Table C2). This highlights the importance of developing signal 
detection methods using the specific database for which they are intended. 
7.3.5. Timing of exposures in EUROmediCAT data 
Strengths and limitations of EUROmediCAT data were discussed in chapter 6 (see section 
6.4.3). A main strength of EUROmediCAT is in the standardised and detailed CA coding and 
information regarding first trimester medication use. Data cleaning was carried out prior to 
these analyses to ensure that only valid first trimester exposures were included. However, 
as with any large dataset comprising a range of data sources, it must also be acknowledged 
that it is impossible to capture and clean all data issues without going through all records 
individually (which of course is not feasible in practice). The lack of information on the exact 
timing of exposures and the dosage of many recorded medication exposures is an 
important limitation of EUROmediCAT data. No distinction can be made, for example, 
between a medication exposure taken at a low dose over a few days at the end of the first 
trimester, and exposure to the same medication at a high dose throughout the first 3 weeks 
of pregnancy. Furthermore, whilst the first trimester is commonly regarded as the critical 
period for development of most major CAs, it has also been demonstrated that different 
CAs have different critical periods within this time [Czeizel, 2008]. Whilst the critical period 
of development mostly occurs during the second and third gestational months, there are 
some CAs for which this period occurs after the first trimester [Scheuerle and Aylsworth, 
2016]. It is therefore not possible to know whether exposures in the EUROmediCAT 
database actually occurred during the critical period for developments for each specific CA 
analysed here. This again highlights how signal detection is only part of the wider process of 
signal management. For any identified medication-CA signal, further consideration and 
investigation is required regarding the timing, duration and dosage of the particular 
medication exposures, and how these may relate to the known critical period for that 
particular CA. This further reinforces the fact that combinations of a number of different 
tools and data sources need to be utilised in order to obtain the timeliest, most accurate 




7.3.6. Evaluation of signal detection methods  
Another key issue in signal detection analysis for any type of data is the lack of “gold 
standard” references for validation of signals when testing and comparing different 
methods of analysis [Almenoff June et al., 2005, Stephenson and Hauben, 2007]. 
Retrospective analyses applied to real data have been performed for various types of 
reporting datasets, which aim to measure methods in terms of their ability to identify 
previously known and validated signals. However, the selection of a definite set of 
“reference signals” is not straightforward, especially considering that the reason signal 
detection is being done is to find new signals and these can vary widely for different types 
of exposures and outcomes (i.e. they can be highly database specific). For 
pharmacovigilance data, the Observational Medical Outcomes Partnership (OMOP) is a 
research initiative which aims to recommend methods for analysis of large medication 
safety datasets [Stang et al., 2010, Ryan et al., 2012]. As part of this initiative, an extensively 
validated “gold standard” reference list of almost 400 positive and negative test cases 
(medication-event combinations) has been complied by the OMOP [Ryan et al., 2013]. This 
reference list focuses on four health outcomes (acute myocardial infarction, acute kidney 
injury, acute liver injury, and upper gastrointestinal bleeding) and does not include 
information regarding CAs. Other researchers have compiled similar lists, for example a 
reference standard including 10 AEs judged to be the most important outcomes across the 
field of pharmacovigilance was put together in order to compare signal detection methods 
for use with electronic healthcare records [Coloma et al., 2013]. This reference standard 
included 44 known positive associations and 50 highly unlikely “negative controls”. 
Reference lists such as these have been published and are publicly available; however, they 
are again specific to the types of AEs included in the lists and hence are not of use for the 
purposes of signal detection for CA data. In other studies, retrospective real data 
application has also been done for some specific examples in a variety of settings, with 
some studies comparing the different methods [Lindquist et al., 2000, Szarfman et al., 2002, 
Hauben et al., 2005]. Limited “reference sets” have also been used, which have generally 
lacked verified true negative signals (i.e. controls) and instead focus on positive test cases 
only, for example see Hochberg et al. [2009] and Ahmed et al. [2012]. Ahmed et al. [2012] 
used three sets of up to 335 reference signals based on investigations into possible adverse 
medication reactions that were launched by the French pharmacovigilance system, with 
inclusion in a set corresponding to the level of support from pharmacovigilance data for 




adverse effect was actually confirmed, and there were also no negative controls included in 
this reference set. All these reference lists are specific to certain types of AE, but none focus 
on CAs. 
Another strategy has been the use of simulation studies to compare methods [Roux et al., 
2005, Almenoff J. S. et al., 2006, Matsushita et al., 2007]. Simulation studies are useful for 
estimating and comparing methods in terms of their statistical properties and various 
metrics such as the quantification of false positive and negative rates. The main advantage 
of such an approach is that the definition of a “true” signal is definite. In particular, it is not 
possible to ascertain true false negatives when analysing actual databases. However, it is 
difficult to judge the appropriateness of any simulation model for use with real data and 
simulation studies need to be complemented by studies in actual reporting databases. The 
absolute performance of a method has been demonstrated to be highly database specific 
and should therefore be assessed directly on the database for which it is intended to be 
used in practice [Candore et al., 2015]. 
The lack of existing knowledge on the teratogenic effect of medicines used during 
pregnancy meant it was difficult to determine a “reference set” of signals on which 
methods used in this thesis could be evaluated (see section 4.3 for further discussion on 
this). Indeed, the “reference set” used to evaluate the previous EUROmediCAT signal 
detection analysis consisted only of eight validated medication-CA combinations [Luteijn et 
al., 2016]. Of these 8 combinations, one had no exposures and one had only 3 exposures in 
the EUROmediCAT data. For analyses in this thesis, the Australian risk categorisation system 
was used in an attempt to achieve a quantitative measure of each method’s relative 
performance. Drawbacks regarding the use of this system have been discussed in previous 
chapters, including the lack of specificity to different CAs and the considerable proportion 
(35%) of ATC medications that did not have an assigned risk category. Although this 
categorisation database does not explicitly include “negative control” medications, it 
should be reasonable to expect that the “low risk” categories would be less likely to appear 
as signals in a signal detection analysis. This is also a problematic assumption, however, due 
to those signals arising as a result of confounding by indication or co-medication, i.e. where 
the signal represents an association likely to be due to reasons other than a teratogenic 
effect of the medication in question. A main weakness of the use of this risk categorisation 
system for signal detection analyses with CA data is that medications are classified as “high 
risk” in general, rather than being specific to particular CAs. However, as highlighted 




absolute strengths of a signal detection procedure, but rather to directly compare methods. 
The weaknesses with the use of measures based on the risk categories (e.g. “high risk” 
proportion and identification rate) should therefore be the same for all of the methods 
considered.  
7.3.7. Lack of a healthy control population 
Case-control studies using only malformed foetuses exposed to at least one medication 
cannot produce estimates of the relative odds of a CA for any medication exposure 
compared to healthy (i.e. non-exposed and non-malformed) controls [Prieto and Martinez-
Frias, 2000]. This type of study design is therefore not able to assess whether a medication 
raises the risk of any CA in general in the population, and it should be emphasised that 
evidence of a specific increased risk of one CA in this type of study is therefore only relative 
to the risks associated with other CAs. On the other hand, one advantage of this type of 
study design is that we know, by definition of their inclusion, that each case in the data was 
definitely exposed to at least one medication, hence some biases associated with the use of 
a healthy control population (e.g. recall and recording biases) are likely to be minimised.  
7.4. Potential areas for further research 
7.4.1. ATC codes including multiple substances 
A potential issue with the use of ATC hierarchies to group medications is that a number of 
substances are given different ATC codes depending on their strength or route of 
administration, if their therapeutic uses are clearly different [WHO Collaborating Centre for 
Drug Statistics Methodology, 2011]. Separate ATC codes, for example, are given for 
different pharmaceutical forms of a substance if applied externally to a body surface 
(topical) or internally administered to the circulatory system (systemic). The main 
therapeutic use of a medication may also differ between countries, and when a product has 
more than one indication there can be several options for its classification; the WHO 
international working group for medication statistics methodology decides upon the final 
classification of such substances. Using ATC3 pharmacological subgroup codes to group 
medications for these analyses therefore means that the same substance could be in 
different groups according to differing therapeutic use or local application. Although topical 
medications are excluded from signal detection analyses, there remain various potential 
routes of administration such as tablets or injections, which can be given ATC codes across 




product can vary according to its usage. Furthermore, there are several “combination” 
products that have two or more active ingredients. These can sometimes be classified in 
multiple ATC3 or ATC4 levels, such that a particular substance may appear in several 
different ATC3 groups, depending if it is the main active ingredient or a main ingredient in 
combination with one or more other active ingredient. In previous EUROmediCAT signal 
detection analyses, substances with several potential ATC codes available were identified 
and their ATC5 codes replaced with the substance name [Luteijn et al., 2016]. In this thesis, 
however, the main aim was to assess whether grouping by ATC coding was useful and 
hence substances were not re-coded in this way. When these methods are implemented 
for use in future EUROmediCAT signal detection analyses, further consideration will need to 
be given as to how these substances are dealt with in terms of their grouping by ATC3 
codes. For example, one approach might be to group the substances together using only 
one of their ATC5 codes. In the dataset for these analyses there were only 35 substances 
with multiple (up to ten) possible ATC codes, and it is therefore feasible that these are 
considered on a case-by-case basis. 
7.4.2. Dealing with known teratogens in the analysis 
A main aim of any signal detection study is to provide a balance between identifying the 
highest possible number of true signals, whilst avoiding wasting time and resources 
following up on false positive associations. It should also be remembered that signal 
detection analyses are designed to be conducted on a regular basis. This means that the 
number of newly generated signals will be considerably smaller for analyses after the initial 
run, which has already been performed for EUROmediCAT data by Luteijn et al. [2016]. Sets 
of signals for subsequent analyses should therefore constitute a smaller workload once 
discounting the known associations that do not need further follow up. It may also then be 
of interest to include those combinations with small cell counts in the list of potential 
signals, as these could allow early detection of potential teratogens. This highlights another 
important matter that has not been directly addressed in this thesis, which is how to deal 
with previously known teratogens. That is, should medications known to be teratogenic be 
removed from the database prior to an updated signal detection analysis? If known 
associations are included in the data each time they will continue to crop up as signals as 
long as there are new exposures occurring in the dataset. This may be the case, even for 
known teratogens, for example if they relate to a type of medication that is necessary for a 




any known associations in the data since this may be informative to other medications 
within the same group for which there is less information. The double FDR procedure also 
presents a good argument for including known teratogens in future signal detection 
analyses due to the use of groupings by medications, where a strong signal in any group will 
ensure that this group is included in the second step of the double FDR procedure. 
However, it should also be noted that when doing future analyses, a medication that has 
already been identified as a signal may eventually “drop out” due to there being few or no 
new cases after they are known to be harmful (when a potential teratogenic medication is 
identified there may be a rapid worldwide switch to the recommendation, prescription and 
use of alternative medications). There are also previously reported signals that have been 
followed up and subsequently deemed to have been triggered by a factor other than a 
teratogenic effect of the medication in question; this does not, however, rule out the 
possibility that such a medication may actually be teratogenic, which might become evident 
if further exposed cases are recorded in later data updates. Some of these issues have been 
discussed by Lerch et al. [2015], who examined aspects of “resignalling”, whereby already 
evaluated signals (whether reasoned to be teratogenic or not following further studies) are 
included in the dataset in each re-analysis. This was done according to a range of situations, 
including the use of different resignalling criteria and thresholds for signal detection in 
terms of the resulting workload. The authors concluded that some true signals will only be 
discovered upon resignalling.  
Another related question is how to handle data from previous years in each updated 
analysis; should all potential data be included each time in order to increase the power, or 
should only the latest X years of data be considered in order to reduce the dimension of the 
data and focus on newer medications. These points also raise again the question of how 
frequently signal detection analyses should be performed, e.g. should it be monthly, 
quarterly, annually or less frequently. For each updated analysis, the updated results 
require careful review, placing a burden of additional work on the organisation monitoring 
the data. A balance is therefore required between the earliest possible detection of new 
signals and controlling the workload of assessing resulting signals that are false positives. 
Lerch et al. [2015] also evaluated the effect of varying the periodicity of analyses for their 
particular database and concluded that monthly signal detection analyses should be 
performed in order to achieve earlier detection of new potential signals. For CA data, 
however, there would not likely be enough new cases on a monthly basis to warrant such 




their data to be collected and collated and EUROmediCAT registries therefore only add 
updated information to the central database on an annual basis. As routine signal detection 
analyses of EUROmediCAT data has been developed and initiated in recent years, there is 
currently new data available, which should be included in an updated signal detection 
analysis. A further analysis of EUROmediCAT data is therefore planned, using the double 
FDR method developed in this thesis and including additional data from 2012 onwards, as 
well as data from those registries that were not included in this thesis. Any new potential 
signals that result from this updated analysis will be fully investigated in collaboration with 
EUROmediCAT members and registries.  
7.5. Concluding remarks 
The findings of this thesis are relevant for CA surveillance programmes wishing to carry out 
regular statistical monitoring analyses. This applies in particular to those using EUROCAT 
defined subgroups for CAs and ATC coding for medications, however these conclusions also 
remain relevant for CA data where other types of coding are used. It is recommended that 
current methods of analysing each CA separately remain an appropriate for the detection 
of potential changes in prevalence of CAs. The double FDR procedure, however, is 
recommended for use in routine signal detection analyses of teratogens in CA data. The 
double FDR can help identify potentially teratogenic medications that may be missed by the 
existing single FDR procedure, and in addition may result in less false positive associations 
requiring detailed follow-up. This should continue to be accompanied with the follow up of 
any new potential signals identified as well as the dissemination of resulting information, 
and this will help patients make appropriate decisions based on the most up-to-date 
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Appendix A: Supplementary material for Chapter 3 
Table A1. Coding of EUROCAT subgroups included in analysis of changes in prevalence of CAs (taken from EUROCAT Guide 1.3 Table 8.2). 
Anomaly Description Of Anomaly ICD10 code Comments 
All Congenital Anomalies   Q*, D215, D821, D1810, 
P350, P351, P371 
Exclude all minor anomalies 
Nervous system   Q00, Q01, Q02, Q03, 
Q04, Q05, Q06, Q07 
  
Neural  tube defects Neural tube defects include anencephalus, 
encephalocele, spina bifida and iniencephalus 
Q00, Q01, Q05   
       Anencephalus and similar Total or partial absence of brain tissue and the cranial 
vault. The face and eyes are present. (incompatible 
with life) 
Q00   
       Encephalocele Cystic expansion of meninges and brain tissue outside 
the cranium. Covered by normal or atrophic skin. 
Q01 exclude if associated with 
anencephalus 
       Spina Bifida Midline defect of the osseous spine usually affecting 
the posterior arches resulting in a herniation or 
exposure of the spinal cord and/or meninges 
Q05 exclude if associated with 
anencephalus, or 
encephalocele 
Congenital heart defects   Q20-Q26 exclude patent ductus 
arteriosus (PDA) in 
preterm/LBW babies (<37 





Severe CHD § Severe congenital heart defects have higher perinatal 
mortality and TOPFA rates. Most livebirths require 
surgery for survival. It includes: single ventricle, 
tricuspid atresia, Ebstein’s anomaly, hypoplastic left 
heart, hypoplastic right heart, common arterial 
truncus, transposition of great vessels, atrioventricular 
septal defects, tetralogy of fallot, pulmonary valve 
atresia, aortic valve atresia/stenosis, coarctation of 




Q234, Q251, Q262 
  
Common arterial truncus Presence of a large single arterial vessel at the base of 
the heart (from which the aortic arch, pulmonary and 
coronary arteries originate), always accompanied by a 
large subvulvar septal defect. 
Q200   
Transposition of great vessels Total separation of circulation with the aorta arising 
from the right ventricle and the pulmonary artery from 
the left ventricle 
Q203   
Single ventricle Only one complete ventricle with an inlet valve and an 
outlet portion even though the outlet valve is atretic 
Q204   
Ventricular septal defect Defect in the ventricular septum Q210   
Atrial septal defect Defect in the atrial septum Q211   
Atrioventricular septal defect Central defect of the cardiac septa and a common 
atrioventricular valve, includes primum ASD defects 
Q212   
Tetralogy of Fallot VSD close to the aortic valves, infundibular and 
pulmonary valve stenosis and over-riding aorta across 
the VSD 
Q213   
Tricuspid atresia and stenosis Obstruction of the tricuspid valve and hypoplasia of 
the right ventricle 
Q224   




small right ventricle 
Pulmonary valve stenosis Obstruction or narrowing of the pulmonary valves 
which may impair blood flow through the valves 
Q221   
Pulmonary valve atresia Lack of patency or failure of formation altogether of 
the pulmonary valve, resulting in obstruction of the 
blood flow from the right ventricle to the pulmonary 
artery 
Q220   
Aortic valve atresia/stenosis § Occlusion of aortic valve or stenosis of varying degree, 
often associated with bicuspid valves 
Q230   
Hypoplastic left heart Hypoplasia of the left ventricle, outflow tract and 
ascending aorta resulting from an obstructive lesion of 
the left side of the heart 
Q234   
Hypoplastic right heart § Hypoplasia of the right ventricle, always associated 
with other cardiac malformations 
Q226   
Coarctation of aorta Constriction in the region of aorta where the ductus 
joins aorta 
Q251   
Total anomalous pulmonary 
venous return 
All four pulmonary veins drain to right atrium or one of 
the venous tributaries 
Q262   
PDA as only CHD in term infants 
(>=37 weeks) 
  Q250    
Digestive system   Q38-Q39, Q402-Q409, 
Q41-Q45 exclude Q381, 
Q382, Q3850, Q430, 
Q4320, Q4381, Q4382 
  
Oesophageal atresia with or 
without tracheo-oesophageal 
fistula 
Occlusion or narrowing of the oesophagus with or 
without tracheo-oesophagael fistula 




Duodenal atresia or stenosis Occlusion or narrowing of duodenum Q410 exclude if also annular 
pancreas (Q451, 75172) 
Atresia or stenosis of other parts 
of small intestine 
Occlusion or narrowing of other parts of small 
intestine 
Q411-Q418   
Ano-rectal atresia and stenosis Imperforate anus or absence or narrowing of the 
communication canal between the rectum and anus 
with or without fistula to neighbouring organs 
Q420-Q423   
Hirschsprung's disease Absence of the parasympatic ganglion nerve cells 
(aganglionosis) of the wall of the colon or rectum. May 
result in cong megacolon 
Q431   
Atresia of bile ducts Congenital absence of the lumen of the extrahepatic 
bile ducts 
Q442   
Annular pancreas pancreas surrounds the duodenum causing stenosis Q451   
Diaphragmatic hernia Defect in the diaphragm with protrusion of abdominal 
content into the thoracic cavity. Various degree of lung 
hypoplasia on the affected side 
Q790   
Chromosomal   Q90-Q93, Q96-Q99 
exclude Q936 
microdeletions excluded 
Down Syndrome/trisomy 21 karyotype 47,xx +21 or 47,xy +21 and 
translocations/mosaicism 
Q90   
Patau syndrome/trisomy 13 karyotype 47,xx +13 or 47,xy +13 and 
translocations/mosaicism 
Q914-Q917   
Edwards syndrome/trisomy 18 karyotype 47,xx +18 or 47,xy +18 and 
translocations/mosaicism 
Q910-Q913   
Turner syndrome karyotype 45,x or structural anomalies of X 
chromosome 
Q96   




A1. Bonferroni adjustment to confidence intervals for multiple testing 
within groups of congenital anomalies 
Adjustments to 95% CIs for estimated trends in frequentist individual models were done 
using a Bonferroni correction to adjust for the number of Congenital Anomalies (CAs) in 
each analysis. This reflects the fact that estimates in individual models are being compared 
to Bayesian hierarchical models where multiple tests are not done since all the CAs are 
included in one model.  
In practise this means that instead of a 95% confidence level, a (1 −
𝛼
𝑘
) % interval was 
used, where 𝑘 is the number of tests in each group and 𝛼 = 5%. If the estimated yearly 
change in prevalence 𝛽 is assumed to have an approximate Normal distribution with zero 
mean and standard error 𝑆𝐸(𝛽), then a (1 − α)% CI for 𝛽 is constructed as  
(1 − 𝛼)% 𝐶𝐼 = 𝛽 ± 𝑧𝛼/2 ∗ 𝑆𝐸(𝛽) 
Here 𝑧𝛼/2 is the critical value of the standard Normal distribution. For a 95% CI, 𝑧𝛼/2 =
𝑧0.05 = 1.96, hence 
95% 𝐶𝐼 = 𝛽 ± 1.96 ∗ 𝑆𝐸(𝛽) 
Adjusted values for 𝑧0.025 were used to calculate the adjusted 95% CIs when taking into 
account multiple testing within groups of CAs in individual Poisson models 
95% 𝐶𝐼𝑎𝑑𝑗    =     𝛽 ± 𝑧0.025/𝑘 ∗ 𝑆𝐸(𝛽)    =     𝛽 ± 𝑧𝑎𝑑𝑗0.025 ∗ 𝑆𝐸(𝛽) 
Table A2. Critical values used to adjust 95% CIs for multiple testing in individual 
models for groups of CAs in chapter 3. 










Adjusted 𝒛𝟎.𝟎𝟐𝟓 value 
for calculation of 
adjusted CIs 
(𝑧𝑎𝑑𝑗0.025) 
Neural tube defects 3 98.33 2.34 
Chromosomal 5 99.00 2.58 
Digestive system 16 99.39 2.95 
Congenital heart 
defects 







Table A3. R and JAGS code for models described in section 3.5.3. 
Model Example R/JAGS code 
1 
glmer(cases ~ yr + (1|obs.eff), offset=log(totalb), data=data, 
family=poisson(link="log")) 
2 
glmer(cases ~ yr + (1|centre) + (1|obs.eff), offset=log(totalb), 
data=data, family=poisson(link="log")) 
3 
glmer(cases ~ yr + (yr|CA) + (1|obs.eff), offset=log(totalb), 
data=data, family=poisson(link="log")) 
4 
glmer(cases ~ yr + (yr|CA) + (1|centre) + (1|obs.eff), 
offset=log(totalb), data=data, family=poisson(link="log")) 
5 
model {     
    for (i in 1:n.obs) { 
      y[i] ~ dpois(lambda[i]) 
      log(lambda[i]) <- mu[i] 
      mu[i] <-  offs[i] + u0[CA[i]] + u1[CA[i]]*x[i] + 
epsilon[i] 
      epsilon[i] ~ dnorm(0, tau.e) 
    } 
     
    tau.e <- pow(sigma.e,-2) 
    sigma.e ~ dunif(0, 10) 
     
    for (k in 1:n.CA) { 
      u0[k] ~ dnorm(mu.u0, tau.u0) 
      u1[k] ~ dnorm(mu.u1, tau.u1) 
    } 
     
    mu.u0 ~ dnorm(0, 0.001) 
    tau.u0 <- pow(sigma.u0,-2) 
    sigma.u0 ~ dunif(0, 10) 
    mu.u1 ~ dnorm(0, 0.001) 
    tau.u1 <- pow(sigma.u1,-2) 
    sigma.u1 ~ dunif(0, 10) 





model {     
    for (i in 1:n.obs) { 
      y[i] ~ dpois(lambda[i]) 
      log(lambda[i]) <- mu[i] 
      mu[i]<-offs[i] + u[reg[i]] + u0[CA[i]]+ u1[CA[i]]*x[i] + 
epsilon[i] 
      epsilon[i] ~ dnorm(0, tau.e) 
    } 
    tau.e <- pow(sigma.e,-2) 
    sigma.e ~ dunif(0, 10) 
     
    for (j in 1:n.reg) { 
      u[j] ~ dnorm(mu.u, tau.u) 
    } 
    for (k in 1:n.CA) { 
      u0[k] ~ dnorm(mu.u0, tau.u0) 
      u1[k] ~ dnorm(mu.u1, tau.u1) 
    } 
     
    mu.u ~ dnorm(0, 0.001) 
    tau.u <- pow(sigma.u,-2) 
    sigma.u ~ dunif(0, 10) 
    mu.u0 ~ dnorm(0, 0.001) 
    tau.u0 <- pow(sigma.u0,-2) 
    sigma.u0 ~ dunif(0, 10) 
    mu.u1 ~ dnorm(0, 0.001) 
    tau.u1 <- pow(sigma.u1,-2) 
    sigma.u1 ~ dunif(0, 10)     
  } 
6B 
model {     
    for (i in 1:n.obs) { 
      y[i] ~ dpois(lambda[i]) 
      log(lambda[i]) <- mu[i] 
      mu[i]<-offs[i] + u0[reg[i]] + u1[CA[i]]*x[i] + epsilon[i] 
      epsilon[i] ~ dnorm(0, tau.e) 
    } 
    tau.e <- pow(sigma.e,-2)  # Priors 
    sigma.e ~ dunif(0, 10)  
     
    for (j in 1:n.reg) { 
      u0[j] ~ dnorm(mu.u0[CA[j]], tau.u0[CA[j]]) 
    } 
    for (k in 1:n.CA) { 
      mu.u0[k] ~ dnorm(mu.jk, tau.jk) 
      tau.u0[k] <- pow(sigma.u0[k], -2) 
      sigma.u0[k] ~ dunif(0, 10) 
      u1[k] ~ dnorm(mu.u1, tau.u1) 
    } 
    mu.jk  ~ dnorm(0, 0.001) 
    tau.jk <- pow(sigma.jk, -2) 
    sigma.jk ~ dunif(0, 10) 
    mu.u1 ~ dnorm(0, 0.001) 
    tau.u1 <- pow(sigma.b,-2) 
    sigma.u1 ~ dunif(0, 10)     




Table A4. Summary of notation for models in chapter 3. 
Model  Model notation 
 














𝑙𝑜𝑔(𝜆𝑡𝑗) = 𝑙𝑜𝑔(𝑝𝑡𝑗) + (𝛽0 + 𝑢𝑗) + 𝛽1𝑥𝑡𝑗  + 𝜀𝑡𝑗 
 
 𝑢𝑗 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝑗
2) 
𝜀𝑡𝑗 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝜀
2) 
 






𝑙𝑜𝑔(𝜆𝑡𝑘) = 𝑙𝑜𝑔(𝑝𝑡𝑘) + (𝛽0  + 𝑢0𝑘) + (𝛽1 + 𝑢1𝑘)𝑥𝑡𝑘  + 𝜀𝑡𝑘 
 
 𝑢0𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎0𝑘
2 ) 
 𝑢1𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎1𝑘
2 ) 
𝜀𝑡𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝜀
2) 
 




model + registry 
𝑦𝑡𝑗𝑘~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑡𝑗𝑘) 
𝑙𝑜𝑔(𝜆𝑡𝑗𝑘) = 𝑙𝑜𝑔(𝑝𝑡𝑗𝑘) + (𝛽0 + 𝑢0𝑘 + 𝑢𝑗) + (𝛽1 + 𝑢1𝑘)𝑥𝑡𝑗𝑘  + 𝜀𝑡𝑗𝑘 
 
 𝑢0𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎0𝑘
2 ) 
 𝑢1𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎1𝑘
2 ) 
 𝑢𝑗 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝑗
2) 
𝜀𝑡𝑗𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝜀
2) 
 






𝑙𝑜𝑔(𝜆𝑡𝑘) = 𝑙𝑜𝑔(𝑝𝑡𝑘) + 𝑢0𝑘 + 𝑢1𝑘𝑥𝑡𝑘  + 𝜀𝑡𝑘 
 
 𝑢0𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢0, 𝜏𝑢0) 
 𝑢1𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢1, 𝜏𝑢1) 
𝜀𝑡𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜏ԑ) 
 
𝜇𝑢0,  𝜇𝑢1~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 0.001) 
𝜏𝑢0 =  
1
𝜎𝑢0
2 , 𝜏𝑢1 =  
1
𝜎𝑢1















model + registry 
(A) 
𝑦𝑡𝑗𝑘~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑡𝑗𝑘) 
𝑙𝑜𝑔(𝜆𝑡𝑗𝑘) = 𝑙𝑜𝑔(𝑝𝑡𝑗𝑘) +  𝑢𝑗 +  𝑢0𝑘 + 𝑢1𝑘𝑥𝑡𝑗𝑘  + 𝜀𝑡𝑗𝑘 
 
 𝑢0𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢0, 𝜏𝑢0) 
 𝑢1𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢1, 𝜏𝑢1) 
 𝑢𝑗 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑗, 𝜏𝑗) 
𝜀𝑡𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜏ԑ) 
 
𝜇𝑢0,  𝜇𝑢1~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 0.001) 
𝜏𝑢0 =  
1
𝜎𝑢0
2 , 𝜏𝑢1 =  
1
𝜎𝑢1
2 , 𝜏𝑗 =  
1
𝜎𝑗









model + registry 
(B) 
𝑦𝑡𝑗𝑘~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑡𝑗𝑘) 
𝑙𝑜𝑔(𝜆𝑡𝑗𝑘) = 𝑙𝑜𝑔(𝑝𝑡𝑗𝑘) +  𝑢0𝑗𝑘 + 𝑢1𝑘𝑥𝑡𝑗𝑘  + 𝜀𝑡𝑗𝑘 
 
 𝑢0𝑗𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢0, 𝜏𝑢0) 
 𝑢1𝑘 ~ 𝑛𝑜𝑟𝑚𝑎𝑙(𝜇𝑢1, 𝜏𝑢1) 
𝜀𝑡𝑘  ~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 𝜏ԑ) 
 
𝜇𝑢0,  𝜇𝑢1~ 𝑛𝑜𝑟𝑚𝑎𝑙(0, 0.001) 
𝜏𝑢0 =  
1
𝜎𝑢0
2 , 𝜏𝑢1 =  
1
𝜎𝑢1










A2. Example script to run a Bayesian hierarchical model in R and JAGS 
## MODEL 5. Bayesian Poisson model grouping CAs, pooling over registry 
 
# model specification 
cat("model { 
     
    # Likelihood 
    for (i in 1:n.obs) { 
      y[i] ~ dpois(lambda[i]) 
      log(lambda[i]) <- mu[i] 
      mu[i] <-  offs[i] + u0[CA[i]] + u1[CA[i]]*x[i] + epsilon[i] 
      epsilon[i] ~ dnorm(0, tau.e) 
    } 
     
    # Priors 
    tau.e <- pow(sigma.e,-2) 
    sigma.e ~ dunif(0, 100) 
     
    for (k in 1:n.CA) { 
      u0[k] ~ dnorm(mu.u0, tau.u0) 
      u1[k] ~ dnorm(mu.u1, tau.u1) 
    } 
     
    # hyperpriors 
    mu.u0 ~ dnorm(0, 0.001) 
    tau.u0 <- pow(sigma.u0,-2) 
    sigma.u0 ~ dunif(0, 10) 
    mu.u1 ~ dnorm(0, 0.001) 
    tau.u1 <- pow(sigma.u1,-2) 
    sigma.u1 ~ dunif(0, 10) 
 }", file="m5.txt") 
 




# set parameters to be monitored 
params5 <- c("u0","mu.u0","sigma.u0","u1","mu.u1","sigma.u1","sigma.e") 
 
# set initial values for each chain using random numbers from the 
normal and uniform distributions 
inits.m5 <- function(chain) return(switch(chain,  
  "1"=list(u0=10*rnorm(n.CA), mu.u0=10*rnorm(1), sigma.u0=10*runif(1), 
 u1=10*rnorm(n.CA), mu.u1=10*rnorm(1), sigma.u1=10*runif(1), 
 sigma.e=runif(1), .RNG.name='base::Wichmann-Hill', .RNG.seed=1987),  
  "2"=list(u0=10*rnorm(n.CA), mu.u0=10*rnorm(1), sigma.u0=10*runif(1), 
 u1=10*rnorm(n.CA), mu.u1=10*rnorm(1), sigma.u1=10*runif(1),  
 sigma.e=runif(1), .RNG.name='base::Wichmann-Hill', .RNG.seed=2015),  
  "3"=list(u0=10*rnorm(n.CA), mu.u0=10*rnorm(1), sigma.u0=10*runif(1),  
 u1=10*rnorm(n.CA), mu.u1=10*rnorm(1), sigma.u1=10*runif(1),  
 sigma.e=runif(1), .RNG.name='base::Wichmann-Hill', .RNG.seed=1234))) 
 
# bundle the data 









# initialise the model in JAGS 
jags.m5 <- jags.model('m5.txt', jags.dat5, n.chains=3, inits=inits.m5, 
 n.adapt=1000) 
update(jags.m5,500)  #burn in 
list.samplers(jags.m5)  #check which samplers are being used 
 
# run length control (pilot run) 
m5 <- coda.samples.dic(jags.m5, params5, n.iter=5000, thin=1) 
raftery.diag(m5$samples) 
 
# run coda.samples with DIC module 
m5 <- coda.samples.dic(jags.m5, params5, n.iter=100000, thin=5) 
 










## visually assessing convergence 
 
# trace plots, mixing of chains 
xyplot(m5$samples[][,1:5], strip=F, strip.left=T) 
xyplot(m5$samples[][,6:11], strip=F, strip.left=T) 
 
# shape of posterior distributions 
densityplot(m5$samples[][,1:5], strip=F, strip.left=T) 








A3. Choice of priors for estimation of variance parameters in 
hierarchical models 
A half-Cauchy prior distribution can be coded in JAGS as described in Gelman and Pardoe2. 
For example, a half-Cauchy prior for the variance parameter sigma.u1 (i.e. the estimated SD 
of the random slopes across all CA subgroups) and a scale parameter S can be calculated as 
follows 
• The half-Cauchy prior for sigma.u1 is given by dividing a Normal distribution z.u1 





• The precision of z.u1 is 






• The distribution is restricted to be greater than zero, since the SD cannot take 
negative values  
z.u0 ~ Normal(0, zprec)I(0,) 
 
• A chi-square distribution with 1 degree of freedom is used 
chiSq.u0 ~ Gamma(0.5, 0.5) 
 
This can similarly be coded in an rjags model using a truncated t distribution as follows 
sigma.u1 ~ dt(0, zprec, 1)I(0,) 
                                                          
2 Gelman A & Pardoe I (2006). Bayesian Measures of Explained Variance and Pooling in Multilevel 




A4. Supplementary results for analysis of prevalence in neural tube defects 




























1 No No NTDs -0.001 (-0.011, 0.010) 0.908 0    90.2 
   Anencephaly 0.004 (-0.013, 0.021) 0.621 0    79.4 
   Encephalocele -0.021 (-0.055, 0.012) 0.212 0    66.5 
   Spina Bifida 0.000 (-0.016, 0.015) 0.965 0     85.1 
2 No Yes NTDs -0.001 (-0.013, 0.010) 0.816 0.056 0.287   1063.2 
   Anencephaly 0.004 (-0.014, 0.021) 0.691 0.079 0.422   885.7 
   Encephalocele -0.021 (-0.055, 0.012) 0.208 0 0.370   618.2 
   Spina Bifida -0.001 (-0.017, 0.015) 0.933 0.060 0.242   885.7 
3 Yes No NTDs -0.006 (-0.023, 0.012) 0.536 0 n/a 0.692 a 0.010 a 232.9 
   Anencephaly 0.0002       
   Encephalocele -0.019       
   Spina Bifida 0.003       
4 Yes Yes NTDs -0.006 (-0.024, 0.011) 0.485 0.124 0.296 0.695 a 0.009 a 2466.9 
   Anencephaly -0.001       
   Encephalocele -0.019       
    Spina Bifida 0.002       





Table A6. Notation in Bayesian hierarchical models for neural tube defects. 
Parameter Description 
u0[1] Random intercept for Anencephaly subgroup 
u0[2] Random intercept for Encephalocele subgroup 
u0[3] Random intercept for Spina bifida subgroup 
mu.u0 Mean of random intercepts for NTD subgroups 
sigma.u0 Standard deviation of random intercepts for NTD subgroups 
u1[1] Random slope (trend) for Anencephaly subgroup 
u1[2] Random slope (trend) for Encephalocele subgroup 
u1[3] Random slope (trend) for Spina bifida subgroup 
mu.u1 Mean of random slopes for NTD subgroups 
sigma.u1 Standard deviation of random slopes for NTD subgroups 
r[j] Random intercept for registry j 
mu.r Mean of random slopes for registries 
sigma.r Standard deviation of random slopes for registries 






The Raftery-Lewis diagnostic 
The Raftery-Lewis diagnostic for each model was based on a pilot run of 5000 samples with 
thin=1. The dependence factor estimates how much the autocorrelation inflates the 
required sample size, with mean values >5 (across all chains) indicating strong 
autocorrelation. The total estimated required sample size gives the approximate iterations 
required to estimate the 95% posterior confidence limits (i.e. the 0.025 and 0.975 quantiles, 
with probability=0.95) to have actual posterior probability within 0.0125 (the accuracy) of 
that estimated. Therefore, the 95% PCIs would have actual posterior probability between 
0.925 and 0.975, with confidence limits from between the 0.0125–0.0375 quantile up to 
the 0.9625–0.9875 quantile.  
Table A7. Raftery-Lewis diagnostic for Bayesian hierarchical model for neural 
tube defects pooled over registries (model 5). 
Parameter Burn-in (M) Total estimated 






quantile 0.025 0.975 0.025 0.975 0.025 0.975 
u1[1] 2.3 3.0 635 690 1.1 1.1 
u1[2] 3.3 3.0 717 705 1.2 1.2 
u1[3] 2.7 2.0 634 608 1.1 1.0 
mu.u1 6.7 11.7 1360 2117 2.3 3.5 
sigma.u1 3.3 11.7 721 1986 1.2 3.3 
u0[1] 3.7 3.3 763 691 1.3 1.2 
u0[2] 4.0 3.7 811 772 1.4 1.3 
u0[3] 6.0 3.0 1157 701 1.9 1.2 
mu.u0 19.0 18.3 4172 3869 7.0 6.5 
sigma.u0 29.3 80.0 5331 14134 8.9 23.6 





Table A8. Summary of posterior distribution for NTDs model 5. 
Parameter Mean SD 2.5% 50% 97.5% ESS a PSRF b 
u0[1] -7.784 0.027 -7.837 -7.784 -7.731 60,545 1 
u0[2] -9.162 0.050 -9.261 -9.162 -9.065 58,569 1 
u0[3] -7.612 0.025 -7.662 -7.612 -7.563 60,046 1 
mu.u0 -8.160 1.680 -11.690 -8.176 -4.499 60,844 1 
sigma.u0 2.282 1.907 0.525 1.577 7.969 28,850 1 
u1[1] 0.002 0.009 -0.014 0.002 0.020 40,700 1 
u1[2] -0.012 0.015 -0.046 -0.010 0.013 22,144 1 
u1[3] -0.001 0.008 -0.017 -0.001 0.015 45,818 1 
mu.u1 -0.004 0.139 -0.118 -0.002 0.102 80,276 1.18 
sigma.u1 0.070 0.234 0.001 0.018 0.508 471 1.2 
sigma.e 0.029 0.021 0.001 0.025 0.079 2,407 1 
a Effective sample size   
b Estimated potential scale reduction factor 
 
 



























 Autocorrelation function plots for NTDs model 5: random intercepts 





Table A9. Raftery-Lewis diagnostic for model 6A. 
Parameter Burn-in (M) Total estimated 





quantile 0.025 0.975 0.025 0.975 0.025 0.975 
u1[1] 8.3 7.3 1444 1424 2.4 2.4 
u1[2] 18.7 12.0 3293 2200 5.5 3.7 
u1[3] 6.3 8.7 1142 1676 1.9 2.8 
mu.u1 20.0 20.7 3310 4903 5.5 8.2 
sigma.u1 36.0 75.3 6279 13094 10.4 21.8 
u0[1] 105.0 78.0 17772 13043 29.6 21.7 
u0[2] 119.3 70.0 20664 12091 34.5 20.2 
u0[3] 102.3 89.7 16996 14622 28.3 24.4 
mu.u0 7.0 9.0 1345 1775 2.2 3.0 
sigma.u0 3.3 13.7 750 2293 1.3 3.8 
r[1] 77.7 111.0 13418 19120 22.4 31.9 
r[2] 87.7 111.3 15043 19676 25.1 32.8 
r[3] 78.0 96.7 13065 16319 21.8 27.2 
r[4] 77.7 70.3 13331 12025 22.2 20.0 
r[5] 110.3 102.3 18965 17867 31.6 29.8 
r[6] 76.3 85.0 13380 14633 22.3 24.4 
r[7] 100.7 160.0 16807 29071 28.0 48.6 
r[8] 91.3 96.3 15448 15918 25.7 26.5 
r[9] 75.0 170.7 13018 29811 21.7 49.7 
r[10] 80.0 89.0 13962 15173 23.3 25.3 
r[11] 107.3 119.7 18140 20614 30.2 34.3 
r[12] 84.3 93.0 14535 16229 24.2 27.1 
r[13] 144.0 131.3 24926 21930 41.5 36.6 
r[14] 83.3 122.7 13739 20757 22.9 34.6 
r[15] 81.7 166.0 13691 30404 22.8 50.8 
r[16] 87.3 123.7 15383 21040 25.6 35.1 
r[17] 111.7 119.0 17977 19595 29.9 32.7 
r[18] 91.7 112.3 15447 19397 25.8 32.3 
mu.r 60.0 100.7 10447 17532 17.4 29.2 
sigma.r 4.7 7.7 862 1326 1.4 2.2 





Table A10. Summary of posterior distribution for model 6A. 
Parameter Mean SD 2.5% 50% 97.5% ESS PSRF a 
u0[1] -4.868 19.379 -38.700 -2.324 27.959 11.6 4.93 
u0[2] -6.236 19.380 -40.070 -3.687 26.587 11.7 4.93 
u0[3] -4.684 19.379 -38.530 -2.133 28.143 11.6 4.93 
mu.u0 -5.253 19.401 -39.170 -2.763 27.687 12.6 4.83 
sigma.u0 2.311 1.935 0.523 1.598 8.038 27661.0 1 
u1[1] 0.002 0.009 -0.015 0.001 0.019 30183.4 1 
u1[2] -0.012 0.015 -0.047 -0.010 0.013 16141.1 1 
u1[3] -0.002 0.008 -0.018 -0.002 0.013 32577.6 1 
mu.u1 -0.005 0.102 -0.105 -0.003 0.089 101156.7 1.16 
sigma.u1 0.054 0.145 0.001 0.018 0.374 2907.4 1.13 
r[1] -3.141 19.379 -35.980 -5.700 30.698 11.6 4.93 
r[2] -2.895 19.378 -35.720 -5.442 30.927 11.8 4.93 
r[3] -2.883 19.379 -35.720 -5.427 30.945 11.7 4.93 
r[4] -3.489 19.379 -36.300 -6.034 30.364 11.6 4.93 
r[5] -3.462 19.379 -36.290 -6.010 30.390 11.6 4.93 
r[6] -3.256 19.378 -36.070 -5.798 30.573 11.7 4.93 
r[7] -3.041 19.379 -35.870 -5.591 30.805 11.7 4.93 
r[8] -3.220 19.379 -36.070 -5.766 30.599 11.5 4.93 
r[9] -2.967 19.378 -35.790 -5.513 30.875 11.5 4.93 
r[10] -3.076 19.379 -35.890 -5.609 30.739 11.5 4.93 
r[11] -3.344 19.379 -36.170 -5.888 30.497 11.6 4.93 
r[12] -2.838 19.379 -35.660 -5.386 30.988 11.6 4.93 
r[13] -2.679 19.379 -35.510 -5.229 31.161 11.6 4.93 
r[14] -2.411 19.379 -35.250 -4.952 31.435 11.6 4.93 
r[15] -2.916 19.379 -35.740 -5.468 30.906 11.6 4.93 
r[16] -2.828 19.379 -35.660 -5.371 31.012 11.5 4.93 
r[17] -2.844 19.379 -35.670 -5.392 30.986 11.6 4.93 
r[18] -2.662 19.378 -35.490 -5.207 31.185 11.5 4.93 
mu.r -2.997 19.378 -35.840 -5.543 30.842 11.5 4.93 
sigma.r 0.322 0.066 0.221 0.313 0.477 49262.5 1 
sigma.e 0.120 0.038 0.040 0.122 0.188 965.8 1.02 






 Trace plots for model 6a: group level parameters. 
 






 Trace plots for model 6A: random intercepts for registry. 
 






 Density plots for model 6A: random intercepts and slopes for CAs. 
 






 Autocorrelation function plots for model 6A: random intercepts and 






Table A11. Raftery-Lewis diagnostic for model 6B. 
Parameter Burn-in (M) Total estimated 





quantile 0.025 0.975 0.025 0.975 0.025 0.975 
u1[1] 7.3 6.7 1293 1207 2.2 2.0 
u1[2] 18.0 11.3 3239 2053 5.4 3.4 
u1[3] 7.7 7.3 1554 1422 2.6 2.4 
mu.u1 10.0 10.0 1940 1949 3.2 3.2 
sigma.u1 34.0 75.3 5825 13060 9.7 21.8 
u0[1], r[1] 7.7 10.0 1421 2013 2.4 3.4 
u0[1], r[2] 15.0 13.3 2611 2562 4.4 4.3 
u0[1], r[3] 7.7 8.0 1356 1645 2.3 2.7 
u0[1], r[4] 6.7 9.0 1345 1675 2.2 2.8 
u0[1], r[5] 13.3 12.0 2308 2147 3.9 3.6 
u0[1], r[6] 6.7 9.0 1137 1675 1.9 2.8 
u0[1], r[7] 13.3 11.3 2549 2146 4.2 3.6 
u0[1], r[8] 16.7 14.0 2889 2375 4.8 4.0 
u0[1], r[9] 8.3 10.7 1519 1906 2.5 3.2 
u0[1], r[10] 12.0 7.3 2137 1340 3.6 2.2 
u0[1], r[11] 18.0 10.0 2967 1837 4.9 3.1 
u0[1], r[12] 7.3 8.7 1513 1670 2.5 2.8 
u0[1], r[13] 4.0 3.7 784 746 1.3 1.2 
u0[1], r[14] 7.0 8.3 1220 1567 2.0 2.6 
u0[1], r[15] 3.3 3.3 737 713 1.2 1.2 
u0[1], r[16] 12.7 8.7 2335 1604 3.9 2.7 
u0[1], r[17] 15.7 16.3 2671 2965 4.5 4.9 
u0[1], r[18] 7.3 8.7 1300 1625 2.2 2.7 
mu.u0[1] 3.0 2.0 664 611 1.1 1.0 
sigma.u0[1] 5.7 7.0 1116 1281 1.9 2.1 
u0[2], r[1] 5.3 7.0 1033 1422 1.7 2.4 
u0[2], r[2] 9.3 11.7 1840 2150 3.1 3.6 
u0[2], r[3] 4.3 4.3 991 863 1.7 1.4 
u0[2], r[4] 12.0 9.3 2028 1670 3.4 2.8 
u0[2], r[5] 27.7 14.7 5260 2653 8.8 4.4 
u0[2], r[6] 7.3 8.3 1530 1454 2.6 2.4 
u0[2], r[7] 13.3 15.7 2346 2491 3.9 4.2 
u0[2], r[8] 19.3 20.0 3494 3652 5.8 6.1 
u0[2], r[9] 10.3 11.0 1822 2078 3.0 3.5 
u0[2], r[10] 7.3 5.7 1317 1104 2.2 1.8 
u0[2], r[11] 10.0 11.3 1766 1982 2.9 3.3 
u0[2], r[12] 6.0 7.0 1048 1325 1.7 2.2 
u0[2], r[13] 8.0 11.3 1500 2046 2.5 3.4 
u0[2], r[14] 10.7 15.3 1814 2853 3.0 4.8 
u0[2], r[15] 6.7 6.3 1198 1084 2.0 1.8 




u0[2], r[17] 10.0 12.7 1660 2380 2.8 4.0 
u0[2], r[18] 6.0 7.0 1111 1315 1.9 2.2 
mu.u0[2] 4.7 3.0 938 686 1.6 1.1 
sigma.u0[2] 15.7 10.7 2690 1885 4.5 3.1 
u0[3], r[1] 13.7 12.7 2300 2437 3.8 4.1 
u0[3], r[2] 14.0 15.3 2767 2674 4.6 4.5 
u0[3], r[3] 10.3 9.0 1863 1623 3.1 2.7 
u0[3], r[4] 7.0 7.3 1287 1281 2.1 2.1 
u0[3], r[5] 14.0 15.0 2660 2799 4.4 4.7 
u0[3], r[6] 6.3 7.7 1124 1380 1.9 2.3 
u0[3], r[7] 11.3 9.0 2224 1665 3.7 2.8 
u0[3], r[8] 16.0 11.7 2925 2020 4.9 3.4 
u0[3], r[9] 7.7 6.7 1406 1247 2.3 2.1 
u0[3], r[10] 14.7 12.0 2589 2237 4.3 3.7 
u0[3], r[11] 20.3 16.7 3642 2893 6.1 4.8 
u0[3], r[12] 11.7 13.3 2056 2406 3.4 4.0 
u0[3], r[13] 6.0 5.0 1079 908 1.8 1.5 
u0[3], r[14] 10.7 10.7 1953 1843 3.3 3.1 
u0[3], r[15] 5.3 4.3 944 980 1.6 1.6 
u0[3], r[16] 9.3 8.0 1827 1556 3.0 2.6 
u0[3], r[17] 14.0 12.0 2288 2133 3.8 3.6 
u0[3], r[18] 8.0 6.3 1485 1140 2.5 1.9 
mu.u0[3] 2.3 2.7 639 654 1.1 1.1 
sigma.u0[3] 7.0 10.0 1458 1800 2.4 3.0 
mu.ar 7.3 7.7 1483 1698 2.5 2.8 
sigma.ar 3.7 12.7 741 2324 1.2 3.9 







Table A12. Summary of posterior distribution for model 6B. 
Parameter Mean SD 2.5% 50% 97.5% ESS PSRF a 
u1[1] 0.002 0.008 -0.014 0.001 0.018 31311.4 1 
u1[2] -0.012 0.015 -0.046 -0.010 0.013 15622.4 1 
u1[3] -0.001 0.007 -0.016 -0.001 0.013 32375.1 1 
mu.u1 -0.004 0.110 -0.102 -0.003 0.093 97477.3 1.08 
sigma.u1 0.059 0.176 0.001 0.018 0.391 595.6 1.11 
u0[1], r[1] -8.258 0.136 -8.532 -8.255 -8.000 32261.8 1 
u0[1], r[2] -9.629 0.242 -10.140 -9.615 -9.188 19185.4 1 
u0[1], r[3] -7.717 0.100 -7.920 -7.715 -7.525 38498.4 1 
u0[1], r[4] -7.608 0.105 -7.818 -7.607 -7.409 38077.9 1 
u0[1], r[5] -9.524 0.235 -10.010 -9.512 -9.091 20311.4 1 
u0[1], r[6] -7.779 0.106 -7.993 -7.778 -7.577 40597.2 1 
u0[1], r[7] -7.671 0.143 -7.958 -7.669 -7.397 32076.4 1 
u0[1], r[8] -9.148 0.250 -9.658 -9.141 -8.674 20885.0 1 
u0[1], r[9] -7.566 0.125 -7.818 -7.565 -7.325 36731.8 1 
u0[1], r[10] -8.383 0.129 -8.642 -8.381 -8.137 33251.8 1 
u0[1], r[11] -9.531 0.209 -9.962 -9.523 -9.146 22416.4 1 
u0[1], r[12] -8.073 0.109 -8.292 -8.070 -7.865 36793.2 1 
u0[1], r[13] -7.636 0.059 -7.752 -7.635 -7.522 57353.9 1 
u0[1], r[14] -9.227 0.116 -9.459 -9.225 -9.005 35038.9 1 
u0[1], r[15] -7.553 0.056 -7.664 -7.552 -7.445 59382.5 1 
u0[1], r[16] -8.060 0.151 -8.367 -8.056 -7.776 29228.7 1 
u0[1], r[17] -9.266 0.239 -9.757 -9.258 -8.818 19427.2 1 
u0[1], r[18] -7.789 0.125 -8.041 -7.786 -7.551 35170.6 1 
mu.u0[1] -7.932 0.119 -8.173 -7.931 -7.700 52345.6 1 
sigma.u0[1] 0.475 0.100 0.320 0.461 0.709 37986.0 1 
u0[2], r[1] -7.470 0.076 -7.621 -7.469 -7.324 48266.3 1 
u0[2], r[2] -8.989 0.147 -9.286 -8.987 -8.706 27880.6 1 
u0[2], r[3] -7.392 0.072 -7.536 -7.391 -7.253 49499.3 1 
u0[2], r[4] -8.235 0.140 -8.520 -8.232 -7.970 31909.5 1 
u0[2], r[5] -9.987 0.320 -10.680 -9.963 -9.433 12221.4 1 
u0[2], r[6] -7.719 0.106 -7.930 -7.717 -7.518 37688.9 1 
u0[2], r[7] -7.851 0.201 -8.262 -7.846 -7.471 21073.2 1 
u0[2], r[8] -9.169 0.302 -9.790 -9.161 -8.596 15916.1 1 
u0[2], r[9] -7.554 0.157 -7.869 -7.552 -7.252 30816.0 1 
u0[2], r[10] -7.713 0.092 -7.898 -7.712 -7.537 40528.9 1 
u0[2], r[11] -9.047 0.165 -9.380 -9.044 -8.733 26608.8 1 
u0[2], r[12] -7.627 0.086 -7.798 -7.627 -7.462 41043.0 1 
u0[2], r[13] -7.329 0.103 -7.536 -7.327 -7.132 38087.4 1 
u0[2], r[14] -8.710 0.190 -9.090 -8.707 -8.347 20233.8 1 
u0[2], r[15] -7.105 0.092 -7.290 -7.105 -6.928 37884.8 1 
u0[2], r[16] -8.495 0.163 -8.826 -8.490 -8.189 29355.5 1 
u0[2], r[17] -8.969 0.192 -9.353 -8.966 -8.603 23426.7 1 




mu.u0[2] -9.212 0.119 -9.454 -9.209 -8.980 34869.8 1 
sigma.u0[2] 0.425 0.114 0.243 0.410 0.688 16673.7 1 
u0[3], r[1] -8.745 0.233 -9.227 -8.736 -8.315 20256.5 1 
u0[3], r[2] -8.974 0.231 -9.440 -8.970 -8.531 20435.5 1 
u0[3], r[3] -7.848 0.139 -8.131 -7.844 -7.586 31753.2 1 
u0[3], r[4] -7.686 0.094 -7.875 -7.685 -7.503 40918.5 1 
u0[3], r[5] -9.264 0.184 -9.642 -9.260 -8.917 23751.8 1 
u0[3], r[6] -7.656 0.089 -7.832 -7.655 -7.486 42033.4 1 
u0[3], r[7] -8.511 0.127 -8.766 -8.509 -8.270 36034.4 1 
u0[3], r[8] -9.572 0.200 -9.989 -9.565 -9.202 21778.1 1 
u0[3], r[9] -8.034 0.100 -8.235 -8.032 -7.844 37998.1 1 
u0[3], r[10] -7.993 0.181 -8.361 -7.989 -7.652 23423.4 1 
u0[3], r[11] -8.942 0.254 -9.444 -8.939 -8.450 19157.7 1 
u0[3], r[12] -7.769 0.149 -8.073 -7.765 -7.485 28144.5 1 
u0[3], r[13] -7.620 0.080 -7.778 -7.619 -7.466 42596.3 1 
u0[3], r[14] -8.689 0.130 -8.951 -8.687 -8.442 31516.3 1 
u0[3], r[15] -7.393 0.071 -7.533 -7.392 -7.257 50857.1 1 
u0[3], r[16] -7.468 0.080 -7.630 -7.467 -7.314 42300.5 1 
u0[3], r[17] -9.314 0.177 -9.673 -9.310 -8.978 25512.5 1 
u0[3], r[18] -7.680 0.085 -7.850 -7.679 -7.518 41675.0 1 
mu.u0[3] -7.658 0.071 -7.799 -7.657 -7.518 51122.2 1 
sigma.u0[3] 0.272 0.060 0.178 0.264 0.411 41844.3 1 
mu.ar** -8.241 1.719 -11.820 -8.253 -4.503 61471.2 1 
sigma.ar** 2.268 1.916 0.504 1.559 8.014 30373.1 1 
sigma.e 0.064 0.039 0.002 0.063 0.140 239.6 1.02 
*Estimated potential scale reduction factor 
**mu.ar is the mean intercept across all CA*registry combinations, and sigma.ar the SD of the 







 Trace plots for model 6b: group level parameters. 
Note that in Figure A14 mu.ar is the mean intercept across all CA-registry combinations, 
sigma.ar the SD of the intercepts across all CA-registry combinations, mu.u1 the mean slope 
and sigma.u1 the SD of the trends across the three NTD subgroups. 
 







 Trace plots for model 6B: random slope in each CA subgroup. 
 
 
 Trace plots for model 6b: random intercepts for intercepts for 
registries in the first CA subgroup (Note that the trace plots look the same for 






 Autocorrelation function plots for model 6b: group level parameters. 
 
 
 Autocorrelation function plots for model 6b: mean and SD for random 














 Individual registry results for average annual trend in prevalence of 
Neural Tube Defect subgroups 2003-2012, with 99% confidence band for overall 




Table A13. Run times for JAGS and Stan models 5, 6a and 6b. 
Model Programme Run time in seconds Run time in minutes 
5 JAGS 49.7 0.8 
 
Stan 136.3 2.3 
6a JAGS 859.2 14.3 
 
Stan 31596.4 526.6 
6b JAGS 889.8 14.8 
 
Stan 4362.2 72.7 
 
Table A14. Comparison of posterior distributions for JAGS and Stan models 5, 6a 
and 6b. 
  JAGS     Stan     
Parameter Mean (95% CI) ESS 
PSRF 
a 




u0[1] -7.78 (-7.84, -7.73) 60,545 1 -7.78 (-7.83, -7.73) 382 1.02 
u0[2] -9.16 (-9.26, -9.07) 58,569 1 -9.17 (-9.26, -9.08) 29 1.07 
u0[3] -7.61 (-7.66, -7.56) 60,046 1 -7.61 (-7.66, -7.57) 264 1.02 
mu.u0 -8.16 (-11.69, -4.5) 60,844 1 -1.42 (-57.49, 58.6) 96 1.03 
sigma.u0 2.28 (0.53, 7.97) 28,850 1 7.59 (4.69, 9.83) 86 1.04 
u1[1] 0.002 (-0.01, 0.02) 40,700 1 0.001 (-0.01, 0.02) 37 1.07 
u1[2] -0.01 (-0.05, 0.01) 22,144 1 -0.01 (-0.05, 0.01) 77 1.04 
u1[3] -0.001 (-0.02, 0.02) 45,818 1 -0.001 (-0.02, 0.01) 202 1.01 
mu.u1 -0.004 (-0.12, 0.1) 80,276 1.18 -0.03 (-0.15, 0.07) 2,299 1.01 
sigma.u1 0.07 (0.001, 0.51) 471 1.2 0.083 (0.001, 0.47) 537 1.01 
sigma.e 0.03 (0.001, 0.08) 2,407 1 0.026 (0.004, 0.08) 25 1.08 
MODEL 6a 
u0[1] -4.87 (-38.7, 27.96) 12 4.93 0.08 (-5.87, 3.74) 178 1.01 
u0[2] -6.24 (-40.07, 26.58) 12 4.93 -1.29 (-7.24, 2.37) 178 1.01 
u0[3] -4.68 (-38.53, 28.14) 12 4.93 0.26 (-5.68, 3.91) 178 1.01 
mu.u0 -5.25 (-39.17, 27.68) 13 4.83 0.47 (-62.28, 63) 1,664 1.00 
sigma.u0 2.31 (0.52, 8.03) 27,661 1 2.44 (0.5, 8.35) 249 1.01 
u1[1] 0.002 (-0.02, 0.02) 30,183 1 0.002 (-0.01, 0.02) 1,409 1.00 
u1[2] -0.01 (-0.05, 0.01) 16,141 1 -0.01 (-0.05, 0.01) 665 1.01 
u1[3] -0.002 (-0.02, 0.01) 32,578 1 -0.003 (-0.02, 0.01) 3,837 1.00 
mu.u1 -0.01 (-0.11, 0.09) 101,157 1.16 -0.01 (-0.12, 0.1) 1,909 1.00 
sigma.u1 0.05 (0, 0.37) 2,907 1.13 0.08 (0, 0.47) 2,598 1.00 
r[1] -3.14 (-35.98, 30.7) 12 4.93 -8.09 (-11.74, -2.12) 178 1.01 
r[2] -2.9 (-35.72, 30.93) 12 4.93 -7.84 (-11.52, -1.88) 178 1.01 
r[3] -2.88 (-35.72, 30.95) 12 4.93 -7.83 (-11.48, -1.89) 178 1.01 
r[4] -3.49 (-36.3, 30.36) 12 4.93 -8.44 (-12.1, -2.48) 178 1.01 
r[5] -3.46 (-36.29, 30.39) 12 4.93 -8.41 (-12.07, -2.46) 178 1.01 
r[6] -3.26 (-36.07, 30.57) 12 4.93 -8.2 (-11.85, -2.26) 178 1.01 




r[8] -3.22 (-36.07, 30.6) 12 4.93 -8.17 (-11.82, -2.21) 178 1.01 
r[9] -2.97 (-35.79, 30.88) 12 4.93 -7.92 (-11.57, -1.97) 178 1.01 
r[10] -3.08 (-35.89, 30.74) 12 4.93 -8.02 (-11.68, -2.07) 178 1.01 
r[11] -3.34 (-36.17, 30.50) 12 4.93 -8.29 (-11.96, -2.35) 178 1.01 
r[12] -2.84 (-35.66, 30.99) 12 4.93 -7.79 (-11.43, -1.82) 178 1.01 
r[13] -2.68 (-35.51, 31.16) 12 4.93 -7.62 (-11.27, -1.68) 178 1.01 
r[14] -2.41 (-35.25, 31.44) 12 4.93 -7.36 (-11.02, -1.41) 178 1.01 
r[15] -2.92 (-35.74, 30.91) 12 4.93 -7.86 (-11.53, -1.9) 178 1.01 
r[16] -2.83 (-35.66, 31.01) 12 4.93 -7.77 (-11.41, -1.83) 178 1.01 
r[17] -2.84 (-35.67, 30.99) 12 4.93 -7.79 (-11.44, -1.84) 178 1.01 
r[18] -2.66 (-35.49, 31.19) 12 4.93 -7.61 (-11.26, -1.66) 178 1.01 
mu.r -3.00 (-35.84, 30.84) 12 4.93 -7.94 (-11.6, -1.98) 178 1.01 
sigma.r 0.32 (0.22, 0.48) 49,263 1 0.32 (0.22, 0.47) 2,616 1.00 
sigma.e 0.12 (0.04, 0.19) 966 1.02 0.13 (0.05, 0.2) 329 1.00 
MODEL 6b 
u1[1] 0.002 (-0.01, 0.02) 31,311 1 0.002 (-0.01, 0.02) 4,143 1.00 
u1[2] -0.01 (-0.05, 0.01) 15,622 1 -0.01 (-0.05, 0.01) 2,769 1.00 
u1[3] -0.001 (-0.02, 0.01) 32,375 1 -0.001 (-0.02, 0.01) 2,459 1.00 
mu.u1 -0.004 (-0.1, 0.09) 97,477 1.08 -0.01 (-0.11, 0.1) 2,979 1.00 
sigma.u1 0.06 (0.001, 0.39) 596 1.11 0.07 (0.002, 0.43) 5,429 1.00 
u0[1], r[1] -8.26 (-8.53, -8.00) 32,262 1 -8.26 (-8.53, -8) 14,883 1.00 
u0[1], r[2] -9.63 (-10.14, -9.19) 19,185 1 -9.63 (-10.13, -9.19) 10,957 1.00 
u0[1], r[3] -7.72 (-7.92, -7.53) 38,498 1 -7.72 (-7.92, -7.52) 21,116 1.00 
u0[1], r[4] -7.61 (-7.82, -7.41) 38,078 1 -7.61 (-7.82, -7.41) 8,552 1.00 
u0[1], r[5] -9.52 (-10.01, -9.09) 20,311 1 -9.53 (-10.03, -9.08) 3,959 1.00 
u0[1], r[6] -7.78 (-7.99, -7.58) 40,597 1 -7.78 (-8, -7.57) 4,031 1.00 
u0[1], r[7] -7.67 (-7.96, -7.4) 32,076 1 -7.67 (-7.96, -7.4) 23,890 1.00 
u0[1], r[8] -9.15 (-9.66, -8.67) 20,885 1 -9.15 (-9.66, -8.68) 8,256 1.00 
u0[1], r[9] -7.57 (-7.82, -7.33) 36,732 1 -7.57 (-7.82, -7.32) 19,012 1.00 
u0[1], r[10] -8.38 (-8.64, -8.14) 33,252 1 -8.38 (-8.64, -8.14) 4,617 1.00 
u0[1], r[11] -9.53 (-9.96, -9.15) 22,416 1 -9.52 (-9.95, -9.14) 10,257 1.00 
u0[1], r[12] -8.07 (-8.29, -7.87) 36,793 1 -8.07 (-8.3, -7.86) 3,277 1.00 
u0[1], r[13] -7.64 (-7.75, -7.52) 57,354 1 -7.64 (-7.75, -7.52) 23,866 1.00 
u0[1], r[14] -9.23 (-9.46, -9.01) 35,039 1 -9.23 (-9.46, -9) 6,919 1.00 
u0[1], r[15] -7.55 (-7.66, -7.45) 59,383 1 -7.55 (-7.67, -7.44) 4,659 1.00 
u0[1], r[16] -8.06 (-8.37, -7.78) 29,229 1 -8.06 (-8.37, -7.77) 8,423 1.00 
u0[1], r[17] -9.27 (-9.76, -8.82) 19,427 1 -9.27 (-9.78, -8.82) 2,722 1.00 
u0[1], r[18] -7.79 (-8.04, -7.55) 35,171 1 -7.79 (-8.05, -7.55) 17,260 1.00 
mu.u0[1] -7.93 (-8.17, -7.7) 52,346 1 -7.93 (-8.17, -7.7) 13,947 1.00 
sigma.u0[1] 0.48 (0.32, 0.71) 37,986 1 0.48 (0.32, 0.71) 6,974 1.00 
u0[2], r[1] -7.47 (-7.62, -7.32) 48,266 1 -7.47 (-7.62, -7.32) 13,795 1.00 
u0[2], r[2] -8.99 (-9.29, -8.71) 27,881 1 -8.99 (-9.28, -8.71) 5,218 1.00 
u0[2], r[3] -7.39 (-7.54, -7.25) 49,499 1 -7.39 (-7.54, -7.25) 20,982 1.00 
u0[2], r[4] -8.24 (-8.52, -7.97) 31,910 1 -8.24 (-8.53, -7.97) 2,473 1.00 




u0[2], r[6] -7.72 (-7.93, -7.52) 37,689 1 -7.72 (-7.93, -7.52) 5,224 1.00 
u0[2], r[7] -7.85 (-8.26, -7.47) 21,073 1 -7.85 (-8.26, -7.46) 8,201 1.00 
u0[2], r[8] -9.17 (-9.79, -8.6) 15,916 1 -9.17 (-9.78, -8.6) 4,338 1.00 
u0[2], r[9] -7.55 (-7.87, -7.25) 30,816 1 -7.56 (-7.89, -7.25) 2,091 1.00 
u0[2], r[10] -7.71 (-7.9, -7.54) 40,529 1 -7.71 (-7.9, -7.54) 18,568 1.00 
u0[2], r[11] -9.05 (-9.38, -8.73) 26,609 1 -9.05 (-9.38, -8.73) 6,201 1.00 
u0[2], r[12] -7.63 (-7.8, -7.46) 41,043 1 -7.63 (-7.8, -7.46) 19,581 1.00 
u0[2], r[13] -7.33 (-7.54, -7.13) 38,087 1 -7.33 (-7.54, -7.13) 15,431 1.00 
u0[2], r[14] -8.71 (-9.09, -8.35) 20,234 1 -8.71 (-9.08, -8.35) 19,563 1.00 
u0[2], r[15] -7.11 (-7.29, -6.93) 37,885 1 -7.11 (-7.29, -6.93) 9,322 1.00 
u0[2], r[16] -8.5 (-8.83, -8.19) 29,356 1 -8.49 (-8.82, -8.19) 21,907 1.00 
u0[2], r[17] -8.97 (-9.35, -8.6) 23,427 1 -8.97 (-9.35, -8.61) 19,295 1.00 
u0[2], r[18] -7.54 (-7.74, -7.35) 41,382 1 -7.54 (-7.74, -7.35) 13,385 1.00 
mu.u0[2] -9.21 (-9.45, -8.98) 34,870 1 -9.21 (-9.47, -8.98) 2,579 1.00 
sigma.u0[2] 0.43 (0.24, 0.69) 16,674 1 0.43 (0.25, 0.69) 21,921 1.00 
u0[3], r[1] -8.75 (-9.23, -8.32) 20,257 1 -8.74 (-9.23, -8.32) 15,226 1.00 
u0[3], r[2] -8.97 (-9.44, -8.53) 20,436 1 -8.98 (-9.43, -8.53) 12,481 1.00 
u0[3], r[3] -7.85 (-8.13, -7.59) 31,753 1 -7.85 (-8.13, -7.59) 12,676 1.00 
u0[3], r[4] -7.69 (-7.88, -7.5) 40,919 1 -7.69 (-7.88, -7.51) 12,530 1.00 
u0[3], r[5] -9.26 (-9.64, -8.92) 23,752 1 -9.26 (-9.64, -8.91) 5,839 1.00 
u0[3], r[6] -7.66 (-7.83, -7.49) 42,033 1 -7.66 (-7.84, -7.48) 12,207 1.00 
u0[3], r[7] -8.51 (-8.77, -8.27) 36,034 1 -8.52 (-8.78, -8.27) 4,559 1.00 
u0[3], r[8] -9.57 (-9.99, -9.20) 21,778 1 -9.57 (-9.99, -9.20) 16,125 1.00 
u0[3], r[9] -8.03 (-8.24, -7.84) 37,998 1 -8.03 (-8.23, -7.84) 16,010 1.00 
u0[3], r[10] -7.99 (-8.36, -7.65) 23,423 1 -7.99 (-8.36, -7.65) 4,937 1.00 
u0[3], r[11] -8.94 (-9.44, -8.45) 19,158 1 -8.95 (-9.44, -8.46) 17,097 1.00 
u0[3], r[12] -7.77 (-8.07, -7.49) 28,145 1 -7.77 (-8.07, -7.49) 12,571 1.00 
u0[3], r[13] -7.62 (-7.78, -7.47) 42,596 1 -7.62 (-7.78, -7.47) 9,952 1.00 
u0[3], r[14] -8.69 (-8.95, -8.44) 31,516 1 -8.69 (-8.95, -8.44) 16,491 1.00 
u0[3], r[15] -7.39 (-7.53, -7.26) 50,857 1 -7.39 (-7.53, -7.26) 21,386 1.00 
u0[3], r[16] -7.47 (-7.63, -7.31) 42,301 1 -7.47 (-7.63, -7.31) 13,245 1.00 
u0[3], r[17] -9.31 (-9.67, -8.98) 25,513 1 -9.32 (-9.68, -8.97) 5,350 1.00 
u0[3], r[18] -7.68 (-7.85, -7.52) 41,675 1 -7.68 (-7.85, -7.51) 2,509 1.00 
mu.u0[3] -7.66 (-7.81, -7.52) 51,122 1 -7.66 (-7.82, -7.52) 7,705 1.00 
sigma.u0[3] 0.27 (0.18, 0.41) 41,844 1 0.27 (0.18, 0.41) 6,904 1.00 
mu.ar b -8.24 (-11.82, -4.51) 61,471 1 -8.25 (-11.95, -4.57) 5,772 1.00 
sigma.a b 2.27 (0.50, 8.01) 30,373 1 2.27 (0.50, 8.01) 8,671 1.00 
sigma.e 0.06 (0.002, 0.14) 240 1.02 0.08 (0.02, 0.15) 239 1.01 
a PSRF and Rhat are the Estimated potential scale reduction factor for JAGs and Stan, respectively 
b mu.ar is the mean intercept across all CA*registry combinations, and sigma.ar the SD of the 
intercepts across all CA*registry combinations 




Table A15. Comparison of posterior distributions with different values for prior distributions, NTDs model 5. 
Parameter Mean (95% CI) ESS   Mean (95% CI) ESS   Mean (95% CI) ESS 
Prior for variances / means Uniform(0, 10) / Normal(0, 0.001)  Uniform(0, 100) /   Normal(0, 0.001) Uniform(0, 10) /   Normal (0, 0.0001)  
u0[1] -7.784 (-7.837, -7.731) 60,545   -7.784 (-7.837, -7.731) 59,981   -7.784 (-7.837, -7.731) 60,000 
u0[2] -9.162 (-9.261, -9.065) 58,569   -9.162 (-9.262, -9.065) 59,112   -9.162 (-9.26, -9.066) 57,162 
u0[3] -7.612 (-7.662, -7.563) 60,046   -7.612 (-7.662, -7.563) 60,000   -7.612 (-7.661, -7.563) 60,474 
mu.u0 -8.16 (-11.69, -4.499) 60,844   -8.058 (-14.054, -1.275) 28,326   -8.174 (-11.92, -4.39) 59,079 
sigma.u0 2.282 (0.525, 7.969) 28,850   3.846 (0.529, 21.678) 1,639   2.308 (0.524, 8.026) 28,557 
u1[1] 0.002 (-0.014, 0.02) 40,700   0.002 (-0.014, 0.02) 42,805   0.002 (-0.014, 0.02) 42,921 
u1[2] -0.012 (-0.046, 0.013) 22,144   -0.012 (-0.046, 0.013) 24,708   -0.012 (-0.046, 0.013) 26,008 
u1[3] -0.001 (-0.017, 0.015) 45,818   -0.001 (-0.017, 0.015) 46,148   -0.001 (-0.017, 0.015) 48,094 
mu.u1 -0.004 (-0.118, 0.102) 80,276   -0.003 (-0.105, 0.095) 70,369   -0.004 (-0.1, 0.085) 61,964 
sigma.u1 0.07 (0.001, 0.508) 471.5   0.058 (0.001, 0.41) 736   0.049 (0.001, 0.332) 1,852 
sigma.e 0.029 (0.001, 0.079) 2,407   0.03 (0.001, 0.079) 2,476   0.03 (0.002, 0.078) 2,602 
Prior for variances / means Cauchy, scale=5 / Normal(0, 0.001)   Cauchy, scale=10 /  Normal(0, 0.001)  Cauchy, scale=25 /  Normal(0, 0.0001) 
u0[1] -7.784 (-7.837, -7.732) 60,000   -7.784 (-7.837, -7.731) 60,014   -7.784 (-7.837, -7.732) 59,319 
u0[2] -9.162 (-9.261, -9.066) 60,633   -9.162 (-9.261, -9.066) 59,227   -9.162 (-9.26, -9.066) 60,804 
u0[3] -7.612 (-7.662, -7.564) 60,652   -7.612 (-7.662, -7.563) 60,012   -7.612 (-7.662, -7.563) 60,875 
mu.u0 -8.167 (-11.12, -5.168) 55,584   -8.139 (-11.76, -4.198) 64,587   -8.146 (-12.9, -3.157) 57,867 
sigma.u0 1.976 (0.508, 7.035) 11,925   2.426 (0.52, 9.615) 6,151   2.986 (0.53, 13.621) 6,244 
u1[1] 0.002 (-0.014, 0.02) 42,484   0.002 (-0.014, 0.02) 45,339   0.002 (-0.014, 0.02) 42,277 
u1[2] -0.012 (-0.046, 0.013) 25,292   -0.012 (-0.046, 0.013) 22,904   -0.012 (-0.047, 0.013) 18,831 
u1[3] -0.001 (-0.017, 0.015) 45,519   -0.001 (-0.017, 0.015) 47,543   -0.001 (-0.017, 0.015) 46,176 
mu.u1 -0.004 (-0.106, 0.09) 45,590   -0.003 (-0.111, 0.104) 112,730   -0.002 (-0.184, 0.18) 82,230 
sigma.u1 0.057 (0.001, 0.401) 1,093   0.08 (0.001, 0.474) 836   0.126 (0.001, 1.462) 315 




A5. Supplementary results for analysis of prevalence in chromosomal anomalies  

























cAIC 422 4465 - - - 
Deviance 456 4565 - - - 
Residual DF 44 888 - - - 
Mean Deviance - - 400 4333 4246 
Penalty - - 20 130 136 
DIC (penalised deviance) - - 420 4463 4382 
Multivariate PSRF - - 1.00 2.54 1.01 
Mean SD for overdispersion parameter 0.035 0.104 0.037 0.103 0.066 
Mean SD of registry intercepts - 0.272 - 0.296 
1.941  a 
Mean SD of CA intercepts 1.098 1.102 1.906 1.915 
Mean SD of CA trends 0.026 0.026 0.054 0.054 0.050 
Estimated correlation between CA intercepts and slopes 0.820 0.830 - - - 
a SD of the intercepts across all CA*registry combinations  
 
Table A17. Model fit for hierarchical models including three chromosomal trisomy subgroups. 






















cAIC 299 2998 - - - 
Deviance 293 3077 - - - 
Residual DF 175 530 - - - 
Mean Deviance - - 260 2906 2885 
Penalty - - 15 95 93 
DIC (penalised deviance) - - 275 3001 2978 
Multivariate PSRF - - 1.00 2.11 1.01 
Mean SD for overdispersion parameter 0.034 0.091 0.041 0.090 0.063 
Mean SD of registry intercepts - 0.272 - 0.295 
2.858 a 
Mean SD of CA intercepts 0.961 0.966 2.855 2.858 
Mean SD of CA trends 0.0003 0.004 0.032 0.016 0.033 
Estimated correlation between CA intercepts and slopes 1 1 - - - 





A6. Supplementary results for analysis of prevalence in digestive system CAs 

























cAIC 599 5009 - - - 
Deviance 589 5067 - - - 
Residual DF 74 1425 - - - 
Mean Deviance - - 523 4894 4713 
Penalty - - 29 158 123 
DIC (penalised deviance) - - 552 5007 4836 
Multivariate PSRF - - 1.00 2.55 1.03 
Mean SD for overdispersion parameter 0.075 0.190 0.075 0.187 0.058 
Mean SD of registry intercepts - 0.141 - 0.153 
1.382 a 
Mean SD of CA intercepts 0.991 0.991 1.320 1.322 
Mean SD of CA trends 0.014 0.015 0.018 0.018 0.018 
Estimated correlation between CA intercepts and slopes 0.99 0.97 - - - 





A7. Supplementary results for analysis of prevalence in congenital 
heart defects 
 
 Total prevalence of congenital heart defect subgroups in severity 











 Total prevalence of congenital heart defect subgroups in severity 






Table A19. Model 5 with additional severity grouping; summary of posterior 
distribution for overall and severity group-level parameters. 
Type Parameter Mean SD 2.5% 50% 97.5% ESS 
Mean intercepts mu.u0 -8.482 1.989 -12.530 -8.637 -3.874 54,917 
 mu.u0.grp[1] -9.330 0.545 -10.350 -9.354 -8.180 45,378 
 mu.u0.grp[2] -8.747 0.328 -9.403 -8.748 -8.089 54,727 
 mu.u0.grp[3] -7.508 1.372 -10.180 -7.342 -4.990 33,926 
Mean trends mu.u1 -0.001 0.115 -0.150 0.000 0.147 79,848 
 mu.u1.grp[1] 0.004 0.017 -0.030 0.003 0.038 43,386 
 mu.u1.grp[2] 0.006 0.008 -0.011 0.006 0.022 26,452 
 mu.u1.grp[3] -0.012 0.038 -0.067 -0.012 0.042 47,969 
SD for 
intercepts 
sigma.u0 2.554 2.184 0.134 1.863 8.522 24,626 
 sigma.u0.grp[1] 1.121 0.680 0.468 0.936 2.917 27,709 
 sigma.u0.grp[2] 0.892 0.318 0.498 0.822 1.710 45,627 
 sigma.u0.grp[3] 2.528 1.914 0.584 1.899 7.951 32,027 
SD for trends sigma.u1 0.079 0.178 0.001 0.028 0.526 1,706 
 sigma.u1.grp[1] 0.033 0.030 0.002 0.026 0.103 8,709 
 sigma.u1.grp[2] 0.014 0.010 0.001 0.013 0.037 10,593 
 sigma.u1.grp[3] 0.067 0.145 0.006 0.035 0.302 1,266 
Overdispersion  sigma.e 0.083 0.012 0.062 0.082 0.107 18,183 
Severity group 1:       
Single ventricle u1[3] 0.023 0.022 -0.013 0.020 0.069 22,140 
Tricuspid atresia 
and stenosis 
u1[8] 0.013 0.018 -0.020 0.012 0.053 35,006 
Ebsteins 
anomaly 
u1[9] -0.019 0.023 -0.070 -0.016 0.019 23,349 
Hypoplastic left 
heart 
u1[13] -0.006 0.013 -0.032 -0.005 0.018 35,980 
Hypoplastic 
right heart 
u1[14] 0.012 0.020 -0.025 0.010 0.056 36,733 
Severity group 2:       
Common 
arterial truncus 
u1[1] 1.23E-08 0.015 -0.034 0.002 0.025 28,137 
Transposition of 
great vessels 
u1[2] 0.007 0.010 -0.012 0.007 0.027 43,341 
Atrioventricular 
Septal Defect 
u1[6] 0.013 0.011 -0.007 0.012 0.038 29,400 
Tetralogy of 
Fallot 
u1[7] 0.019 0.012 -0.002 0.017 0.045 18,907 
Pulmonary 
valve atresia 
u1[11] 0.004 0.012 -0.022 0.005 0.027 38,088 
Aortic valve 
atresia/stenosis 
u1[12] 0.006 0.011 -0.017 0.007 0.029 42,959 
Coarctation of 
aorta 









Severity group 3:       
Ventricular 
Septal Defect 
u1[4] -0.004 0.010 -0.024 -0.003 0.016 45,651 
Atrial Septal 
Defect 
u1[5] -0.038 0.011 -0.058 -0.038 -0.017 48,068 
Pulmonary 
valve stenosis 


































cAIC 1311 13,189 - - - - 
Deviance 1451 14,277 - - - - 
Residual DF 165 3036 - - - - 
Mean Deviance - - 1226 1149 11,128 11,857 
Penalty - - 85 75 1192 856 
DIC (penalised deviance) - - 1312 1224 12,320 12,722 
Multivariate PSRF - - 1.00 1.00 1.25 1.02 
Mean SD for overdispersion parameter 0.090 0.466 0.092 0.083 0.439 0.247 
Mean SD of registry intercepts - 0.283 - - 0.288 
1.277 b 
Mean SD of CA intercepts 1.122 1.132 1.260 2.553 1.315 
Mean SD of CA trends 0.017 0.006 0.019 0.079 0.011 0.015 
Estimated correlation between CA intercepts and slopes -0.47 -0.89 - - - - 
a Model 5 including random effects for severity group 
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Use of Hierarchical Models to Analyze European Trends
in Congenital Anomaly Prevalence
Alana Cavadino1, David Prieto-Merino2,3,4, Marie-Claude Addor5, Larraitz Arriola6,
Fabrizio Bianchi7, Elizabeth Draper8, Ester Garne9, Ruth Greenlees10, Martin Haeusler11,
Babak Khoshnood12, Jenny Kurinczuk13, Bob McDonnell14, Vera Nelen15,
Mary O’Mahony16, Hanitra Randrianaivo17, Judith Rankin18, Anke Rissmann19,
David Tucker20, Christine Verellen-Dumoulin21, Hermien de Walle22, Diana Wellesley23,
and Joan K. Morris*1
Background: Surveillance of congenital anomalies is important to identify
potential teratogens. Despite known associations between different anomalies,
current surveillance methods examine trends within each subgroup
separately. We aimed to evaluate whether hierarchical statistical methods that
combine information from several subgroups simultaneously would enhance
current surveillance methods using data collected by EUROCAT, a European
network of population-based congenital anomaly registries. Methods: Ten-year
trends (2003 to 2012) in 18 EUROCAT registries over 11 countries were
analyzed for the following groups of anomalies: neural tube defects,
congenital heart defects, digestive system, and chromosomal anomalies.
Hierarchical Poisson regression models that combined related subgroups
together according to EUROCAT’s hierarchy of subgroup coding were applied.
Results from hierarchical models were compared with those from Poisson
models that consider each congenital anomaly separately. Results:
Hierarchical models gave similar results as those obtained when considering
each anomaly subgroup in a separate analysis. Hierarchical models that
included only around three subgroups showed poor convergence and were
generally found to be over-parameterized. Larger sets of anomaly subgroups
were found to be too heterogeneous to group together in this way.
Conclusion: There were no substantial differences between independent
analyses of each subgroup and hierarchical models when using the
EUROCAT anomaly subgroups. Considering each anomaly separately,
therefore, remains an appropriate method for the detection of potential
changes in prevalence by surveillance systems. Hierarchical models do,
however, remain an interesting alternative method of analysis when
considering the risks of specific exposures in relation to the prevalence of
congenital anomalies, which could be investigated in other studies.
Birth Defects Research (Part A) 106:480–10, 2016.
VC 2016 Wiley Periodicals, Inc.
Key words: congenital anomalies; trends; prevalence; hierarchical models
Introduction
Congenital anomalies are structural or functional abnormal-
ities that are present at birth. They are a leading worldwide
cause of fetal and infant death, chronic illness, and disability
in childhood; a diverse group of disorders for which only
around 50% can be linked to a specific known cause or risk
factor (World Health Organization, 2014). Causes of congeni-
tal anomaly include a wide range of both genetic and
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environmental factors such as maternal age, nutritional sta-
tus, or exposure to certain medications. It is important to
identify risk factors for congenital anomalies, in particular
the early identification of new potentially teratogenic
exposures.
Following the thalidomide disaster, congenital anomaly
registries were established worldwide to facilitate surveil-
lance and research into the causes of birth defects
(McBride, 1961; Khoury et al., 1994). A European network
of such population-based registries, EUROCAT, provides
important epidemiologic information on congenital anoma-
lies by collecting data on over 1.7 million births from 43
registries in 23 countries across Europe (EUROCAT, 2016).
EUROCAT annually monitors the birth prevalence of spe-
cific anomalies to detect new or continuing trends, identi-
fying new potentially teratogenic exposures and evaluating
the effectiveness of primary prevention policies (Dolk,
2005).
Surveillance of congenital anomalies is often performed
using defined sets of subgroups, such as the EUROCAT
anomaly subgroups (EUROCAT, 2005). Many of these sub-
groups overlap, for example, the congenital heart defects
(CHD) subgroup includes further subgroups such as ven-
tricular septal defects, atrial septal defects, and tetralogy
of Fallot (ToF). Despite known relationships among many
of the subgroups, current surveillance methods examine
trends, clusters, or associations between risk factors and
anomalies within each subgroup separately (Loane et al.,
2011b; EUROCAT, 2015). Relevant information on relation-
ships between anomalies across the different subgroups is,
therefore, not currently being incorporated in surveillance
analyses; hence, it is possible that important associations
or trends are not being detected by the current methods.
Congenital anomaly surveillance methods that combine
information from several subgroups simultaneously may
enhance the analysis of any particular anomaly by consid-
ering what is happening in related or similar anomalies.
The aim of this study is to evaluate whether hierarchical
statistical methods that combine information from several
subgroups within the same congenital anomaly group




This study is based on routinely collected EUROCAT data
from 18 full member registries in 11 European countries:
Austria (Styria registry), Belgium (Antwerp and Hainaut),
Denmark (Odense), France (Paris and Isle de la Reunion),
Germany (Saxony-Anhalt) Ireland (Cork & Kerry and Dub-
lin), Italy (Tuscany), Netherlands (Northern Netherlands),
Spain (Basque Country), Switzerland (Vaud), and the
United Kingdom (East Midlands & South Yorkshire, North-
ern England, Thames Valley, Wales, and Wessex). Data
were extracted from the EUROmediCAT central database in
February 2015, including only registries with a total prev-
alence of all anomalies greater than 2% and available data
for at least 9 years of the 10-year period from 01 January
2003 to 31 December 2012. All coding was done accord-
ing to EUROCAT guide 1.3 (www.eurocat-network.eu/con-
tent/EUROCAT-Guide-1.3.pdf) (EUROCAT, 2005), which
uses a hierarchy of codes to classify all cases of nonminor
congenital anomaly into 89 EUROCAT anomaly subgroups.
EUROCAT anomaly subgroups are grouped in a hierarchi-
cal structure, with the highest level being the major organ
groups, within which there are further classes.
Spina bifida, for example, is in the neural tube defects
(NTD) subgroup, which is within the nervous system
group of anomalies. A case may be counted only once in
each of the lowest level EUROCAT subgroups, but if it has
multiple anomalies, it will be counted in multiple sub-
groups. Cases with genetic conditions (genetic syndromes/
microdeletions, teratogenic syndromes with malformations,
or chromosomal anomalies) were excluded from all analy-
ses of nonchromosomal anomaly. Data are collected for all
birth outcomes, including live and stillbirths and termina-
tions of pregnancy for fetal anomaly. Further details
regarding the registries, methods of case ascertainment,
and data collection and processing are described else-
where (EUROCAT, 2005; Boyd et al., 2011; Greenlees et al.,
2011).
STATISTICAL METHODS
The most recent 10 years of data available were assessed
for changes in prevalence for the following groups of
anomalies: NTDs, autosomal chromosome anomalies,
CHDs, and digestive system anomalies. Poisson regression
was used to model prevalence rates for the number of
congenital anomaly cases each year, with the log total
births included as an offset to account for the differing
population size each year. Estimated average yearly 10-
year trends in prevalence obtained from individual models
(separate Poisson models for each anomaly subgroup with
no information sharing between anomaly subgroups) were
compared with those obtained from hierarchical models
(one Poisson model fitting related anomaly subgroups
simultaneously with sharing of information between
anomaly subgroups).
For CHDs, there are 16 standard subgroups (EUROCAT,
2005) that have previously been grouped using a hierarchi-
cal severity ranking according to perinatal mortality rates in
nonchromosomal cases, formed of three ordered groups
from severity I (high perinatal mortality) to severity III (low
perinatal mortality) (EUROCAT, 2009) (Table 1). A two level
hierarchy that includes the grouping of CHDs by these sever-
ity subgroups was also considered. A data-level variance
component was used to directly model potential overdisper-
sion in the data for hierarchical models (Gelman and Hill,
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2007). Models were also repeated with the inclusion of a
term to take account of the random effects of registry.
All statistical analyses were conducted in R (R Develop-
ment Core Team, 2008). Markov Chain Monte Carlo sam-
pling methods were used to obtain estimates of variability
around the random effects in hierarchical models by using
Gibbs sampling (Casella and George, 1992) in the Bayesian
analysis program JAGS by means of the R package rjags
(Plummer, 2003). Results from hierarchical models are pre-
sented as annual percentage changes in prevalence and their
95% posterior credible intervals (PCIs), which can be
thought of as the Bayesian equivalent of 95% confidence
intervals (CIs) and where we say there is a 95% probability
that the true trend in prevalence lies within this interval. If
the 95% CI or PCI does not include zero then we consider
this a “statistically significant” average annual change in
prevalence or a “signal.” The resulting estimates are only
valid if convergence has occurred, which is assessed graphi-
cally and by using convergence diagnostics in the R package
coda (Plummer et al., 2003). Further details on the use of
the Bayesian hierarchical models in JAGs can be found in the
Supplementary Materials, which are available online.
Results
A total of 103,507 cases of congenital anomaly (81,147
cases excluding genetic conditions) were available for anal-
ysis from a combined population of 4,097,142 births over
18 registries during the 10-year study period. Trends
were assessed in 4167 NTD, 13,358 chromosomal, 25,273
CHD, and 7683 digestive system anomaly cases (Table 1).
The rarest subgroup included in these analyses was the
digestive system anomaly annular pancreas, with only 57
cases in the combined population over the 10 years giving
an estimated total prevalence of 0.1 cases per 10,000
births. The most common anomaly subgroup was the CHD
ventricular septal defect, with an estimated total preva-
lence of almost 28 cases per 10,000 births (Table 1).
MODELS FOR NTDS
There were no changes in prevalence for any of the NTD
subgroups, with estimated average annual trends remain-
ing very similar for individual and hierarchical models and
95% CIs and PCIs including zero (no change) for all esti-
mates (Fig. 1). There was some “shrinkage” in the esti-
mates toward the group mean in the hierarchical model,
in particular for encephalocele, although this estimated
trend was not significant in either model.
MODELS FOR CHROMOSOMAL ANOMALIES
In individual models, an increasing trend of 1.7% (95% CI,
0.7–2.6%) and 1.8% (95% CI, 0.4–3.1%) per year on aver-
age was observed for Down and Edwards syndromes,
respectively (Fig. 2), but there was no significant change
in prevalence of Patau syndrome. Trends in prevalence
were similar when combining the three anomalies together
TABLE 1. Total Prevalence of Selected Groups and Subgroups of Congenital
Anomalies per 10,000 births, Using Data Covering 4,097,142 Births from 18
EUROCAT Registries, 2003 to 2012





Neural tube defects 4,167 10.2 (9.9, 10.5)
Anencephaly 1,709 4.2 (4.0, 4.4)
Encephalocele 430 1.0 (1.0, 1.2)
Spina bifida 2,028 4.9 (4.7, 5.2)
Autosomal chromosome anomalies 13,358 32.6 (32.1, 33.2)
Down syndrome / trisomy 21 9,854 24.1 (23.6, 24.5)
Patau syndrome / trisomy 13 942 2.3 (2.2, 2.5)
Edwards syndrome / trisomy 18 2,562 6.3 (6.0, 6.5)
Congenital heart defects 25,273 61.7 (60.9, 62.4)
Severity group I:
Single ventricle 249 0.6 (0.5, 0.7)
Tricuspid atresia and stenosis 286 0.7 (0.6, 0.8)
Ebstein’s anomaly 212 0.5 (0.5, 0.6)
Hypoplastic left heart 1,127 2.8 (2.6, 2.9)
Hypoplastic right heart 205 0.5 (0.4, 0.6)
Severity group II:
Common arterial truncus 233 0.6 (0.5, 0.6)
Transposition of great vessels 1,467 3.6 (3.4, 3.8)
Atrioventricular septal defect 838 2.0 (1.9, 2.2)
Tetralogy of Fallot 1,187 2.9 (2.7, 3.1)
Pulmonary valve atresia 425 1.0 (0.9, 1.1)
Aortic valve atresia/stenosis 540 1.3 (1.2, 1.4)
Coarctation of aorta 1,488 3.6 (3.4, 3.8)
Total anomalous pulmonary venous return 299 0.7 (0.6, 0.8)
Severity group III:
Ventricular septal defect 11,262 27.5 (27.0, 28.0)
Atrial septal defect 5,226 12.8 (12.4, 13.1)
Pulmonary valve stenosis 1,850 4.5 (4.3, 4.7)
Digestive system anomalies 7,683 18.8 (18.3, 19.2)
Oesophageal atresia with or without
tracheo-esophageal fistula
890 2.2 (2.0, 2.3)
Duodenal atresia or stenosis 377 0.9 (0.8, 1.0)
Atresia or stenosis of other parts
of small intestine
393 1.0 (0.9, 1.1)
Ano-rectal atresia and stenosis 1,157 2.8 (2.7, 3.0)
Hirschsprung’s disease 548 1.3 (1.2, 1.5)
Atresia of bile ducts 122 0.3 (0.2, 0.4)
Annular pancreas 57 0.1 (0.1, 0.2)
Diaphragmatic hernia 1,030 2.5 (2.4, 2.7)
aIncluding livebirths, stillbirths, and terminations of pregnancy after
prenatal diagnosis.
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in a hierarchical model; the estimated trend for Patau syn-
drome increased slightly toward the average of the three
trends but the 95% PCI still included zero (Fig. 2).
MODELS FOR CONGENITAL HEART DEFECTS
Of all cases with CHD, 85.5% were counted in one of the
three EUROCAT severity groups for CHDs, excluding those
with patent ductus arteriosus in term infants as well as
several other CHDs that are not assigned a specific sub-
group code according to EUROCAT’s coding hierarchy. In
individual models, decreasing trends for atrial septal
defect (ASD) and pulmonary valve stenosis (PVS), and an
increasing trend for ToF were observed (Fig. 3). When
using a hierarchical model that combined all CHDs (Fig.
3), the estimated trends for PVS and ToF attenuated
toward the null. The only significant change in prevalence
in the hierarchical model was for ASD, which attenuated
slightly to 3.0% on average from the estimated 4.1% in an
individual model. Average annual changes in prevalence
for the other CHD subgroups were a mix of increasing and
decreasing trends, none of which were statistically signifi-
cant in either model. When including severity subgroup as
an additional level in a hierarchical model for CHDs (Fig.
3), the trends for ASD and PVS remained significant, with
estimated average changes in prevalence very similar to
those obtained in individual models. The increasing trend
for ToF was not statistically significant when grouping all
CHDs together, whether including the severity grouping or
not.
MODELS FOR DIGESTIVE SYSTEM ANOMALIES
There were no significant trends in prevalence for any of
the digestive system subgroups for individual or hierarchi-
cal models (Fig. 4), with estimated trends in the hierarchi-
cal model generally attenuating toward the mean of the
estimated trends across the eight subgroups, which was
again close to the null value of no trend. Subgroups that
were less precisely estimated were more affected by the
information in other subgroups, giving more marked dif-
ferences in estimated trends in the less common anoma-
lies for individual models compared with a hierarchical
model.
MODEL ASSESSMENT FOR HIERARCHICAL MODELS
Parameters for hierarchical models that included a reason-
able number of subgroups (i.e., eight or more for the
digestive system anomalies) displayed good convergence.
Hierarchical models for smaller groups of anomalies (e.g.,
models for NTDs and autosomal anomalies including only
three subgroups) showed poor convergence due to over
parameterization in the model. Further details on model
diagnostics for hierarchical models are given in the Sup-
plementary Materials.
INCLUDING A REGISTRY EFFECT
All models were repeated with the inclusion of a random
effect for registry to assess the effect of accounting for dif-
ferences at the registry level. The estimated trends in
prevalence of each anomaly subgroup remained very simi-
lar to those described above when including the effect of
registry for all models (data not shown). Hierarchical mod-
els that included a registry effect, in particular those with
only a small number of subgroups, demonstrated an over-
all lack of convergence.
FIGURE 1. Estimated average annual trends in
prevalence of neural tube defects with 95%
posterior credibility intervals.
BIRTH DEFECTS RESEARCH (PART A) 106:480–488 (2016) 483
Discussion
For all examples of congenital anomaly subgroups consid-
ered in these analyses, estimated trends in prevalence
were similar whether considering anomalies separately
(individual models) or together (hierarchical model). Iden-
tified trends were consistent with other studies. Increasing
trends in chromosomal anomalies were observed, which
are known to be due to maternal age and changes in pre-
natal screening practices (Cocchi et al., 2010; Loane et al.,
2013). NTD prevalence remained stable in EUROCAT regis-
tries, as has been observed elsewhere (Botto et al., 2006;
Khoshnood et al., 2015). This might be explained by the
lack of folic acid fortification in Europe and poor uptake of
folic acid supplementation; in the United Kingdom, for
example, under 30% of women took folic acid before their
pregnancy in 2011 to 2012 (Bestwick et al., 2014).
Prevalence in three of the digestive system anomaly
subgroups was found to be significantly increasing in the
latest EUROCAT statistical monitoring report (EUROCAT,
2015). A similar estimated increase in prevalence in these
three subgroups was observed here, although these trends
did not reach statistical significance in independent mod-
els due to the smaller number of registries included.
Increases in the prevalence of the CHDs single ventricle
(severity group I), ToF and atrioventricular septal defect
(severity group II) were consistent with previous findings
(EUROCAT, 2015). Estimated decreases in prevalence of
ASD and PVS, however, were not consistent with those
observed in other studies, where either no significant
changes or increasing trends have been observed (van der
Linde et al., 2011; EUROCAT, 2015). Published prevalence
estimates in CHDs are known to vary substantially due to
differing definitions of cases across studies, and it is likely
that the differences in estimated trends here reflect
changes in reporting for these anomalies (in recent years
EUROCAT have focused on only reporting ASD cases that
have been confirmed after 6 months of age) or differing
prenatal screening practices in this particular set of regis-
tries (Hoffman and Kaplan, 2002; Garne et al., 2012;
Baardman et al., 2014).
Hierarchical models have proven useful in the field of
pharmacovigilance, where they have been used in the
detection of potential adverse drug reactions (Berry and
Berry, 2004; Xia et al., 2011; Crooks et al., 2012). Natural
hierarchies in drug and adverse event coding have been
used to group similar drugs or adverse events together,
such that models for each drug-adverse event combination
incorporate information from analyses of other similar
drugs and adverse events (Prieto-Merino et al., 2011). In
this study, the same rationale was applied to congenital
anomalies; however, the situation here was different com-
pared with that for adverse drug reactions, where the
hierarchical classification systems may provide more natu-
ral hierarchies than the grouping of anomalies according
to the defined subgroups.
Indeed, the EUROCAT subgroup coding hierarchy pro-
vides sets of anomalies that are too heterogeneous in prac-
tice to be grouped together when analyzing changes in
prevalence. This is because the “shrinkage,” a key feature
of hierarchical models (Gelman and Hill, 2007) whereby
the estimated trend for each subgroup is influenced
toward the average trend over all subgroups in the model,
will largely pull estimates toward the null if there is a mix-
ture of increasing and decreasing trends, as was the case
FIGURE 2. Estimated average annual trends in
prevalence of chromosomal anomaly sub-
groups with 95% posterior credibility intervals.
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for CHD and digestive anomalies. It is possible, therefore,
that potential changes in prevalence in analyses of groups
of anomalies such as these could actually be masked by
hierarchical models.
On the other hand, this shrinkage can help control esti-
mates based on small counts by including information from
the rest of the group. Moreover, this can be thought of as a
natural “penalization” considering that a hierarchical model
is simultaneously looking for changes in prevalence in
numerous subgroups, compared with individual models
where this multiple testing aspect is not taken into account
(and several false positive results are, therefore, likely). For
a group where the mean trend across subgroups is close to
the null, this penalization will mean that the estimated trend
is no longer a “signal” in the hierarchical model, for example
as seen for the CHD ToF in severity group II (Fig. 3). For a
group where the mean trend is not so close to the null, how-
ever, this penalization might actually lead to an increase in
the strength and precision of a signal, for example for ASD in
severity group III (Fig. 3). Furthermore, the same signal
might be reduced or enhanced depending on which group-
ing is used; for example, the trend in PVS is attenuated if
considering all CHD groups together but maintained if also
including the severity grouping in the hierarchical model
(Fig. 3). This highlights how the posterior distribution is sen-
sitive to the prior information, which here is the way the
groups have been defined.
EUROCAT subgroups that were considered to be related,
for example etiologically similar or in the same organ system
class, were still found to vary considerably in terms of their
differing proportional yearly changes in prevalence. It is
well known (Greenland, 2000; Gelman and Hill, 2007), and
has been seen here in the case of NTDs and autosomal tris-
omy groups of anomalies, that a random effects model with
FIGURE 3. Estimated average annual trends in
prevalence of congenital heart defect sub-
groups with 95% posterior credibility intervals.
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only three levels for the random effect parameter does not
perform well, with such models showing poor convergence
and over-parameterization. There may be other larger
groups of anomalies that are similar enough to be analyzed
together that were not considered here, and in fact there are
known relationships between anomalies that lie within dif-
ferent groups of the EUROCAT hierarchy. In addition to
NTDs, for example, there are several other anomalies across
different body systems that are known to be sensitive to
folate levels during pregnancy, including CHDs, clefts, and
limb reduction defects (Wilson et al., 2015). If there was evi-
dence that folate levels had been increasing in Europe, then
it would have been useful to have analyzed all these anoma-
lies as a hierarchical model. However, from examining the
NTDs alone here and in other studies, no such change has
occurred in Europe; hence, such models were not further
investigated. Similarly, EUROCAT now includes a VATER/
VACTERL association subgroup that comprises anomalies of
the vertebra, anal atresia, CHDs, trachea-esophageal fistula,
esophageal atresia, radial anomaly, and limb defect, which
are known to occur together more frequently than expected
by chance. However, the heterogeneity of trends in just the
CHD component of this subgroup indicates that hierarchical
models are not likely to add any useful information to such an
analysis.
When examining congenital anomaly prevalence, there
are many factors that are likely to have an influence, such
as reporting, case ascertainment, or screening practices.
Hierarchical models might be more relevant, then, when
considering the risks of specific exposures in relation to
prevalence of congenital anomalies. It would, therefore, be
worthwhile investigating the application of hierarchical
models in such situations, for example, when looking at
the risk of medications taken during the first trimester of
pregnancy.
STRENGTHS AND LIMITATIONS OF THIS STUDY
EUROCAT registries collect data that is ascertained from
multiple sources and includes information on all major
structural congenital and chromosomal anomalies (Boyd
et al., 2011; Loane et al., 2011a), providing high quality
population-based data across multiple European countries
and allowing the inclusion of a large number of congenital
anomaly cases covering over four million births over 10
years for this study. EUROCAT registries include information
on cases of prenatal diagnosis followed by termination of
pregnancy, enabling the inclusion of cases that would other-
wise have gone undiagnosed, or unreported among sponta-
neous abortions or stillbirths. One potential limitation of
this study is that it was not possible to include data from all
of the EUROCAT member registries in these analyses; hence,
some trends that were seen in the latest statistical monitor-
ing report did not reach statistical significance here, likely
due to the smaller sample sizes included. However, it does
not seem likely that increasing the sample size would have
improved the performance of hierarchical models.
CONCLUSIONS
In summary, the hierarchical models considered here demon-
strated that sharing information between subgroups of
anomalies can provide a sensible “penalization,” helping to
avoid false positive signals by shrinking the estimated trends
toward the null when there is no evidence of other trends in
the rest of the group, while maintaining signals of changes in
FIGURE 4. Estimated average annual trends in
prevalence of digestive system subgroups with
95% posterior credibility intervals.
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prevalence when there are others in the group. Using the
EUROCAT hierarchy of anomaly subgroups, however, pre-
sented no substantial differences between the independent
analyses of each subgroup and hierarchical models. When
using EUROCAT subgroups for analysis, therefore, considering
each congenital anomaly separately remains an appropriate
method for the detection of potential changes in prevalence
by relevant surveillance systems. Hierarchical models do,
however, remain an interesting and potentially useful alter-
native method of analysis when considering the risks of spe-
cific exposures in relation to the prevalence of congenital
anomalies, and this could be investigated in other studies.
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Appendix B: Supplementary material for Chapter 5 
B1. Chapter 5 figures with ATC4 groupings 
 
 Effective workload and the number of medication signals in each risk category using the group BH procedure. Results are for 
grouping of medication-CA combinations by ATC2, ATC3 codes and CA subgroups according to cut-offs for FDR level from 5% to 50% (Figure 
5.2 with ATC4 groupings added). 






























































 Effective workload and the number of medication signals in each risk category using the group BH procedure. Results are for 
grouping of medication-CA combinations by ATC2, ATC3, ATC4 codes and CA subgroups according to cut-offs for FDR level from 5% to 50% 
(Figure 5.3 with ATC4 groupings added). 
 






























































 Effective workload and the number of medication signals in each risk category using the double FDR procedure. Results are for 
grouping of medication-CA combinations by ATC2, ATC3, ATC4 codes and CA subgroups according to cut-offs for FDR level from 5% to 50% 
(Figure 5.4 with ATC4 groupings added). 
  






























































  “High risk” proportion (percent of all signals that are in the “high risk” category) against effective workload (total number of 
signals) for FDR by group, group BH and double FDR methods. Grouping is by ATC2, ATC3, ATC4 codes and by CA subgroup, and each point 





 Identification rate (proportion of all “high risk” combinations 
identified as signals) against effective workload (the total number of signals) for 
FDR by group, group BH and double FDR methods. Grouping is by ATC2, ATC3 
codes and by CA subgroup, and each point corresponds to a different level of 
FDR for that type of grouping in 5% increments from 5% to 50% (Figure 5.6 with 









** RUNNING Fisher's exact tests for each medication-CA combination 
 
clear 
set obs 1 
gen CA str1 = "a" 
save tmp,replace 
 
use "ALL_meds_anoms_long.dta", clear 
gen v1=1 
 
foreach i of varlist A01AA01-V07AB99 { 
foreach k of varlist a1-a36 { 
 
preserve 
   
 *excluding data for registries with no records of medication i 
  egen Exp = max(`i'), by(centre) 
  drop if Exp == 0 
  drop Exp 
  di "drug: `i', CA: `k'" 
 
 *excluding data for registries with no records of the CA k 
  egen Exp = max(`k'), by(centre) 
  drop if Exp == 0 & r(N) != 0 
  drop Exp 
  count 
 
 *Fisher’s exact test 
  capture cs `k' `i', exact 
 
 *storing the estimates 
  gen p = `r(p1_exact)' 
  gen rr str30 = string(round(`r(rr)', 0.01)) + " (" +  
string(round(`r(lb_rr)', 0.01)) + " - " + string(round(`r(ub_rr)', 0.01)) 
+ ")" 
  loc lab`k': variable label `k' 
  gen CA = "`lab`k''"  
  collapse (sum) v1 `k', by (`i' p rr CA) 
  rename (v1 `k') (control case) 
  reshape wide control case, i(rr p CA) j(`i') 
  replace control0 = control0 - case0 
  replace control1 = control1 - case1  
  rename (control0 control1 case0 case1) (AnoDno AnoDyes AyesDno AyesDyes) 
  gen ATC = "`i'" 
  append using tmp 









*some data sorting 
use tmp, clear 
drop if CA == "a" 
drop if AyesDno == 0 & AyesDyes == 0 
save InterimResATC5, replace 
 
*---------------------------------------------------------* 
*The following do file flags medication-CA combinations that are signals 
using 
- no adjustment for multiple testing 
- single FDR adjustment  
- double FDR adjustment 
 
This is done in a loop for a range of FDR cut-off values (here 5%, 10%, 
20%, 30%, 40% and 50%) 
 
*------------------- START OF LOOP ----------------------* 
 
local siglevel "05 1 2 3 4 5" 







*combinations with an unadjusted P-value < 𝜶%  
gen f_noadj`i'=1 if p<`alpha' 
tab f_noadj`i' 
 
*single FDR (one-step BH procedure) 
qqvalue p, method(simes) qvalue(pbh`i') 





***double FDR, STEP 1: define a representative P-value for each group 
pistar by choosing the smallest FDR-adjusted P-value within each group 
 
*FDR adjustment within each group 
bys grp: qqvalue p, method(simes) qvalue(pgrp`i') 
 
*tag the smallest FDR-adjusted P-value in each group 
bys grp: egen pistar`i'=min(pgrp`i') 
replace pistar`i'=. if tag!=1 
 
*apply an FDR adjustment over the representative P-values from each group 
qqvalue pistar`i', method(simes) qvalue(pistt`i') 
 
*signals are flagged if the representative P-value is < alpha AND the P-
value from step 2 is < alpha  
gen tmp=1 if pistt`i'<`alpha' 
bys grp:egen F`i'=max(tmp) 
drop tmp 





***double FDR, STEP 2: applying a single FDR adjustment to the P-values in 
F  
qqvalue p if F`i'==1, method(simes) qvalue(pdfdr`i') 
 









Appendix C: Supplementary material for Chapter 6 
C1. Code used to specify BHMs in JAGS and R for chapter 6 
No information sharing: Poisson model 
for (i in 1:dmax) { 
  for (j in 1:CAmax){ 
     
    c[i,j] ~ dpois(p[i,j]) 
    p[i,j] <- (PRR[i,j])*(E[i,j]) 
    E[i,j] <- (CA[j]*d[i])/N 
    PRR[i,j] <- exp(lambda[i,j]) 
    lambda[i,j] ~ dnorm(0, 0.33)  
  } 
} 
No information sharing: Negative Binomial model 
for (i in 1:dmax) { 
  for (j in 1:CAmax){ 
     
    c[i,j] ~ dnegbin(p[i,j], r[i,j]) 
    p[i,j] <- r[i,j] / (r[i,j] + mu[i,j]) 
    mu[i,j] <- (PRR[i,j])*(E[i,j]) 
    E[i,j] <- (CA[j]*d[i])/N 
    PRR[i,j] <- exp(lambda[i,j]) 
    lambda [i,j] ~ dnorm(0, 0.33) 
    r[i,j] ~ dunif(0,1000) 
  } 
} 
Information sharing for medications only: Poisson model 
for (i in 1:dmax) { 
  for (j in 1:CAmax){ 
     
    c[i,j] ~ dpois(p[i,j]) 
    p[i,j] <- (PRR[i,j])*(E[i,j]) 
    E[i,j] <- (d[i]*CA[j])/N 
    PRR[i,j] <- exp(lambda[i,j]) 
     
    #grouping by ATC medication codes 
    lambda[i,j] ~ dnorm(theta[groupd[i]], tau[groupd[i]]) 
  } 
} 
     
for (k in 1:groupdmax){ 
    theta[k] ~ dnorm(0, 0.33) 
    tau[k] <- 1/sigma2[k] 
    sigma2[k] <- pow(sigma[k],2) 






Information sharing for medications only: Negative binomial model 
for (i in 1:dmax) { 
 for (j in 1:CAmax){ 
    c[i,j] ~ dnegbin(p[i,j], r) 
    p[i,j] <- r / (r + mu[i,j]) 
    mu[i,j] <- (PRR[i,j])*(E[i,j]) 
    E[i,j] <- (CA[j]*d[i])/N 
    PRR[i,j] <- exp(lambda[i,j]) 
    lambda[i,j] ~ dnorm(theta[groupd[i]], tau[groupd[i]]) 
  } 
} 
 r ~ dunif(0, 1000) 
 
for (k in 1:groupdmax){ 
    theta[k] ~ dnorm(0, 0.33) 
    tau[k] <- 1/sigma2[k] 
    sigma2[k] <- pow(sigma[k],2) 
    sigma[k] ~ dunif(0,100) 
} 
Information sharing for CAs only: Poisson model 
for (i in 1:dmax) { 
  for (j in 1:CAmax){ 
     
    c[i,j] ~ dpois(p[i,j]) 
    p[i,j] <- (PRR[i,j])*(E[i,j]) 
    E[i,j] <- (CA[j]*d[i])/N 
    PRR[i,j] <- exp(lambda[i,j]) 
     
    #grouping by type of CA 
    lambda[i,j] ~ dnorm(theta[groupCA[j]], tau[groupCA [j]]) 
  } 
} 
     
for (l in 1:groupCAmax){ 
    theta[l] ~ dnorm(0, 0.33) 
    tau[l] <- 1/sigma2[l] 
    sigma2[l] <- pow(sigma[l],2) 
    sigma[l] ~ dunif(0,100) 
} 
 
Information sharing for CAs only: Negative binomial 
for (i in 1:dmax) { 
 for (j in 1:CAmax){ 
    c[i,j] ~ dnegbin(p[i,j], r) 
    p[i,j] <- r / (r + mu[i,j]) 
    mu[i,j] <- (PRR[i,j])*(E[i,j]) 
    E[i,j] <- (CA[j]*d[i])/N 
    PRR[i,j] <- exp(lambda[i,j]) 
   lambda[i,j] ~ dnorm(theta[groupCA[j]], tau[groupCA[j]]) 
  } 
} 





for (l in 1:groupCAmax){ 
    theta[l] ~ dnorm(0, 0.33) 
    tau[l] <- 1/sigma2[l] 
    sigma2[l] <- pow(sigma[l],2) 
    sigma[l] ~ dunif(0,100) 
} 
Information sharing in two dimensions (medications and CAs): Poisson model 
for (i in 1:dmax) { 
  for (j in 1:CAmax){ 
    c[i,j] ~ dpois(p[i,j]) 
    p[i,j] <- (PRR[i,j])*(E[i,j]) 
    E[i,j] <- (d[i]*CA[j])/N 
    PRR[i,j] <- exp(lambda[i,j]) 
     
   #grouping by type of CA and ATC3 medication codes 
   lambda[i,j] ~ dnorm(theta[groupd[i],groupCA[j]], 
tau[groupd[i],groupCA[j]]) 
  } 
} 
     
for (k in 1:groupdmax){ 
  for (l in 1:groupCAmax){ 
    theta[k,l] ~ dnorm(0, 0.33) 
    tau[k,l] <- 1/sigma2[k,l] 
    sigma2[k,l] <- pow(sigma[k,l],2) 
    sigma[k,l] ~ dunif(0,100) 
  } 
} 
Information sharing in two dimensions (medications and CAs): Negative Binomial 
model 
for (i in 1:dmax) { 
 for (j in 1:CAmax){ 
    c[i,j] ~ dnegbin(p[i,j], r) 
    p[i,j] <- r / (r + mu[i,j]) 
    mu[i,j] <- (PRR[i,j])*(E[i,j]) 
    E[i,j] <- (CA[j]*d[i])/N 
    PRR[i,j] <- exp(lambda[i,j]) 
    lambda[i,j] ~ dnorm(theta[groupd[i],groupCA[j]], 
tau[groupd[i],groupCA[j]]) 
  } 
} 
 r ~ dunif(0, 1000) 
 
for (k in 1:groupdmax){ 
 for (l in 1:groupCAmax){ 
    theta[k,l] ~ dnorm(0, 0.33) 
    tau[k,l] <- 1/sigma2[k,l] 
    sigma2[k,l] <- pow(sigma[k,l],2) 






C2. Sensitivity analyses for BHMs in chapter 6 
Table C1. Observed and expected counts for congenital heart defects, oro-facial 
clefts and limb CAs in association with human insulin medication A10AC01. The 
marginal total count for A10AC01 is 𝑐𝑖. = 141 and the total count for all 
exposures across the dataset is 𝑁 = 26,765. 
CA subgroup 
Marginal total 
for CA (𝑐.𝑗) 
Counts for CA in 
combination with 
A10AC01 
Observed Expected a 
Congenital heart defects 
 
 
 Aortic valve atresia/stenosis 197 2 1.0 
Atrial septal defect 2,046 21 10.8 
Atrioventricular septal defect 246 1 1.3 
Coarctation of aorta 351 4 1.8 
Common arterial truncus 55 1 0.3 
Ebstein's anomaly 48 0 0.3 
Hypoplastic right heart 28 0 0.1 
Patent ductus arteriosus as only CHD in 
term infants 404 11 2.1 
Pulmonary valve atresia 115 0 0.6 
Pulmonary valve stenosis 468 4 2.5 
Single ventricle 84 2 0.4 
Tetralogy of Fallot 325 2 1.7 
Total anomalous pulmonary venous return 48 0 0.3 
Transposition of great vessels 357 6 1.9 
Tricuspid atresia and stenosis 69 0 0.4 
Ventricular septal defect 3,964 29 20.9 




 Cleft lip with or without palate 1,047 0 5.5 




 Club foot - talipes equinovarus 1,293 5 6.8 
Limb reduction 658 1 3.5 
Polydactyly 909 3 4.8 
Syndactyly 557 1 2.9 
a The marginal total count for A10AC01 is 𝑐𝑖. = 141 and the total count for all exposures across the 











Table C2. Sensitivity of the thresholds used to define signals for Poisson BHMs in chapter 6. 
Type of grouping 
PCI cut-off 
level 
Number of signals as displayed 
in Table 6.9 
Signals as in Table 6.9, with 
threshold raised to lower 95% 
PCI >2 a 
Percentage of signals retained 
after change in threshold to 
lower 95% PCI >2 a 
Combinations Medications Combinations Medications 
No grouping 95% 223 159 21 21 10% 
Discrete grouping by medications 95% 21 15 1 1 7% 
Discrete grouping by CAs 95% 10 8 1 1 13% 
Discrete grouping by medications 
and CAs 
95% 112 71 8 8 4% 
a An additional restriction excluding combinations with less than 3 exposure counts changes numbers only for the Poisson BHMs with no grouping; this 
reduces to only 16 combinations (for 16 medications) being signals 






 Example of protective associations caused by a combination of signals for the same medication in another group of CAs, and 
shrinkage for small groups with low cell counts: human insulin A10AC01 in combination with congenital heart defects, oro-facial clefts and 
limb CAs. The dashed lines in the BHM show the mean 𝑙𝑜𝑔(𝑃𝑅𝑅) across each group of CAs in combination with the A10A group of ATC3 
medications.
Aortic valve atresia/stenosis (c=2)
Atrial septal defect (c=21)
Atrioventricular septal defect (c=1)
Coarctation of aorta (c=4)
Common arterial truncus (c=1)
Ebstein's anomaly (c=0)
Hypoplastic right heart (c=0)
Pulmonary valve atresia (c=0)
Pulmonary valve stenosis (c=4)
Single ventricle (c=2)
Tetralogy of Fallot (c=2)
Total anomalous pulm venous return (c=0)
Transposition of great vessels (c=6)
Tricuspid atresia and stenosis (c=0)
Unspecified CHD (c=11)
Ventricular septal defect (c=29)
A10AC01 & Congential Heart Defects  




A10AC01 & Limb Anomalies  
Cleft lip with or without palate (c=0)
Cleft palate (c=2)
A10AC01 & Oro-facial clefts 
Patent ductus arteriosus (c=11)














 Example of a protective association in a medication-CA group with a high proportion of zero cell counts: eight digestive system 
CAs in combination with three A03F medications for functional gastrointestinal disorders. The dashed line in the BHM shows the mean 
𝑙𝑜𝑔(𝑃𝑅𝑅) across the group of A03F medications and digestive system CAs 
Annular pancreas (c=0)
Ano-rectal atresia and stenosis (c=0)
Atresia of bile ducts (c=0)
Atresia/stenosis, other part of small intestine (c=0)
Diaphragmatic hernia (c=0)
Duodenal atresia or stenosis (c=0)
Hirschsprung's disease (c=0)
Oesophageal atresia (c=0)
A03FA & Digestive anomalies:
 
Annular pancreas (c=0)
Ano-rectal atresia and stenosis (c=2)
Atresia of bile ducts (c=0)
Atresia/stenosis, other part of small intestine (c=0)
Diaphragmatic hernia (c=4)
Duodenal atresia or stenosis (c=0)
Hirschsprung's disease (c=2)
Oesophageal atresia (c=3)
A03FA01 & Digestive anomalies:
 
Annular pancreas (c=0)
Ano-rectal atresia and stenosis (c=0)
Atresia of bile ducts (c=0)
Atresia/stenosis, other part of small intestine (c=0)
Diaphragmatic hernia (c=0)
Duodenal atresia or stenosis (c=0)
Hirschsprung's disease (c=0)
Oesophageal atresia (c=0)
A03FA03 & Digestive anomalies:
-4 -2 0 2 -4 -2 0 2 -4 -2 0 2
Single FDR:
no grouping
Double FDR:
grouping
by medication
BHM: grouping
by medication
& anomaly
logPRR (95% PCI)
